-DOCSTART- -X- -X- O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Discharge NN NN O
Summary NN NN O
- NN NN O
Mesothelioma NNP NNP B-PROBLEM
- NN NN O
1 NN NN O
Description NN NN O
: NN NN O
Mesothelioma NNP NNP B-PROBLEM
, NN NN O
pleural NNP NNP B-PROBLEM
effusion NNP NNP I-PROBLEM
, NN NN O
atrial NNP NNP B-PROBLEM
fibrillation NNP NNP I-PROBLEM
, NN NN O
anemia NNP NNP B-PROBLEM
, NN NN O
ascites NNP NNP B-PROBLEM
, NN NN O
esophageal NNP NNP B-PROBLEM
reflux NNP NNP I-PROBLEM
, NN NN O
and NN NN O
history NN NN O
of NN NN O
deep NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PRINCIPAL NN NN O
DIAGNOSIS NN NN O
: NN NN O
Mesothelioma NNP NNP B-PROBLEM
. NN NN O

SECONDARY NN NN O
DIAGNOSES NN NN O
: NN NN O
Pleural NNP NNP B-PROBLEM
effusion NNP NNP I-PROBLEM
, NN NN O
atrial NNP NNP B-PROBLEM
fibrillation NNP NNP I-PROBLEM
, NN NN O
anemia NNP NNP B-PROBLEM
, NN NN O
ascites NNP NNP B-PROBLEM
, NN NN O
esophageal NNP NNP B-PROBLEM
reflux NNP NNP I-PROBLEM
, NN NN O
and NN NN O
history NN NN O
of NN NN O
deep NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
. NN NN O

PROCEDURES NN NN O

1 NN NN O
. NN NN O
On NN NN O
August NNP NNP B-DATE
24 NNP NNP I-DATE
, NNP NNP I-DATE
2007 NNP NNP I-DATE
, NN NN O
decortication NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
lung NNP NNP I-TREATMENT
with NN NN O
pleural NNP NNP B-TEST
biopsy NNP NNP I-TEST
and NN NN O
transpleural NNP NNP B-TEST
fluoroscopy NNP NNP I-TEST
. NN NN O

2 NN NN O
. NN NN O
On NN NN O
August NNP NNP B-DATE
20 NNP NNP I-DATE
, NNP NNP I-DATE
2007 NNP NNP I-DATE
, NN NN O
thoracentesis NNP NNP B-TREATMENT
. NN NN O

3 NN NN O
. NN NN O
On NN NN O
August NNP NNP B-DATE
31 NNP NNP I-DATE
, NNP NNP I-DATE
2007 NNP NNP I-DATE
, NN NN O
Port-A-Cath NNP NNP B-TREATMENT
placement NNP NNP I-TREATMENT
. NN NN O

HISTORY NN NN O
AND NN NN O
PHYSICAL NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
41-year-old NN NN O
Vietnamese NN NN O
female NN NN O
with NN NN O
a NNP NNP B-PROBLEM
nonproductive NNP NNP I-PROBLEM
cough NNP NNP I-PROBLEM
that NN NN O
started NN NN O
last NN NN O
week NN NN O
. NN NN O

She NN NN O
has NN NN O
had NN NN O
right-sided NNP NNP B-PROBLEM
chest NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
radiating NN NN O
to NN NN O
her NN NN O
back NN NN O
with NN NN O
fever NNP NNP B-PROBLEM
starting NN NN O
yesterday NN NN O
. NN NN O

She NN NN O
has NN NN O
a NN NN O
history NN NN O
of NN NN O
pericarditis NNP NNP B-PROBLEM
and NN NN O
pericardectomy NNP NNP B-TREATMENT
in NN NN O
May NNP NNP B-DATE
2006 NNP NNP I-DATE
and NN NN O
developed NN NN O
cough NNP NNP B-PROBLEM
with NN NN O
right-sided NNP NNP B-PROBLEM
chest NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
and NN NN O
went NN NN O
to NN NN O
an NN NN O
urgent NN NN O
care NN NN O
center NN NN O
. NN NN O

Chest NNP NNP B-TEST
x-ray NNP NNP I-TEST
revealed NN NN O
right-sided NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
effusion NNP NNP I-PROBLEM
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O

1 NN NN O
. NN NN O
Pericardectomy NNP NNP B-TREATMENT
. NN NN O

2 NN NN O
. NN NN O
Pericarditis NNP NNP B-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
Atrial NNP NNP B-PROBLEM
fibrillation NNP NNP I-PROBLEM
. NN NN O

4 NN NN O
. NN NN O
RNCA NN NN O
with NN NN O
intracranial NNP NNP B-TREATMENT
thrombolytic NNP NNP I-TREATMENT
treatment NNP NNP I-TREATMENT
. NN NN O

5 NN NN O
PTA NN NN O
of NN NN O
MCA NN NN O
. NN NN O

6 NN NN O
. NN NN O
Mesenteric NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
. NN NN O

7 NN NN O
. NN NN O
Pericardial NNP NNP B-TREATMENT
window NNP NNP I-TREATMENT
. NN NN O

8 NN NN O
. NN NN O
Cholecystectomy NNP NNP B-TREATMENT
. NN NN O

9 NN NN O
. NN NN O
Left NNP NNP B-TEST
thoracentesis NNP NNP I-TEST
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
No NN NN O
family NN NN O
history NN NN O
of NN NN O
coronary NNP NNP B-PROBLEM
artery NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
CVA NNP NNP B-PROBLEM
, NN NN O
diabetes NNP NNP B-PROBLEM
, NN NN O
CHF NNP NNP B-PROBLEM
or NN NN O
MI NNP NNP B-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
has NN NN O
one NN NN O
family NN NN O
member NN NN O
, NN NN O
a NN NN O
sister NN NN O
, NN NN O
with NN NN O
history NN NN O
of NN NN O
cancer NNP NNP B-PROBLEM
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
is NN NN O
married NN NN O
. NN NN O

Employed NN NN O
with NN NN O
the NN NN O
US NN NN O
Post NN NN O
Office NN NN O
. NN NN O

She NN NN O
is NN NN O
a NN NN O
mother NN NN O
of NN NN O
three NN NN O
. NN NN O

Denies NN NN O
tobacco NN NN O
, NN NN O
alcohol NN NN O
or NN NN O
illicit NN NN O
drug NN NN O
use NN NN O
. NN NN O

MEDICATIONS NN NN O

1 NN NN O
. NN NN O
Coumadin NNP NNP B-DRUG
1 NNP NNP I-DRUG
mg NNP NNP I-DRUG
daily NN NN O
. NN NN O

Last NN NN O
INR NNP NNP B-TEST
was NN NN O
on NN NN O
Tuesday NNP NNP B-DATE
, NN NN O
August NNP NNP B-DATE
14 NNP NNP I-DATE
, NNP NNP I-DATE
2007 NNP NNP I-DATE
, NN NN O
and NN NN O
her NNP NNP B-TEST
INR NNP NNP I-TEST
was NN NN O
2.3 NN NN O
. NN NN O

2 NN NN O
. NN NN O
Amiodarone NNP NNP B-DRUG
100 NNP NNP I-DRUG
mg NNP NNP I-DRUG
p.o NNP NNP I-DRUG
. NN NN O

daily NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
Complete NN NN O
review NN NN O
of NN NN O
systems NNP NNP B-TEST
negative NN NN O
except NN NN O
as NN NN O
in NN NN O
pulmonary NN NN O
as NN NN O
noted NN NN O
above NN NN O
. NN NN O

The NN NN O
patient NN NN O
also NN NN O
reports NN NN O
occasional NNP NNP B-PROBLEM
numbness NNP NNP I-PROBLEM
and NN NN O
tingling NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
arm NNP NNP I-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
Blood NNP NNP B-TEST
pressure NNP NNP I-TEST
123/95 NN NN O
, NN NN O
heart NNP NNP B-TEST
rate NNP NNP I-TEST
83 NN NN O
, NN NN O
respirations NNP NNP B-TEST
20 NN NN O
, NN NN O
temperature NNP NNP B-TEST
97 NN NN O
, NN NN O
and NN NN O
oxygen NNP NNP B-TEST
saturation NNP NNP I-TEST
97% NN NN O
. NN NN O

GENERAL NN NN O
: NN NN O
Positive NN NN O
nonproductive NNP NNP B-PROBLEM
cough NNP NNP I-PROBLEM
and NN NN O
pain NNP NNP B-PROBLEM
with NN NN O
coughing NNP NNP B-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
Pupils NN NN O
are NN NN O
equal NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
and NN NN O
accommodation NN NN O
. NN NN O

Tympanic NN NN O
membranes NN NN O
are NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

No NN NN O
lymphadenopathy NNP NNP B-PROBLEM
. NN NN O

No NN NN O
masses NNP NNP B-PROBLEM
. NN NN O

RESPIRATORY NN NN O
: NN NN O
Pleural NNP NNP B-PROBLEM
friction NNP NNP I-PROBLEM
rub NNP NNP I-PROBLEM
is NN NN O
noted NN NN O
. NN NN O

GI NN NN O
: NN NN O
Soft NN NN O
, NN NN O
nondistended NNP NNP B-PROBLEM
, NN NN O
and NN NN O
nontender NNP NNP B-PROBLEM
. NN NN O

Positive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
organomegaly NNP NNP B-PROBLEM
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
edema NNP NNP B-PROBLEM
, NN NN O
no NN NN O
clubbing NNP NNP B-PROBLEM
, NN NN O
no NN NN O
cyanosis NNP NNP B-PROBLEM
, NN NN O
no NN NN O
tenderness NNP NNP B-PROBLEM
. NN NN O

Full NN NN O
range NN NN O
of NN NN O
motion NN NN O
. NN NN O

Normal NN NN O
pulses NN NN O
in NN NN O
all NN NN O
extremities NN NN O
. NN NN O

SKIN NN NN O
: NN NN O
No NN NN O
breakdown NNP NNP B-PROBLEM
or NN NN O
lesions NNP NNP B-PROBLEM
. NN NN O

No NN NN O
ulcers NNP NNP B-PROBLEM
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Grossly NN NN O
intact NN NN O
. NN NN O

No NN NN O
focal NNP NNP B-PROBLEM
deficits NNP NNP I-PROBLEM
. NN NN O

Awake NN NN O
, NN NN O
alert NN NN O
, NN NN O
and NN NN O
oriented NN NN O
to NN NN O
person NN NN O
, NN NN O
place NN NN O
, NN NN O
and NN NN O
time NN NN O
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
Labs NNP NNP B-TEST
are NN NN O
pending NN NN O
. NN NN O

HOSPITAL NN NN O
COURSE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
admitted NN NN O
for NN NN O
a NNP NNP B-PROBLEM
right-sided NNP NNP I-PROBLEM
pleural NNP NNP I-PROBLEM
effusion NNP NNP I-PROBLEM
for NN NN O
thoracentesis NNP NNP B-TREATMENT
on NN NN O
Monday NNP NNP B-DATE
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
. NN NN O
Her NN NN O
Coumadin NNP NNP B-DRUG
was NN NN O
placed NN NN O
on NN NN O
hold NN NN O
. NN NN O

A NNP NNP B-TEST
repeat NNP NNP I-TEST
echocardiogram NNP NNP I-TEST
was NN NN O
checked NN NN O
. NN NN O

She NN NN O
was NN NN O
started NN NN O
on NN NN O
prophylaxis NNP NNP B-TREATMENT
for NN NN O
DVT NNP NNP B-PROBLEM
with NN NN O
Lovenox NNP NNP B-TREATMENT
40 NN NN O
mg NN NN O
subcutaneously NN NN O
. NN NN O

Her NN NN O
history NN NN O
dated NN NN O
back NN NN O
to NN NN O
March NNP NNP B-DATE
2005 NNP NNP I-DATE
when NN NN O
she NN NN O
first NN NN O
sought NN NN O
medical NN NN O
attention NN NN O
for NN NN O
evidence NN NN O
of NN NN O
pericarditis NNP NNP B-PROBLEM
, NN NN O
which NN NN O
was NN NN O
treated NN NN O
with NN NN O
pericardial NNP NNP B-TREATMENT
window NNP NNP I-TREATMENT
in NN NN O
an NN NN O
outside NN NN O
hospital NN NN O
, NN NN O
at NN NN O
that NN NN O
time NN NN O
she NN NN O
was NN NN O
also NN NN O
found NN NN O
to NN NN O
have NN NN O
mesenteric NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
and NN NN O
thrombosis NNP NNP B-PROBLEM
, NN NN O
is NN NN O
now NN NN O
anticoagulated NNP NNP B-TREATMENT
. NN NN O

Her NN NN O
pericardial NN NN O
fluid NN NN O
was NN NN O
accumulated NN NN O
and NN NN O
she NN NN O
was NN NN O
seen NN NN O
by NN NN O
Dr NN NN O
. NN NN O
Y NNP NNP B-NAME
. NN NN O

At NN NN O
that NN NN O
time NN NN O
, NN NN O
she NN NN O
was NN NN O
recommended NN NN O
for NN NN O
pericardectomy NNP NNP B-TREATMENT
, NN NN O
which NN NN O
was NN NN O
performed NN NN O
by NN NN O
Dr NN NN O
. NN NN O
Z NNP NNP B-NAME
. NN NN O

Review NN NN O
of NN NN O
her NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
from NN NN O
March NNP NNP B-DATE
2006 NNP NNP I-DATE
prior NN NN O
to NN NN O
her NNP NNP B-TREATMENT
pericardectomy NNP NNP I-TREATMENT
, NN NN O
already NN NN O
shows NN NN O
bilateral NNP NNP B-PROBLEM
plural NNP NNP I-PROBLEM
effusions NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
improved NN NN O
clinically NN NN O
after NN NN O
the NNP NNP B-TREATMENT
pericardectomy NNP NNP I-TREATMENT
with NN NN O
resolution NN NN O
of NN NN O
her NNP NNP B-PROBLEM
symptoms NNP NNP I-PROBLEM
. NN NN O

Recently NN NN O
, NN NN O
she NN NN O
was NN NN O
readmitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
with NN NN O
chest NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
and NN NN O
found NN NN O
to NN NN O
have NN NN O
bilateral NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
effusion NNP NNP I-PROBLEM
, NN NN O
the NN NN O
right NN NN O
greater NN NN O
than NN NN O
the NN NN O
left NN NN O
. NN NN O

CT NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
chest NNP NNP I-TEST
also NN NN O
revealed NN NN O
a NNP NNP B-PROBLEM
large NNP NNP I-PROBLEM
mediastinal NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
. NN NN O

We NN NN O
reviewed NN NN O
the NNP NNP B-TEST
pathology NNP NNP I-TEST
obtained NN NN O
from NN NN O
the NNP NNP B-TREATMENT
pericardectomy NNP NNP I-TREATMENT
in NN NN O
March NNP NNP B-DATE
2006 NNP NNP I-DATE
, NN NN O
which NN NN O
was NN NN O
diagnostic NN NN O
of NN NN O
mesothelioma NNP NNP B-PROBLEM
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
chest NNP NNP B-TREATMENT
tube NNP NNP I-TREATMENT
placement NNP NNP I-TREATMENT
for NN NN O
drainage NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
fluid NNP NNP I-PROBLEM
occurred NN NN O
and NN NN O
thoracoscopy NNP NNP B-TREATMENT
with NN NN O
fluid NNP NNP B-TEST
biopsies NNP NNP I-TEST
, NN NN O
which NN NN O
were NN NN O
performed NN NN O
, NN NN O
which NN NN O
revealed NN NN O
epithelioid NNP NNP B-PROBLEM
malignant NNP NNP I-PROBLEM
mesothelioma NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
then NN NN O
stained NN NN O
with NN NN O
a NNP NNP B-TEST
PET NNP NNP I-TEST
CT NNP NNP I-TEST
, NN NN O
which NN NN O
showed NN NN O
extensive NNP NNP B-PROBLEM
uptake NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
chest NNP NNP I-PROBLEM
, NN NN O
bilateral NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
pericardial NNP NNP I-PROBLEM
effusions NNP NNP I-PROBLEM
, NN NN O
and NN NN O
lymphadenopathy NNP NNP B-PROBLEM
. NN NN O

She NN NN O
also NN NN O
had NN NN O
acidic NNP NNP B-PROBLEM
fluid NNP NNP I-PROBLEM
, NN NN O
pectoral NNP NNP B-PROBLEM
and NNP NNP I-PROBLEM
intramammary NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
and NN NN O
uptake NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
L4 NNP NNP I-PROBLEM
with NN NN O
SUV NNP NNP B-TEST
of NN NN O

4 NN NN O
. NN NN O
This NN NN O
was NN NN O
consistent NN NN O
with NN NN O
stage NNP NNP B-PROBLEM
III NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

Her NNP NNP B-TEST
repeat NNP NNP I-TEST
echocardiogram NNP NNP I-TEST
showed NN NN O
an NNP NNP B-TEST
ejection NNP NNP I-TEST
fraction NNP NNP I-TEST
of NN NN O
45% NN NN O
to NN NN O
49% NN NN O
. NN NN O

She NN NN O
was NN NN O
transferred NN NN O
to NN NN O
Oncology NN NN O
service NN NN O
and NN NN O
started NN NN O
on NN NN O
chemotherapy NNP NNP B-DRUG
on NN NN O
September NNP NNP B-DATE
1 NNP NNP I-DATE
, NNP NNP I-DATE
2007 NNP NNP I-DATE
with NN NN O
cisplatin NNP NNP B-DRUG
75 NNP NNP I-DRUG
mg/centimeter NNP NNP I-DRUG
squared NN NN O
equaling NN NN O
109 NNP NNP B-DRUG
mg NNP NNP I-DRUG
IV NNP NNP I-DRUG
piggyback NNP NNP I-DRUG
over NN NN O
2 NN NN O
hours NN NN O
on NN NN O
September NNP NNP B-DATE
1 NNP NNP I-DATE
, NNP NNP I-DATE
2007 NNP NNP I-DATE
, NN NN O
Alimta NNP NNP B-DRUG
500 NNP NNP I-DRUG
mg/ NNP NNP I-DRUG
centimeter NNP NNP I-DRUG
squared NNP NNP I-DRUG
equaling NNP NNP I-DRUG
730 NNP NNP I-DRUG
mg NNP NNP I-DRUG
IV NNP NNP I-DRUG
piggyback NNP NNP I-DRUG
over NN NN O
10 NN NN O
minutes NN NN O
. NN NN O

This NN NN O
was NN NN O
all NN NN O
initiated NN NN O
after NN NN O
a NNP NNP B-TREATMENT
Port-A-Cath NNP NNP I-TREATMENT
was NN NN O
placed NN NN O
. NN NN O

The NN NN O
chemotherapy NNP NNP B-DRUG
was NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
discharged NN NN O
the NN NN O
following NN NN O
day NN NN O
after NN NN O
discontinuing NN NN O
IV NNP NNP B-DRUG
fluid NNP NNP I-DRUG
and NNP NNP I-DRUG
IV NNP NNP I-DRUG
. NN NN O

Her NNP NNP B-TREATMENT
Port-A-Cath NNP NNP I-TREATMENT
was NN NN O
packed NN NN O
with NN NN O
heparin NNP NNP B-DRUG
according NN NN O
to NN NN O
protocol NN NN O
. NN NN O

DISCHARGE NN NN O
MEDICATIONS NN NN O
: NN NN O
Zofran NNP NNP B-DRUG
, NN NN O
Phenergan NNP NNP B-DRUG
, NN NN O
Coumadin NNP NNP B-DRUG
, NN NN O
and NN NN O
Lovenox NNP NNP B-DRUG
, NN NN O
and NN NN O
Vicodin NNP NNP B-DRUG
DISCHARGE NN NN O
INSTRUCTIONS NN NN O
: NN NN O
She NN NN O
was NN NN O
instructed NN NN O
to NN NN O
followup NN NN O
with NN NN O
Dr NN NN O
. NN NN O
XYZ NNP NNP B-NAME
in NN NN O
the NN NN O
office NN NN O
to NN NN O
check NN NN O
her NNP NNP B-TEST
INR NNP NNP I-TEST
on NN NN O
Tuesday NNP NNP B-DATE
. NN NN O

She NN NN O
was NN NN O
instructed NN NN O
to NN NN O
call NN NN O
if NN NN O
she NN NN O
had NN NN O
any NN NN O
other NN NN O
questions NN NN O
or NN NN O
concerns NN NN O
in NN NN O
the NN NN O
interim NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
mesothelioma NNP NNP B-PROBLEM
, NN NN O
pleural NNP NNP B-PROBLEM
effusion NNP NNP I-PROBLEM
, NN NN O
atrial NNP NNP B-PROBLEM
fibrillation NNP NNP I-PROBLEM
, NN NN O
anemia NNP NNP B-PROBLEM
, NN NN O
ascites NNP NNP B-PROBLEM
, NN NN O
esophageal NNP NNP B-PROBLEM
reflux NNP NNP I-PROBLEM
, NN NN O
deep NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
, NN NN O
port-a-cath NNP NNP B-TREATMENT
placement NNP NNP I-TREATMENT
, NN NN O
port NNP NNP B-TREATMENT
a NNP NNP I-TREATMENT
cath NNP NNP I-TREATMENT
, NN NN O
iv NNP NNP B-TREATMENT
piggyback NNP NNP I-TREATMENT
, NN NN O
venous NNP NNP B-PROBLEM
thrombosis NNP NNP I-PROBLEM
, NN NN O
atrial NNP NNP B-PROBLEM
, NN NN O
thrombosis NNP NNP B-PROBLEM
, NN NN O
pericardial NNP NNP B-TREATMENT
, NN NN O
lymphadenopathy NNP NNP B-PROBLEM
, NN NN O
fluid NNP NNP B-PROBLEM
, NN NN O
pericardectomy NNP NNP B-TREATMENT
, NN NN O
chest NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
pleural NNP NNP I-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
BCCa NNP NNP B-TREATMENT
Excision NNP NNP I-TREATMENT
- NNP NNP I-TREATMENT
Lower NNP NNP I-TREATMENT
Lid NNP NNP I-TREATMENT
Description NNP NNP I-TREATMENT
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
large NNP NNP B-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NN NN O
lower NN NN O
lid NN NN O
, NN NN O
and NN NN O
repaired NN NN O
with NN NN O
used NN NN O
dorsal NNP NNP B-TREATMENT
conjunctival NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
in NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
upper NNP NNP I-TREATMENT
lid NNP NNP I-TREATMENT
and NN NN O
a NNP NNP B-TREATMENT
large NNP NNP I-TREATMENT
preauricular NNP NNP I-TREATMENT
skin NNP NNP I-TREATMENT
graft NNP NNP I-TREATMENT
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Extremely NNP NNP B-PROBLEM
large NNP NNP I-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NNP NNP B-PROBLEM
lower NNP NNP I-PROBLEM
lid NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Extremely NNP NNP B-PROBLEM
large NNP NNP I-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NNP NNP B-PROBLEM
lower NNP NNP I-PROBLEM
lid NNP NNP I-PROBLEM
. NN NN O

TITLE NN NN O
OF NN NN O
OPERATION NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
large NNP NNP B-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NN NN O
lower NN NN O
lid NN NN O
, NN NN O
and NN NN O
repaired NN NN O
with NN NN O
used NN NN O
dorsal NNP NNP B-TREATMENT
conjunctival NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
in NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
upper NNP NNP I-TREATMENT
lid NNP NNP I-TREATMENT
and NN NN O
a NNP NNP B-TREATMENT
large NNP NNP I-TREATMENT
preauricular NNP NNP I-TREATMENT
skin NNP NNP I-TREATMENT
graft NNP NNP I-TREATMENT
. NN NN O

PROCEDURE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
brought NN NN O
into NN NN O
the NN NN O
operating NN NN O
room NN NN O
and NN NN O
prepped NN NN O
and NN NN O
draped NN NN O
in NN NN O
usual NN NN O
fashion NN NN O
. NN NN O

Xylocaine NNP NNP B-DRUG
2% NNP NNP I-DRUG
with NN NN O
epinephrine NNP NNP B-DRUG
was NNP NNP I-DRUG
injected NNP NNP I-DRUG
beneath NN NN O
the NN NN O
conjunctiva NN NN O
and NN NN O
skin NN NN O
of NN NN O
the NN NN O
lower NN NN O
lid NN NN O
and NN NN O
also NN NN O
beneath NN NN O
the NN NN O
conjunctiva NN NN O
and NN NN O
skin NN NN O
of NN NN O
the NN NN O
upper NN NN O
lid NN NN O
. NN NN O

A NNP NNP B-PROBLEM
frontal NNP NNP I-PROBLEM
nerve NNP NNP I-PROBLEM
block NNP NNP I-PROBLEM
was NN NN O
also NN NN O
given NN NN O
on NN NN O
the NN NN O
right NN NN O
upper NN NN O
lid NN NN O
. NN NN O

The NN NN O
anesthetic NNP NNP B-DRUG
agent NNP NNP I-DRUG
was NN NN O
also NN NN O
injected NN NN O
in NN NN O
the NN NN O
right NN NN O
preauricular NN NN O
region NN NN O
which NN NN O
would NN NN O
provide NN NN O
a NNP NNP B-TREATMENT
donor NNP NNP I-TREATMENT
graft NNP NNP I-TREATMENT
for NN NN O
the NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
lid NNP NNP I-PROBLEM
defect NNP NNP I-PROBLEM
. NN NN O

The NN NN O
area NN NN O
was NN NN O
marked NN NN O
with NN NN O
a NN NN O
marking NN NN O
pen NN NN O
with NN NN O
margins NN NN O
of NN NN O
3 NN NN O
to NN NN O
4 NN NN O
mm NN NN O
, NN NN O
and NN NN O
a NNP NNP B-TREATMENT
#15 NNP NNP I-TREATMENT
Bard-Parker NNP NNP I-TREATMENT
blade NNP NNP I-TREATMENT
was NN NN O
used NN NN O
to NN NN O
make NN NN O
an NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
at NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
nasal NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
temporal NNP NNP I-PROBLEM
margins NNP NNP I-PROBLEM
of NN NN O
the NNP NNP B-PROBLEM
lesion NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
carried NN NN O
inferiorly NN NN O
, NN NN O
and NN NN O
using NN NN O
a NNP NNP B-TREATMENT
Steven NNP NNP I-TREATMENT
scissors NNP NNP I-TREATMENT
the NN NN O
normal NN NN O
skin NN NN O
, NN NN O
muscle NN NN O
, NN NN O
and NN NN O
conjunctiva NN NN O
was NN NN O
excised NNP NNP B-TREATMENT
inferiorly NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-TEST
specimen NNP NNP I-TEST
was NN NN O
then NN NN O
marked NN NN O
and NN NN O
sent NN NN O
to NN NN O
pathology NN NN O
for NN NN O
frozen NNP NNP B-TEST
section NNP NNP I-TEST
. NN NN O

Bleeding NNP NNP B-PROBLEM
was NN NN O
controlled NN NN O
with NN NN O
a NNP NNP B-TREATMENT
wet-field NNP NNP I-TREATMENT
cautery NNP NNP I-TREATMENT
, NN NN O
and NN NN O
the NN NN O
right NN NN O
upper NN NN O
lid NN NN O
was NN NN O
everted NN NN O
, NN NN O
and NN NN O
an NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
3 NN NN O
mm NN NN O
above NN NN O
the NN NN O
lid NN NN O
margin NN NN O
with NN NN O
the NNP NNP B-TREATMENT
Bard-Parker NNP NNP I-TREATMENT
blade NNP NNP I-TREATMENT
in NN NN O
the NN NN O
entire NN NN O
length NN NN O
of NN NN O
the NN NN O
upper NN NN O
lid NN NN O
. NN NN O

The NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
reached NN NN O
the NN NN O
orbicularis NN NN O
, NN NN O
and NN NN O
Steven NNP NNP B-TREATMENT
scissors NNP NNP I-TREATMENT
were NN NN O
used NN NN O
to NN NN O
separate NN NN O
the NN NN O
tarsus NN NN O
from NN NN O
the NN NN O
underlying NN NN O
orbicularis NN NN O
. NN NN O

Vertical NN NN O
cuts NN NN O
were NN NN O
made NN NN O
nasally NN NN O
and NN NN O
temporally NN NN O
, NN NN O
and NN NN O
a NNP NNP B-TREATMENT
large NNP NNP I-TREATMENT
dorsal NNP NNP I-TREATMENT
conjunctival NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
was NN NN O
fashioned NN NN O
with NN NN O
the NN NN O
conjunctiva NN NN O
attached NN NN O
superiorly NN NN O
. NN NN O

It NN NN O
was NN NN O
placed NN NN O
into NN NN O
the NNP NNP B-PROBLEM
defect NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
lid NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
sutured NNP NNP I-PROBLEM
with NN NN O
multiple NNP NNP B-TREATMENT
interrupted NNP NNP I-TREATMENT
6-0 NNP NNP I-TREATMENT
Vicryl NNP NNP I-TREATMENT
sutures NNP NNP I-TREATMENT
nasally NN NN O
, NN NN O
temporally NN NN O
, NN NN O
and NN NN O
inferiorly NN NN O
. NN NN O

The NNP NNP B-PROBLEM
defect NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
skin NNP NNP I-PROBLEM
was NN NN O
measured NN NN O
and NN NN O
an NNP NNP B-TREATMENT
appropriate NNP NNP I-TREATMENT
large NNP NNP I-TREATMENT
preauricular NNP NNP I-TREATMENT
graft NNP NNP I-TREATMENT
was NN NN O
excised NN NN O
from NN NN O
the NN NN O
right NN NN O
preauricular NN NN O
region NN NN O
. NN NN O

The NNP NNP B-PROBLEM
defect NNP NNP I-PROBLEM
was NN NN O
closed NN NN O
with NN NN O
interrupted NNP NNP B-TREATMENT
5-0 NNP NNP I-TREATMENT
Prolene NNP NNP I-TREATMENT
sutures NNP NNP I-TREATMENT
, NN NN O
and NN NN O
the NNP NNP B-TREATMENT
preauricular NNP NNP I-TREATMENT
graft NNP NNP I-TREATMENT
was NN NN O
sutured NN NN O
in NN NN O
place NN NN O
with NN NN O
multiple NNP NNP B-TREATMENT
interrupted NNP NNP I-TREATMENT
6-0 NNP NNP I-TREATMENT
silk NNP NNP I-TREATMENT
sutures NNP NNP I-TREATMENT
. NN NN O

The NN NN O
upper NN NN O
border NN NN O
of NN NN O
the NNP NNP B-TREATMENT
graft NNP NNP I-TREATMENT
was NN NN O
attached NN NN O
to NN NN O
the NN NN O
upper NN NN O
lid NN NN O
after NN NN O
incision NNP NNP B-PROBLEM
was NN NN O
made NN NN O
in NN NN O
the NNP NNP B-TREATMENT
gray NNP NNP I-TREATMENT
line NNP NNP I-TREATMENT
with NN NN O
a NNP NNP B-TREATMENT
Superblade NNP NNP I-TREATMENT
, NN NN O
and NN NN O
the NN NN O
superior NN NN O
portion NN NN O
of NN NN O
the NNP NNP B-TREATMENT
skin NNP NNP I-TREATMENT
graft NNP NNP I-TREATMENT
was NN NN O
sutured NN NN O
to NN NN O
the NN NN O
upper NN NN O
lid NN NN O
through NN NN O
the NN NN O
anterior NN NN O
lamella NN NN O
created NN NN O
by NN NN O
the NNP NNP B-PROBLEM
razor NNP NNP I-PROBLEM
blade NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
. NN NN O

Cryotherapy NNP NNP B-TREATMENT
was NN NN O
then NN NN O
used NN NN O
to NN NN O
treat NN NN O
the NN NN O
nasal NN NN O
and NN NN O
temporal NN NN O
margins NN NN O
of NN NN O
the NN NN O
area NN NN O
of NN NN O
excision NNP NNP B-TREATMENT
because NN NN O
of NN NN O
positive NNP NNP B-PROBLEM
margins NNP NNP I-PROBLEM
, NN NN O
and NN NN O
following NN NN O
this NN NN O
an NN NN O
antibiotic NNP NNP B-DRUG
steroid NNP NNP I-DRUG
ointment NNP NNP I-DRUG
was NN NN O
instilled NN NN O
and NN NN O
a NNP NNP B-TREATMENT
light NNP NNP I-TREATMENT
pressure NNP NNP I-TREATMENT
dressing NNP NNP I-TREATMENT
was NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
well NN NN O
and NN NN O
was NN NN O
sent NN NN O
to NN NN O
recovery NN NN O
room NN NN O
in NN NN O
good NN NN O
condition NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
cryotherapy NNP NNP B-TREATMENT
, NN NN O
steven NNP NNP B-TREATMENT
scissors NNP NNP I-TREATMENT
, NN NN O
conjunctiva NNP NNP B-TREATMENT
, NNP NNP I-TREATMENT
conjunctival NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
, NN NN O
frontal NNP NNP B-PROBLEM
nerve NNP NNP I-PROBLEM
block NNP NNP I-PROBLEM
, NN NN O
frozen NN NN O
section NN NN O
, NN NN O
lower NNP NNP B-TREATMENT
lid NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
orbicularis NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
skin NNP NNP I-TREATMENT
graft NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
nasal NNP NNP I-TREATMENT
and NNP NNP I-TREATMENT
temporal NNP NNP I-TREATMENT
margins NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
dorsal NNP NNP I-TREATMENT
conjunctival NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
upper NNP NNP I-TREATMENT
lid NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
basal NNP NNP I-TREATMENT
, NN NN O
carcinoma NNP NNP B-PROBLEM
, NN NN O
preauricular NN NN O
, NN NN O
incision NNP NNP B-PROBLEM
, NN NN O
conjunctival NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Anemia NNP NNP B-PROBLEM
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Refractory NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
that NN NN O
is NN NN O
transfusion NNP NNP B-PROBLEM
dependent NNP NNP I-PROBLEM
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
he NN NN O
has NN NN O
been NN NN O
admitted NN NN O
for NN NN O
anemia NNP NNP B-PROBLEM
with NN NN O
hemoglobin NNP NNP B-TEST
of NN NN O
7.1 NN NN O
and NN NN O
requiring NN NN O
transfusion NNP NNP B-TREATMENT
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
DIAGNOSIS NN NN O
: NN NN O
Refractory NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
that NN NN O
is NN NN O
transfusion NNP NNP B-PROBLEM
dependent NNP NNP I-PROBLEM
. NN NN O

CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
I NN NN O
needed NN NN O
a NN NN O
blood NNP NNP B-DRUG
transfusion NNP NNP I-DRUG
. NN NN O

HISTORY NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
78-year-old NN NN O
gentleman NN NN O
with NN NN O
no NN NN O
substantial NN NN O
past NN NN O
medical NN NN O
history NN NN O
except NN NN O
for NN NN O
diabetes NNP NNP B-PROBLEM
. NN NN O

He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
comorbid NNP NNP I-PROBLEM
complications NNP NNP I-PROBLEM
of NN NN O
the NNP NNP B-PROBLEM
diabetes NNP NNP I-PROBLEM
including NN NN O
kidney NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
heart NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
stroke NNP NNP B-PROBLEM
, NN NN O
vision NNP NNP B-PROBLEM
loss NNP NNP I-PROBLEM
, NN NN O
or NN NN O
neuropathy NNP NNP B-PROBLEM
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
he NN NN O
has NN NN O
been NN NN O
admitted NN NN O
for NN NN O
anemia NNP NNP B-PROBLEM
with NN NN O
hemoglobin NNP NNP B-TEST
of NN NN O
7.1 NN NN O
and NN NN O
requiring NN NN O
transfusion NNP NNP B-TREATMENT
. NN NN O

He NN NN O
reports NN NN O
that NN NN O
he NN NN O
has NN NN O
no NN NN O
signs NN NN O
or NN NN O
symptom NN NN O
of NN NN O
bleeding NNP NNP B-PROBLEM
and NN NN O
had NN NN O
a NN NN O
blood NNP NNP B-DRUG
transfusion NNP NNP I-DRUG
approximately NN NN O
two NN NN O
months NN NN O
ago NN NN O
and NN NN O
actually NN NN O
several NN NN O
weeks NN NN O
before NN NN O
that NN NN O
blood NNP NNP B-DRUG
transfusion NNP NNP I-DRUG
, NN NN O
he NN NN O
had NN NN O
a NNP NNP B-TREATMENT
transfusion NNP NNP I-TREATMENT
for NN NN O
anemia NNP NNP B-PROBLEM
. NN NN O

He NN NN O
has NN NN O
been NN NN O
placed NN NN O
on NN NN O
B12 NNP NNP B-DRUG
, NN NN O
oral NNP NNP B-DRUG
iron NNP NNP I-DRUG
, NN NN O
and NN NN O
Procrit NNP NNP B-DRUG
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
we NN NN O
are NN NN O
asked NN NN O
to NN NN O
evaluate NN NN O
him NN NN O
for NN NN O
further NN NN O
causes NN NN O
and NN NN O
treatment NNP NNP B-TREATMENT
for NN NN O
his NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
constitutional NNP NNP I-PROBLEM
complaints NNP NNP I-PROBLEM
except NN NN O
for NN NN O
fatigue NNP NNP B-PROBLEM
, NN NN O
malaise NNP NNP B-PROBLEM
, NN NN O
and NN NN O
some NNP NNP B-PROBLEM
dyspnea NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
no NN NN O
adenopathy NNP NNP B-PROBLEM
that NN NN O
he NN NN O
reports NN NN O
. NN NN O

No NN NN O
fevers NNP NNP B-PROBLEM
, NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
, NN NN O
bone NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
rash NNP NNP B-PROBLEM
, NN NN O
arthralgias NNP NNP B-PROBLEM
, NN NN O
or NN NN O
myalgias NNP NNP B-PROBLEM
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Diabetes NNP NNP B-PROBLEM
. NN NN O

PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O
: NN NN O
Hernia NNP NNP B-TREATMENT
repair NNP NNP I-TREATMENT
. NN NN O

ALLERGIES NN NN O
: NN NN O
He NN NN O
has NN NN O
no NN NN O
allergies NNP NNP B-PROBLEM
. NN NN O

MEDICATIONS NN NN O
: NN NN O
Listed NN NN O
in NN NN O
the NN NN O
chart NN NN O
and NN NN O
include NN NN O
Coumadin NNP NNP B-DRUG
, NN NN O
Lasix NNP NNP B-DRUG
, NN NN O
metformin NNP NNP B-DRUG
, NN NN O
folic NNP NNP B-DRUG
acid NNP NNP I-DRUG
, NN NN O
diltiazem NNP NNP B-DRUG
, NN NN O
B12 NNP NNP B-DRUG
, NN NN O
Prevacid NNP NNP B-DRUG
, NN NN O
and NN NN O
Feosol NNP NNP B-DRUG
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
is NN NN O
a NN NN O
tobacco NN NN O
user NN NN O
. NN NN O

He NN NN O
does NN NN O
not NN NN O
drink NN NN O
. NN NN O

He NN NN O
lives NN NN O
alone NN NN O
, NN NN O
but NN NN O
has NN NN O
family NN NN O
and NN NN O
social NN NN O
support NN NN O
to NN NN O
look NN NN O
on NN NN O
him NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Negative NN NN O
for NN NN O
blood NNP NNP B-PROBLEM
or NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
disorders NNP NNP I-PROBLEM
according NN NN O
to NN NN O
the NN NN O
patient NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
GENERAL NN NN O
: NN NN O
He NN NN O
is NN NN O
an NN NN O
elderly NN NN O
gentleman NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

He NN NN O
is NN NN O
sitting NN NN O
up NN NN O
in NN NN O
bed NN NN O
eating NN NN O
his NN NN O
breakfast NN NN O
. NN NN O

He NN NN O
is NN NN O
alert NN NN O
and NN NN O
oriented NN NN O
and NN NN O
answering NN NN O
questions NN NN O
appropriately NN NN O
. NN NN O

VITAL NN NN O
SIGNS NN NN O
: NN NN O
Blood NNP NNP B-TEST
pressure NNP NNP I-TEST
of NN NN O
110/60 NN NN O
, NN NN O
pulse NNP NNP B-TEST
of NN NN O
99 NN NN O
, NN NN O
respiratory NNP NNP B-TEST
rate NNP NNP I-TEST
of NN NN O
14 NN NN O
, NN NN O
and NN NN O
temperature NNP NNP B-TEST
of NN NN O
97.4 NN NN O
. NN NN O

He NN NN O
is NN NN O
69 NN NN O
inches NN NN O
tall NN NN O
and NN NN O
weighs NN NN O
174 NN NN O
pounds NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
Sclerae NN NN O
show NN NN O
mild NNP NNP B-PROBLEM
arcus NNP NNP I-PROBLEM
senilis NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
. NN NN O

Left NN NN O
is NN NN O
clear NN NN O
. NN NN O

Pupils NN NN O
are NN NN O
equally NN NN O
round NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O

Extraocular NN NN O
movements NN NN O
are NN NN O
intact NN NN O
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

Trachea NN NN O
is NN NN O
midline NN NN O
. NN NN O

No NN NN O
jugular NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
pressure NNP NNP I-PROBLEM
distention NNP NNP I-PROBLEM
is NN NN O
noted NN NN O
. NN NN O

No NN NN O
adenopathy NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
cervical NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
areas NNP NNP I-PROBLEM
. NN NN O

CHEST NN NN O
: NN NN O
Clear NN NN O
. NN NN O

HEART NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
and NN NN O
nontender NNP NNP B-PROBLEM
. NN NN O

There NN NN O
may NN NN O
be NN NN O
some NNP NNP B-PROBLEM
fullness NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
quadrant NNP NNP I-PROBLEM
, NN NN O
although NN NN O
I NN NN O
do NN NN O
not NN NN O
appreciate NN NN O
a NN NN O
true NN NN O
spleen NN NN O
with NN NN O
inspiration NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
clubbing NNP NNP B-PROBLEM
, NN NN O
but NN NN O
there NN NN O
is NN NN O
some NNP NNP B-PROBLEM
edema NNP NNP I-PROBLEM
, NN NN O
but NN NN O
no NN NN O
cyanosis NNP NNP B-PROBLEM
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

DERMATOLOGIC NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

CARDIOVASCULAR NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

IMPRESSION NN NN O
: NN NN O
At NN NN O
this NN NN O
time NN NN O
is NN NN O
refractory NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
, NN NN O
which NN NN O
is NN NN O
transfusion NNP NNP B-PROBLEM
dependent NNP NNP I-PROBLEM
. NN NN O

He NN NN O
is NN NN O
on NN NN O
B12 NNP NNP B-DRUG
, NN NN O
iron NNP NNP B-DRUG
, NN NN O
folic NNP NNP B-DRUG
acid NNP NNP I-DRUG
, NN NN O
and NN NN O
Procrit NNP NNP B-DRUG
. NN NN O

There NN NN O
are NN NN O
no NN NN O
sign NN NN O
or NN NN O
symptom NN NN O
of NN NN O
blood NNP NNP B-PROBLEM
loss NNP NNP I-PROBLEM
and NN NN O
a NNP NNP B-TEST
recent NNP NNP I-TEST
esophagogastroduodenoscopy NNP NNP I-TEST
, NN NN O
which NN NN O
was NN NN O
negative NN NN O
. NN NN O

His NNP NNP B-TEST
creatinine NNP NNP I-TEST
was NN NN O

1 NN NN O
. NN NN O
My NN NN O
impression NN NN O
at NN NN O
this NN NN O
time NN NN O
is NN NN O
that NN NN O
he NN NN O
probably NN NN O
has NN NN O
an NNP NNP B-PROBLEM
underlying NNP NNP I-PROBLEM
myelodysplastic NNP NNP I-PROBLEM
syndrome NNP NNP I-PROBLEM
or NN NN O
bone NNP NNP B-PROBLEM
marrow NNP NNP I-PROBLEM
failure NNP NNP I-PROBLEM
. NN NN O

His NNP NNP B-TEST
creatinine NNP NNP I-TEST
on NN NN O
this NN NN O
hospitalization NN NN O
was NN NN O
up NN NN O
slightly NN NN O
to NN NN O
1.6 NN NN O
and NN NN O
this NN NN O
may NN NN O
contribute NN NN O
to NN NN O
his NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

RECOMMENDATIONS NN NN O
: NN NN O
At NN NN O
this NN NN O
time NN NN O
, NN NN O
my NN NN O
recommendation NN NN O
for NN NN O
the NN NN O
patient NN NN O
is NN NN O
that NN NN O
he NN NN O
undergoes NN NN O
further NNP NNP B-TEST
serologic NNP NNP I-TEST
evaluation NNP NNP I-TEST
with NN NN O
reticulocyte NNP NNP B-TEST
count NNP NNP I-TEST
, NN NN O
serum NNP NNP B-TEST
protein NNP NNP I-TEST
, NN NN O
and NN NN O
electrophoresis NNP NNP B-TEST
, NN NN O
LDH NNP NNP B-TEST
, NN NN O
B12 NNP NNP B-TEST
, NN NN O
folate NNP NNP B-TEST
, NN NN O
erythropoietin NNP NNP B-DRUG
level NN NN O
, NN NN O
and NN NN O
he NN NN O
should NN NN O
undergo NN NN O
a NNP NNP B-TREATMENT
bone NNP NNP I-TREATMENT
marrow NNP NNP I-TREATMENT
aspiration NNP NNP I-TREATMENT
and NN NN O
biopsy NNP NNP B-TEST
. NN NN O

I NN NN O
have NN NN O
discussed NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
in NN NN O
detail NN NN O
which NN NN O
the NN NN O
patient NN NN O
. NN NN O

I NN NN O
have NN NN O
discussed NN NN O
the NN NN O
risks NN NN O
, NN NN O
benefits NN NN O
, NN NN O
and NN NN O
successes NN NN O
of NN NN O
that NN NN O
treatment NN NN O
and NN NN O
usefulness NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
and NN NN O
predicting NN NN O
his NN NN O
cause NN NN O
of NN NN O
refractory NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
and NN NN O
further NN NN O
therapeutic NNP NNP B-TREATMENT
interventions NNP NNP I-TREATMENT
, NN NN O
which NN NN O
might NN NN O
be NN NN O
beneficial NN NN O
to NN NN O
him NN NN O
. NN NN O

He NN NN O
is NN NN O
willing NN NN O
to NN NN O
proceed NN NN O
with NN NN O
the NNP NNP B-TEST
studies NNP NNP I-TEST
I NN NN O
have NN NN O
described NN NN O
to NN NN O
him NN NN O
. NN NN O

We NN NN O
will NN NN O
order NN NN O
an NNP NNP B-TEST
ultrasound NNP NNP I-TEST
of NNP NNP I-TEST
his NNP NNP I-TEST
abdomen NNP NNP I-TEST
because NN NN O
of NN NN O
the NN NN O
possible NN NN O
fullness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
spleen NNP NNP I-PROBLEM
, NN NN O
and NN NN O
I NN NN O
will NN NN O
probably NN NN O
see NN NN O
him NN NN O
in NN NN O
follow NN NN O
up NN NN O
after NN NN O
this NNP NNP B-TREATMENT
hospitalization NNP NNP I-TREATMENT
. NN NN O

As NN NN O
always NN NN O
, NN NN O
we NN NN O
greatly NN NN O
appreciate NN NN O
being NN NN O
able NN NN O
to NN NN O
participate NN NN O
in NN NN O
the NN NN O
care NN NN O
of NN NN O
your NN NN O
patient NN NN O
. NN NN O

We NN NN O
appreciate NN NN O
the NN NN O
consultation NN NN O
of NN NN O
the NN NN O
patient NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
electrophoresis NNP NNP B-TEST
, NN NN O
ldh NNP NNP B-TEST
, NN NN O
b12 NNP NNP B-TEST
, NN NN O
folate NNP NNP B-TEST
, NN NN O
erythropoietin NNP NNP B-DRUG
level NN NN O
, NN NN O
reticulocyte NNP NNP B-TEST
count NNP NNP I-TEST
, NN NN O
serum NNP NNP B-TEST
protein NNP NNP I-TEST
, NN NN O
blood NNP NNP B-TEST
transfusion NNP NNP I-TEST
, NN NN O
bone NNP NNP B-PROBLEM
marrow NNP NNP I-PROBLEM
, NN NN O
refractory NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
, NN NN O
anemia NNP NNP B-PROBLEM
, NN NN O
myalgias NNP NNP B-PROBLEM
, NN NN O
marrow NNP NNP B-PROBLEM
, NN NN O
bone NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Intensity-Modulated NN NN O
Radiation NN NN O
Therapy NN NN O
Description NN NN O
: NN NN O
Intensity-modulated NNP NNP B-TREATMENT
radiation NNP NNP I-TREATMENT
therapy NNP NNP I-TREATMENT
is NN NN O
a NN NN O
complex NN NN O
set NN NN O
of NN NN O
procedures NNP NNP B-TREATMENT
which NN NN O
requires NN NN O
appropriate NN NN O
positioning NN NN O
and NN NN O
immobilization NNP NNP B-TREATMENT
typically NN NN O
with NN NN O
customized NNP NNP B-TREATMENT
immobilization NNP NNP I-TREATMENT
devices NNP NNP I-TREATMENT
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
INTENSITY-MODULATED NNP NNP B-TREATMENT
RADIATION NNP NNP I-TREATMENT
THERAPY NNP NNP I-TREATMENT
Intensity-modulated NNP NNP I-TREATMENT
radiation NNP NNP I-TREATMENT
therapy NNP NNP I-TREATMENT
is NN NN O
a NN NN O
complex NN NN O
set NN NN O
of NN NN O
procedures NNP NNP B-TREATMENT
which NN NN O
requires NN NN O
appropriate NN NN O
positioning NN NN O
and NN NN O
immobilization NNP NNP B-TREATMENT
typically NN NN O
with NN NN O
customized NNP NNP B-TREATMENT
immobilization NNP NNP I-TREATMENT
devices NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
planning NN NN O
process NN NN O
requires NN NN O
at NN NN O
least NN NN O
4 NN NN O
hours NN NN O
of NN NN O
physician NN NN O
time NN NN O
. NN NN O

The NN NN O
technology NN NN O
is NN NN O
appropriate NN NN O
in NN NN O
this NN NN O
patient's NN NN O
case NN NN O
due NN NN O
to NN NN O
the NN NN O
fact NN NN O
that NN NN O
the NN NN O
target NN NN O
volume NN NN O
is NN NN O
adjacent NN NN O
to NN NN O
significant NN NN O
radiosensitive NN NN O
structures NN NN O
. NN NN O

Sequential NNP NNP B-TEST
CT NNP NNP I-TEST
scans NNP NNP I-TEST
are NN NN O
obtained NN NN O
and NN NN O
transferred NN NN O
to NN NN O
the NN NN O
treatment NN NN O
planning NN NN O
software NN NN O
. NN NN O

Extensive NNP NNP B-TEST
analysis NNP NNP I-TEST
occurs NN NN O
. NN NN O

The NN NN O
target NN NN O
volumes NN NN O
, NN NN O
including NN NN O
margins NN NN O
for NN NN O
uncertainty NN NN O
, NN NN O
patient NN NN O
movement NN NN O
and NN NN O
occult NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
extension NNP NNP I-PROBLEM
are NN NN O
selected NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
organs NN NN O
at NN NN O
risk NN NN O
are NN NN O
outlined NN NN O
. NN NN O

Doses NN NN O
are NN NN O
selected NN NN O
both NN NN O
for NN NN O
targets NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
for NN NN O
organs NN NN O
at NN NN O
risk NN NN O
. NN NN O

Associated NNP NNP B-TREATMENT
dose NNP NNP I-TREATMENT
constraints NNP NNP I-TREATMENT
are NN NN O
placed NN NN O
. NN NN O

Inverse NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
planning NN NN O
is NN NN O
then NN NN O
performed NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
the NN NN O
physics NN NN O
staff NN NN O
. NN NN O

These NN NN O
are NN NN O
reviewed NN NN O
by NN NN O
the NN NN O
physician NN NN O
and NN NN O
ultimately NN NN O
performed NN NN O
only NN NN O
following NN NN O
approval NN NN O
by NN NN O
the NN NN O
physician NN NN O
. NN NN O

Multiple NNP NNP B-TREATMENT
beam NNP NNP I-TREATMENT
arrangements NNP NNP I-TREATMENT
may NN NN O
be NN NN O
tested NN NN O
for NN NN O
appropriateness NN NN O
and NN NN O
optimal NNP NNP B-TREATMENT
dose NNP NNP I-TREATMENT
delivery NNP NNP I-TREATMENT
in NN NN O
order NN NN O
to NN NN O
maximize NN NN O
the NN NN O
chance NN NN O
of NN NN O
controlling NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
while NN NN O
minimizing NN NN O
exposure NN NN O
to NN NN O
organs NN NN O
at NN NN O
risk NN NN O
. NN NN O

This NN NN O
is NN NN O
performed NN NN O
in NN NN O
hopes NN NN O
of NN NN O
minimizing NN NN O
associated NNP NNP B-PROBLEM
complications NNP NNP I-PROBLEM
. NN NN O

The NN NN O
physician NN NN O
delineates NN NN O
the NN NN O
treatment NN NN O
type NN NN O
, NN NN O
number NN NN O
of NN NN O
fractions NN NN O
and NN NN O
total NN NN O
volume NN NN O
. NN NN O

During NN NN O
the NN NN O
time NN NN O
of NN NN O
treatment NNP NNP B-TREATMENT
, NN NN O
there NN NN O
is NN NN O
extensive NNP NNP B-TREATMENT
physician NNP NNP I-TREATMENT
intervention NNP NNP I-TREATMENT
, NN NN O
monitoring NNP NNP B-TEST
the NN NN O
patient NN NN O
set NN NN O
up NN NN O
and NN NN O
tolerance NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
specific NN NN O
QA NN NN O
is NN NN O
performed NN NN O
by NN NN O
the NN NN O
physics NN NN O
staff NN NN O
under NN NN O
the NN NN O
physician's NN NN O
direction NN NN O
. NN NN O

In NN NN O
view NN NN O
of NN NN O
the NN NN O
above NN NN O
, NN NN O
the NNP NNP B-TREATMENT
special NNP NNP I-TREATMENT
procedure NNP NNP I-TREATMENT
code NN NN O
77470 NN NN O
is NN NN O
deemed NN NN O
appropriate NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
multiple NNP NNP B-TREATMENT
beam NNP NNP I-TREATMENT
arrangements NNP NNP I-TREATMENT
, NN NN O
intensity NNP NNP B-TREATMENT
modulated NNP NNP I-TREATMENT
radiation NNP NNP I-TREATMENT
therapy NNP NNP I-TREATMENT
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Neck NN NN O
Dissection NN NN O
Description NN NN O
: NN NN O
Left NNP NNP B-PROBLEM
neck NNP NNP I-PROBLEM
dissection NNP NNP I-PROBLEM
. NN NN O

Metastatic NNP NNP B-PROBLEM
papillary NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
left NNP NNP B-PROBLEM
neck NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
had NN NN O
thyroid NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
papillary NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
type NNP NNP I-PROBLEM
, NN NN O
removed NN NN O
with NN NN O
a NNP NNP B-TREATMENT
total NNP NNP I-TREATMENT
thyroidectomy NNP NNP I-TREATMENT
and NN NN O
then NN NN O
subsequently NNP NNP B-PROBLEM
recurrent NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
was NN NN O
removed NN NN O
with NN NN O
a NNP NNP B-TREATMENT
paratracheal NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Metastatic NNP NNP B-PROBLEM
papillary NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
left NN NN O
neck NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Metastatic NNP NNP B-PROBLEM
papillary NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
left NN NN O
neck NN NN O
. NN NN O

OPERATION NN NN O
PERFORMED NN NN O
: NN NN O
Left NNP NNP B-TREATMENT
neck NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
. NN NN O

ANESTHESIA NN NN O
: NN NN O
General NN NN O
endotracheal NN NN O
. NN NN O

INDICATIONS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
very NN NN O
nice NN NN O
gentleman NN NN O
, NN NN O
who NN NN O
has NN NN O
had NN NN O
thyroid NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
papillary NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
type NNP NNP I-PROBLEM
, NN NN O
removed NN NN O
with NN NN O
a NNP NNP B-TREATMENT
total NNP NNP I-TREATMENT
thyroidectomy NNP NNP I-TREATMENT
and NN NN O
then NN NN O
subsequently NNP NNP B-PROBLEM
recurrent NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
was NN NN O
removed NN NN O
with NN NN O
a NNP NNP B-TREATMENT
paratracheal NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
. NN NN O

He NN NN O
now NN NN O
has NN NN O
evidence NN NN O
of NN NN O
lesion NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
mid NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
and NN NN O
the NN NN O
left NN NN O
superior NN NN O
neck NN NN O
on NN NN O
ultrasound NNP NNP B-TEST
, NN NN O
which NN NN O
are NN NN O
suspicious NN NN O
for NN NN O
recurrent NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

Left NNP NNP B-TREATMENT
neck NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
is NN NN O
indicated NN NN O
. NN NN O

DESCRIPTION NN NN O
OF NN NN O
OPERATION NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
placed NN NN O
on NN NN O
the NN NN O
operating NN NN O
room NN NN O
table NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
. NN NN O

After NN NN O
adequate NN NN O
general NN NN O
endotracheal NN NN O
anesthesia NNP NNP B-DRUG
was NN NN O
administered NN NN O
, NN NN O
the NN NN O
table NN NN O
was NN NN O
then NN NN O
turned NN NN O
. NN NN O

A NNP NNP B-TREATMENT
shoulder NNP NNP I-TREATMENT
roll NNP NNP I-TREATMENT
placed NN NN O
under NN NN O
the NN NN O
shoulders NN NN O
and NN NN O
the NN NN O
face NN NN O
was NN NN O
placed NN NN O
in NN NN O
an NN NN O
extended NN NN O
fashion NN NN O
. NN NN O

The NN NN O
left NN NN O
neck NN NN O
, NN NN O
chest NN NN O
, NN NN O
and NN NN O
face NN NN O
were NN NN O
prepped NN NN O
with NN NN O
Betadine NNP NNP B-TREATMENT
and NN NN O
draped NNP NNP B-TREATMENT
in NN NN O
a NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

A NNP NNP B-PROBLEM
hockey NNP NNP I-PROBLEM
stick NNP NNP I-PROBLEM
skin NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
performed NN NN O
, NN NN O
extending NN NN O
a NNP NNP B-TREATMENT
previous NNP NNP I-TREATMENT
incision NNP NNP I-TREATMENT
line NNP NNP I-TREATMENT
superiorly NN NN O
towards NN NN O
the NN NN O
mastoid NN NN O
cortex NN NN O
through NN NN O
skin NN NN O
, NN NN O
subcutaneous NN NN O
tissue NN NN O
and NN NN O
platysma NN NN O
with NN NN O
Bovie NNP NNP B-TREATMENT
electrocautery NNP NNP I-TREATMENT
on NN NN O
cut NN NN O
mode NN NN O
. NN NN O

Subplatysmal NNP NNP B-TREATMENT
superior NNP NNP I-TREATMENT
and NNP NNP I-TREATMENT
inferior NNP NNP I-TREATMENT
flaps NNP NNP I-TREATMENT
were NN NN O
raised NN NN O
. NN NN O

The NNP NNP B-TREATMENT
dissection NNP NNP I-TREATMENT
was NN NN O
left NNP NNP B-PROBLEM
lateral NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
dissection NNP NNP I-PROBLEM
encompassing NN NN O
zones NN NN O
1 NN NN O
, NN NN O
2A NN NN O
, NN NN O
2B NN NN O
, NN NN O
3 NN NN O
, NN NN O
and NN NN O
the NN NN O
superior NN NN O
portion NN NN O
of NN NN O

4 NN NN O
. NN NN O
The NN NN O
sternocleidomastoid NN NN O
muscle NN NN O
was NN NN O
unwrapped NN NN O
at NN NN O
its NN NN O
fascial NN NN O
attachment NN NN O
and NN NN O
this NN NN O
was NN NN O
taken NN NN O
back NN NN O
posterior NN NN O
to NN NN O
the NN NN O
XI NN NN O
cranial NN NN O
nerve NN NN O
into NN NN O
the NN NN O
superior NN NN O
posterior NN NN O
most NN NN O
triangle NN NN O
of NN NN O
the NN NN O
neck NN NN O
. NN NN O

This NN NN O
was NN NN O
carried NN NN O
forward NN NN O
off NN NN O
of NN NN O
the NN NN O
deep NN NN O
rooted NN NN O
muscles NN NN O
including NN NN O
the NNP NNP B-PROBLEM
splenius NNP NNP I-PROBLEM
capitis NNP NNP I-PROBLEM
and NN NN O
anterior NNP NNP B-PROBLEM
and NNP NNP I-PROBLEM
middle NNP NNP I-PROBLEM
scalenes NNP NNP I-PROBLEM
taken NN NN O
medially NN NN O
off NN NN O
of NN NN O
these NN NN O
muscles NN NN O
including NN NN O
the NN NN O
fascia NN NN O
of NN NN O
the NN NN O
muscles NN NN O
, NN NN O
stripped NN NN O
from NN NN O
the NN NN O
carotid NN NN O
artery NN NN O
, NN NN O
the NN NN O
X NN NN O
cranial NN NN O
nerve NN NN O
, NN NN O
the NN NN O
internal NN NN O
jugular NN NN O
vein NN NN O
and NN NN O
then NN NN O
carried NN NN O
anteriorly NN NN O
to NN NN O
the NN NN O
lateral NN NN O
most NN NN O
extent NN NN O
of NN NN O
the NNP NNP B-PROBLEM
dissection NNP NNP I-PROBLEM
previously NN NN O
done NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
in NN NN O
the NN NN O
paratracheal NN NN O
region NN NN O
. NN NN O

The NN NN O
submandibular NN NN O
gland NN NN O
was NN NN O
removed NN NN O
as NN NN O
well NN NN O
. NN NN O

The NN NN O
X NN NN O
, NN NN O
XI NN NN O
, NN NN O
and NN NN O
XII NN NN O
cranial NN NN O
nerves NN NN O
were NN NN O
preserved NN NN O
. NN NN O

The NN NN O
internal NN NN O
jugular NN NN O
vein NN NN O
and NN NN O
carotid NN NN O
artery NN NN O
were NN NN O
preserved NN NN O
as NN NN O
well NN NN O
. NN NN O

Copious NNP NNP B-TREATMENT
irrigation NNP NNP I-TREATMENT
of NN NN O
the NNP NNP B-PROBLEM
wound NNP NNP I-PROBLEM
bed NNP NNP I-PROBLEM
showed NN NN O
no NN NN O
identifiable NNP NNP B-PROBLEM
bleeding NNP NNP I-PROBLEM
at NN NN O
the NN NN O
termination NN NN O
of NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
. NN NN O

There NN NN O
were NN NN O
two NNP NNP B-PROBLEM
obviously NNP NNP I-PROBLEM
positive NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
in NN NN O
this NNP NNP B-PROBLEM
neck NNP NNP I-PROBLEM
dissection NNP NNP I-PROBLEM
. NN NN O

One NN NN O
was NN NN O
left NN NN O
medial NN NN O
neck NN NN O
just NN NN O
lateral NN NN O
to NN NN O
the NNP NNP B-PROBLEM
previous NNP NNP I-PROBLEM
tracheal NNP NNP I-PROBLEM
dissection NNP NNP I-PROBLEM
and NN NN O
one NN NN O
was NN NN O
in NN NN O
the NN NN O
mid NN NN O
region NN NN O
of NN NN O
zone NN NN O

2 NN NN O
. NN NN O
A NNP NNP B-TREATMENT
#10 NNP NNP I-TREATMENT
flat NNP NNP I-TREATMENT
fluted NNP NNP I-TREATMENT
Blake NNP NNP I-TREATMENT
drain NNP NNP I-TREATMENT
was NN NN O
placed NN NN O
through NN NN O
a NNP NNP B-PROBLEM
separate NNP NNP I-PROBLEM
stab NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
and NN NN O
it NN NN O
was NN NN O
secured NN NN O
to NN NN O
the NN NN O
skin NN NN O
with NN NN O
a NNP NNP B-TREATMENT
2-0 NNP NNP I-TREATMENT
silk NNP NNP I-TREATMENT
ligature NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-PROBLEM
wound NNP NNP I-PROBLEM
was NN NN O
closed NN NN O
in NN NN O
layers NN NN O
using NN NN O
a NNP NNP B-TREATMENT
3-0 NNP NNP I-TREATMENT
Vicryl NNP NNP I-TREATMENT
in NN NN O
a NNP NNP B-TREATMENT
buried NNP NNP I-TREATMENT
knot NNP NNP I-TREATMENT
interrupted NN NN O
fashion NN NN O
for NN NN O
the NN NN O
subcutaneous NN NN O
tissue NN NN O
and NN NN O
the NN NN O
skin NN NN O
was NN NN O
closed NN NN O
with NN NN O
staples NNP NNP B-TREATMENT
. NN NN O

A NNP NNP B-TREATMENT
fluff NNP NNP I-TREATMENT
and NNP NNP I-TREATMENT
Kling NNP NNP I-TREATMENT
pressure NNP NNP I-TREATMENT
dressing NNP NNP I-TREATMENT
was NN NN O
then NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
extubated NN NN O
in NN NN O
the NN NN O
operating NN NN O
room NN NN O
, NN NN O
brought NN NN O
to NN NN O
the NN NN O
recovery NN NN O
room NN NN O
in NN NN O
satisfactory NN NN O
condition NN NN O
. NN NN O

There NN NN O
were NN NN O
no NN NN O
intraoperative NNP NNP B-PROBLEM
complications NNP NNP I-PROBLEM
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
metastatic NNP NNP B-PROBLEM
papillary NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
thyroidectomy NNP NNP B-TREATMENT
, NN NN O
thyroid NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
papillary NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
type NNP NNP I-PROBLEM
, NN NN O
dissection NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
metastatic NNP NNP I-PROBLEM
, NN NN O
paratracheal NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
papillary NNP NNP I-PROBLEM
, NN NN O
cancer NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
HDR NN NN O
Brachytherapy NN NN O
Description NN NN O
: NN NN O
HDR NNP NNP B-TREATMENT
Brachytherapy NNP NNP I-TREATMENT
( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
HDR NN NN O
BRACHYTHERAPY NN NN O
The NNP NNP B-TREATMENT
intracavitary NNP NNP I-TREATMENT
brachytherapy NNP NNP I-TREATMENT
applicator NNP NNP I-TREATMENT
was NN NN O
placed NN NN O
appropriately NN NN O
and NN NN O
secured NN NN O
after NN NN O
the NN NN O
patient NN NN O
was NN NN O
identified NN NN O
. NN NN O

Simulation NNP NNP B-TEST
films NNP NNP I-TEST
were NN NN O
obtained NN NN O
, NN NN O
documenting NN NN O
its NN NN O
positioning NN NN O
. NN NN O

The NN NN O
3-dimensional NN NN O
treatment NN NN O
planning NN NN O
process NN NN O
was NN NN O
accomplished NN NN O
utilizing NN NN O
the NNP NNP B-TEST
CT NNP NNP I-TEST
derived NN NN O
data NN NN O
. NN NN O

A NN NN O
treatment NN NN O
plan NN NN O
was NN NN O
selected NN NN O
utilizing NN NN O
sequential NN NN O
dwell NN NN O
positions NN NN O
within NN NN O
a NNP NNP B-TREATMENT
single NNP NNP I-TREATMENT
catheter NNP NNP I-TREATMENT
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
treatment NN NN O
area NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
appropriately NN NN O
positioned NN NN O
and NN NN O
the NN NN O
position NN NN O
of NN NN O
the NNP NNP B-TREATMENT
intracavitary NNP NNP I-TREATMENT
device NNP NNP I-TREATMENT
was NN NN O
checked NN NN O
. NN NN O

Catheter NNP NNP B-TEST
length NNP NNP I-TEST
measurements NNP NNP I-TEST
were NN NN O
taken NN NN O
. NN NN O

Appropriate NN NN O
measurements NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
probe NNP NNP I-TEST
dimensions NNP NNP I-TEST
and NN NN O
assembly NN NN O
were NN NN O
also NN NN O
performed NN NN O
. NN NN O

The NNP NNP B-TREATMENT
applicator NNP NNP I-TREATMENT
was NN NN O
attached NN NN O
to NN NN O
the NNP NNP B-TREATMENT
HDR NNP NNP I-TREATMENT
after-loader NNP NNP I-TREATMENT
device NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-TREATMENT
device NNP NNP I-TREATMENT
ran NN NN O
through NN NN O
its NN NN O
checking NN NN O
sequences NN NN O
appropriately NN NN O
and NN NN O
the NNP NNP B-TREATMENT
brachytherapy NNP NNP I-TREATMENT
was NN NN O
then NN NN O
delivered NN NN O
without NN NN O
difficulty NNP NNP B-PROBLEM
or NN NN O
complication NNP NNP B-PROBLEM
. NN NN O

The NNP NNP B-TREATMENT
brachytherapy NNP NNP I-TREATMENT
source NN NN O
was NN NN O
appropriately NN NN O
removed NN NN O
back NN NN O
to NN NN O
the NNP NNP B-TREATMENT
brachytherapy NNP NNP I-TREATMENT
safe NN NN O
within NN NN O
the NNP NNP B-TREATMENT
device NNP NNP I-TREATMENT
. NN NN O

Radiation NNP NNP B-TEST
screening NNP NNP I-TEST
was NN NN O
performed NN NN O
with NN NN O
the NNP NNP B-TREATMENT
Geiger-Muller NNP NNP I-TREATMENT
counter NNP NNP I-TREATMENT
both NN NN O
prior NN NN O
to NN NN O
and NN NN O
after NN NN O
the NNP NNP B-TREATMENT
brachytherapy NNP NNP I-TREATMENT
procedure NNP NNP I-TREATMENT
was NN NN O
completed NN NN O
and NN NN O
the NN NN O
results NN NN O
were NN NN O
deemed NN NN O
appropriate NN NN O
. NN NN O

Following NN NN O
completion NN NN O
of NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
, NN NN O
the NNP NNP B-TREATMENT
intracavitary NNP NNP I-TREATMENT
device NNP NNP I-TREATMENT
was NN NN O
removed NN NN O
without NN NN O
difficulty NNP NNP B-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
in NN NN O
no NN NN O
apparent NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
and NN NN O
was NN NN O
discharged NN NN O
home NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
geiger-muller NNP NNP B-TREATMENT
, NN NN O
treatment NNP NNP B-TREATMENT
planning NN NN O
, NN NN O
hdr NNP NNP B-TREATMENT
brachytherapy NNP NNP I-TREATMENT
, NN NN O
intracavitary NNP NNP B-TREATMENT
, NN NN O
applicator NNP NNP B-TREATMENT
, NN NN O
brachytherapy NNP NNP B-TREATMENT
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Biopsy NNP NNP B-TEST
- NN NN O
Cervical NN NN O
Lymph NN NN O
Node NN NN O
Description NN NN O
: NN NN O
Excisional NNP NNP B-TEST
biopsy NNP NNP I-TEST
of NN NN O
right NNP NNP B-PROBLEM
cervical NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Cervical NNP NNP B-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Cervical NNP NNP B-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

PROCEDURE NN NN O
: NN NN O
Excisional NNP NNP B-TEST
biopsy NNP NNP I-TEST
of NNP NNP I-TEST
right NNP NNP I-TEST
cervical NNP NNP I-TEST
lymph NNP NNP I-TEST
node NNP NNP I-TEST
. NN NN O

ANESTHESIA NN NN O
: NN NN O
General NN NN O
endotracheal NN NN O
anesthesia NNP NNP B-DRUG
. NN NN O

SPECIMEN NN NN O
: NN NN O
Right NNP NNP B-PROBLEM
cervical NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
. NN NN O

EBL NNP NNP B-TEST
: NN NN O
10 NN NN O
cc NN NN O
. NN NN O

COMPLICATIONS NN NN O
: NN NN O
None NN NN O
. NN NN O

FINDINGS NN NN O
: NN NN O
Enlarged NNP NNP B-PROBLEM
level NNP NNP I-PROBLEM
2 NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
was NN NN O
identified NN NN O
and NN NN O
removed NN NN O
and NN NN O
sent NN NN O
for NN NN O
pathologic NNP NNP B-TEST
examination NNP NNP I-TEST
. NN NN O

FLUIDS NN NN O
: NN NN O
Please NN NN O
see NN NN O
anesthesia NN NN O
report NN NN O
. NN NN O

URINE NN NN O
OUTPUT NN NN O
: NN NN O
None NN NN O
recorded NN NN O
during NN NN O
the NN NN O
case NN NN O
. NN NN O

INDICATIONS NN NN O
FOR NN NN O
PROCEDURE NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
43-year-old NN NN O
female NN NN O
with NN NN O
a NN NN O
several-year NN NN O
history NN NN O
of NN NN O
persistent NNP NNP B-PROBLEM
cervical NNP NNP I-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

She NN NN O
reports NN NN O
that NN NN O
it NN NN O
is NN NN O
painful NNP NNP B-PROBLEM
to NN NN O
palpation NNP NNP B-TEST
on NNP NNP I-TEST
the NNP NNP I-TEST
right NNP NNP I-TEST
and NN NN O
has NN NN O
had NN NN O
multiple NNP NNP B-TEST
CT NNP NNP I-TEST
scans NNP NNP I-TEST
as NN NN O
well NN NN O
as NN NN O
an NNP NNP B-TEST
FNA NNP NNP I-TEST
which NN NN O
were NN NN O
all NN NN O
nondiagnostic NN NN O
. NN NN O

After NN NN O
risks NN NN O
and NN NN O
benefits NN NN O
of NN NN O
surgery NNP NNP B-TREATMENT
were NN NN O
discussed NN NN O
with NN NN O
the NN NN O
patient NN NN O
, NN NN O
an NN NN O
informed NN NN O
consent NN NN O
was NN NN O
obtained NN NN O
. NN NN O

She NN NN O
was NN NN O
scheduled NN NN O
for NN NN O
an NNP NNP B-TEST
excisional NNP NNP I-TEST
biopsy NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
right NNP NNP I-TEST
cervical NNP NNP I-TEST
lymph NNP NNP I-TEST
node NNP NNP I-TEST
. NN NN O

PROCEDURE NN NN O
IN NN NN O
DETAIL NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
and NN NN O
placed NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
. NN NN O

She NN NN O
was NN NN O
anesthetized NN NN O
with NN NN O
general NN NN O
endotracheal NN NN O
anesthesia NNP NNP B-DRUG
. NN NN O

The NN NN O
neck NN NN O
was NN NN O
then NN NN O
prepped NNP NNP B-TREATMENT
and NNP NNP I-TREATMENT
draped NNP NNP I-TREATMENT
in NN NN O
the NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

Again NN NN O
, NN NN O
noted NN NN O
on NN NN O
palpation NNP NNP B-TEST
there NN NN O
was NN NN O
an NNP NNP B-PROBLEM
enlarged NNP NNP I-PROBLEM
level NNP NNP I-PROBLEM
2 NNP NNP I-PROBLEM
cervical NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
. NN NN O

A NNP NNP B-PROBLEM
3-cm NNP NNP I-PROBLEM
horizontal NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
over NN NN O
this NN NN O
lymph NN NN O
node NN NN O
. NN NN O

Dissection NNP NNP B-TREATMENT
was NN NN O
carried NN NN O
down NN NN O
until NN NN O
the NN NN O
sternocleidomastoid NN NN O
muscle NN NN O
was NN NN O
identified NN NN O
. NN NN O

The NNP NNP B-PROBLEM
enlarged NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
that NN NN O
measured NN NN O
approximately NN NN O
2 NN NN O
cm NN NN O
in NN NN O
diameter NN NN O
was NN NN O
identified NN NN O
and NN NN O
was NN NN O
removed NN NN O
and NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
for NN NN O
touch NNP NNP B-TEST
prep NNP NNP I-TEST
evaluation NNP NNP I-TEST
. NN NN O

The NN NN O
area NN NN O
was NN NN O
then NN NN O
explored NN NN O
for NN NN O
any NNP NNP B-PROBLEM
other NNP NNP I-PROBLEM
enlarged NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
. NN NN O

None NN NN O
were NN NN O
identified NN NN O
, NN NN O
and NN NN O
hemostasis NNP NNP B-TREATMENT
was NN NN O
achieved NN NN O
with NN NN O
electrocautery NNP NNP B-TREATMENT
. NN NN O

A NNP NNP B-TREATMENT
quarter-inch NNP NNP I-TREATMENT
Penrose NNP NNP I-TREATMENT
drain NNP NNP I-TREATMENT
was NN NN O
placed NN NN O
in NN NN O
the NNP NNP B-PROBLEM
wound NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
wound NNP NNP I-PROBLEM
was NN NN O
then NN NN O
irrigated NN NN O
and NN NN O
closed NN NN O
with NN NN O
3-0 NN NN O
interrupted NN NN O
Vicryl NNP NNP B-TREATMENT
sutures NNP NNP I-TREATMENT
for NN NN O
a NNP NNP B-TREATMENT
deep NNP NNP I-TREATMENT
closure NNP NNP I-TREATMENT
followed NN NN O
by NN NN O
a NNP NNP B-TREATMENT
running NNP NNP I-TREATMENT
4-0 NNP NNP I-TREATMENT
Prolene NNP NNP I-TREATMENT
subcuticular NNP NNP I-TREATMENT
suture NNP NNP I-TREATMENT
. NN NN O

Mastisol NNP NNP B-TREATMENT
and NN NN O
Steri-Strip NNP NNP B-TREATMENT
were NN NN O
placed NN NN O
over NN NN O
the NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
, NN NN O
and NN NN O
sterile NNP NNP B-TREATMENT
bandage NNP NNP I-TREATMENT
was NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
this NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
well NN NN O
and NN NN O
was NN NN O
extubated NN NN O
without NN NN O
complications NNP NNP B-PROBLEM
and NN NN O
transported NN NN O
to NN NN O
the NN NN O
recovery NN NN O
room NN NN O
in NN NN O
stable NN NN O
condition NN NN O
. NN NN O

She NN NN O
will NN NN O
return NN NN O
to NN NN O
the NN NN O
office NN NN O
tomorrow NN NN O
in NN NN O
followup NN NN O
to NN NN O
have NN NN O
the NNP NNP B-TREATMENT
Penrose NNP NNP I-TREATMENT
drain NNP NNP I-TREATMENT
removed NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
lymphadenopathy NNP NNP B-PROBLEM
, NN NN O
excisional NNP NNP B-TEST
biopsy NNP NNP I-TEST
, NN NN O
fna NNP NNP B-TEST
, NN NN O
mastisol NNP NNP B-TREATMENT
, NN NN O
penrose NNP NNP B-TREATMENT
drain NNP NNP I-TREATMENT
, NN NN O
cervical NNP NNP B-TREATMENT
, NNP NNP I-TREATMENT
cervical NNP NNP I-TREATMENT
lymph NNP NNP I-TREATMENT
node NNP NNP I-TREATMENT
, NN NN O
endotracheal NNP NNP B-TREATMENT
anesthesia NNP NNP I-TREATMENT
, NN NN O
lymph NNP NNP B-TREATMENT
node NNP NNP I-TREATMENT
, NN NN O
sternocleidomastoid NNP NNP B-TREATMENT
, NNP NNP I-TREATMENT
cervical NNP NNP I-TREATMENT
lymph NNP NNP I-TREATMENT
, NN NN O
lymph NNP NNP B-TREATMENT
, NN NN O
anesthesia NNP NNP B-DRUG
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Metastatic NNP NNP B-PROBLEM
Ovarian NNP NNP I-PROBLEM
Cancer NNP NNP I-PROBLEM
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
A NN NN O
very NN NN O
pleasant NN NN O
66-year-old NN NN O
woman NN NN O
with NN NN O
recurrent NNP NNP B-PROBLEM
metastatic NNP NNP I-PROBLEM
ovarian NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULTATION NN NN O
: NN NN O
Metastatic NNP NNP B-PROBLEM
ovarian NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
Mrs NN NN O
. NN NN O

ABCD NN NN O
is NN NN O
a NN NN O
very NN NN O
nice NN NN O
66-year-old NN NN O
woman NN NN O
who NN NN O
is NN NN O
followed NN NN O
in NN NN O
clinic NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
for NN NN O
history NN NN O
of NN NN O
renal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
as NN NN O
well NN NN O
as NN NN O
ovarian NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
which NN NN O
was NN NN O
initially NN NN O
diagnosed NN NN O
10 NN NN O
years NN NN O
ago NN NN O
, NN NN O
but NN NN O
over NN NN O
the NN NN O
last NN NN O
several NN NN O
months NN NN O
has NN NN O
recurred NN NN O
and NN NN O
is NN NN O
now NN NN O
metastatic NNP NNP B-PROBLEM
. NN NN O

She NN NN O
last NN NN O
saw NN NN O
Dr NN NN O
. NN NN O
X NN NN O
in NN NN O
clinic NN NN O
towards NN NN O
the NN NN O
beginning NN NN O
of NN NN O
this NN NN O
month NN NN O
. NN NN O

She NN NN O
has NN NN O
been NN NN O
receiving NN NN O
gemcitabine NNP NNP B-DRUG
and NN NN O
carboplatin NNP NNP B-DRUG
, NN NN O
and NN NN O
she NN NN O
receives NN NN O
three NN NN O
cycles NN NN O
of NN NN O
this NN NN O
with NN NN O
the NN NN O
last NN NN O
one NN NN O
being NN NN O
given NN NN O
on NN NN O
12/15/08 NNP NNP B-DATE
. NN NN O

She NN NN O
was NN NN O
last NN NN O
seen NN NN O
in NN NN O
clinic NN NN O
on NN NN O
12/22/08 NNP NNP B-DATE
by NN NN O
Dr NN NN O
. NN NN O
Y NNP NNP B-NAME
. NN NN O

At NN NN O
that NN NN O
point NN NN O
, NN NN O
her NNP NNP B-TEST
white NNP NNP I-TEST
count NNP NNP I-TEST
was NN NN O
0.9 NN NN O
with NN NN O
the NNP NNP B-TEST
hemoglobin NNP NNP I-TEST
of NN NN O
10.3 NN NN O
, NN NN O
hematocrit NNP NNP B-TEST
of NN NN O
30% NN NN O
, NN NN O
and NN NN O
platelets NNP NNP B-TEST
of NN NN O
81,000 NN NN O
. NN NN O

Her NNP NNP B-TEST
ANC NNP NNP I-TEST
was NN NN O
0.5 NN NN O
. NN NN O

She NN NN O
was NN NN O
started NN NN O
on NN NN O
prophylactic NN NN O
Augmentin NNP NNP B-DRUG
as NN NN O
well NN NN O
as NN NN O
Neupogen NNP NNP B-TREATMENT
shots NNP NNP I-TREATMENT
. NN NN O

She NN NN O
has NN NN O
also NN NN O
had NN NN O
history NN NN O
of NN NN O
recurrent NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
effusions NNP NNP I-PROBLEM
with NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
knee NNP NNP I-PROBLEM
for NN NN O
thoracentesis NNP NNP B-TREATMENT
. NN NN O

She NN NN O
had NN NN O
two NN NN O
of NN NN O
these NN NN O
performed NN NN O
in NN NN O
November NNP NNP B-DATE
and NN NN O
the NN NN O
last NN NN O
one NN NN O
was NN NN O
done NN NN O
about NN NN O
a NN NN O
week NN NN O
ago NN NN O
. NN NN O

Over NN NN O
the NN NN O
last NN NN O
2 NN NN O
or NN NN O
3 NN NN O
days NN NN O
, NN NN O
she NN NN O
states NN NN O
she NN NN O
has NN NN O
been NN NN O
getting NN NN O
more NNP NNP B-PROBLEM
short NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
. NN NN O

Her NN NN O
history NN NN O
is NN NN O
somewhat NN NN O
limited NN NN O
today NN NN O
as NN NN O
she NN NN O
is NN NN O
very NNP NNP B-PROBLEM
tired NNP NNP I-PROBLEM
and NN NN O
falls NN NN O
asleep NN NN O
readily NN NN O
. NN NN O

Her NN NN O
history NN NN O
comes NN NN O
from NN NN O
herself NN NN O
but NN NN O
also NN NN O
from NN NN O
the NN NN O
review NN NN O
of NN NN O
the NN NN O
records NN NN O
. NN NN O

Overall NN NN O
, NN NN O
her NNP NNP B-PROBLEM
shortness NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
has NN NN O
been NN NN O
going NN NN O
on NN NN O
for NN NN O
the NN NN O
past NN NN O
few NN NN O
weeks NN NN O
related NN NN O
to NN NN O
her NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
effusions NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
seen NN NN O
in NN NN O
the NN NN O
emergency NN NN O
room NN NN O
this NN NN O
time NN NN O
and NN NN O
on NN NN O
chest NNP NNP B-TEST
x-ray NNP NNP I-TEST
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NNP NNP B-PROBLEM
new NNP NNP I-PROBLEM
right-sided NNP NNP I-PROBLEM
pulmonic NNP NNP I-PROBLEM
consolidative NNP NNP I-PROBLEM
infiltrate NNP NNP I-PROBLEM
, NN NN O
which NN NN O
was NN NN O
felt NN NN O
to NN NN O
be NN NN O
possibly NN NN O
related NN NN O
to NN NN O
pneumonia NNP NNP B-PROBLEM
. NN NN O

She NN NN O
specifically NN NN O
denied NN NN O
any NN NN O
fevers NNP NNP B-PROBLEM
or NN NN O
chills NNP NNP B-PROBLEM
. NN NN O

However NN NN O
, NN NN O
she NN NN O
was NN NN O
complaining NN NN O
of NN NN O
chest NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

She NN NN O
states NN NN O
that NN NN O
the NNP NNP B-PROBLEM
chest NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
was NN NN O
located NN NN O
in NN NN O
the NN NN O
substernal NN NN O
area NN NN O
, NN NN O
described NN NN O
as NN NN O
aching NNP NNP B-PROBLEM
, NN NN O
coming NN NN O
and NN NN O
going NN NN O
and NN NN O
associated NN NN O
with NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
and NN NN O
cough NNP NNP B-PROBLEM
. NN NN O

When NN NN O
she NN NN O
did NN NN O
cough NNP NNP B-PROBLEM
, NN NN O
it NN NN O
was NN NN O
nonproductive NN NN O
. NN NN O

While NN NN O
in NN NN O
the NN NN O
emergency NN NN O
room NN NN O
on NN NN O
examination NNP NNP B-TEST
, NN NN O
her NNP NNP B-TEST
vital NNP NNP I-TEST
signs NNP NNP I-TEST
were NN NN O
stable NN NN O
except NN NN O
that NN NN O
she NN NN O
required NN NN O
5 NNP NNP B-TREATMENT
liters NNP NNP I-TREATMENT
nasal NNP NNP I-TREATMENT
cannula NNP NNP I-TREATMENT
to NN NN O
maintain NN NN O
oxygen NNP NNP B-TEST
saturations NNP NNP I-TEST
. NN NN O

An NNP NNP B-TEST
EKG NNP NNP I-TEST
was NN NN O
performed NN NN O
, NN NN O
which NN NN O
showed NN NN O
sinus NNP NNP B-PROBLEM
rhythm NNP NNP I-PROBLEM
without NN NN O
any NN NN O
evidence NN NN O
of NN NN O
Q NNP NNP B-PROBLEM
waves NNP NNP I-PROBLEM
or NN NN O
other NNP NNP B-PROBLEM
ischemic NNP NNP I-PROBLEM
changes NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-TEST
chest NNP NNP I-TEST
x-ray NNP NNP I-TEST
described NN NN O
above NN NN O
showed NN NN O
a NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
infiltrate NNP NNP I-PROBLEM
. NN NN O

A NNP NNP B-TEST
V/Q NNP NNP I-TEST
scan NNP NNP I-TEST
was NN NN O
done NN NN O
, NN NN O
which NN NN O
showed NN NN O
a NNP NNP B-PROBLEM
small NNP NNP I-PROBLEM
mismatched NNP NNP I-PROBLEM
defect NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
and NN NN O
a NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
defect NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
. NN NN O

The NN NN O
findings NN NN O
were NN NN O
compatible NN NN O
with NN NN O
an NN NN O
indeterminate NN NN O
study NN NN O
for NN NN O
a NNP NNP B-PROBLEM
pulmonary NNP NNP I-PROBLEM
embolism NNP NNP I-PROBLEM
. NN NN O

Apparently NN NN O
, NN NN O
an NNP NNP B-TEST
ultrasound NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
lower NNP NNP I-TEST
extremities NNP NNP I-TEST
was NN NN O
done NN NN O
and NN NN O
was NN NN O
negative NN NN O
for NN NN O
DVT NNP NNP B-PROBLEM
. NN NN O

There NN NN O
was NN NN O
apparently NN NN O
still NN NN O
some NN NN O
concern NN NN O
that NN NN O
this NN NN O
might NN NN O
be NN NN O
pulmonary NNP NNP B-PROBLEM
embolism NNP NNP I-PROBLEM
and NN NN O
she NN NN O
was NN NN O
started NN NN O
on NN NN O
Lovenox NNP NNP B-TREATMENT
. NN NN O

There NN NN O
was NN NN O
also NN NN O
concern NN NN O
for NN NN O
pneumonia NNP NNP B-PROBLEM
and NN NN O
she NN NN O
was NN NN O
started NN NN O
on NN NN O
Zosyn NNP NNP B-DRUG
as NN NN O
well NN NN O
as NN NN O
vancomycin NNP NNP B-DRUG
and NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
we NN NN O
have NN NN O
been NN NN O
consulted NN NN O
to NN NN O
help NN NN O
follow NN NN O
along NN NN O
with NN NN O
this NN NN O
patient NN NN O
who NN NN O
is NN NN O
well NN NN O
known NN NN O
to NN NN O
our NN NN O
clinic NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O

1 NN NN O
. NN NN O
Ovarian NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
- NN NN O
This NN NN O
was NN NN O
initially NN NN O
diagnosed NN NN O
about NN NN O
10 NN NN O
years NN NN O
ago NN NN O
and NN NN O
treated NN NN O
with NN NN O
surgical NNP NNP B-TREATMENT
resection NNP NNP I-TREATMENT
including NN NN O
TAH NNP NNP B-TREATMENT
and NN NN O
BSO NNP NNP B-TREATMENT
. NN NN O

This NN NN O
has NN NN O
recurred NN NN O
over NN NN O
the NN NN O
last NN NN O
couple NN NN O
of NN NN O
months NN NN O
with NN NN O
metastatic NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
History NN NN O
of NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
- NN NN O
She NN NN O
has NN NN O
been NN NN O
treated NN NN O
with NN NN O
bilateral NNP NNP B-TREATMENT
mastectomy NNP NNP I-TREATMENT
with NN NN O
the NN NN O
first NN NN O
one NN NN O
about NN NN O
14 NN NN O
years NN NN O
and NN NN O
the NN NN O
second NN NN O
one NN NN O
about NN NN O
5 NN NN O
years NN NN O
ago NN NN O
. NN NN O

She NN NN O
has NN NN O
had NN NN O
no NN NN O
recurrent NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

3 NN NN O
. NN NN O
Renal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
- NN NN O
She NN NN O
is NN NN O
status NN NN O
post NN NN O
nephrectomy NNP NNP B-TREATMENT
. NN NN O

4 NN NN O
. NN NN O
Hypertension NNP NNP B-PROBLEM
. NN NN O

5 NN NN O
. NN NN O
Anxiety NNP NNP B-PROBLEM
disorder NNP NNP I-PROBLEM
. NN NN O

6 NN NN O
. NN NN O
Chronic NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
from NN NN O
neuropathy NNP NNP B-PROBLEM
secondary NN NN O
to NN NN O
chemotherapy NNP NNP B-DRUG
from NN NN O
breast NNP NNP B-TREATMENT
cancer NNP NNP I-TREATMENT
treatment NNP NNP I-TREATMENT
. NN NN O

7 NN NN O
. NN NN O
Ongoing NN NN O
tobacco NN NN O
use NN NN O
. NN NN O

PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O

1 NN NN O
. NN NN O
Recent NN NN O
and NN NN O
multiple NNP NNP B-TREATMENT
thoracentesis NNP NNP I-TREATMENT
as NN NN O
described NN NN O
above NN NN O
. NN NN O

2 NN NN O
. NN NN O
Bilateral NNP NNP B-TREATMENT
mastectomies NNP NNP I-TREATMENT
. NN NN O

3 NN NN O
. NN NN O
Multiple NNP NNP B-TREATMENT
abdominal NNP NNP I-TREATMENT
surgeries NNP NNP I-TREATMENT
. NN NN O

4 NN NN O
. NN NN O
Cholecystectomy NNP NNP B-TREATMENT
. NN NN O

5 NN NN O
. NN NN O
Remote NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
ankle NNP NNP I-PROBLEM
fracture NNP NNP I-PROBLEM
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

MEDICATIONS NN NN O
: NN NN O
At NN NN O
home NN NN O
, NN NN O

1 NN NN O
. NN NN O
Atenolol NNP NNP B-DRUG
50 NNP NNP I-DRUG
mg NNP NNP I-DRUG
daily NN NN O

2 NN NN O
. NN NN O
Ativan NNP NNP B-DRUG
p.r.n NN NN O
. NN NN O

3 NN NN O
. NN NN O
Clonidine NNP NNP B-DRUG
0.1 NNP NNP I-DRUG
mg NNP NNP I-DRUG
nightly NN NN O
. NN NN O

4 NN NN O
. NN NN O
Compazine NNP NNP B-DRUG
p.r.n NN NN O
. NN NN O

5 NN NN O
. NN NN O
Dilaudid NNP NNP B-TREATMENT
p.r.n NN NN O
. NN NN O

6 NN NN O
. NN NN O
Gabapentin NNP NNP B-DRUG
300 NNP NNP I-DRUG
mg NNP NNP I-DRUG
p.o NNP NNP I-DRUG
. NN NN O

t.i.d NN NN O
. NN NN O

7 NN NN O
. NN NN O
K-Dur NNP NNP B-DRUG
20 NNP NNP I-DRUG
mEq NNP NNP I-DRUG
p.o NNP NNP I-DRUG
. NN NN O

daily NN NN O
. NN NN O

8 NN NN O
. NN NN O
Lasix NNP NNP B-DRUG
unknown NN NN O
dose NN NN O
daily NN NN O
. NN NN O

9 NN NN O
. NN NN O
Norvasc NNP NNP B-DRUG
5 NNP NNP I-DRUG
mg NNP NNP I-DRUG
daily NN NN O
. NN NN O

10 NN NN O
. NN NN O
Zofran NNP NNP B-DRUG
p.r.n NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
smokes NN NN O
about NN NN O
6-7 NN NN O
cigarettes NN NN O
per NN NN O
day NN NN O
and NN NN O
has NN NN O
done NN NN O
so NN NN O
for NN NN O
more NN NN O
than NN NN O
50 NN NN O
years NN NN O
. NN NN O

She NN NN O
quit NN NN O
smoking NN NN O
about NN NN O
6 NN NN O
weeks NN NN O
ago NN NN O
. NN NN O

She NN NN O
occasionally NN NN O
has NN NN O
alcohol NN NN O
. NN NN O

She NN NN O
is NN NN O
married NN NN O
and NN NN O
has NN NN O
3 NN NN O
children NN NN O
. NN NN O

She NN NN O
lives NN NN O
at NN NN O
home NN NN O
with NN NN O
her NN NN O
husband NN NN O
. NN NN O

She NN NN O
used NN NN O
to NN NN O
work NN NN O
as NN NN O
a NN NN O
unit NN NN O
clerk NN NN O
at NN NN O
XYZ NN NN O
Medical NN NN O
Center NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Both NN NN O
her NN NN O
mother NN NN O
and NN NN O
father NN NN O
had NN NN O
a NN NN O
history NN NN O
of NN NN O
lung NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
and NN NN O
both NN NN O
were NN NN O
smokers NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
GENERAL/CONSTITUTIONAL NN NN O
: NN NN O
She NN NN O
has NN NN O
not NN NN O
had NN NN O
any NNP NNP B-PROBLEM
fever NNP NNP I-PROBLEM
, NN NN O
chills NNP NNP B-PROBLEM
, NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
, NN NN O
but NN NN O
has NN NN O
had NN NN O
fatigue NNP NNP B-PROBLEM
and NN NN O
weight NNP NNP B-PROBLEM
loss NNP NNP I-PROBLEM
of NN NN O
unspecified NN NN O
amount NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
She NN NN O
has NN NN O
not NN NN O
had NN NN O
trouble NN NN O
with NN NN O
headaches NNP NNP B-PROBLEM
; NN NN O

mouth NN NN O
, NN NN O
jaw NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
teeth NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
; NN NN O

change NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
vision NNP NNP I-PROBLEM
; NN NN O

double NN NN O
vision NN NN O
; NN NN O

or NN NN O
loss NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
hearing NNP NNP I-PROBLEM
or NN NN O
ringing NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
ears NNP NNP I-PROBLEM
. NN NN O

CHEST NN NN O
: NN NN O
Per NN NN O
the NN NN O
HPI NN NN O
, NN NN O
she NN NN O
has NN NN O
had NN NN O
some NNP NNP B-PROBLEM
increasing NNP NNP I-PROBLEM
dyspnea NNP NNP I-PROBLEM
, NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
with NN NN O
exertion NN NN O
, NN NN O
cough NNP NNP B-PROBLEM
, NN NN O
but NN NN O
no NN NN O
sputum NNP NNP B-PROBLEM
production NNP NNP I-PROBLEM
or NN NN O
hemoptysis NNP NNP B-PROBLEM
. NN NN O

CVS NNP NNP B-TEST
: NN NN O
She NN NN O
has NN NN O
had NN NN O
the NN NN O
episodes NN NN O
of NN NN O
chest NNP NNP B-PROBLEM
pains NNP NNP I-PROBLEM
as NN NN O
described NN NN O
above NN NN O
but NN NN O
has NN NN O
not NN NN O
had NN NN O
, NN NN O
PND NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
orthopnea NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
extremity NNP NNP I-PROBLEM
swelling NNP NNP I-PROBLEM
or NN NN O
palpitations NNP NNP B-PROBLEM
. NN NN O

GI NN NN O
: NN NN O
No NN NN O
heartburn NNP NNP B-PROBLEM
, NN NN O
odynophagia NNP NNP B-PROBLEM
, NN NN O
dysphagia NNP NNP B-PROBLEM
, NN NN O
nausea NNP NNP B-PROBLEM
, NN NN O
vomiting NNP NNP B-PROBLEM
, NN NN O
diarrhea NNP NNP B-PROBLEM
, NN NN O
constipation NNP NNP B-PROBLEM
, NN NN O
blood NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
stool NNP NNP I-PROBLEM
, NN NN O
and NN NN O
black NNP NNP B-PROBLEM
tarry NNP NNP I-PROBLEM
stools NNP NNP I-PROBLEM
. NN NN O

GU NN NN O
: NN NN O
No NN NN O
dysuria NNP NNP B-PROBLEM
, NN NN O
burning NNP NNP B-PROBLEM
with NNP NNP I-PROBLEM
urination NNP NNP I-PROBLEM
, NN NN O
kidney NNP NNP B-PROBLEM
stones NNP NNP I-PROBLEM
, NN NN O
and NN NN O
difficulty NNP NNP B-PROBLEM
voiding NNP NNP I-PROBLEM
. NN NN O

MUSCULOSKELETAL NN NN O
: NN NN O
No NN NN O
new NNP NNP B-PROBLEM
back NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
hip NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
rib NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
swollen NNP NNP B-PROBLEM
joints NNP NNP I-PROBLEM
, NN NN O
history NN NN O
of NN NN O
gout NNP NNP B-PROBLEM
, NN NN O
or NN NN O
muscle NNP NNP B-PROBLEM
weakness NNP NNP I-PROBLEM
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
She NN NN O
has NN NN O
been NN NN O
diffusely NNP NNP B-PROBLEM
weak NNP NNP I-PROBLEM
but NN NN O
no NN NN O
lateralizing NNP NNP B-PROBLEM
loss NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
strength NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
feeling NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
some NNP NNP B-PROBLEM
chronic NNP NNP I-PROBLEM
neuropathic NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
and NN NN O
numbness NNP NNP B-PROBLEM
as NN NN O
described NN NN O
above NN NN O
in NN NN O
the NN NN O
past NN NN O
medical NN NN O
history NN NN O
. NN NN O

She NN NN O
is NN NN O
fatigued NNP NNP B-PROBLEM
and NN NN O
tired NNP NNP B-PROBLEM
today NN NN O
and NN NN O
falls NN NN O
asleep NN NN O
while NN NN O
talking NN NN O
but NN NN O
is NN NN O
easily NN NN O
arousable NN NN O
. NN NN O

Some NN NN O
of NN NN O
this NN NN O
is NN NN O
related NN NN O
to NN NN O
her NN NN O
lack NN NN O
of NN NN O
sleep NN NN O
over NN NN O
the NN NN O
admission NN NN O
thus NN NN O
far NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
Her NNP NNP B-TEST
T-max NNP NNP I-TEST
is NN NN O
99.3 NN NN O
. NN NN O

Her NNP NNP B-TEST
pulse NNP NNP I-TEST
is NN NN O
54 NN NN O
, NN NN O
her NNP NNP B-TEST
respirations NNP NNP I-TEST
is NN NN O
12 NN NN O
, NN NN O
and NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
118/61 NN NN O
. NN NN O

GENERAL NN NN O
: NN NN O
Somewhat NNP NNP B-PROBLEM
fatigued NNP NNP I-PROBLEM
appearing NN NN O
but NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
NC/AT NNP NNP B-PROBLEM
. NN NN O

Sclerae NNP NNP B-PROBLEM
anicteric NNP NNP I-PROBLEM
. NN NN O

Conjunctiva NN NN O
clear NN NN O
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
without NN NN O
any NNP NNP B-PROBLEM
erythema NNP NNP I-PROBLEM
, NN NN O
exudate NNP NNP B-PROBLEM
, NN NN O
or NN NN O
discharge NNP NNP B-PROBLEM
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

Nontender NNP NNP B-PROBLEM
. NN NN O

No NN NN O
elevated NNP NNP B-PROBLEM
JVP NNP NNP I-PROBLEM
. NN NN O

No NN NN O
thyromegaly NNP NNP B-PROBLEM
. NN NN O

No NN NN O
thyroid NNP NNP B-PROBLEM
nodules NNP NNP I-PROBLEM
. NN NN O

CHEST NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
and NN NN O
percussion NNP NNP B-TEST
bilaterally NN NN O
with NN NN O
decreased NNP NNP B-PROBLEM
breath NNP NNP I-PROBLEM
sounds NNP NNP I-PROBLEM
on NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
. NN NN O

CVS NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

No NN NN O
murmurs NNP NNP B-PROBLEM
, NN NN O
gallops NNP NNP B-PROBLEM
or NN NN O
rubs NNP NNP B-PROBLEM
. NN NN O

Normal NN NN O
S1 NN NN O
and NN NN O
S2 NN NN O
. NN NN O

No NN NN O
S3 NNP NNP B-PROBLEM
or NN NN O
S4 NNP NNP B-PROBLEM
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
, NN NN O
nontender NNP NNP B-PROBLEM
, NN NN O
nondistended NNP NNP B-PROBLEM
. NN NN O

Normoactive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
guarding NNP NNP B-PROBLEM
or NN NN O
rebound NNP NNP B-PROBLEM
. NN NN O

No NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

No NN NN O
masses NNP NNP B-PROBLEM
. NN NN O

MUSCULOSKELETAL NN NN O
: NN NN O
Generalized NNP NNP B-PROBLEM
muscle NNP NNP I-PROBLEM
weakness NNP NNP I-PROBLEM
but NN NN O
no NN NN O
joint NNP NNP B-PROBLEM
swelling NNP NNP I-PROBLEM
or NN NN O
other NNP NNP B-PROBLEM
abnormalities NNP NNP I-PROBLEM
. NN NN O

SKIN NN NN O
: NN NN O
No NN NN O
rashes NNP NNP B-PROBLEM
, NN NN O
bruising NNP NNP B-PROBLEM
, NN NN O
or NN NN O
petechia NNP NNP B-PROBLEM
. NN NN O

No NN NN O
non-healing NNP NNP B-PROBLEM
wounds NNP NNP I-PROBLEM
or NN NN O
ulcerations NNP NNP B-PROBLEM
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
She NN NN O
is NN NN O
oriented NN NN O
x3 NN NN O
but NN NN O
she NN NN O
falls NN NN O
asleep NN NN O
readily NN NN O
. NN NN O

On NN NN O
exam NNP NNP B-TEST
and NN NN O
conversation NN NN O
, NN NN O
her NN NN O
cranial NN NN O
nerves NN NN O
are NN NN O
intact NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
sensory NNP NNP B-PROBLEM
loss NNP NNP I-PROBLEM
. NN NN O

Her NN NN O
strength NN NN O
is NN NN O
symmetric NN NN O
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
Her NNP NNP B-TEST
white NNP NNP I-TEST
blood NNP NNP I-TEST
cell NNP NNP I-TEST
count NNP NNP I-TEST
is NN NN O
8.0 NN NN O
, NN NN O
hemoglobin NNP NNP B-TEST
11.1 NN NN O
, NN NN O
hematocrit NNP NNP B-TEST
33.2% NN NN O
, NN NN O
and NN NN O
platelets NNP NNP B-TEST
29,000 NN NN O
. NN NN O

Her NNP NNP B-TEST
differential NNP NNP I-TEST
shows NN NN O
2% NNP NNP B-PROBLEM
metamyelocytes NNP NNP I-PROBLEM
, NN NN O
57% NN NN O
neutrophils NNP NNP B-TEST
, NN NN O
29% NN NN O
bands NNP NNP B-TEST
, NN NN O
6% NN NN O
lymphocytes NNP NNP B-TEST
, NN NN O
5% NNP NNP B-TEST
monocytes NNP NNP I-TEST
, NN NN O
and NN NN O
1% NNP NNP B-TEST
eosinophils NNP NNP I-TEST
. NN NN O

Her NNP NNP B-TEST
sodium NNP NNP I-TEST
is NN NN O
138 NN NN O
, NN NN O
potassium NNP NNP B-TEST
4.0 NN NN O
, NN NN O
chloride NNP NNP B-TEST
101 NN NN O
, NN NN O
CO2 NNP NNP B-TEST
of NN NN O
23 NN NN O
, NN NN O
BUN NNP NNP B-TEST
21 NN NN O
, NN NN O
creatinine NNP NNP B-TEST
1.4 NN NN O
, NN NN O
glucose NNP NNP B-TEST
107 NN NN O
, NN NN O
and NN NN O
calcium NNP NNP B-TEST
8.7 NN NN O
. NN NN O

Her NNP NNP B-TEST
INR NNP NNP I-TEST
is NN NN O
1.0 NN NN O
, NN NN O
PT NNP NNP B-TEST
of NN NN O
12 NN NN O
, NN NN O
and NN NN O
PTT NNP NNP B-TEST

24 NN NN O
. NN NN O
Urinalysis NNP NNP B-TEST
negative NN NN O
for NN NN O
nitrite NNP NNP B-PROBLEM
and NN NN O
leukocyte NNP NNP B-TEST
esterase NNP NNP I-TEST
with NN NN O
moderate NNP NNP B-PROBLEM
epithelial NNP NNP I-PROBLEM
cells NNP NNP I-PROBLEM
, NN NN O
bacteria NNP NNP B-PROBLEM
, NN NN O
white NNP NNP B-TEST
blood NNP NNP I-TEST
cells NNP NNP I-TEST
, NN NN O
and NN NN O
yeast NNP NNP B-PROBLEM
suggesting NN NN O
of NN NN O
contamination NNP NNP B-PROBLEM
. NN NN O

Her NNP NNP B-TEST
troponins NNP NNP I-TEST
have NN NN O
been NN NN O
negative NN NN O
x3 NN NN O
. NN NN O

IMAGINING NN NN O
DATA NN NN O
: NN NN O
CT NNP NNP B-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
her NNP NNP I-TEST
chest NNP NNP I-TEST
on NN NN O
12/25/08 NNP NNP B-DATE
shows NN NN O
bilateral NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
effusions NNP NNP I-PROBLEM
, NN NN O
larger NN NN O
on NN NN O
the NN NN O
right NN NN O
than NN NN O
the NN NN O
left NN NN O
but NN NN O
these NN NN O
are NN NN O
somewhat NN NN O
decreased NN NN O
in NN NN O
size NN NN O
compared NN NN O
to NN NN O
the NNP NNP B-TEST
prior NNP NNP I-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
at NN NN O
the NN NN O
end NN NN O
of NN NN O
November NNP NNP B-DATE
. NN NN O

There NN NN O
is NN NN O
some NNP NNP B-PROBLEM
consolidative NNP NNP I-PROBLEM
atelectasis NNP NNP I-PROBLEM
at NN NN O
the NN NN O
bilateral NN NN O
basis NN NN O
. NN NN O

There NN NN O
is NN NN O
some NNP NNP B-PROBLEM
peripheral NNP NNP I-PROBLEM
interstitial NNP NNP I-PROBLEM
opacifications NNP NNP I-PROBLEM
noted NN NN O
in NN NN O
the NN NN O
right NN NN O
lung NN NN O
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
in NN NN O
the NN NN O
left NN NN O
lung NN NN O
possibly NN NN O
consistent NN NN O
with NN NN O
pneumonitis NNP NNP B-PROBLEM
. NN NN O

There NN NN O
are NN NN O
small NNP NNP B-PROBLEM
peripheral NNP NNP I-PROBLEM
nodular NNP NNP I-PROBLEM
densities NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
both NNP NNP I-PROBLEM
lungs NNP NNP I-PROBLEM
unchanged NN NN O
compared NN NN O
to NN NN O
prior NNP NNP B-TEST
scan NNP NNP I-TEST
. NN NN O

There NN NN O
is NN NN O
an NNP NNP B-PROBLEM
enlarged NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
gland NNP NNP I-PROBLEM
again NN NN O
noted NN NN O
without NN NN O
change NN NN O
. NN NN O

ASSESSMENT NN NN O
: NN NN O
ABCD NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
66-year-old NN NN O
woman NN NN O
with NN NN O
recurrent NNP NNP B-PROBLEM
metastatic NNP NNP I-PROBLEM
ovarian NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
known NN NN O
to NN NN O
our NN NN O
clinic NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
she NN NN O
has NN NN O
been NN NN O
admitted NN NN O
for NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
with NN NN O
possible NN NN O
presumed NN NN O
pneumonia NNP NNP B-PROBLEM
. NN NN O

The NN NN O
possibility NN NN O
of NN NN O
a NNP NNP B-PROBLEM
PE NNP NNP I-PROBLEM
also NN NN O
remains NN NN O
and NN NN O
the NN NN O
plan NN NN O
has NN NN O
been NN NN O
to NN NN O
do NN NN O
a NNP NNP B-TEST
CTA NNP NNP I-TEST
once NN NN O
her NNP NNP B-TEST
kidney NNP NNP I-TEST
function NNP NNP I-TEST
improves NN NN O
. NN NN O

Currently NN NN O
, NN NN O
she NN NN O
is NN NN O
being NN NN O
treated NN NN O
with NN NN O
broad-spectrum NNP NNP B-DRUG
antibiotics NNP NNP I-DRUG
and NN NN O
Lovenox NNP NNP B-TREATMENT
prophylactically NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
it NN NN O
does NN NN O
not NN NN O
appear NN NN O
that NN NN O
her NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
effusions NNP NNP I-PROBLEM
have NN NN O
increased NN NN O
and NN NN O
this NN NN O
would NN NN O
not NN NN O
be NN NN O
the NN NN O
etiology NN NN O
behind NN NN O
her NNP NNP B-PROBLEM
worsening NNP NNP I-PROBLEM
symptoms NNP NNP I-PROBLEM
. NN NN O

Her NNP NNP B-TEST
blood NNP NNP I-TEST
counts NNP NNP I-TEST
appear NN NN O
to NN NN O
be NN NN O
recovering NN NN O
from NN NN O
chemotherapy NNP NNP B-DRUG
except NN NN O
for NN NN O
the NN NN O
fact NN NN O
that NN NN O
her NNP NNP B-TEST
platelets NNP NNP I-TEST
have NN NN O
gone NN NN O
lower NN NN O
. NN NN O

It NN NN O
is NN NN O
unclear NN NN O
as NN NN O
to NN NN O
the NN NN O
etiology NN NN O
behind NN NN O
this NN NN O
but NN NN O
may NN NN O
still NN NN O
be NN NN O
related NN NN O
to NN NN O
chemotherapy NNP NNP B-DRUG
effect NN NN O
. NN NN O

This NN NN O
also NN NN O
could NN NN O
be NN NN O
related NN NN O
to NN NN O
consumptive NNP NNP B-PROBLEM
process NNP NNP I-PROBLEM
such NN NN O
as NN NN O
DIC NNP NNP B-PROBLEM
in NN NN O
the NN NN O
face NN NN O
of NN NN O
infections NNP NNP B-PROBLEM
or NN NN O
medication NNP NNP B-PROBLEM
effect NNP NNP I-PROBLEM
. NN NN O

We NN NN O
will NN NN O
keep NN NN O
track NN NN O
of NN NN O
her NNP NNP B-TEST
blood NNP NNP I-TEST
counts NNP NNP I-TEST
over NN NN O
this NN NN O
admission NN NN O
. NN NN O

We NN NN O
will NN NN O
continue NN NN O
to NN NN O
follow NN NN O
along NN NN O
through NN NN O
the NN NN O
course NN NN O
of NN NN O
her NN NN O
admission NN NN O
. NN NN O

She NN NN O
has NN NN O
requested NN NN O
being NN NN O
full NNP NNP B-TREATMENT
code NNP NNP I-TREATMENT
. NN NN O

I NN NN O
went NN NN O
back NN NN O
and NN NN O
looked NN NN O
at NN NN O
Dr NN NN O
. NN NN O
X's NN NN O
chart NN NN O
after NN NN O
our NN NN O
clinic NN NN O
chart NN NN O
and NN NN O
at NN NN O
the NN NN O
last NN NN O
visit NN NN O
with NN NN O
Dr NN NN O
. NN NN O
X NN NN O
and NN NN O
Dr NN NN O
. NN NN O
Y NNP NNP B-NAME
, NN NN O
she NN NN O
confirmed NN NN O
that NN NN O
she NN NN O
wanted NN NN O
to NN NN O
be NN NN O
DNR/DNI NN NN O
. NN NN O

I NN NN O
am NN NN O
not NN NN O
sure NN NN O
why NN NN O
this NN NN O
is NN NN O
changed NN NN O
and NN NN O
I NN NN O
will NN NN O
address NN NN O
this NN NN O
issue NN NN O
with NN NN O
her NN NN O
once NN NN O
she NN NN O
is NN NN O
more NN NN O
alert NN NN O
. NN NN O

Thank NN NN O
you NN NN O
very NN NN O
much NN NN O
for NN NN O
this NN NN O
consult NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
renal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
metastatic NNP NNP B-PROBLEM
ovarian NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
, NN NN O
pleural NNP NNP B-PROBLEM
effusions NNP NNP I-PROBLEM
, NN NN O
cancer NNP NNP B-PROBLEM
, NN NN O
ovarian NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
recurrent NNP NNP I-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Breast NN NN O
Radiation NN NN O
Therapy NN NN O
Followup NN NN O
Description NN NN O
: NN NN O
Breast NN NN O
radiation NN NN O
therapy NN NN O
followup NN NN O
note NN NN O
. NN NN O

Left NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
adenocarcinoma NNP NNP I-PROBLEM
stage NNP NNP I-PROBLEM
T3 NNP NNP I-PROBLEM
N1b NN NN O
M0 NN NN O
, NN NN O
stage NNP NNP B-PROBLEM
IIIA NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
DIAGNOSIS NN NN O
: NN NN O
Left NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
adenocarcinoma NNP NNP I-PROBLEM
stage NN NN O
T3 NN NN O
N1b NN NN O
M0 NN NN O
, NN NN O
stage NNP NNP B-PROBLEM
IIIA NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
been NN NN O
found NN NN O
more NN NN O
recently NN NN O
to NN NN O
have NN NN O
stage NNP NNP B-PROBLEM
IV NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
with NN NN O
metastatic NNP NNP B-PROBLEM
deposits NNP NNP I-PROBLEM
and NN NN O
recurrence NNP NNP B-PROBLEM
involving NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
chest NNP NNP I-PROBLEM
wall NNP NNP I-PROBLEM
and NN NN O
lower NNP NNP B-PROBLEM
left NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O

1 NN NN O
. NN NN O
Glucosamine NNP NNP B-DRUG
complex NNP NNP I-DRUG
. NN NN O

2 NN NN O
. NN NN O
Toprol NNP NNP B-DRUG
XL NNP NNP I-DRUG
. NN NN O

3 NN NN O
. NN NN O
Alprazolam NNP NNP B-DRUG

4 NN NN O
. NN NN O
Hydrochlorothiazide NNP NNP B-DRUG
. NN NN O

5 NN NN O
. NN NN O
Dyazide NNP NNP B-DRUG
. NN NN O

6 NN NN O
. NN NN O
Centrum NN NN O
. NN NN O

Dr NN NN O
. NN NN O
X NN NN O
has NN NN O
given NN NN O
her NN NN O
some NN NN O
carboplatin NNP NNP B-DRUG
and NN NN O
Taxol NNP NNP B-DRUG
more NN NN O
recently NN NN O
and NN NN O
feels NN NN O
that NN NN O
she NN NN O
would NN NN O
benefit NN NN O
from NN NN O
electron NNP NNP B-DRUG
beam NNP NNP I-DRUG
radiotherapy NNP NNP I-DRUG
to NN NN O
the NN NN O
left NN NN O
chest NN NN O
wall NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
neck NN NN O
. NN NN O

She NN NN O
previously NN NN O
received NN NN O
a NN NN O
total NN NN O
of NN NN O
46.8 NN NN O
Gy NN NN O
in NN NN O
26 NN NN O
fractions NN NN O
of NN NN O
external NNP NNP B-TREATMENT
beam NNP NNP I-TREATMENT
radiotherapy NNP NNP I-TREATMENT
to NN NN O
the NN NN O
left NN NN O
supraclavicular NN NN O
area NN NN O
. NN NN O

As NN NN O
such NN NN O
, NN NN O
I NN NN O
feel NN NN O
that NN NN O
we NN NN O
could NN NN O
safely NN NN O
re-treat NN NN O
the NN NN O
lower NN NN O
neck NN NN O
. NN NN O

Her NNP NNP B-TEST
weight NNP NNP I-TEST
has NN NN O
increased NN NN O
to NN NN O
189.5 NN NN O
from NN NN O
185.2 NN NN O
. NN NN O

She NN NN O
does NN NN O
complain NN NN O
of NN NN O
some NNP NNP B-PROBLEM
coughing NNP NNP I-PROBLEM
and NN NN O
fatigue NNP NNP B-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
NECK NN NN O
: NN NN O
On NN NN O
physical NNP NNP B-TEST
examination NNP NNP I-TEST
palpable NN NN O
lymphadenopathy NNP NNP B-PROBLEM
is NN NN O
present NN NN O
in NN NN O
the NN NN O
left NN NN O
lower NN NN O
neck NN NN O
and NN NN O
supraclavicular NN NN O
area NN NN O
. NN NN O

No NN NN O
other NNP NNP B-PROBLEM
cervical NNP NNP I-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
or NN NN O
supraclavicular NNP NNP B-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
is NN NN O
present NN NN O
. NN NN O

RESPIRATORY NN NN O
: NN NN O
Good NN NN O
air NN NN O
entry NN NN O
bilaterally NN NN O
. NN NN O

Examination NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
chest NNP NNP I-TEST
wall NNP NNP I-TEST
reveals NN NN O
a NNP NNP B-PROBLEM
small NNP NNP I-PROBLEM
lesion NNP NNP I-PROBLEM
where NN NN O
the NNP NNP B-PROBLEM
chest NNP NNP I-PROBLEM
wall NNP NNP I-PROBLEM
recurrence NNP NNP I-PROBLEM
was NN NN O
resected NNP NNP B-TREATMENT
. NN NN O

No NN NN O
lumps NNP NNP B-PROBLEM
, NN NN O
bumps NNP NNP B-PROBLEM
or NN NN O
evidence NN NN O
of NN NN O
disease NNP NNP B-PROBLEM
involving NN NN O
the NN NN O
right NN NN O
breast NN NN O
is NN NN O
present NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Normal NN NN O
bowel NN NN O
sounds NN NN O
, NN NN O
no NN NN O
hepatomegaly NNP NNP B-PROBLEM
. NN NN O

No NN NN O
tenderness NNP NNP B-PROBLEM
on NN NN O
deep NNP NNP B-TEST
palpation NNP NNP I-TEST
. NN NN O

She NN NN O
has NN NN O
just NN NN O
started NN NN O
her NN NN O
last NN NN O
cycle NN NN O
of NN NN O
chemotherapy NNP NNP B-DRUG
today NN NN O
, NN NN O
and NN NN O
she NN NN O
wishes NN NN O
to NN NN O
visit NN NN O
her NN NN O
daughter NN NN O
in NN NN O
Brooklyn NN NN O
, NN NN O
New NN NN O
York NN NN O
. NN NN O

After NN NN O
this NN NN O
she NN NN O
will NN NN O
return NN NN O
in NN NN O
approximately NN NN O
3 NN NN O
to NN NN O
4 NN NN O
weeks NN NN O
and NN NN O
begin NN NN O
her NN NN O
radiotherapy NNP NNP B-DRUG
treatment NN NN O
at NN NN O
that NN NN O
time NN NN O
. NN NN O

I NN NN O
look NN NN O
forward NN NN O
to NN NN O
keeping NN NN O
you NN NN O
informed NN NN O
of NN NN O
her NN NN O
progress NN NN O
. NN NN O

Thank NN NN O
you NN NN O
for NN NN O
having NN NN O
allowed NN NN O
me NN NN O
to NN NN O
participate NN NN O
in NN NN O
her NN NN O
care NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
carboplatin NNP NNP B-DRUG
, NN NN O
taxol NNP NNP B-DRUG
, NN NN O
radiation NNP NNP B-TREATMENT
therapy NNP NNP I-TREATMENT
, NN NN O
breast NNP NNP B-PROBLEM
adenocarcinoma NNP NNP I-PROBLEM
, NN NN O
beam NNP NNP B-TREATMENT
radiotherapy NNP NNP I-TREATMENT
, NN NN O
chest NNP NNP B-TREATMENT
wall NNP NNP I-TREATMENT
, NN NN O
radiotherapy NNP NNP B-TREATMENT
, NN NN O
supraclavicular NNP NNP B-TREATMENT
, NN NN O
lymphadenopathy NNP NNP B-PROBLEM
, NN NN O
adenocarcinoma NNP NNP B-PROBLEM
, NN NN O
breast NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Lymph NN NN O
Node NN NN O
Excisional NN NN O
Biopsy NN NN O
Description NN NN O
: NN NN O
Left NNP NNP B-TEST
axillary NNP NNP I-TEST
lymph NNP NNP I-TEST
node NNP NNP I-TEST
excisional NNP NNP I-TEST
biopsy NNP NNP I-TEST
. NN NN O

Left NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Left NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Left NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
. NN NN O

PROCEDURE NN NN O
: NN NN O
Left NNP NNP B-TEST
axillary NNP NNP I-TEST
lymph NNP NNP I-TEST
node NNP NNP I-TEST
excisional NNP NNP I-TEST
biopsy NNP NNP I-TEST
. NN NN O

ANESTHESIA NN NN O
: NN NN O
LMA NNP NNP B-TREATMENT
. NN NN O

INDICATIONS NN NN O
: NN NN O
Patient NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
woman NN NN O
who NN NN O
in NN NN O
2006 NNP NNP B-DATE
had NN NN O
breast NNP NNP B-TREATMENT
conservation NNP NNP I-TREATMENT
therapy NNP NNP I-TREATMENT
with NN NN O
radiation NNP NNP B-TREATMENT
only NN NN O
. NN NN O

Note NN NN O
, NN NN O
she NN NN O
refused NN NN O
her NNP NNP B-TREATMENT
CMF NNP NNP I-TREATMENT
adjuvant NNP NNP I-TREATMENT
therapy NNP NNP I-TREATMENT
and NN NN O
this NN NN O
was NN NN O
for NN NN O
a NNP NNP B-PROBLEM
triple-negative NNP NNP I-PROBLEM
infiltrating NNP NNP I-PROBLEM
ductal NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
. NN NN O

Patient NN NN O
has NN NN O
been NN NN O
following NN NN O
with NN NN O
Dr NN NN O
. NN NN O
Diener NNP NNP B-NAME
and NN NN O
Dr NN NN O
. NN NN O
Wilmot NNP NNP B-NAME
. NN NN O

I NN NN O
believe NN NN O
that NN NN O
genetic NN NN O
counseling NN NN O
had NN NN O
been NN NN O
recommended NN NN O
to NN NN O
her NN NN O
and NN NN O
obviously NN NN O
the NN NN O
CMF NN NN O
was NN NN O
recommended NN NN O
, NN NN O
but NN NN O
she NN NN O
declined NN NN O
both NN NN O
. NN NN O

She NN NN O
presented NN NN O
to NN NN O
the NN NN O
office NN NN O
with NN NN O
left NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
in NN NN O
view NN NN O
of NN NN O
the NN NN O
high-risk NN NN O
nature NN NN O
of NN NN O
her NNP NNP B-PROBLEM
lesion NNP NNP I-PROBLEM
. NN NN O

I NN NN O
recommended NN NN O
that NN NN O
she NN NN O
have NN NN O
this NNP NNP B-TREATMENT
lymph NNP NNP I-TREATMENT
node NNP NNP I-TREATMENT
removed NN NN O
. NN NN O

The NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
, NN NN O
purpose NN NN O
, NN NN O
risk NN NN O
, NN NN O
expected NN NN O
benefits NN NN O
, NN NN O
potential NNP NNP B-PROBLEM
complications NNP NNP I-PROBLEM
, NN NN O
alternative NN NN O
forms NN NN O
of NN NN O
therapy NNP NNP B-TREATMENT
were NN NN O
discussed NN NN O
with NN NN O
her NN NN O
and NN NN O
she NN NN O
was NN NN O
agreeable NN NN O
to NN NN O
surgery NNP NNP B-TREATMENT
. NN NN O

TECHNIQUE NN NN O
: NN NN O
Patient NN NN O
was NN NN O
identified NN NN O
, NN NN O
then NN NN O
taken NN NN O
into NN NN O
the NN NN O
operating NN NN O
room NN NN O
where NN NN O
after NN NN O
induction NN NN O
of NN NN O
appropriate NN NN O
anesthesia NNP NNP B-DRUG
, NN NN O
her NNP NNP B-TREATMENT
left NNP NNP I-TREATMENT
chest NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
neck NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
axilla NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
and NNP NNP I-TREATMENT
arm NNP NNP I-TREATMENT
were NN NN O
prepped NN NN O
with NN NN O
Betadine NNP NNP B-DRUG
solution NNP NNP I-DRUG
, NN NN O
draped NN NN O
in NN NN O
a NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

An NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
at NN NN O
the NN NN O
hairline NN NN O
, NN NN O
carried NN NN O
down NN NN O
by NN NN O
sharp NNP NNP B-TREATMENT
dissection NNP NNP I-TREATMENT
through NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
clavipectoral NNP NNP I-TREATMENT
fascia NNP NNP I-TREATMENT
. NN NN O

I NN NN O
was NN NN O
able NN NN O
to NN NN O
easily NN NN O
palpate NN NN O
the NN NN O
lymph NN NN O
node NN NN O
and NN NN O
grasp NN NN O
it NN NN O
with NN NN O
a NNP NNP B-TREATMENT
figure-of-eight NNP NNP I-TREATMENT
2-0 NNP NNP I-TREATMENT
silk NNP NNP I-TREATMENT
suture NNP NNP I-TREATMENT
and NN NN O
by NN NN O
sharp NNP NNP B-TREATMENT
dissection NNP NNP I-TREATMENT
, NN NN O
was NN NN O
carried NN NN O
to NN NN O
hemoclip NNP NNP B-DRUG
all NN NN O
attached NN NN O
structures NN NN O
. NN NN O

The NN NN O
lymph NN NN O
node NN NN O
was NN NN O
excised NNP NNP B-TREATMENT
in NN NN O
its NN NN O
entirety NN NN O
. NN NN O

The NNP NNP B-PROBLEM
wound NNP NNP I-PROBLEM
was NN NN O
irrigated NN NN O
. NN NN O

The NN NN O
lymph NN NN O
node NN NN O
sent NN NN O
to NN NN O
pathology NN NN O
. NN NN O

The NNP NNP B-PROBLEM
wound NNP NNP I-PROBLEM
was NN NN O
then NN NN O
closed NN NN O
. NN NN O

Hemostasis NN NN O
was NN NN O
assured NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
recovery NN NN O
room NN NN O
in NN NN O
stable NN NN O
condition NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
axillary NNP NNP B-TEST
lymph NNP NNP I-TEST
node NNP NNP I-TEST
excisional NNP NNP I-TEST
biopsy NNP NNP I-TEST
, NN NN O
sharp NNP NNP B-TREATMENT
dissection NNP NNP I-TREATMENT
, NN NN O
excisional NNP NNP B-TEST
biopsy NNP NNP I-TEST
, NN NN O
lymph NNP NNP B-TEST
node NNP NNP I-TEST
, NNP NNP I-TEST
axillary NNP NNP I-TEST
, NNP NNP I-TEST
excisional NNP NNP I-TEST
, NN NN O
biopsy NNP NNP B-TEST
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Cholangiocarcinoma NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
cholangiocarcinoma NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
is NN NN O
noted NN NN O
to NN NN O
have NN NN O
an NNP NNP B-PROBLEM
increase NNP NNP I-PROBLEM
in NN NN O
her NNP NNP B-TEST
liver NNP NNP I-TEST
function NNP NNP I-TEST
tests NNP NNP I-TEST
on NN NN O
routine NNP NNP B-TEST
blood NNP NNP I-TEST
work NNP NNP I-TEST
. NN NN O

Ultrasound NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
abdomen NNP NNP I-TEST
showed NN NN O
gallbladder NNP NNP B-PROBLEM
sludge NNP NNP I-PROBLEM
and NN NN O
gallbladder NNP NNP B-PROBLEM
findings NNP NNP I-PROBLEM
consistent NN NN O
with NN NN O
adenomyomatosis NNP NNP B-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULTATION NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
cholangiocarcinoma NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
77-year-old NN NN O
female NN NN O
who NN NN O
is NN NN O
noted NN NN O
to NN NN O
have NN NN O
an NNP NNP B-PROBLEM
increase NNP NNP I-PROBLEM
in NN NN O
her NNP NNP B-TEST
liver NNP NNP I-TEST
function NNP NNP I-TEST
tests NNP NNP I-TEST
on NN NN O
routine NNP NNP B-TEST
blood NNP NNP I-TEST
work NNP NNP I-TEST
in NN NN O
December NNP NNP B-DATE
2009 NNP NNP I-DATE
. NN NN O

Ultrasound NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
abdomen NNP NNP I-TEST
showed NN NN O
gallbladder NNP NNP B-PROBLEM
sludge NNP NNP I-PROBLEM
and NN NN O
gallbladder NNP NNP B-PROBLEM
findings NNP NNP I-PROBLEM
consistent NN NN O
with NN NN O
adenomyomatosis NNP NNP B-PROBLEM
. NN NN O

Common NN NN O
bile NN NN O
duct NN NN O
was NN NN O
noted NN NN O
to NN NN O
be NN NN O
10 NN NN O
mm NN NN O
in NN NN O
size NN NN O
on NN NN O
that NNP NNP B-TEST
ultrasound NNP NNP I-TEST
. NN NN O

She NN NN O
then NN NN O
underwent NN NN O
a NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
abdomen NNP NNP I-TEST
in NN NN O
July NNP NNP B-DATE
2010 NNP NNP I-DATE
, NN NN O
which NN NN O
showed NN NN O
intrahepatic NNP NNP B-PROBLEM
ductal NNP NNP I-PROBLEM
dilatation NNP NNP I-PROBLEM
with NN NN O
the NN NN O
common NN NN O
bile NN NN O
duct NN NN O
size NN NN O
being NN NN O
12.7 NN NN O
mm NN NN O
. NN NN O

She NN NN O
then NN NN O
underwent NN NN O
an NNP NNP B-TEST
MRI NNP NNP I-TEST
MRCP NNP NNP I-TEST
, NN NN O
which NN NN O
was NN NN O
notable NN NN O
for NN NN O
stricture NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
distal NNP NNP I-PROBLEM
common NNP NNP I-PROBLEM
bile NNP NNP I-PROBLEM
duct NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
then NN NN O
referred NN NN O
to NN NN O
gastroenterology NN NN O
and NN NN O
underwent NN NN O
an NNP NNP B-TEST
ERCP NNP NNP I-TEST
. NN NN O

On NN NN O
August NNP NNP B-DATE
24 NNP NNP I-DATE
, NNP NNP I-DATE
2010 NNP NNP I-DATE
, NN NN O
she NN NN O
underwent NN NN O
the NNP NNP B-TEST
endoscopic NNP NNP I-TEST
retrograde NNP NNP I-TEST
cholangiopancreatography NNP NNP I-TEST
. NN NN O

She NN NN O
was NN NN O
noted NN NN O
to NN NN O
have NN NN O
a NNP NNP B-PROBLEM
stricturing NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
mid-to-proximal NNP NNP I-PROBLEM
common NNP NNP I-PROBLEM
bile NNP NNP I-PROBLEM
duct NNP NNP I-PROBLEM
consistent NN NN O
with NN NN O
cholangiocarcinoma NNP NNP B-PROBLEM
. NN NN O

A NNP NNP B-TREATMENT
temporary NNP NNP I-TREATMENT
biliary NNP NNP I-TREATMENT
stent NNP NNP I-TREATMENT
was NN NN O
placed NN NN O
across NN NN O
the NNP NNP B-PROBLEM
biliary NNP NNP I-PROBLEM
stricture NNP NNP I-PROBLEM
. NN NN O

Blood NNP NNP B-TEST
work NNP NNP I-TEST
was NN NN O
obtained NN NN O
during NN NN O
the NN NN O
hospitalization NN NN O
. NN NN O

She NN NN O
was NN NN O
also NN NN O
noted NN NN O
to NN NN O
have NN NN O
an NNP NNP B-PROBLEM
elevated NNP NNP I-PROBLEM
CA99 NNP NNP I-PROBLEM
. NN NN O

She NN NN O
comes NN NN O
in NN NN O
to NN NN O
clinic NN NN O
today NN NN O
for NN NN O
initial NN NN O
Medical NN NN O
Oncology NN NN O
consultation NN NN O
. NN NN O

After NN NN O
she NN NN O
sees NN NN O
me NN NN O
this NN NN O
morning NN NN O
, NN NN O
she NN NN O
has NN NN O
a NN NN O
follow-up NN NN O
consultation NN NN O
with NN NN O
a NN NN O
surgeon NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Significant NN NN O
for NN NN O
hypertension NNP NNP B-PROBLEM
and NN NN O
hyperlipidemia NNP NNP B-PROBLEM
. NN NN O

In NN NN O
July NNP NNP B-DATE
, NN NN O
she NN NN O
had NN NN O
eye NNP NNP B-TREATMENT
surgery NNP NNP I-TREATMENT
on NNP NNP I-TREATMENT
her NNP NNP I-TREATMENT
left NNP NNP I-TREATMENT
eye NNP NNP I-TREATMENT
for NN NN O
a NNP NNP B-TREATMENT
muscle NNP NNP I-TREATMENT
repair NNP NNP I-TREATMENT
. NN NN O

Other NNP NNP B-TREATMENT
surgeries NNP NNP I-TREATMENT
include NN NN O
left NNP NNP B-TREATMENT
ankle NNP NNP I-TREATMENT
surgery NNP NNP I-TREATMENT
for NN NN O
a NNP NNP B-PROBLEM
fractured NNP NNP I-PROBLEM
ankle NNP NNP I-PROBLEM
in NN NN O
2000 NNP NNP B-DATE
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Diovan NNP NNP B-DRUG
80/12.5 NNP NNP I-DRUG
mg NNP NNP I-DRUG
daily NN NN O
, NN NN O
Lipitor NNP NNP B-DRUG
10 NNP NNP I-DRUG
mg NNP NNP I-DRUG
daily NN NN O
, NN NN O
Lutein NNP NNP B-DRUG
20 NNP NNP I-DRUG
mg NNP NNP I-DRUG
daily NN NN O
, NN NN O
folic NNP NNP B-DRUG
acid NNP NNP I-DRUG
0.8 NNP NNP I-DRUG
mg NNP NNP I-DRUG
daily NN NN O
and NN NN O
multivitamin NNP NNP B-DRUG
daily NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Notable NN NN O
for NN NN O
heart NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

She NN NN O
had NN NN O
three NN NN O
brothers NN NN O
that NN NN O
died NN NN O
of NN NN O
complications NNP NNP B-PROBLEM
from NN NN O
open NNP NNP B-TREATMENT
heart NNP NNP I-TREATMENT
surgery NNP NNP I-TREATMENT
. NN NN O

Her NN NN O
parents NN NN O
and NN NN O
brothers NN NN O
all NN NN O
had NN NN O
hypertension NNP NNP B-PROBLEM
. NN NN O

Her NN NN O
younger NN NN O
brother NN NN O
died NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O
18 NN NN O
of NN NN O
infection NNP NNP B-PROBLEM
from NN NN O
a NN NN O
butcher's NN NN O
shop NN NN O
. NN NN O

He NN NN O
was NN NN O
cutting NNP NNP B-TREATMENT
Argentinean NNP NNP I-TREATMENT
beef NNP NNP I-TREATMENT
and NN NN O
contracted NN NN O
an NNP NNP B-PROBLEM
infection NNP NNP I-PROBLEM
and NN NN O
died NN NN O
within NN NN O
24 NN NN O
hours NN NN O
. NN NN O

She NN NN O
has NN NN O
one NN NN O
brother NN NN O
that NN NN O
is NN NN O
living NN NN O
who NN NN O
has NN NN O
angina NNP NNP B-PROBLEM
and NN NN O
a NN NN O
sister NN NN O
who NN NN O
is NN NN O
84 NN NN O
with NN NN O
dementia NNP NNP B-PROBLEM
. NN NN O

She NN NN O
has NN NN O
two NN NN O
adult NN NN O
sons NN NN O
who NN NN O
are NN NN O
in NN NN O
good NN NN O
health NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
The NN NN O
patient NN NN O
has NN NN O
been NN NN O
married NN NN O
to NN NN O
her NN NN O
second NN NN O
husband NN NN O
for NN NN O
the NN NN O
past NN NN O
ten NN NN O
years NN NN O
. NN NN O

Her NN NN O
first NN NN O
husband NN NN O
died NN NN O
in NN NN O
1995 NNP NNP B-DATE
. NN NN O

She NN NN O
does NN NN O
not NN NN O
have NN NN O
a NN NN O
smoking NN NN O
history NN NN O
and NN NN O
does NN NN O
not NN NN O
drink NN NN O
alcohol NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
The NN NN O
patient NN NN O
reports NN NN O
a NNP NNP B-PROBLEM
change NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
bowels NNP NNP I-PROBLEM
ever NN NN O
since NN NN O
she NN NN O
had NN NN O
the NNP NNP B-TREATMENT
stent NNP NNP I-TREATMENT
placed NN NN O
. NN NN O

She NN NN O
has NN NN O
noted NN NN O
some NNP NNP B-PROBLEM
weight NNP NNP I-PROBLEM
loss NNP NNP I-PROBLEM
, NN NN O
but NN NN O
she NN NN O
notes NN NN O
that NN NN O
that NN NN O
is NN NN O
due NN NN O
to NN NN O
not NN NN O
eating NN NN O
very NN NN O
well NN NN O
. NN NN O

She NN NN O
has NN NN O
had NN NN O
some NNP NNP B-PROBLEM
mild NNP NNP I-PROBLEM
fatigue NNP NNP I-PROBLEM
, NN NN O
but NN NN O
prior NN NN O
to NN NN O
her NN NN O
diagnosis NN NN O
she NN NN O
had NN NN O
absolutely NN NN O
no NN NN O
symptoms NNP NNP B-PROBLEM
. NN NN O

As NN NN O
mentioned NN NN O
above NN NN O
, NN NN O
she NN NN O
was NN NN O
noted NN NN O
to NN NN O
have NN NN O
abnormal NNP NNP B-PROBLEM
alkaline NNP NNP I-PROBLEM
phosphatase NNP NNP I-PROBLEM
and NN NN O
total NNP NNP B-TEST
bilirubin NNP NNP I-TEST
, NN NN O
AST NNP NNP B-TEST
and NN NN O
ALT NNP NNP B-TEST
, NN NN O
which NN NN O
prompted NN NN O
the NN NN O
followup NN NN O
. NN NN O

She NN NN O
has NN NN O
had NN NN O
some NNP NNP B-PROBLEM
difficulty NNP NNP I-PROBLEM
with NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
vision NNP NNP I-PROBLEM
that NN NN O
has NN NN O
improved NN NN O
with NN NN O
her NNP NNP B-TREATMENT
recent NNP NNP I-TREATMENT
surgical NNP NNP I-TREATMENT
procedure NNP NNP I-TREATMENT
. NN NN O

She NN NN O
denies NN NN O
any NN NN O
fevers NNP NNP B-PROBLEM
, NN NN O
chills NNP NNP B-PROBLEM
, NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
had NN NN O
loose NNP NNP B-PROBLEM
stools NNP NNP I-PROBLEM
. NN NN O

The NN NN O
rest NN NN O
of NN NN O
her NNP NNP B-TEST
review NNP NNP I-TEST
of NNP NNP I-TEST
systems NNP NNP I-TEST
is NN NN O
negative NN NN O
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
VITALS NN NN O
: NN NN O
BP NNP NNP B-TEST
: NN NN O
108/60 NN NN O
. NN NN O

HEART NN NN O
RATE NN NN O
: NN NN O

80 NN NN O
. NN NN O
TEMP NNP NNP B-TEST
: NN NN O
98.5 NN NN O
. NN NN O

Weight NNP NNP B-TEST
: NN NN O
75 NN NN O
kg NN NN O
. NN NN O

GEN NN NN O
: NN NN O
She NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
female NN NN O
, NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
She NN NN O
has NN NN O
obvious NNP NNP B-PROBLEM
strabismus NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
eye NNP NNP I-PROBLEM
with NN NN O
medial NNP NNP B-PROBLEM
deviation NNP NNP I-PROBLEM
. NN NN O

Her NN NN O
pupils NN NN O
are NN NN O
equal NN NN O
, NN NN O
round NN NN O
, NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
cervical NNP NNP B-PROBLEM
or NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

CV NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
; NN NN O

normal NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
, NN NN O
no NN NN O
murmurs NNP NNP B-PROBLEM
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
, NN NN O
nontender NNP NNP B-PROBLEM
, NN NN O
and NN NN O
nondistended NNP NNP B-PROBLEM
. NN NN O

No NN NN O
palpable NNP NNP B-PROBLEM
masses NNP NNP I-PROBLEM
. NN NN O

No NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

EXT NN NN O
: NN NN O
Lower NN NN O
extremities NN NN O
are NN NN O
without NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

LABORATORY NN NN O
STUDIES NN NN O
: NN NN O
Sodium NNP NNP B-TEST
141 NN NN O
, NN NN O
glucose NNP NNP B-TEST
111 NN NN O
, NN NN O
total NNP NNP B-TEST
bilirubin NNP NNP I-TEST
2.3 NN NN O
, NN NN O
alkaline NNP NNP B-TEST
phosphatase NNP NNP I-TEST
941 NN NN O
, NN NN O
AST NNP NNP B-TEST
161 NN NN O
, NN NN O
and NN NN O
ALT NNP NNP B-TEST
220 NN NN O
. NN NN O

White NNP NNP B-TEST
blood NNP NNP I-TEST
cell NNP NNP I-TEST
count NNP NNP I-TEST
4.3 NN NN O
, NN NN O
hemoglobin NNP NNP B-TEST
11.6 NN NN O
, NN NN O
hematocrit NNP NNP B-TEST
35 NN NN O
, NN NN O
and NN NN O
platelets NNP NNP B-TEST
156,000 NN NN O
. NN NN O

Total NNP NNP B-TEST
bilirubin NNP NNP I-TEST
from NN NN O
August NNP NNP B-DATE
25 NNP NNP I-DATE
, NNP NNP I-DATE
2010 NNP NNP I-DATE
was NN NN O
1.6 NN NN O
, NN NN O
alkaline NNP NNP B-TEST
phosphatase NNP NNP I-TEST
735 NN NN O
, NN NN O
AST NNP NNP B-TEST
123 NN NN O
, NN NN O
ALT NNP NNP B-TEST
184 NN NN O
, NN NN O
CA99 NNP NNP B-TEST
is NN NN O
109 NN NN O
. NN NN O

Bile NNP NNP B-TEST
duct NNP NNP I-TEST
brushings NNP NNP I-TEST
are NN NN O
notable NN NN O
for NN NN O
atypical NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
clusters NNP NNP I-PROBLEM
present NN NN O
, NN NN O
highly NN NN O
suspicious NN NN O
for NN NN O
carcinoma NNP NNP B-PROBLEM
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
77-year-old NN NN O
female NN NN O
who NN NN O
has NN NN O
findings NN NN O
suspicious NN NN O
for NN NN O
a NNP NNP B-PROBLEM
cholangiocarcinoma NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
referred NN NN O
to NN NN O
our NN NN O
office NN NN O
to NN NN O
discuss NN NN O
this NN NN O
diagnosis NN NN O
. NN NN O

I NN NN O
spent NN NN O
greater NN NN O
than NN NN O
an NN NN O
hour NN NN O
with NN NN O
the NN NN O
patient NN NN O
and NN NN O
her NN NN O
husband NN NN O
discussing NN NN O
this NN NN O
potential NN NN O
diagnosis NN NN O
, NN NN O
reviewing NN NN O
the NN NN O
anatomy NN NN O
and NN NN O
answering NN NN O
questions NN NN O
. NN NN O

She NN NN O
is NN NN O
yet NN NN O
to NN NN O
have NN NN O
a NN NN O
surgical NN NN O
consultation NN NN O
, NN NN O
and NN NN O
we NN NN O
discussed NN NN O
the NNP NNP B-PROBLEM
difficulty NNP NNP I-PROBLEM
that NN NN O
we NN NN O
sometimes NN NN O
have NN NN O
with NN NN O
patients NN NN O
meeting NN NN O
surgical NN NN O
criteria NN NN O
to NN NN O
manage NN NN O
cholangiocarcinoma NNP NNP B-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
also NN NN O
had NN NN O
questions NN NN O
about NN NN O
the NN NN O
Medical NN NN O
University NN NN O
and NN NN O
possibly NN NN O
seeking NN NN O
a NN NN O
second NN NN O
opinion NN NN O
. NN NN O

She NN NN O
will NN NN O
contact NN NN O
our NN NN O
office NN NN O
after NN NN O
her NN NN O
surgical NN NN O
consultation NN NN O
if NN NN O
she NN NN O
needs NN NN O
assistance NN NN O
with NN NN O
obtaining NN NN O
a NN NN O
second NN NN O
opinion NN NN O
. NN NN O

We NN NN O
also NN NN O
talked NN NN O
about NN NN O
our NN NN O
clinical NN NN O
research NN NN O
program NN NN O
here NN NN O
. NN NN O

Currently NN NN O
, NN NN O
we NN NN O
do NN NN O
have NN NN O
a NN NN O
Phase NN NN O
II NN NN O
Study NN NN O
for NN NN O
advanced NNP NNP B-PROBLEM
gallbladder NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
or NN NN O
cholangiocarcinoma NNP NNP B-PROBLEM
for NN NN O
patients NN NN O
that NN NN O
are NN NN O
unresectable NN NN O
. NN NN O

We NN NN O
will NN NN O
go NN NN O
ahead NN NN O
and NN NN O
provide NN NN O
her NN NN O
with NN NN O
a NN NN O
consent NN NN O
form NN NN O
so NN NN O
that NN NN O
she NN NN O
can NN NN O
look NN NN O
that NN NN O
over NN NN O
and NN NN O
it NN NN O
will NN NN O
give NN NN O
her NN NN O
some NN NN O
more NN NN O
information NN NN O
about NN NN O
the NNP NNP B-PROBLEM
malignancy NNP NNP I-PROBLEM
and NN NN O
treatment NNP NNP B-TREATMENT
approaches NNP NNP I-TREATMENT
. NN NN O

We NN NN O
will NN NN O
schedule NN NN O
her NN NN O
for NN NN O
followup NN NN O
in NN NN O
three NN NN O
weeks NN NN O
. NN NN O

We NN NN O
will NN NN O
also NN NN O
schedule NN NN O
her NN NN O
for NN NN O
PET/CT NNP NNP B-TEST
scan NNP NNP I-TEST
for NN NN O
staging NNP NNP B-TEST
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
liver NNP NNP B-TEST
function NNP NNP I-TEST
tests NNP NNP I-TEST
, NN NN O
gallbladder NN NN O
, NN NN O
sludge NNP NNP B-PROBLEM
, NN NN O
adenomyomatosis NNP NNP B-PROBLEM
, NN NN O
intrahepatic NNP NNP B-PROBLEM
ductal NNP NNP I-PROBLEM
dilatation NNP NNP I-PROBLEM
, NN NN O
bile NNP NNP B-TEST
duct NNP NNP I-TEST
, NN NN O
ercp NNP NNP B-TEST
, NN NN O
mrcp NNP NNP B-TEST
, NN NN O
cholangiopancreatography NNP NNP B-TEST
, NN NN O
gastroenterology NN NN O
, NN NN O
common NNP NNP B-PROBLEM
bile NNP NNP I-PROBLEM
duct NNP NNP I-PROBLEM
, NN NN O
oropharynx NN NN O
, NN NN O
cholangiocarcinoma NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
BCCa NN NN O
Excision NN NN O
- NN NN O
Nasal NN NN O
Tip NN NN O
Description NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
nasal NNP NNP B-PROBLEM
tip NNP NNP I-PROBLEM
basal NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
previous NNP NNP B-PROBLEM
positive NNP NNP I-PROBLEM
biopsy NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
nasal NNP NNP B-PROBLEM
tip NNP NNP I-PROBLEM
, NN NN O
previous NNP NNP B-PROBLEM
positive NNP NNP I-PROBLEM
biopsy NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
nasal NNP NNP B-PROBLEM
tip NNP NNP I-PROBLEM
, NN NN O
previous NNP NNP B-PROBLEM
positive NNP NNP I-PROBLEM
biopsy NNP NNP I-PROBLEM
. NN NN O

OPERATION NN NN O
PERFORMED NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
nasal NNP NNP B-PROBLEM
tip NNP NNP I-PROBLEM
basal NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

Total NN NN O
area NN NN O
of NN NN O
excision NNP NNP B-TREATMENT
, NN NN O
approximately NN NN O
1 NN NN O
cm NN NN O
to NN NN O
12 NN NN O
mm NN NN O
frozen NNP NNP B-TEST
section NNP NNP I-TEST
x2 NN NN O
, NN NN O
final NN NN O
margins NN NN O
clear NN NN O
. NN NN O

INDICATION NN NN O
: NN NN O
A NN NN O
66-year-old NN NN O
female NN NN O
for NN NN O
excision NNP NNP B-TREATMENT
of NN NN O
nasal NNP NNP B-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

This NN NN O
area NN NN O
is NN NN O
to NN NN O
be NN NN O
excised NN NN O
accordingly NN NN O
and NN NN O
closed NN NN O
. NN NN O

We NN NN O
had NN NN O
multiple NN NN O
discussions NN NN O
regarding NN NN O
types NN NN O
of NN NN O
closure NNP NNP B-TREATMENT
. NN NN O

SUMMARY NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
brought NN NN O
to NN NN O
the NN NN O
OR NN NN O
in NN NN O
satisfactory NN NN O
condition NN NN O
and NN NN O
placed NN NN O
supine NN NN O
on NN NN O
the NN NN O
OR NN NN O
table NN NN O
. NN NN O

Underwent NN NN O
general NN NN O
anesthesia NNP NNP B-DRUG
along NN NN O
with NN NN O
Marcaine NNP NNP B-DRUG
in NN NN O
the NN NN O
nasal NN NN O
tip NN NN O
areas NN NN O
for NN NN O
planned NNP NNP B-TREATMENT
excision NNP NNP I-TREATMENT
. NN NN O

The NN NN O
area NN NN O
was NN NN O
injected NN NN O
, NN NN O
after NN NN O
sterile NNP NNP B-TREATMENT
prep NNP NNP I-TREATMENT
and NN NN O
drape NNP NNP B-TREATMENT
, NN NN O
with NN NN O
Marcaine NNP NNP B-DRUG
0.25% NNP NNP I-DRUG
with NNP NNP I-DRUG
1:200,000 NNP NNP I-DRUG
adrenaline NNP NNP B-DRUG
. NN NN O

The NNP NNP B-TEST
specimen NNP NNP I-TEST
was NN NN O
sent NN NN O
to NN NN O
pathology NN NN O
. NN NN O

Margins NN NN O
were NN NN O
still NN NN O
positive NN NN O
at NN NN O
the NN NN O
inferior NN NN O
6 NN NN O
o'clock NN NN O
***** NN NN O
margin NN NN O
and NN NN O
this NN NN O
was NN NN O
resubmitted NN NN O
accordingly NN NN O
. NN NN O

Final NN NN O
margins NN NN O
were NN NN O
clear NN NN O
. NN NN O

Closure NNP NNP B-TREATMENT
consisted NN NN O
of NN NN O
undermining NN NN O
circumferentially NN NN O
. NN NN O

Advancement NN NN O
closure NNP NNP B-TREATMENT
with NN NN O
dog NNP NNP B-TREATMENT
ear NNP NNP I-TREATMENT
removal NNP NNP I-TREATMENT
distally NN NN O
and NN NN O
proximally NN NN O
was NN NN O
accomplished NN NN O
without NN NN O
difficulty NN NN O
. NN NN O

Closure NNP NNP B-TREATMENT
with NN NN O
interrupted NN NN O
5-0 NN NN O
Monocryl NNP NNP B-TREATMENT
running NNP NNP I-TREATMENT
7-0 NNP NNP I-TREATMENT
nylon NNP NNP I-TREATMENT
followed NN NN O
by NN NN O
Xeroform NNP NNP B-TREATMENT
gauze NNP NNP I-TREATMENT
, NN NN O
light NNP NNP B-TREATMENT
pressure NNP NNP I-TREATMENT
dressing NNP NNP I-TREATMENT
, NN NN O
and NN NN O
Steri-Strips NNP NNP B-TREATMENT
. NN NN O

The NN NN O
patient NN NN O
is NN NN O
discharged NN NN O
on NN NN O
minocycline NNP NNP B-DRUG
and NN NN O
Darvocet-N NNP NNP B-DRUG
100 NNP NNP I-DRUG
. NN NN O

NOTE NN NN O
: NN NN O
The NNP NNP B-TREATMENT
2.6 NNP NNP I-TREATMENT
mm NNP NNP I-TREATMENT
loupe NNP NNP I-TREATMENT
magnification NNP NNP I-TREATMENT
was NN NN O
utilized NN NN O
throughout NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
. NN NN O

No NN NN O
complications NNP NNP B-PROBLEM
noted NN NN O
with NN NN O
excellent NN NN O
and NN NN O
all NN NN O
clear NN NN O
margins NN NN O
at NN NN O
the NN NN O
termination NN NN O
. NN NN O

An NNP NNP B-TREATMENT
advancement NNP NNP I-TREATMENT
closure NNP NNP I-TREATMENT
technique NNP NNP I-TREATMENT
was NN NN O
utilized NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
closure NNP NNP B-TREATMENT
, NN NN O
steri-strips NNP NNP B-TREATMENT
, NN NN O
xeroform NNP NNP B-TREATMENT
gauze NNP NNP I-TREATMENT
, NN NN O
excision NNP NNP B-TREATMENT
, NN NN O
light NNP NNP B-TREATMENT
pressure NNP NNP I-TREATMENT
dressing NNP NNP I-TREATMENT
, NN NN O
loupe NNP NNP B-TEST
magnification NNP NNP I-TEST
, NN NN O
nasal NNP NNP B-TREATMENT
tip NNP NNP I-TREATMENT
, NN NN O
basal NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
basal NN NN O
cell NN NN O
, NN NN O
cell NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
biopsy NNP NNP B-TEST
, NN NN O
basal NN NN O
, NN NN O
carcinoma NNP NNP B-PROBLEM
, NN NN O
nasal NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Colon NNP NNP B-PROBLEM
Polyps NNP NNP I-PROBLEM
- NN NN O
Genetic NN NN O
Counseling NN NN O
Description NN NN O
: NN NN O
Genetic NN NN O
counseling NN NN O
for NN NN O
a NN NN O
strong NN NN O
family NN NN O
history NN NN O
of NN NN O
colon NNP NNP B-PROBLEM
polyps NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
had NN NN O
colonoscopies NNP NNP B-TEST
required NN NN O
every NN NN O
five NN NN O
years NN NN O
and NN NN O
every NN NN O
time NN NN O
she NN NN O
has NN NN O
polyps NNP NNP B-PROBLEM
were NN NN O
found NN NN O
. NN NN O

She NN NN O
reports NN NN O
that NN NN O
of NN NN O
her NN NN O
11 NN NN O
brothers NN NN O
and NN NN O
sister NN NN O
7 NN NN O
have NN NN O
had NN NN O
precancerous NNP NNP B-PROBLEM
polyps NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULT NN NN O
: NN NN O
Genetic NN NN O
counseling NN NN O
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
61-year-old NN NN O
female NN NN O
with NN NN O
a NN NN O
strong NN NN O
family NN NN O
history NN NN O
of NN NN O
colon NNP NNP B-PROBLEM
polyps NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
reports NN NN O
her NNP NNP B-PROBLEM
first NNP NNP I-PROBLEM
polyps NNP NNP I-PROBLEM
noted NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O

50 NN NN O
. NN NN O
She NN NN O
has NN NN O
had NN NN O
colonoscopies NNP NNP B-TEST
required NN NN O
every NN NN O
five NN NN O
years NN NN O
and NN NN O
every NN NN O
time NN NN O
she NN NN O
has NN NN O
polyps NNP NNP B-PROBLEM
were NN NN O
found NN NN O
. NN NN O

She NN NN O
reports NN NN O
that NN NN O
of NN NN O
her NN NN O
11 NN NN O
brothers NN NN O
and NN NN O
sister NN NN O
7 NN NN O
have NN NN O
had NN NN O
precancerous NNP NNP B-PROBLEM
polyps NNP NNP I-PROBLEM
. NN NN O

She NN NN O
does NN NN O
have NN NN O
an NN NN O
identical NN NN O
twice NN NN O
who NN NN O
is NN NN O
the NN NN O
one NN NN O
of NN NN O
the NN NN O
11 NN NN O
who NN NN O
has NN NN O
never NN NN O
had NN NN O
a NN NN O
history NN NN O
of NN NN O
polyps NNP NNP B-PROBLEM
. NN NN O

She NN NN O
also NN NN O
has NN NN O
history NN NN O
of NN NN O
several NNP NNP B-PROBLEM
malignancies NNP NNP I-PROBLEM
in NN NN O
the NN NN O
family NN NN O
. NN NN O

Her NN NN O
father NN NN O
died NN NN O
of NN NN O
a NNP NNP B-PROBLEM
brain NNP NNP I-PROBLEM
tumor NNP NNP I-PROBLEM
at NN NN O
the NN NN O
age NN NN O
of NN NN O

81 NN NN O
. NN NN O
There NN NN O
is NN NN O
no NN NN O
history NN NN O
of NN NN O
knowing NN NN O
whether NN NN O
this NN NN O
was NN NN O
a NNP NNP B-PROBLEM
primary NNP NNP I-PROBLEM
brain NNP NNP I-PROBLEM
tumor NNP NNP I-PROBLEM
or NN NN O
whether NN NN O
it NN NN O
is NN NN O
a NNP NNP B-PROBLEM
metastatic NNP NNP I-PROBLEM
brain NNP NNP I-PROBLEM
involvement NNP NNP I-PROBLEM
. NN NN O

Her NN NN O
sister NN NN O
died NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O
65 NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
two NN NN O
maternal NN NN O
aunts NN NN O
with NN NN O
history NN NN O
of NN NN O
lung NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
both NN NN O
of NN NN O
whom NN NN O
were NN NN O
smoker NN NN O
. NN NN O

Also NN NN O
a NN NN O
paternal NN NN O
grandmother NN NN O
who NN NN O
was NN NN O
diagnosed NN NN O
with NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
at NN NN O
86 NN NN O
and NN NN O
a NN NN O
paternal NN NN O
grandfather NN NN O
who NN NN O
had NN NN O
lung NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

There NN NN O
is NN NN O
no NN NN O
other NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
history NNP NNP I-PROBLEM
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Significant NN NN O
for NN NN O
asthma NNP NNP B-PROBLEM
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Include NN NN O
Serevent NNP NNP B-DRUG
two NNP NNP I-DRUG
puffs NNP NNP I-DRUG
daily NN NN O
and NN NN O
Nasonex NNP NNP B-DRUG
two NNP NNP I-DRUG
sprays NNP NNP I-DRUG
daily NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
Include NN NN O
penicillin NNP NNP B-DRUG
. NN NN O

She NN NN O
is NN NN O
also NN NN O
allergic NNP NNP B-PROBLEM
seafood NNP NNP I-PROBLEM
; NN NN O

crab NN NN O
and NN NN O
mobster NNP NNP B-TREATMENT
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
married NN NN O
. NN NN O

She NN NN O
was NN NN O
born NN NN O
and NN NN O
raised NN NN O
in NN NN O
South NN NN O
Dakota NN NN O
. NN NN O

She NN NN O
moved NN NN O
to NN NN O
Colorado NN NN O
37 NN NN O
years NN NN O
ago NN NN O
. NN NN O

She NN NN O
attended NN NN O
collage NN NN O
at NN NN O
the NN NN O
Colorado NN NN O
University NN NN O
. NN NN O

She NN NN O
is NN NN O
certified NN NN O
public NN NN O
account NN NN O
. NN NN O

She NN NN O
does NN NN O
not NN NN O
smoke NN NN O
. NN NN O

She NN NN O
drinks NN NN O
socially NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
The NN NN O
patient NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
dark NNP NNP I-PROBLEM
stool NNP NNP I-PROBLEM
or NN NN O
blood NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
stool NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
had NN NN O
occasional NNP NNP B-PROBLEM
night NNP NNP I-PROBLEM
sweats NNP NNP I-PROBLEM
and NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
, NN NN O
and NN NN O
cough NNP NNP B-PROBLEM
associated NN NN O
with NN NN O
her NNP NNP B-PROBLEM
asthma NNP NNP I-PROBLEM
. NN NN O

She NN NN O
also NN NN O
complains NN NN O
of NN NN O
some NNP NNP B-PROBLEM
acid NNP NNP I-PROBLEM
reflux NNP NNP I-PROBLEM
as NN NN O
well NN NN O
as NN NN O
anxiety NNP NNP B-PROBLEM
. NN NN O

She NN NN O
does NN NN O
report NN NN O
having NN NN O
knee NNP NNP B-TREATMENT
surgery NNP NNP I-TREATMENT
for NN NN O
torn NN NN O
ACL NN NN O
on NN NN O
the NN NN O
left NN NN O
knee NN NN O
and NN NN O
has NN NN O
some NNP NNP B-PROBLEM
arthritis NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
that NNP NNP I-PROBLEM
knee NNP NNP I-PROBLEM
. NN NN O

The NN NN O
rest NN NN O
of NN NN O
her NNP NNP B-TEST
review NNP NNP I-TEST
of NNP NNP I-TEST
systems NNP NNP I-TEST
is NN NN O
negative NN NN O
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
VITALS NN NN O
: NN NN O
BP NNP NNP B-TEST
: NN NN O
110/58 NN NN O
. NN NN O

HEART NN NN O
RATE NN NN O
: NN NN O

76 NN NN O
. NN NN O
TEMP NNP NNP B-TEST
: NN NN O
98.2 NN NN O
. NN NN O

Weight NNP NNP B-TEST
: NN NN O
79.1 NN NN O
kg NN NN O
. NN NN O

GEN NN NN O
: NN NN O
She NN NN O
is NN NN O
very NN NN O
pleasant NN NN O
female NN NN O
, NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
Pupils NN NN O
are NN NN O
equal NN NN O
, NN NN O
round NN NN O
, NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O

Sclerae NN NN O
are NN NN O
anicteric NNP NNP B-PROBLEM
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
cervical NNP NNP B-PROBLEM
or NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

CV NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
; NN NN O

normal NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
, NN NN O
no NN NN O
murmurs NNP NNP B-PROBLEM
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
. NN NN O

She NN NN O
has NN NN O
positive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

EXT NN NN O
: NN NN O
No NN NN O
lower NNP NNP B-PROBLEM
extremity NNP NNP I-PROBLEM
edema NNP NNP I-PROBLEM
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
61-year-old NN NN O
female NN NN O
with NN NN O
strong NN NN O
family NN NN O
history NN NN O
of NN NN O
colon NNP NNP B-PROBLEM
polyps NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
reports NN NN O
that NN NN O
her NN NN O
siblings NN NN O
have NN NN O
been NN NN O
very NN NN O
diligent NN NN O
about NN NN O
their NN NN O
preventing NN NN O
health NN NN O
and NN NN O
no NN NN O
one NN NN O
besides NN NN O
her NN NN O
sister NN NN O
who NN NN O
presented NN NN O
with NN NN O
the NNP NNP B-PROBLEM
advanced NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
add NN NN O
anything NNP NNP B-PROBLEM
more NNP NNP I-PROBLEM
than NNP NNP I-PROBLEM
precancerous NNP NNP I-PROBLEM
adenomas NNP NNP I-PROBLEM
. NN NN O

We NN NN O
will NN NN O
plan NN NN O
on NN NN O
proceeding NN NN O
with NN NN O
testing NNP NNP B-TEST
for NN NN O
adenomatous NNP NNP B-PROBLEM
polyps NNP NNP I-PROBLEM
. NN NN O

I NN NN O
will NN NN O
see NN NN O
her NN NN O
back NN NN O
in NN NN O
clinic NN NN O
once NN NN O
we NN NN O
get NN NN O
the NN NN O
results NN NN O
. NN NN O

I NN NN O
appreciate NN NN O
the NN NN O
referral NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
family NN NN O
history NN NN O
, NN NN O
strong NN NN O
family NN NN O
history NN NN O
, NN NN O
precancerous NNP NNP B-PROBLEM
polyps NNP NNP I-PROBLEM
, NN NN O
brain NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
, NN NN O
lung NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
genetic NNP NNP B-PROBLEM
counseling NNP NNP I-PROBLEM
, NN NN O
colon NNP NNP B-PROBLEM
polyps NNP NNP I-PROBLEM
, NN NN O
polyps NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Hematology NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Leukocytosis NNP NNP B-PROBLEM
, NN NN O
acute NNP NNP B-PROBLEM
deep NNP NNP I-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
, NN NN O
right NNP NNP B-PROBLEM
lower NNP NNP I-PROBLEM
extremity NNP NNP I-PROBLEM
with NN NN O
bilateral NNP NNP B-PROBLEM
pulmonary NNP NNP I-PROBLEM
embolism NNP NNP I-PROBLEM
, NN NN O
on NN NN O
intravenous NNP NNP B-DRUG
heparin NNP NNP I-DRUG
complicated NN NN O
with NN NN O
acute NNP NNP B-PROBLEM
renal NNP NNP I-PROBLEM
failure NNP NNP I-PROBLEM
for NN NN O
evaluation NNP NNP B-TEST
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULTATION NN NN O
: NN NN O
Acute NNP NNP B-PROBLEM
deep NNP NNP I-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
, NN NN O
right NN NN O
lower NN NN O
extremity NN NN O
with NN NN O
bilateral NNP NNP B-PROBLEM
pulmonary NNP NNP I-PROBLEM
embolism NNP NNP I-PROBLEM
, NN NN O
on NN NN O
intravenous NNP NNP B-DRUG
heparin NNP NNP I-DRUG
complicated NN NN O
with NN NN O
acute NNP NNP B-PROBLEM
renal NNP NNP I-PROBLEM
failure NNP NNP I-PROBLEM
for NN NN O
evaluation NNP NNP B-TEST
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENTING NN NN O
ILLNESS NN NN O
: NN NN O
Briefly NN NN O
, NN NN O
this NN NN O
is NN NN O
a NN NN O
36-year-old NN NN O
robust NN NN O
Caucasian NN NN O
gentleman NN NN O
with NN NN O
no NN NN O
significant NN NN O
past NN NN O
medical NN NN O
or NN NN O
surgical NN NN O
history NN NN O
, NN NN O
who NN NN O
works NN NN O
as NN NN O
a NN NN O
sales NN NN O
representative NN NN O
, NN NN O
doing NN NN O
a NN NN O
lot NN NN O
of NN NN O
traveling NN NN O
by NN NN O
plane NN NN O
and NN NN O
car NN NN O
and NN NN O
attending NN NN O
several NN NN O
sales NN NN O
shows NN NN O
, NN NN O
developed NN NN O
acute NNP NNP B-PROBLEM
shortness NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
with NN NN O
an NN NN O
episode NN NN O
of NN NN O
syncope NNP NNP B-PROBLEM
this NN NN O
weekend NN NN O
and NN NN O
was NN NN O
brought NN NN O
in NN NN O
by NN NN O
paramedics NN NN O
to NN NN O
Hospital NN NN O
. NN NN O

A NNP NNP B-TEST
V/Q NNP NNP I-TEST
scan NNP NNP I-TEST
revealed NN NN O
multiple NNP NNP B-PROBLEM
pulmonary NNP NNP I-PROBLEM
perfusion NNP NNP I-PROBLEM
defects NNP NNP I-PROBLEM
consistent NN NN O
with NN NN O
high NNP NNP B-PROBLEM
probability NNP NNP I-PROBLEM
pulmonary NNP NNP I-PROBLEM
embolism NNP NNP I-PROBLEM
. NN NN O

A NNP NNP B-TEST
Doppler NNP NNP I-TEST
venous NNP NNP I-TEST
study NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
lower NNP NNP I-TEST
extremity NNP NNP I-TEST
also NN NN O
revealed NN NN O
nonocclusive NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
popliteal NNP NNP I-PROBLEM
vein NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
. NN NN O

A NNP NNP B-TEST
CT NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
abdomen NNP NNP I-TEST
and NNP NNP I-TEST
pelvis NNP NNP I-TEST
revealed NN NN O
normal-appearing NN NN O
liver NN NN O
, NN NN O
spleen NN NN O
, NN NN O
and NN NN O
pancreas NN NN O
; NN NN O

however NN NN O
, NN NN O
the NN NN O
right NN NN O
kidney NN NN O
appeared NN NN O
smaller NN NN O
compared NN NN O
to NN NN O
left NN NN O
and NN NN O
suggesting NN NN O
possibility NN NN O
of NN NN O
renal NNP NNP B-PROBLEM
infarct NNP NNP I-PROBLEM
. NN NN O

Renal NNP NNP B-TEST
function NNP NNP I-TEST
on NNP NNP I-TEST
admission NNP NNP I-TEST
was NN NN O
within NN NN O
normal NN NN O
range NN NN O
; NN NN O

however NN NN O
, NN NN O
serial NNP NNP B-TEST
renal NNP NNP I-TEST
function NNP NNP I-TEST
showed NN NN O
rapid NNP NNP B-PROBLEM
increase NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
creatinine NNP NNP I-PROBLEM
to NN NN O
5 NN NN O
today NN NN O
. NN NN O

He NN NN O
has NN NN O
been NN NN O
on NN NN O
intravenous NNP NNP B-DRUG
heparin NNP NNP I-DRUG
and NN NN O
hemodialysis NNP NNP B-TREATMENT
is NN NN O
being NN NN O
planned NN NN O
for NN NN O
tomorrow NN NN O
. NN NN O

Reviewing NN NN O
his NN NN O
history NN NN O
, NN NN O
there NN NN O
is NN NN O
no NN NN O
family NN NN O
members NN NN O
with NN NN O
hypercoagulable NNP NNP B-PROBLEM
state NNP NNP I-PROBLEM
or NN NN O
prior NN NN O
history NN NN O
of NN NN O
any NNP NNP B-PROBLEM
thrombotic NNP NNP I-PROBLEM
complication NNP NNP I-PROBLEM
. NN NN O

He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
recent NNP NNP I-PROBLEM
injury NNP NNP I-PROBLEM
to NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
extremity NNP NNP I-PROBLEM
and NN NN O
in NN NN O
fact NN NN O
denied NN NN O
any NNP NNP B-PROBLEM
calf NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
or NN NN O
swelling NNP NNP B-PROBLEM
. NN NN O

PAST NN NN O
MEDICAL NN NN O
AND NN NN O
SURGICAL NN NN O
HISTORY NN NN O
: NN NN O
Unremarkable NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
is NN NN O
married NN NN O
and NN NN O
has NN NN O
1 NN NN O
son NN NN O
. NN NN O

He NN NN O
has NN NN O
a NN NN O
brother NN NN O
who NN NN O
is NN NN O
healthy NN NN O
. NN NN O

There NN NN O
is NN NN O
no NN NN O
history NN NN O
of NN NN O
tobacco NN NN O
use NN NN O
or NN NN O
alcohol NN NN O
use NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
No NN NN O
family NN NN O
history NN NN O
of NN NN O
hypercoagulable NNP NNP B-PROBLEM
condition NNP NNP I-PROBLEM
. NN NN O

MEDICATIONS NN NN O
: NN NN O
Advil NNP NNP B-DRUG
p.r.n NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
NONE NNP NNP B-DRUG
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
Essentially NN NN O
unremarkable NN NN O
except NN NN O
for NN NN O
sudden NNP NNP B-PROBLEM
onset NNP NNP I-PROBLEM
dyspnea NNP NNP I-PROBLEM
on NN NN O
easy NN NN O
exertion NN NN O
complicated NN NN O
with NN NN O
episode NN NN O
of NN NN O
syncope NNP NNP B-PROBLEM
. NN NN O

He NN NN O
denied NN NN O
any NNP NNP B-PROBLEM
hemoptysis NNP NNP I-PROBLEM
. NN NN O

He NN NN O
denied NN NN O
any NNP NNP B-PROBLEM
calf NNP NNP I-PROBLEM
swelling NNP NNP I-PROBLEM
or NN NN O
pain NNP NNP B-PROBLEM
. NN NN O

Lately NN NN O
, NN NN O
he NN NN O
has NN NN O
been NN NN O
traveling NN NN O
and NN NN O
has NN NN O
been NN NN O
sitting NN NN O
behind NN NN O
a NN NN O
desk NN NN O
for NN NN O
a NN NN O
long NN NN O
period NN NN O
of NN NN O
time NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
GENERAL NN NN O
: NN NN O
He NN NN O
is NN NN O
a NN NN O
robust NN NN O
young NN NN O
gentleman NN NN O
, NN NN O
awake NN NN O
, NN NN O
alert NN NN O
, NN NN O
and NN NN O
hemodynamically NN NN O
stable NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
Sclerae NNP NNP B-PROBLEM
anicteric NNP NNP I-PROBLEM
. NN NN O

Conjunctivae NN NN O
normal NN NN O
. NN NN O

Oropharynx NN NN O
normal NN NN O
. NN NN O

NECK NN NN O
: NN NN O
No NN NN O
adenopathy NNP NNP B-PROBLEM
or NN NN O
thyromegaly NNP NNP B-PROBLEM
. NN NN O

No NN NN O
jugular NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
distention NNP NNP I-PROBLEM
. NN NN O

HEART NN NN O
: NN NN O
Regular NN NN O
. NN NN O

LUNGS NN NN O
: NN NN O
Bilateral NN NN O
air NN NN O
entry NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Obese NNP NNP B-PROBLEM
and NN NN O
benign NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
calf NNP NNP B-PROBLEM
swelling NNP NNP I-PROBLEM
or NN NN O
calf NNP NNP B-PROBLEM
tenderness NNP NNP I-PROBLEM
appreciated NN NN O
. NN NN O

SKIN NN NN O
: NN NN O
No NN NN O
petechiae NNP NNP B-PROBLEM
or NN NN O
ecchymosis NNP NNP B-PROBLEM
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Nonfocal NN NN O
. NN NN O

LABORATORY NN NN O
FINDINGS NN NN O
: NN NN O
Blood NNP NNP B-TEST
count NNP NNP I-TEST
obtained NN NN O
showed NN NN O
a NNP NNP B-TEST
white NNP NNP I-TEST
count NNP NNP I-TEST
of NN NN O
16.8 NN NN O
, NN NN O
hemoglobin NNP NNP B-TEST
14.8 NN NN O
g NN NN O
percent NN NN O
, NN NN O
hematocrit NNP NNP B-TEST
44.6% NN NN O
, NN NN O
MCV NNP NNP B-TEST
94 NN NN O
, NN NN O
and NN NN O
platelet NNP NNP B-TEST
count NNP NNP I-TEST
209,000 NN NN O
. NN NN O

Liver NN NN O
profile NN NN O
normal NN NN O
. NN NN O

Thyroid NNP NNP B-TEST
study NNP NNP I-TEST
revealed NN NN O
a NNP NNP B-TEST
TSH NNP NNP I-TEST
of NN NN O
1.3 NN NN O
. NN NN O

Prothrombin NNP NNP B-TEST
time/INR NNP NNP I-TEST
1.5 NN NN O
, NN NN O
partial NN NN O
thromboplastin NNP NNP B-DRUG
time NN NN O
78.6 NN NN O
seconds NN NN O
. NN NN O

Renal NN NN O
function NN NN O
, NN NN O
BUN NNP NNP B-TEST
44 NN NN O
and NN NN O
creatinine NNP NNP B-TEST
5.7 NN NN O
. NN NN O

Echocardiogram NNP NNP B-TEST
revealed NN NN O
left NNP NNP B-PROBLEM
ventricular NNP NNP I-PROBLEM
hypertrophy NNP NNP I-PROBLEM
with NN NN O
ejection NNP NNP B-TEST
fraction NNP NNP I-TEST
of NN NN O
65% NN NN O
, NN NN O
no NN NN O
intramural NNP NNP B-PROBLEM
thrombus NNP NNP I-PROBLEM
noted NN NN O
. NN NN O

IMPRESSION NN NN O
: NN NN O

1 NN NN O
. NN NN O
Bilateral NNP NNP B-PROBLEM
pulmonary NNP NNP I-PROBLEM
embolism NNP NNP I-PROBLEM
, NN NN O
most NN NN O
consistent NN NN O
with NN NN O
emboli NNP NNP B-PROBLEM
from NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
extremity NNP NNP I-PROBLEM
, NN NN O
on NN NN O
intravenous NNP NNP B-DRUG
heparin NNP NNP I-DRUG
, NN NN O
rule NN NN O
out NN NN O
hereditary NNP NNP B-PROBLEM
hypercoagulable NNP NNP I-PROBLEM
state NNP NNP I-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
Leukocytosis NNP NNP B-PROBLEM
, NN NN O
most NN NN O
likely NN NN O
leukemoid NNP NNP B-PROBLEM
reaction NNP NNP I-PROBLEM
secondary NN NN O
to NN NN O
acute NNP NNP B-PROBLEM
pulmonary NNP NNP I-PROBLEM
embolism/renal NNP NNP I-PROBLEM
infarction NNP NNP I-PROBLEM
, NN NN O
doubt NN NN O
presence NN NN O
of NN NN O
myeloproliferative NNP NNP B-PROBLEM
disorder NNP NNP I-PROBLEM
. NN NN O

3 NN NN O
. NN NN O
Acute NNP NNP B-PROBLEM
renal NNP NNP I-PROBLEM
failure NNP NNP I-PROBLEM
secondary NN NN O
to NN NN O
embolic NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
renal NNP NNP I-PROBLEM
infarction NNP NNP I-PROBLEM
. NN NN O

4 NN NN O
. NN NN O
Obesity NNP NNP B-PROBLEM
. NN NN O

PLAN NN NN O
: NN NN O
From NN NN O
hematologic NN NN O
standpoint NN NN O
, NN NN O
we NN NN O
will NN NN O
await NN NN O
hypercoagulable NNP NNP B-TEST
studies NNP NNP I-TEST
, NN NN O
which NN NN O
have NN NN O
all NN NN O
been NN NN O
sent NN NN O
on NN NN O
admission NN NN O
to NN NN O
see NN NN O
if NN NN O
a NNP NNP B-PROBLEM
hereditary NNP NNP I-PROBLEM
component NNP NNP I-PROBLEM
is NN NN O
at NN NN O
play NN NN O
. NN NN O

For NN NN O
now NN NN O
, NN NN O
we NN NN O
will NN NN O
continue NN NN O
intravenous NNP NNP B-DRUG
heparin NNP NNP I-DRUG
and NN NN O
subsequent NN NN O
oral NNP NNP B-DRUG
anticoagulation NNP NNP I-DRUG
with NN NN O
Coumadin NNP NNP B-DRUG
. NN NN O

In NN NN O
view NN NN O
of NN NN O
worsening NNP NNP B-PROBLEM
renal NNP NNP I-PROBLEM
function NNP NNP I-PROBLEM
, NN NN O
may NN NN O
need NN NN O
temporary NNP NNP B-TREATMENT
hemodialysis NNP NNP I-TREATMENT
until NN NN O
renal NN NN O
function NN NN O
improves NN NN O
. NN NN O

I NN NN O
discussed NN NN O
at NN NN O
length NN NN O
with NN NN O
the NN NN O
patient's NN NN O
wife NN NN O
at NN NN O
the NN NN O
bedside NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
thrombosis NNP NNP B-PROBLEM
, NN NN O
heparin NNP NNP B-DRUG
, NN NN O
leukemoid NNP NNP B-PROBLEM
, NN NN O
pulmonary NNP NNP B-PROBLEM
embolism NNP NNP I-PROBLEM
, NN NN O
renal NNP NNP B-PROBLEM
function NNP NNP I-PROBLEM
, NN NN O
intravenous NNP NNP B-TREATMENT
, NN NN O
leukocytosis NNP NNP B-PROBLEM
, NN NN O
venous NNP NNP B-PROBLEM
, NN NN O
hypercoagulable NNP NNP B-PROBLEM
, NN NN O
embolism NNP NNP B-PROBLEM
, NN NN O
function NN NN O
, NN NN O
hematology NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Parathyroid NN NN O
Adenoma NN NN O
Excision NN NN O
Description NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
right NNP NNP B-PROBLEM
superior NNP NNP I-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
, NN NN O
seen NN NN O
on NN NN O
sestamibi NNP NNP B-TEST
parathyroid NNP NNP I-TEST
scan NNP NNP I-TEST
and NN NN O
an NNP NNP B-TEST
ultrasound NNP NNP I-TEST
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Right NNP NNP B-PROBLEM
superior NNP NNP I-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Right NNP NNP B-PROBLEM
superior NNP NNP I-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
. NN NN O

PROCEDURE NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
right NNP NNP B-PROBLEM
superior NNP NNP I-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
. NN NN O

ANESTHESIA NN NN O
: NN NN O
Local NNP NNP B-DRUG
with NNP NNP I-DRUG
1% NNP NNP I-DRUG
Xylocaine NNP NNP B-DRUG
and NN NN O
anesthesia NNP NNP B-DRUG
standby NN NN O
with NN NN O
sedation NNP NNP B-DRUG
. NN NN O

CLINICAL NN NN O
HISTORY NN NN O
: NN NN O
This NN NN O
80-year-old NN NN O
woman NN NN O
has NN NN O
had NN NN O
some NNP NNP B-PROBLEM
mild NNP NNP I-PROBLEM
dementia NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
begun NN NN O
on NN NN O
Aricept NNP NNP B-DRUG
but NN NN O
could NN NN O
not NN NN O
tolerate NN NN O
that NN NN O
because NN NN O
of NN NN O
strange NNP NNP B-PROBLEM
thoughts NNP NNP I-PROBLEM
and NN NN O
hallucinations NNP NNP B-PROBLEM
. NN NN O

She NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
hypercalcemic NNP NNP B-PROBLEM
. NN NN O

Intact NNP NNP B-TEST
PTH NNP NNP I-TEST
was NN NN O
mildly NNP NNP B-PROBLEM
elevated NNP NNP I-PROBLEM
. NN NN O

A NNP NNP B-TEST
sestamibi NNP NNP I-TEST
parathyroid NNP NNP I-TEST
scan NNP NNP I-TEST
and NN NN O
an NNP NNP B-TEST
ultrasound NNP NNP I-TEST
showed NN NN O
evidence NN NN O
of NN NN O
a NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
superior NNP NNP I-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
. NN NN O

FINDINGS NN NN O
AND NN NN O
PROCEDURE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
placed NN NN O
on NN NN O
the NN NN O
operating NN NN O
table NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
. NN NN O

A NN NN O
time NN NN O
out NN NN O
was NN NN O
taken NN NN O
so NN NN O
that NN NN O
the NN NN O
anesthesia NN NN O
personnel NN NN O
, NN NN O
nursing NN NN O
personnel NN NN O
, NN NN O
surgical NN NN O
team NN NN O
, NN NN O
and NN NN O
patient NN NN O
could NN NN O
confirm NN NN O
the NN NN O
patient's NN NN O
identity NN NN O
, NN NN O
operative NNP NNP B-PROBLEM
site NNP NNP I-PROBLEM
and NN NN O
operative NN NN O
plan NN NN O
. NN NN O

The NN NN O
electronic NN NN O
medical NN NN O
record NN NN O
was NN NN O
reviewed NN NN O
as NN NN O
was NN NN O
the NNP NNP B-TEST
ultrasound NNP NNP I-TEST
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
sedated NNP NNP B-TREATMENT
. NN NN O

A NNP NNP B-TREATMENT
small NNP NNP I-TREATMENT
roll NNP NNP I-TREATMENT
was NN NN O
placed NN NN O
behind NN NN O
the NN NN O
shoulders NN NN O
to NN NN O
moderately NNP NNP B-PROBLEM
hyperextend NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
. NN NN O

The NN NN O
head NN NN O
was NN NN O
supported NN NN O
in NN NN O
a NNP NNP B-TREATMENT
foam NNP NNP I-TREATMENT
head NNP NNP I-TREATMENT
cradle NNP NNP I-TREATMENT
. NN NN O

The NN NN O
neck NN NN O
and NN NN O
chest NN NN O
were NN NN O
prepped NN NN O
with NN NN O
chlorhexidine NNP NNP B-TREATMENT
and NN NN O
isolated NN NN O
with NN NN O
sterile NNP NNP B-TREATMENT
drapes NNP NNP I-TREATMENT
. NN NN O

After NN NN O
infiltration NNP NNP B-PROBLEM
with NN NN O
1% NNP NNP B-DRUG
Xylocaine NNP NNP I-DRUG
with NN NN O
epinephrine NNP NNP B-DRUG
along NN NN O
the NNP NNP B-PROBLEM
planned NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
, NN NN O
a NNP NNP B-PROBLEM
transverse NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
in NN NN O
the NN NN O
skin NN NN O
crease NN NN O
a NN NN O
couple NN NN O
of NN NN O
centimeters NN NN O
above NN NN O
the NN NN O
clavicular NN NN O
heads NN NN O
and NN NN O
carried NN NN O
down NN NN O
through NN NN O
the NN NN O
skin NN NN O
, NN NN O
subcutaneous NN NN O
tissue NN NN O
, NN NN O
and NN NN O
platysma NN NN O
. NN NN O

The NN NN O
larger NN NN O
anterior NN NN O
neck NN NN O
veins NN NN O
were NN NN O
divided NN NN O
between NN NN O
4-0 NNP NNP B-TREATMENT
silk NNP NNP I-TREATMENT
ligatures NNP NNP I-TREATMENT
. NN NN O

Superior NNP NNP B-TREATMENT
and NNP NNP I-TREATMENT
inferior NNP NNP I-TREATMENT
flaps NNP NNP I-TREATMENT
were NN NN O
developed NN NN O
in NN NN O
the NN NN O
subplatysmal NN NN O
plane NN NN O
using NN NN O
electrocautery NNP NNP B-TREATMENT
and NN NN O
blunt NNP NNP B-TREATMENT
dissection NNP NNP I-TREATMENT
. NN NN O

The NN NN O
sternohyoid NN NN O
muscles NN NN O
were NN NN O
separated NN NN O
in NN NN O
the NN NN O
midline NN NN O
, NN NN O
and NN NN O
the NN NN O
right NN NN O
sternohyoid NN NN O
muscle NN NN O
was NN NN O
retracted NN NN O
laterally NN NN O
. NN NN O

The NN NN O
right NN NN O
sternothyroid NN NN O
muscle NN NN O
was NN NN O
divided NN NN O
transversely NN NN O
with NN NN O
the NNP NNP B-TREATMENT
cautery NNP NNP I-TREATMENT
. NN NN O

The NN NN O
right NN NN O
middle NN NN O
thyroid NN NN O
vein NN NN O
was NN NN O
divided NN NN O
between NN NN O
4-0 NNP NNP B-TREATMENT
silk NNP NNP I-TREATMENT
ligatures NNP NNP I-TREATMENT
. NN NN O

The NN NN O
right NN NN O
thyroid NN NN O
lobe NN NN O
was NN NN O
rotated NNP NNP B-PROBLEM
leftward NNP NNP I-PROBLEM
. NN NN O

Posterior NN NN O
to NN NN O
the NN NN O
mid NN NN O
portion NN NN O
of NN NN O
the NN NN O
left NN NN O
thyroid NN NN O
lobe NN NN O
, NN NN O
a NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
superior NNP NNP I-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
moderate NNP NNP I-PROBLEM
size NNP NNP I-PROBLEM
was NN NN O
identified NN NN O
. NN NN O

This NN NN O
was NN NN O
freed NN NN O
up NN NN O
and NN NN O
its NNP NNP B-TREATMENT
pedicle NNP NNP I-TREATMENT
was NN NN O
ligated NN NN O
with NN NN O
small NNP NNP B-TREATMENT
Hemoclips NNP NNP I-TREATMENT
and NN NN O
divided NN NN O
and NN NN O
the NN NN O
gland NN NN O
was NN NN O
removed NN NN O
. NN NN O

It NN NN O
was NN NN O
sent NN NN O
for NN NN O
weight NNP NNP B-TEST
and NN NN O
frozen NNP NNP B-TEST
section NNP NNP I-TEST
. NN NN O

It NN NN O
weighed NN NN O
960 NN NN O
mg NN NN O
and NN NN O
on NN NN O
frozen NNP NNP B-TREATMENT
section NNP NNP I-TREATMENT
was NN NN O
consistent NN NN O
with NN NN O
a NNP NNP B-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
. NN NN O

Prior NN NN O
to NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
, NN NN O
a NNP NNP B-TEST
peripheral NNP NNP I-TEST
blood NNP NNP I-TEST
sample NNP NNP I-TEST
had NN NN O
been NN NN O
obtained NN NN O
and NN NN O
placed NN NN O
in NN NN O
a NNP NNP B-TREATMENT
purple NNP NNP I-TREATMENT
top NNP NNP I-TREATMENT
tube NNP NNP I-TREATMENT
labeled NNP NNP I-TREATMENT
" NN NN O
pre-excision NNP NNP B-TREATMENT
. NN NN O

" NN NN O
It NN NN O
was NN NN O
our NN NN O
intention NN NN O
to NN NN O
monitor NN NN O
intraoperative NN NN O
intact NN NN O
parathyroid NN NN O
hormone NN NN O
10 NN NN O
minutes NN NN O
after NN NN O
removal NNP NNP B-TREATMENT
of NN NN O
this NNP NNP B-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
. NN NN O

However NN NN O
, NN NN O
we NN NN O
could NN NN O
not NN NN O
obtain NN NN O
3 NNP NNP B-DRUG
cc NNP NNP I-DRUG
of NNP NNP I-DRUG
blood NNP NNP I-DRUG
from NN NN O
either NN NN O
the NN NN O
left NN NN O
foot NN NN O
or NN NN O
the NN NN O
left NN NN O
arm NN NN O
after NN NN O
multiple NN NN O
attempts NN NN O
, NN NN O
and NN NN O
therefore NN NN O
, NN NN O
we NN NN O
decided NN NN O
that NN NN O
the NN NN O
chance NN NN O
of NN NN O
cure NN NN O
of NN NN O
hyperparathyroidism NNP NNP B-PROBLEM
by NN NN O
removal NNP NNP B-TREATMENT
of NN NN O
this NNP NNP B-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
was NN NN O
high NN NN O
enough NN NN O
and NN NN O
the NN NN O
improvement NN NN O
in NN NN O
that NN NN O
chance NN NN O
of NN NN O
cure NN NN O
marginal NN NN O
enough NN NN O
that NN NN O
we NN NN O
would NN NN O
terminate NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
without NN NN O
monitoring NNP NNP B-TEST
PTH NNP NNP I-TEST
. NN NN O

The NN NN O
neck NN NN O
was NN NN O
irrigated NN NN O
with NN NN O
saline NNP NNP B-TREATMENT
and NN NN O
hemostasis NNP NNP B-TREATMENT
found NN NN O
to NN NN O
be NN NN O
satisfactory NN NN O
. NN NN O

The NN NN O
sternohyoid NN NN O
muscles NN NN O
were NN NN O
reapproximated NN NN O
with NN NN O
interrupted NN NN O
4-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
. NN NN O

The NN NN O
platysma NN NN O
was NN NN O
closed NN NN O
with NN NN O
interrupted NN NN O
4-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
, NN NN O
and NN NN O
the NNP NNP B-TREATMENT
skin NNP NNP I-TREATMENT
was NN NN O
closed NN NN O
with NN NN O
subcuticular NNP NNP B-TREATMENT
5-0 NNP NNP I-TREATMENT
Monocryl NNP NNP I-TREATMENT
and NN NN O
Dermabond NNP NNP B-TREATMENT
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
awakened NN NN O
and NN NN O
taken NN NN O
to NN NN O
the NN NN O
recovery NN NN O
area NN NN O
in NN NN O
satisfactory NN NN O
condition NN NN O
having NN NN O
tolerated NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
well NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
parathyroid NNP NNP B-PROBLEM
adenoma NNP NNP I-PROBLEM
, NN NN O
superior NNP NNP B-PROBLEM
parathyroid NNP NNP I-PROBLEM
adenoma NNP NNP I-PROBLEM
, NN NN O
excision NNP NNP B-TREATMENT
, NN NN O
sestamibi NNP NNP B-TEST
parathyroid NNP NNP I-TEST
scan NNP NNP I-TEST
, NN NN O
sestamibi NNP NNP B-TEST
parathyroid NNP NNP I-TEST
, NN NN O
parathyroid NNP NNP B-TEST
scan NNP NNP I-TEST
, NN NN O
sternohyoid NNP NNP B-TEST
muscles NNP NNP I-TEST
, NN NN O
superior NNP NNP B-TEST
parathyroid NNP NNP I-TEST
, NN NN O
parathyroid NNP NNP B-TEST
, NN NN O
sestamibi NNP NNP B-TEST
, NN NN O
platysma NNP NNP B-TEST
, NN NN O
adenoma NNP NNP B-PROBLEM
, NN NN O
ultrasound NNP NNP B-TEST
, NN NN O
sternohyoid NN NN O
, NN NN O
thyroid NNP NNP B-TEST
, NN NN O
muscles NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Uterine NN NN O
Papillary NN NN O
Serous NN NN O
Carcinoma NN NN O
Description NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
67-year-old NN NN O
white NN NN O
female NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
uterine NNP NNP B-PROBLEM
papillary NNP NNP I-PROBLEM
serous NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
who NN NN O
is NN NN O
status NN NN O
post NN NN O
6 NN NN O
cycles NN NN O
of NN NN O
carboplatin NNP NNP B-DRUG
and NN NN O
Taxol NNP NNP B-DRUG
, NN NN O
is NN NN O
here NN NN O
today NN NN O
for NN NN O
followup NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
67-year-old NN NN O
white NN NN O
female NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
uterine NNP NNP B-PROBLEM
papillary NNP NNP I-PROBLEM
serous NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
who NN NN O
is NN NN O
status NN NN O
post NN NN O
6 NN NN O
cycles NN NN O
of NN NN O
carboplatin NNP NNP B-DRUG
and NN NN O
Taxol NNP NNP B-DRUG
, NN NN O
is NN NN O
here NN NN O
today NN NN O
for NN NN O
followup NN NN O
. NN NN O

Her NN NN O
last NN NN O
cycle NN NN O
of NN NN O
chemotherapy NNP NNP B-DRUG
was NN NN O
finished NN NN O
on NN NN O
01/18/08 NNP NNP B-DATE
, NN NN O
and NN NN O
she NN NN O
complains NN NN O
about NN NN O
some NNP NNP B-PROBLEM
numbness NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
extremity NNP NNP I-PROBLEM
. NN NN O

This NN NN O
has NN NN O
not NN NN O
gotten NN NN O
worse NN NN O
recently NN NN O
and NN NN O
there NN NN O
is NN NN O
no NN NN O
numbness NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
toes NNP NNP I-PROBLEM
. NN NN O

She NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
tingling NNP NNP I-PROBLEM
or NN NN O
burning NNP NNP B-PROBLEM
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
Negative NN NN O
for NN NN O
any NNP NNP B-PROBLEM
fever NNP NNP I-PROBLEM
, NN NN O
chills NNP NNP B-PROBLEM
, NN NN O
nausea NNP NNP B-PROBLEM
, NN NN O
vomiting NNP NNP B-PROBLEM
, NN NN O
headache NNP NNP B-PROBLEM
, NN NN O
chest NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
, NN NN O
abdominal NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
constipation NNP NNP B-PROBLEM
, NN NN O
diarrhea NNP NNP B-PROBLEM
, NN NN O
melena NNP NNP B-PROBLEM
, NN NN O
hematochezia NNP NNP B-PROBLEM
or NN NN O
dysuria NNP NNP B-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
is NN NN O
concerned NN NN O
about NN NN O
her NNP NNP B-TEST
blood NNP NNP I-TEST
pressure NNP NNP I-TEST
being NN NN O
up NN NN O
a NN NN O
little NN NN O
bit NN NN O
and NN NN O
also NN NN O
a NN NN O
mole NN NN O
that NN NN O
she NN NN O
had NN NN O
noticed NN NN O
for NN NN O
the NN NN O
past NN NN O
few NN NN O
months NN NN O
in NN NN O
her NN NN O
head NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
Temperature NNP NNP B-TEST
35.6 NN NN O
, NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
143/83 NN NN O
, NN NN O
pulse NNP NNP B-TEST
65 NN NN O
, NN NN O
respirations NNP NNP B-TEST
18 NN NN O
, NN NN O
and NN NN O
weight NNP NNP B-TEST
66.5 NN NN O
kg NN NN O
. NN NN O

GENERAL NN NN O
: NN NN O
She NN NN O
is NN NN O
a NN NN O
middle-aged NN NN O
white NN NN O
female NN NN O
, NN NN O
not NN NN O
in NN NN O
any NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
No NN NN O
lymphadenopathy NNP NNP B-PROBLEM
or NN NN O
mucositis NNP NNP B-PROBLEM
. NN NN O

CARDIOVASCULAR NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
cyanosis NNP NNP B-PROBLEM
, NN NN O
clubbing NNP NNP B-PROBLEM
or NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

NEUROLOGICAL NN NN O
: NN NN O
No NN NN O
focal NNP NNP B-PROBLEM
deficits NNP NNP I-PROBLEM
noted NN NN O
. NN NN O

PELVIC NN NN O
: NN NN O
Normal-appearing NN NN O
external NN NN O
genitalia NN NN O
. NN NN O

Vaginal NN NN O
vault NN NN O
with NN NN O
no NN NN O
masses NNP NNP B-PROBLEM
or NN NN O
bleeding NNP NNP B-PROBLEM
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
None NN NN O
today NN NN O
. NN NN O

RADIOLOGIC NN NN O
DATA NN NN O
: NN NN O
CT NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
chest NNP NNP I-TEST
, NNP NNP I-TEST
abdomen NNP NNP I-TEST
, NNP NNP I-TEST
and NNP NNP I-TEST
pelvis NNP NNP I-TEST
from NN NN O
01/28/08 NNP NNP B-DATE
revealed NN NN O
status NN NN O
post NN NN O
total NNP NNP B-TREATMENT
abdominal NNP NNP I-TREATMENT
hysterectomy/bilateral NNP NNP I-TREATMENT
salpingo-oophorectomy NNP NNP I-TREATMENT
with NN NN O
an NN NN O
unremarkable NN NN O
vaginal NN NN O
cuff NN NN O
. NN NN O

No NN NN O
local NNP NNP B-PROBLEM
or NNP NNP I-PROBLEM
distant NNP NNP I-PROBLEM
metastasis NNP NNP I-PROBLEM
. NN NN O

Right NN NN O
probably NN NN O
chronic NNP NNP B-PROBLEM
gonadal NNP NNP I-PROBLEM
vein NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
. NN NN O

ASSESSMENT NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
67-year-old NN NN O
white NN NN O
female NN NN O
with NN NN O
history NN NN O
of NN NN O
uterine NNP NNP B-PROBLEM
papillary NNP NNP I-PROBLEM
serous NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
status NN NN O
post NN NN O
total NNP NNP B-TREATMENT
abdominal NNP NNP I-TREATMENT
hysterectomy NNP NNP I-TREATMENT
and NN NN O
bilateral NNP NNP B-TREATMENT
salpingo-oophorectomy NNP NNP I-TREATMENT
and NN NN O
6 NN NN O
cycles NN NN O
of NN NN O
carboplatin NNP NNP B-DRUG
and NN NN O
Taxol NNP NNP B-DRUG
chemotherapy NNP NNP I-DRUG
. NN NN O

She NN NN O
is NN NN O
doing NN NN O
well NN NN O
with NN NN O
no NN NN O
evidence NN NN O
of NN NN O
disease NNP NNP B-PROBLEM
clinically NN NN O
or NN NN O
radiologically NN NN O
. NN NN O

PLAN NN NN O
: NN NN O

1 NN NN O
. NN NN O
Plan NN NN O
to NN NN O
follow NN NN O
her NN NN O
every NN NN O
3 NN NN O
months NN NN O
and NN NN O
CT NNP NNP B-TEST
scans NNP NNP I-TEST
every NN NN O
6 NN NN O
months NN NN O
for NN NN O
the NN NN O
first NN NN O
2 NN NN O
years NN NN O
. NN NN O

2 NN NN O
. NN NN O
The NN NN O
patient NN NN O
was NN NN O
advised NN NN O
to NN NN O
contact NN NN O
the NN NN O
primary NN NN O
physician NN NN O
for NN NN O
repeat NNP NNP B-TEST
blood NNP NNP I-TEST
pressure NNP NNP I-TEST
check NNP NNP I-TEST
and NN NN O
get NN NN O
started NN NN O
on NN NN O
antihypertensives NNP NNP B-DRUG
if NN NN O
it NN NN O
is NN NN O
persistently NNP NNP B-PROBLEM
elevated NNP NNP I-PROBLEM
. NN NN O

3 NN NN O
. NN NN O
The NN NN O
patient NN NN O
was NN NN O
told NN NN O
that NN NN O
the NN NN O
mole NN NN O
that NN NN O
she NN NN O
is NN NN O
mentioning NN NN O
in NN NN O
her NN NN O
head NN NN O
is NN NN O
no NN NN O
longer NN NN O
palpable NN NN O
and NN NN O
just NN NN O
to NN NN O
observe NN NN O
it NN NN O
for NN NN O
now NN NN O
. NN NN O

4 NN NN O
. NN NN O
The NN NN O
patient NN NN O
was NN NN O
advised NN NN O
about NN NN O
doing NN NN O
Kegel NN NN O
exercises NN NN O
for NN NN O
urinary NNP NNP B-PROBLEM
incontinence NNP NNP I-PROBLEM
, NN NN O
and NN NN O
we NN NN O
will NN NN O
address NN NN O
this NN NN O
issue NN NN O
again NN NN O
during NN NN O
next NN NN O
clinic NN NN O
visit NN NN O
if NN NN O
it NN NN O
is NN NN O
persistent NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
chemotherapy NNP NNP B-DRUG
, NN NN O
uterine NNP NNP B-PROBLEM
papillary NNP NNP I-PROBLEM
serous NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
oophorectomy NNP NNP B-TREATMENT
, NN NN O
carboplatin NNP NNP B-DRUG
, NN NN O
taxol NNP NNP B-DRUG
, NN NN O
abdominal NNP NNP B-TREATMENT
, NNP NNP I-TREATMENT
uterine NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
papillary NNP NNP I-TREATMENT
, NN NN O
carcinoma NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Neuroblastoma NN NN O
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
an NN NN O
11-month-old NN NN O
with NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
stage NNP NNP B-PROBLEM
2 NNP NNP I-PROBLEM
neuroblastoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
gland NNP NNP I-PROBLEM
with NN NN O
favorable NN NN O
Shimada NNP NNP B-NAME
histology NN NN O
and NN NN O
history NN NN O
of NN NN O
stage NNP NNP B-PROBLEM
2 NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
neuroblastoma NNP NNP I-PROBLEM
, NN NN O
status NN NN O
post NN NN O
gross NNP NNP B-TREATMENT
total NNP NNP I-TREATMENT
resection NNP NNP I-TREATMENT
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
VISIT NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
an NN NN O
11-month-old NN NN O
with NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
stage NNP NNP B-PROBLEM
2 NNP NNP I-PROBLEM
neuroblastoma NNP NNP I-PROBLEM
here NN NN O
for NN NN O
ongoing NNP NNP B-TREATMENT
management NNP NNP I-TREATMENT
of NN NN O
his NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
and NN NN O
the NN NN O
visit NN NN O
is NN NN O
supervised NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NNP NNP B-NAME
. NNP NNP I-NAME
HISTORY NNP NNP I-NAME
OF NNP NNP I-NAME
PRESENT NNP NNP I-NAME
ILLNESS NNP NNP I-NAME
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
an NN NN O
11-month-old NN NN O
with NN NN O
neuroblastoma NNP NNP B-PROBLEM
, NN NN O
which NN NN O
initially NN NN O
presented NN NN O
on NN NN O
the NN NN O
left NN NN O
when NN NN O
he NN NN O
was NN NN O
6 NN NN O
weeks NN NN O
old NN NN O
and NN NN O
was NN NN O
completely NN NN O
resected NN NN O
. NN NN O

It NN NN O
was NN NN O
felt NN NN O
to NN NN O
be NN NN O
stage NNP NNP B-PROBLEM

2 NN NN O
. NN NN O
It NN NN O
was NN NN O
not NN NN O
N-Myc NN NN O
amplified NN NN O
and NN NN O
had NN NN O
favorable NN NN O
Shimada NN NN O
histology NN NN O
. NN NN O

In NN NN O
followup NN NN O
, NN NN O
he NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NNP NNP B-PROBLEM
second NNP NNP I-PROBLEM
primary NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
gland NNP NNP I-PROBLEM
, NN NN O
which NN NN O
was NN NN O
biopsied NNP NNP B-TEST
and NN NN O
also NN NN O
consistent NN NN O
with NN NN O
neuroblastoma NNP NNP B-PROBLEM
with NN NN O
favorable NN NN O
Shimada NN NN O
histology NN NN O
. NN NN O

He NN NN O
is NN NN O
now NN NN O
being NN NN O
treated NN NN O
with NN NN O
chemotherapy NNP NNP B-DRUG
per NN NN O
protocol NN NN O
P9641 NN NN O
and NN NN O
not NN NN O
on NN NN O
study NNP NNP B-TEST
. NN NN O

He NN NN O
last NN NN O
received NN NN O
chemotherapy NNP NNP B-DRUG
on NN NN O
05/21/07 NNP NNP B-DATE
, NN NN O
with NN NN O
carboplatin NNP NNP B-DRUG
, NN NN O
cyclophosphamide NNP NNP B-DRUG
, NN NN O
and NN NN O
doxorubicin NNP NNP B-DRUG
. NN NN O

He NN NN O
received NN NN O
G-CSF NNP NNP B-TREATMENT
daily NN NN O
after NN NN O
his NN NN O
chemotherapy NNP NNP B-DRUG
due NN NN O
to NN NN O
neutropenia NNP NNP B-PROBLEM
that NN NN O
delayed NN NN O
his NN NN O
second NN NN O
cycle NN NN O
. NN NN O

In NN NN O
the NN NN O
interval NN NN O
since NN NN O
he NN NN O
was NN NN O
last NN NN O
seen NN NN O
, NN NN O
his NN NN O
mother NN NN O
reports NN NN O
that NN NN O
he NN NN O
had NN NN O
a NN NN O
couple NN NN O
of NN NN O
days NN NN O
of NN NN O
nasal NNP NNP B-PROBLEM
congestion NNP NNP I-PROBLEM
, NN NN O
but NN NN O
it NN NN O
is NN NN O
now NN NN O
improving NN NN O
. NN NN O

He NN NN O
is NN NN O
not NN NN O
acted NN NN O
ill NNP NNP B-PROBLEM
or NN NN O
had NN NN O
any NNP NNP B-PROBLEM
fevers NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
had NN NN O
somewhat NNP NNP B-PROBLEM
diminished NNP NNP I-PROBLEM
appetite NNP NNP I-PROBLEM
, NN NN O
but NN NN O
it NN NN O
seems NN NN O
to NN NN O
be NN NN O
improving NN NN O
now NN NN O
. NN NN O

He NN NN O
is NN NN O
peeing NN NN O
and NN NN O
pooping NN NN O
normally NN NN O
and NN NN O
has NN NN O
not NN NN O
had NN NN O
any NNP NNP B-PROBLEM
diarrhea NNP NNP I-PROBLEM
. NN NN O

He NN NN O
did NN NN O
not NN NN O
have NN NN O
any NNP NNP B-PROBLEM
appreciated NNP NNP I-PROBLEM
nausea NNP NNP I-PROBLEM
or NN NN O
vomiting NNP NNP B-PROBLEM
. NN NN O

He NN NN O
has NN NN O
been NN NN O
restarted NN NN O
on NN NN O
fluconazole NNP NNP B-DRUG
due NN NN O
to NN NN O
having NN NN O
redeveloped NNP NNP B-PROBLEM
thrush NNP NNP I-PROBLEM
recently NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
The NN NN O
following NN NN O
systems NN NN O
reviewed NN NN O
and NN NN O
negative NN NN O
per NN NN O
pathology NN NN O
except NN NN O
as NN NN O
noted NN NN O
above NN NN O
. NN NN O

Eyes NN NN O
, NN NN O
ears NN NN O
, NN NN O
throat NN NN O
, NN NN O
cardiovascular NN NN O
, NN NN O
GI NN NN O
, NN NN O
genitourinary NN NN O
, NN NN O
musculoskeletal NN NN O
skin NN NN O
, NN NN O
and NN NN O
neurologic NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Reviewed NN NN O
as NN NN O
above NN NN O
and NN NN O
otherwise NN NN O
unchanged NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Reviewed NN NN O
and NN NN O
unchanged NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
The NN NN O
patient's NN NN O
parents NN NN O
continued NN NN O
to NN NN O
undergo NN NN O
a NN NN O
separation NN NN O
and NN NN O
divorce NN NN O
. NN NN O

The NN NN O
patient NN NN O
spends NN NN O
time NN NN O
with NN NN O
his NN NN O
father NN NN O
and NN NN O
his NN NN O
family NN NN O
during NN NN O
the NN NN O
first NN NN O
part NN NN O
of NN NN O
the NN NN O
week NN NN O
and NN NN O
with NN NN O
his NN NN O
mother NN NN O
during NN NN O
the NN NN O
second NN NN O
part NN NN O
of NN NN O
the NN NN O
week NN NN O
. NN NN O

MEDICATIONS NN NN O
: NN NN O

1 NN NN O
. NN NN O
Bactrim NNP NNP B-DRUG
32 NNP NNP I-DRUG
mg NNP NNP I-DRUG
by NNP NNP I-DRUG
mouth NNP NNP I-DRUG
twice NN NN O
a NN NN O
day NN NN O
on NN NN O
Friday NNP NNP B-DATE
, NN NN O
Saturday NNP NNP B-DATE
, NN NN O
and NN NN O
Sunday NNP NNP B-DATE
. NN NN O

2 NN NN O
. NN NN O
G-CSF NNP NNP B-TREATMENT
50 NN NN O
mcg NN NN O
subcutaneously NN NN O
given NN NN O
daily NN NN O
in NN NN O
his NN NN O
thighs NN NN O
alternating NN NN O
with NN NN O
each NN NN O
dose NN NN O
. NN NN O

3 NN NN O
. NN NN O
Fluconazole NNP NNP B-DRUG
37.5 NNP NNP I-DRUG
mg NNP NNP I-DRUG
daily NN NN O
. NN NN O

4 NN NN O
. NN NN O
Zofran NNP NNP B-DRUG
1.5 NNP NNP I-DRUG
mg NNP NNP I-DRUG
every NN NN O
6 NN NN O
hours NN NN O
as NN NN O
needed NN NN O
for NN NN O
nausea NNP NNP B-PROBLEM
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

FINDINGS NN NN O
: NN NN O
A NNP NNP B-TEST
detailed NNP NNP I-TEST
physical NNP NNP I-TEST
exam NNP NNP I-TEST
revealed NN NN O
a NN NN O
very NN NN O
active NN NN O
and NN NN O
intractable NN NN O
, NN NN O
well-nourished NN NN O
11-month-old NN NN O
male NN NN O
with NN NN O
weight NNP NNP B-TEST
10.5 NN NN O
kilos NN NN O
and NN NN O
height NNP NNP B-TEST
76.8 NN NN O
cm NN NN O
. NN NN O

Vital NNP NNP B-TEST
Signs NNP NNP I-TEST
: NN NN O
Temperature NNP NNP B-TEST
is NN NN O
35.3 NN NN O
degrees NN NN O
Celsius NN NN O
, NN NN O
pulse NNP NNP B-TEST
is NN NN O
121 NN NN O
beats NN NN O
per NN NN O
minute NN NN O
, NN NN O
respiratory NNP NNP B-TEST
rate NNP NNP I-TEST
32 NN NN O
breaths NN NN O
per NN NN O
minute NN NN O
, NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
135/74 NN NN O
mmHg NN NN O
. NN NN O

Eyes NN NN O
: NN NN O
Conjunctivae NN NN O
are NN NN O
clear NN NN O
, NN NN O
nonicteric NNP NNP B-PROBLEM
. NN NN O

Pupils NN NN O
are NN NN O
equally NN NN O
round NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O

Extraocular NN NN O
muscle NN NN O
movements NN NN O
appear NN NN O
intact NN NN O
with NN NN O
no NN NN O
strabismus NNP NNP B-PROBLEM
. NN NN O

Ears NN NN O
: NN NN O
TMs NN NN O
are NN NN O
clear NN NN O
bilaterally NN NN O
. NN NN O

Oral NN NN O
Mucosa NN NN O
: NN NN O
No NN NN O
thrush NNP NNP B-PROBLEM
is NN NN O
appreciated NN NN O
. NN NN O

No NN NN O
mucosal NNP NNP B-PROBLEM
ulcerations NNP NNP I-PROBLEM
or NN NN O
erythema NNP NNP B-PROBLEM
. NN NN O

Chest NN NN O
: NN NN O
Port-a-Cath NNP NNP B-TREATMENT
is NN NN O
nonerythematous NNP NNP B-PROBLEM
and NN NN O
nontender NNP NNP B-PROBLEM
to NN NN O
VP NNP NNP B-TREATMENT
access NNP NNP I-TREATMENT
port NNP NNP I-TREATMENT
. NN NN O

Respiratory NN NN O
: NN NN O
Good NN NN O
aeration NN NN O
, NN NN O
clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

Cardiovascular NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
, NN NN O
normal NN NN O
S1 NN NN O
and NN NN O
S2 NN NN O
, NN NN O
no NN NN O
murmurs NNP NNP B-PROBLEM
appreciated NN NN O
. NN NN O

Abdomen NN NN O
is NN NN O
soft NN NN O
, NN NN O
nontender NNP NNP B-PROBLEM
, NN NN O
and NN NN O
no NN NN O
organomegaly NNP NNP B-PROBLEM
, NN NN O
unable NN NN O
to NN NN O
appreciate NN NN O
a NNP NNP B-PROBLEM
right-sided NNP NNP I-PROBLEM
abdominal NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
or NN NN O
any NNP NNP B-PROBLEM
other NNP NNP I-PROBLEM
masses NNP NNP I-PROBLEM
. NN NN O

Skin NN NN O
: NN NN O
No NN NN O
rashes NNP NNP B-PROBLEM
. NN NN O

Neurologic NN NN O
: NN NN O
The NN NN O
patient NN NN O
walks NN NN O
without NN NN O
assistance NN NN O
, NN NN O
frequently NN NN O
falls NN NN O
on NN NN O
his NN NN O
bottom NN NN O
. NN NN O

LABORATORY NN NN O
STUDIES NN NN O
: NN NN O
CBC NNP NNP B-TEST
and NN NN O
comprehensive NNP NNP B-TEST
metabolic NNP NNP I-TEST
panel NNP NNP I-TEST
were NN NN O
obtained NN NN O
and NN NN O
they NN NN O
are NN NN O
significant NN NN O
for NN NN O
AST NNP NNP B-TEST
51 NN NN O
, NN NN O
white NNP NNP B-TEST
blood NNP NNP I-TEST
cell NNP NNP I-TEST
count NNP NNP I-TEST
11,440 NN NN O
, NN NN O
hemoglobin NNP NNP B-TEST
10.9 NN NN O
, NN NN O
and NN NN O
platelets NNP NNP B-TEST
202,000 NN NN O
with NN NN O
ANC NNP NNP B-TEST
2974 NNP NNP B-DATE
. NN NN O

Medical NNP NNP B-TEST
tests NNP NNP I-TEST
none NN NN O
. NN NN O

Radiologic NNP NNP B-TEST
studies NNP NNP I-TEST
are NN NN O
none NN NN O
. NN NN O

ASSESSMENT NN NN O
: NN NN O
This NNP NNP B-PROBLEM
patient's NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
is NN NN O
life NN NN O
threatening NN NN O
, NN NN O
currently NN NN O
causing NN NN O
moderately NNP NNP B-PROBLEM
severe NNP NNP I-PROBLEM
side NNP NNP I-PROBLEM
effects NNP NNP I-PROBLEM
. NN NN O

PROBLEMS NN NN O
DIAGNOSES NN NN O
: NN NN O

1 NN NN O
. NN NN O
Neuroblastoma NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
gland NNP NNP I-PROBLEM
with NN NN O
favorable NN NN O
Shimada NN NN O
histology NN NN O
. NN NN O

2 NN NN O
. NN NN O
History NN NN O
of NN NN O
stage NNP NNP B-PROBLEM
2 NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
neuroblastoma NNP NNP I-PROBLEM
, NN NN O
status NN NN O
post NN NN O
gross NNP NNP B-TREATMENT
total NNP NNP I-TREATMENT
resection NNP NNP I-TREATMENT
. NN NN O

3 NN NN O
. NN NN O
Immunosuppression NNP NNP B-TREATMENT
. NN NN O

4 NN NN O
. NN NN O
Mucosal NNP NNP B-PROBLEM
candidiasis NNP NNP I-PROBLEM
. NN NN O

5 NN NN O
. NN NN O
Resolving NNP NNP B-PROBLEM
neutropenia NNP NNP I-PROBLEM
. NN NN O

PROCEDURES NN NN O
AND NN NN O
IMMUNIZATIONS NN NN O
: NN NN O
None NN NN O
. NN NN O

PLANS NN NN O
: NN NN O

1 NN NN O
. NN NN O
Neuroblastoma NNP NNP B-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
will NN NN O
return NN NN O
to NN NN O
the NN NN O
Pediatric NN NN O
Oncology NN NN O
Clinic NN NN O
on NN NN O
06/13/07 NNP NNP B-DATE
to NN NN O
06/15/07 NNP NNP B-DATE
for NN NN O
his NN NN O
third NN NN O
cycle NN NN O
of NN NN O
chemotherapy NNP NNP B-DRUG
. NN NN O

I NN NN O
will NN NN O
plan NN NN O
for NN NN O
restaging NNP NNP B-TEST
with NN NN O
CT NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
abdomen NNP NNP I-TEST
prior NN NN O
to NN NN O
the NN NN O
cycle NN NN O
. NN NN O

2 NN NN O
. NN NN O
Immunosuppression NNP NNP B-TREATMENT
. NN NN O

The NN NN O
patient NN NN O
will NN NN O
continue NN NN O
on NN NN O
his NN NN O
Bactrim NNP NNP B-DRUG
twice NN NN O
a NN NN O
day NN NN O
on NN NN O
Thursday NNP NNP B-DATE
, NN NN O
Friday NNP NNP B-DATE
, NN NN O
and NN NN O
Saturday NNP NNP B-DATE
. NN NN O

Additionally NN NN O
, NN NN O
we NN NN O
will NN NN O
tentatively NN NN O
plan NN NN O
to NN NN O
have NN NN O
him NN NN O
continue NN NN O
fluconazole NNP NNP B-DRUG
since NN NN O
this NN NN O
is NN NN O
his NN NN O
second NN NN O
episode NN NN O
of NN NN O
thrush NNP NNP B-PROBLEM
. NN NN O

3 NN NN O
. NN NN O
Mucosal NNP NNP B-PROBLEM
candidiasis NNP NNP I-PROBLEM
. NN NN O

We NN NN O
will NN NN O
continue NN NN O
fluconazole NNP NNP B-DRUG
for NN NN O
thrush NNP NNP B-PROBLEM
. NN NN O

I NN NN O
am NN NN O
pleased NN NN O
that NN NN O
the NN NN O
clinical NN NN O
evidence NN NN O
of NN NN O
disease NNP NNP B-PROBLEM
appears NN NN O
to NN NN O
have NN NN O
resolved NN NN O
. NN NN O

For NN NN O
resolving NNP NNP B-PROBLEM
neutropenia NNP NNP I-PROBLEM
, NN NN O
I NN NN O
advised NN NN O
Gregory's NN NN O
mother NN NN O
about NN NN O
it NN NN O
is NN NN O
okay NN NN O
to NN NN O
discontinue NN NN O
the NNP NNP B-TREATMENT
G-CSF NNP NNP I-TREATMENT
at NN NN O
this NN NN O
time NN NN O
. NN NN O

We NN NN O
will NN NN O
plan NN NN O
for NN NN O
him NN NN O
to NN NN O
resume NN NN O
G-CSF NNP NNP B-TREATMENT
after NN NN O
his NN NN O
next NN NN O
chemotherapy NNP NNP B-DRUG
and NN NN O
prescription NN NN O
has NN NN O
been NN NN O
sent NN NN O
to NN NN O
the NN NN O
patient's NN NN O
pharmacy NN NN O
. NN NN O

PEDIATRIC NN NN O
ONCOLOGY NN NN O
ATTENDING NN NN O
: NN NN O
I NN NN O
have NN NN O
reviewed NN NN O
the NN NN O
history NN NN O
of NN NN O
the NN NN O
patient NN NN O
. NN NN O

This NN NN O
is NN NN O
an NN NN O
11-month-old NN NN O
with NN NN O
neuroblastoma NNP NNP B-PROBLEM
who NN NN O
received NN NN O
chemotherapy NNP NNP B-DRUG
with NN NN O
carboplatin NNP NNP B-DRUG
, NN NN O
cyclophosphamide NNP NNP B-DRUG
, NN NN O
and NN NN O
doxorubicin NNP NNP B-DRUG
on NN NN O
05/21/07 NNP NNP B-DATE
for NN NN O
cycle NN NN O
2 NN NN O
of NN NN O
POG-9641 NN NN O
due NN NN O
to NN NN O
his NN NN O
prior NN NN O
history NN NN O
of NN NN O
neutropenia NNP NNP B-PROBLEM
, NN NN O
he NN NN O
has NN NN O
been NN NN O
on NN NN O
G-CSF NNP NNP B-TREATMENT
. NN NN O

His NN NN O
ANC NN NN O
is NN NN O
nicely NN NN O
recovered NN NN O
. NN NN O

He NN NN O
will NN NN O
have NN NN O
a NNP NNP B-TEST
restaging NNP NNP I-TEST
CT NNP NNP I-TEST
prior NN NN O
to NN NN O
his NN NN O
next NN NN O
cycle NN NN O
of NN NN O
chemotherapy NNP NNP B-DRUG
and NN NN O
then NN NN O
return NN NN O
for NN NN O
cycle NN NN O
3 NN NN O
chemotherapy NNP NNP B-DRUG
on NN NN O
06/13/07 NNP NNP B-DATE
to NN NN O
06/15/07 NNP NNP B-DATE
. NN NN O

He NN NN O
continues NN NN O
on NN NN O
fluconazole NNP NNP B-DRUG
for NN NN O
recent NN NN O
history NN NN O
of NN NN O
thrush NNP NNP B-PROBLEM
. NN NN O

Plans NN NN O
are NN NN O
otherwise NN NN O
documented NN NN O
above NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
stage NNP NNP B-PROBLEM
2 NNP NNP I-PROBLEM
neuroblastoma NNP NNP I-PROBLEM
, NN NN O
adrenal NNP NNP B-PROBLEM
neuroblastoma NNP NNP I-PROBLEM
, NN NN O
mucosal NNP NNP B-PROBLEM
candidiasis NNP NNP I-PROBLEM
, NN NN O
neutropenia NNP NNP B-PROBLEM
, NN NN O
carboplatin NNP NNP B-DRUG
cyclophosphamide NNP NNP I-DRUG
, NN NN O
pediatric NNP NNP B-PROBLEM
oncology NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
gland NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
neuroblastoma NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
histology NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
nonerythematous NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
gland NNP NNP I-PROBLEM
, NN NN O
chemotherapy NNP NNP B-DRUG
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
T-Cell NN NN O
Lymphoma NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
T-cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
reports NN NN O
swelling NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
submandibular NNP NNP I-PROBLEM
region NNP NNP I-PROBLEM
that NN NN O
occurred NN NN O
all NN NN O
of NN NN O
a NN NN O
sudden NN NN O
about NN NN O
a NN NN O
month NN NN O
and NN NN O
a NN NN O
half NN NN O
ago NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
T-cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
40-year-old NN NN O
gentleman NN NN O
who NN NN O
reports NN NN O
swelling NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
submandibular NNP NNP I-PROBLEM
region NNP NNP I-PROBLEM
that NN NN O
occurred NN NN O
all NN NN O
of NN NN O
a NN NN O
sudden NN NN O
about NN NN O
a NN NN O
month NN NN O
and NN NN O
a NN NN O
half NN NN O
ago NN NN O
. NN NN O

He NN NN O
was NN NN O
originally NN NN O
treated NN NN O
with NN NN O
antibiotics NNP NNP B-DRUG
as NN NN O
a NN NN O
possible NN NN O
tooth NNP NNP B-PROBLEM
abscess NNP NNP I-PROBLEM
. NN NN O

Prior NN NN O
to NN NN O
this NN NN O
event NN NN O
, NN NN O
in NN NN O
March NNP NNP B-DATE
of NNP NNP I-DATE
2010 NNP NNP I-DATE
, NN NN O
he NN NN O
was NN NN O
treated NN NN O
for NN NN O
strep NNP NNP B-PROBLEM
throat NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
at NN NN O
that NN NN O
time NN NN O
was NN NN O
on NN NN O
the NN NN O
right NN NN O
side NN NN O
. NN NN O

About NN NN O
a NN NN O
month NN NN O
ago NN NN O
, NN NN O
he NN NN O
started NN NN O
having NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
reports NN NN O
feeling NN NN O
hot NN NN O
, NN NN O
when NN NN O
he NN NN O
went NN NN O
to NN NN O
bed NN NN O
he NN NN O
fall NN NN O
asleep NN NN O
and NN NN O
would NN NN O
wake NN NN O
up NN NN O
soaked NN NN O
. NN NN O

All NN NN O
these NNP NNP B-PROBLEM
symptoms NNP NNP I-PROBLEM
were NN NN O
preceded NN NN O
by NN NN O
overwhelming NNP NNP B-PROBLEM
fatigue NNP NNP I-PROBLEM
and NN NN O
exhaustion NNP NNP B-PROBLEM
. NN NN O

He NN NN O
reports NN NN O
being NN NN O
under NN NN O
significant NN NN O
amount NN NN O
of NN NN O
stress NN NN O
as NN NN O
he NN NN O
and NN NN O
his NN NN O
mom NN NN O
just NN NN O
recently NN NN O
moved NN NN O
from NN NN O
their NN NN O
house NN NN O
to NN NN O
a NN NN O
mobile NN NN O
home NN NN O
. NN NN O

With NN NN O
the NNP NNP B-PROBLEM
fatigue NNP NNP I-PROBLEM
, NN NN O
he NN NN O
has NN NN O
had NN NN O
some NNP NNP B-PROBLEM
mild NNP NNP I-PROBLEM
chest NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
and NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
, NN NN O
and NN NN O
has NN NN O
also NN NN O
noted NN NN O
a NNP NNP B-PROBLEM
decrease NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
appetite NNP NNP I-PROBLEM
, NN NN O
although NN NN O
he NN NN O
reports NN NN O
his NNP NNP B-TEST
weight NNP NNP I-TEST
has NN NN O
been NN NN O
stable NN NN O
. NN NN O

He NN NN O
also NN NN O
reports NN NN O
occasional NNP NNP B-PROBLEM
headaches NNP NNP I-PROBLEM
with NN NN O
some NNP NNP B-PROBLEM
stabbing NNP NNP I-PROBLEM
and NN NN O
pain NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
feet NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
legs NNP NNP I-PROBLEM
. NN NN O

He NN NN O
also NN NN O
complains NN NN O
of NN NN O
some NNP NNP B-PROBLEM
left NNP NNP I-PROBLEM
groin NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Significant NN NN O
for NN NN O
HIV NNP NNP B-PROBLEM
diagnosed NN NN O
in NN NN O
2000 NNP NNP B-DATE
. NN NN O

He NN NN O
also NN NN O
had NN NN O
mononucleosis NNP NNP B-PROBLEM
at NN NN O
that NN NN O
time NN NN O
. NN NN O

The NN NN O
patient NN NN O
reports NN NN O
being NN NN O
on NN NN O
anti-hepatitis NNP NNP B-TREATMENT
viral NNP NNP I-TREATMENT
therapy NNP NNP I-TREATMENT
period NN NN O
that NN NN O
was NN NN O
very NN NN O
intense NN NN O
. NN NN O

He NN NN O
took NN NN O
the NNP NNP B-TREATMENT
meds NNP NNP I-TREATMENT
for NN NN O
about NN NN O
six NN NN O
months NN NN O
, NN NN O
he NN NN O
reports NN NN O
stopping NN NN O
, NN NN O
and NN NN O
prior NN NN O
to NN NN O
2002 NNP NNP B-DATE
at NN NN O
one NN NN O
point NN NN O
during NN NN O
his NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
, NN NN O
he NN NN O
was NN NN O
profoundly NNP NNP B-PROBLEM
weak NNP NNP I-PROBLEM
and NN NN O
found NN NN O
to NN NN O
have NN NN O
hemoglobin NNP NNP B-TEST
less NN NN O
than NN NN O
4 NN NN O
and NN NN O
required NN NN O
three NNP NNP B-DRUG
units NNP NNP I-DRUG
of NNP NNP I-DRUG
packed NNP NNP I-DRUG
red NNP NNP I-DRUG
blood NNP NNP I-DRUG
cells NNP NNP I-DRUG
. NN NN O

He NN NN O
reports NN NN O
no NN NN O
other NN NN O
history NN NN O
of NN NN O
transfusions NNP NNP B-TREATMENT
. NN NN O

He NN NN O
has NN NN O
history NN NN O
of NN NN O
spontaneous NNP NNP B-PROBLEM
pneumothorax NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
first NNP NNP I-PROBLEM
episode NNP NNP I-PROBLEM
was NN NN O
1989 NN NN O
on NN NN O
his NN NN O
right NN NN O
lung NN NN O
. NN NN O

In NN NN O
1990 NN NN O
he NN NN O
had NN NN O
a NNP NNP B-PROBLEM
slow NNP NNP I-PROBLEM
collapse NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
. NN NN O

He NN NN O
reports NN NN O
no NN NN O
other NN NN O
history NN NN O
of NN NN O
pneumothoraces NNP NNP B-PROBLEM
. NN NN O

In NN NN O
2003 NNP NNP B-DATE
, NN NN O
he NN NN O
had NN NN O
shingles NNP NNP B-PROBLEM
. NN NN O

He NN NN O
went NN NN O
through NN NN O
antiviral NNP NNP B-DRUG
treatment NN NN O
at NN NN O
that NN NN O
time NN NN O
and NN NN O
he NN NN O
also NN NN O
reports NN NN O
another NNP NNP B-PROBLEM
small NNP NNP I-PROBLEM
outbreak NNP NNP I-PROBLEM
in NN NN O
2009 NNP NNP B-DATE
that NN NN O
he NN NN O
treated NN NN O
with NN NN O
topical NNP NNP B-TREATMENT
therapy NNP NNP I-TREATMENT
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Notable NN NN O
for NN NN O
his NN NN O
mother NN NN O
who NN NN O
is NN NN O
currently NN NN O
battling NN NN O
non-small NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

She NN NN O
is NN NN O
a NN NN O
nonsmoker NN NN O
. NN NN O

His NN NN O
sister NN NN O
is NN NN O
Epstein-Barr NNP NNP B-PROBLEM
virus NNP NNP I-PROBLEM
positive NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient's NN NN O
mother NN NN O
also NN NN O
reports NN NN O
that NN NN O
she NN NN O
is NN NN O
Epstein-Barr NNP NNP B-PROBLEM
virus NNP NNP I-PROBLEM
positive NNP NNP I-PROBLEM
. NN NN O

His NN NN O
maternal NN NN O
grandfather NN NN O
died NN NN O
from NN NN O
complications NNP NNP B-PROBLEM
from NN NN O
melanoma NNP NNP B-PROBLEM
. NN NN O

His NN NN O
mother NN NN O
also NN NN O
has NN NN O
diabetes NNP NNP B-PROBLEM
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
single NN NN O
. NN NN O

He NN NN O
currently NN NN O
lives NN NN O
with NN NN O
his NN NN O
mother NN NN O
in NN NN O
house NN NN O
for NN NN O
several NN NN O
both NN NN O
in NN NN O
New NN NN O
York NN NN O
and NN NN O
here NN NN O
in NN NN O
Colorado NN NN O
. NN NN O

His NN NN O
mother NN NN O
moved NN NN O
out NN NN O
to NN NN O
Colorado NN NN O
eight NN NN O
years NN NN O
ago NN NN O
and NN NN O
he NN NN O
has NN NN O
been NN NN O
out NN NN O
here NN NN O
for NN NN O
seven NN NN O
years NN NN O
. NN NN O

He NN NN O
currently NN NN O
is NN NN O
self NN NN O
employed NN NN O
and NN NN O
does NN NN O
antiquing NN NN O
. NN NN O

He NN NN O
has NN NN O
also NN NN O
worked NN NN O
as NN NN O
nurses NN NN O
' NN NN O
aide NN NN O
and NN NN O
worked NN NN O
in NN NN O
group NN NN O
home NN NN O
for NN NN O
the NN NN O
state NN NN O
of NN NN O
New NN NN O
York NN NN O
for NN NN O
the NNP NNP B-PROBLEM
developmentally NNP NNP I-PROBLEM
delayed NNP NNP I-PROBLEM
. NN NN O

He NN NN O
is NN NN O
homosexual NN NN O
, NN NN O
currently NN NN O
not NN NN O
sexually NN NN O
active NN NN O
. NN NN O

He NN NN O
does NN NN O
have NN NN O
smoking NN NN O
history NN NN O
as NN NN O
about NN NN O
a NN NN O
thirteen NN NN O
and NN NN O
a NN NN O
half NN NN O
pack NN NN O
year NN NN O
history NN NN O
of NN NN O
smoking NN NN O
, NN NN O
currently NN NN O
smoking NN NN O
about NN NN O
a NN NN O
quarter NN NN O
of NN NN O
a NN NN O
pack NN NN O
per NN NN O
day NN NN O
. NN NN O

He NN NN O
does NN NN O
not NN NN O
use NN NN O
alcohol NN NN O
or NN NN O
illicit NN NN O
drugs NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
As NN NN O
mentioned NN NN O
above NN NN O
his NN NN O
weight NN NN O
has NN NN O
been NN NN O
fairly NN NN O
stable NN NN O
. NN NN O

Although NN NN O
, NN NN O
he NN NN O
suffered NN NN O
from NN NN O
obesity NNP NNP B-PROBLEM
as NN NN O
a NN NN O
young NN NN O
teenager NN NN O
, NN NN O
but NN NN O
through NN NN O
a NN NN O
period NN NN O
of NN NN O
anorexia NNP NNP B-PROBLEM
, NN NN O
but NN NN O
his NNP NNP B-TEST
weight NNP NNP I-TEST
has NN NN O
been NN NN O
stable NN NN O
now NN NN O
for NN NN O
about NN NN O
20 NN NN O
years NN NN O
. NN NN O

He NN NN O
has NN NN O
had NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
, NN NN O
chest NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
and NN NN O
is NN NN O
also NN NN O
suffering NN NN O
from NN NN O
some NNP NNP B-PROBLEM
depression NNP NNP I-PROBLEM
as NN NN O
well NN NN O
as NN NN O
overwhelming NNP NNP B-PROBLEM
fatigue NNP NNP I-PROBLEM
, NN NN O
stabbing NNP NNP B-PROBLEM
, NN NN O
short-lived NNP NNP B-PROBLEM
headaches NNP NNP I-PROBLEM
and NN NN O
occasional NNP NNP B-PROBLEM
shortness NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
noted NN NN O
some NNP NNP B-PROBLEM
stool NNP NNP I-PROBLEM
irregularity NNP NNP I-PROBLEM
with NN NN O
occasional NNP NNP B-PROBLEM
loose NNP NNP I-PROBLEM
stools NNP NNP I-PROBLEM
and NN NN O
new NN NN O
onset NN NN O
of NN NN O
pain NNP NNP B-PROBLEM
predominantly NN NN O
in NN NN O
left NN NN O
neck NN NN O
. NN NN O

He NN NN O
has NN NN O
had NN NN O
fevers NNP NNP B-PROBLEM
as NN NN O
well NN NN O
. NN NN O

The NN NN O
rest NN NN O
of NN NN O
his NNP NNP B-TEST
review NNP NNP I-TEST
of NNP NNP I-TEST
systems NNP NNP I-TEST
is NN NN O
negative NN NN O
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
VITALS NN NN O
: NN NN O
BP NNP NNP B-TEST
: NN NN O
100/64 NN NN O
. NN NN O

HEART NN NN O
RATE NN NN O
: NN NN O

72 NN NN O
. NN NN O
TEMP NN NN O
: NN NN O

97 NN NN O
. NN NN O
Weight NNP NNP B-TEST
: NN NN O
61.4 NN NN O
kg NN NN O
. NN NN O

GEN NN NN O
: NN NN O
He NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
gentleman NN NN O
, NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
He NN NN O
has NN NN O
obvious NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
submandibular NNP NNP I-PROBLEM
region NNP NNP I-PROBLEM
on NN NN O
the NN NN O
left NN NN O
. NN NN O

His NN NN O
pupils NN NN O
are NN NN O
equal NN NN O
, NN NN O
round NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O

He NN NN O
has NN NN O
a NNP NNP B-PROBLEM
nevus NNP NNP I-PROBLEM
just NN NN O
below NN NN O
his NN NN O
orbit NN NN O
on NN NN O
the NN NN O
right NN NN O
hand NN NN O
side NN NN O
that NN NN O
has NN NN O
some NNP NNP B-PROBLEM
irregularity NNP NNP I-PROBLEM
. NN NN O

His NN NN O
pupils NN NN O
are NN NN O
equal NN NN O
, NN NN O
round NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O

Sclerae NNP NNP B-PROBLEM
anicteric NNP NNP I-PROBLEM
. NN NN O

His NN NN O
oropharynx NN NN O
is NN NN O
clear NN NN O
. NN NN O

He NN NN O
has NN NN O
several NNP NNP B-PROBLEM
missing NNP NNP I-PROBLEM
teeth NNP NNP I-PROBLEM
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

He NN NN O
has NN NN O
large NNP NNP B-PROBLEM
palpable NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
submandibular NNP NNP I-PROBLEM
region NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
firm NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
some NNP NNP B-PROBLEM
shotty NNP NNP I-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
posterior NNP NNP I-PROBLEM
cervical NNP NNP I-PROBLEM
chain NNP NNP I-PROBLEM
bilaterally NNP NNP I-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

CV NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
, NN NN O
normal NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
, NN NN O
no NN NN O
murmurs NNP NNP B-PROBLEM
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
. NN NN O

He NN NN O
has NN NN O
positive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

He NN NN O
has NN NN O
shotty NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
and NN NN O
shotty NNP NNP B-PROBLEM
inguinal NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
. NN NN O

EXT NN NN O
: NN NN O
Lower NN NN O
extremity NN NN O
is NN NN O
without NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

His NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
chest NNP NNP I-TEST
showed NN NN O
prominent NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
bilaterally NNP NNP I-PROBLEM
, NN NN O
largest NN NN O
on NN NN O
the NN NN O
left NN NN O
measuring NN NN O
12 NN NN O
x NN NN O
29 NN NN O
mm NN NN O
. NN NN O

He NN NN O
has NN NN O
borderline NNP NNP B-PROBLEM
enlarge NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
superior NNP NNP I-PROBLEM
hilar NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
measuring NN NN O
9 NN NN O
x NN NN O
11 NN NN O
mm NN NN O
. NN NN O

His NN NN O
lungs NN NN O
are NN NN O
benign NN NN O
appearing NN NN O
by NN NN O
apical NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
parenchymal NNP NNP I-PROBLEM
scarring NNP NNP I-PROBLEM
and NN NN O
very NNP NNP B-PROBLEM
mild NNP NNP I-PROBLEM
peri-septal NNP NNP I-PROBLEM
emphysema NNP NNP I-PROBLEM
. NN NN O

Bones NN NN O
shows NN NN O
mild NNP NNP B-PROBLEM
disk NNP NNP I-PROBLEM
degenerative NNP NNP I-PROBLEM
changes NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
inferior NNP NNP I-PROBLEM
thoracic NNP NNP I-PROBLEM
spine NNP NNP I-PROBLEM
. NN NN O

IMPRESSION NN NN O
: NN NN O

1 NN NN O
. NN NN O
Borderline NNP NNP B-PROBLEM
enlarged NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
superior NNP NNP I-PROBLEM
hilar NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
, NN NN O
otherwise NN NN O
it NN NN O
unremarkable NN NN O
CT NN NN O
of NN NN O
the NN NN O
chest NN NN O
. NN NN O

CT NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
neck NNP NNP I-TEST
shows NN NN O
4.1 NNP NNP B-PROBLEM
x NNP NNP I-PROBLEM
3.0 NNP NNP I-PROBLEM
x NNP NNP I-PROBLEM
3.9 NNP NNP I-PROBLEM
cm NNP NNP I-PROBLEM
heterogenously NNP NNP I-PROBLEM
enhancing NNP NNP I-PROBLEM
lesion NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
submandibular NNP NNP I-PROBLEM
space NNP NNP I-PROBLEM
with NN NN O
central NNP NNP B-PROBLEM
necrosis NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
lesion NNP NNP I-PROBLEM
appears NN NN O
to NN NN O
be NN NN O
separate NN NN O
from NN NN O
the NN NN O
submandibular NN NN O
gland NN NN O
with NN NN O
displacement NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
glands NNP NNP I-PROBLEM
superiorly NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
posteriorly NNP NNP I-PROBLEM
. NN NN O

This NNP NNP B-PROBLEM
lesion NNP NNP I-PROBLEM
is NN NN O
most NN NN O
suspicious NN NN O
for NN NN O
an NNP NNP B-PROBLEM
enlarged NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
. NN NN O

Also NN NN O
, NN NN O
numerous NNP NNP B-PROBLEM
other NNP NNP I-PROBLEM
enlarged NNP NNP I-PROBLEM
enhancing NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
anterior NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
posterior NNP NNP I-PROBLEM
cervical NNP NNP I-PROBLEM
chains NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
region NNP NNP I-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
Prominent NNP NNP B-PROBLEM
palatine NNP NNP I-PROBLEM
tonsils NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
lingular NNP NNP I-PROBLEM
tonsillar NNP NNP I-PROBLEM
tissue NNP NNP I-PROBLEM
bilaterally NNP NNP I-PROBLEM
which NN NN O
may NN NN O
be NN NN O
reactive NN NN O
or NN NN O
could NN NN O
indicate NN NN O
lymphomatous NNP NNP B-PROBLEM
involvement NNP NNP I-PROBLEM
if NN NN O
the NN NN O
patient NN NN O
does NN NN O
have NN NN O
lymphoma NNP NNP B-PROBLEM
. NN NN O

3 NN NN O
. NN NN O
Rim-enhancing NNP NNP B-PROBLEM
lesions NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
parotid NNP NNP I-PROBLEM
gland NNP NNP I-PROBLEM
. NN NN O

These NN NN O
could NN NN O
be NN NN O
Warthin NNP NNP B-PROBLEM
tumors NNP NNP I-PROBLEM
or NN NN O
potentially NN NN O
necrotic NNP NNP B-PROBLEM
intraparotid NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
related NN NN O
to NN NN O
the NN NN O
previously NN NN O
described NN NN O
process NN NN O
in NN NN O
the NN NN O
neck NN NN O
. NN NN O

Pathology NN NN O
for NN NN O
fine NNP NNP B-PROBLEM
needle NNP NNP I-PROBLEM
aspiration NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
mandible NNP NNP I-PROBLEM
shows NN NN O
an NNP NNP B-PROBLEM
atypical NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
population NNP NNP I-PROBLEM
, NN NN O
the NNP NNP B-PROBLEM
atypical NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
population NNP NNP I-PROBLEM
is NN NN O
difficult NN NN O
to NN NN O
define NN NN O
. NN NN O

A NNP NNP B-PROBLEM
neoplastic NNP NNP I-PROBLEM
process NNP NNP I-PROBLEM
is NN NN O
favored NN NN O
. NN NN O

While NN NN O
they NN NN O
are NN NN O
fairly NNP NNP B-PROBLEM
large NNP NNP I-PROBLEM
, NN NN O
they NN NN O
are NN NN O
still NN NN O
within NN NN O
the NN NN O
realm NN NN O
of NN NN O
being NN NN O
lymphoid NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
nature NNP NNP I-PROBLEM
, NN NN O
and NN NN O
they NN NN O
are NN NN O
also NN NN O
discohesive NNP NNP B-PROBLEM
, NN NN O
which NN NN O
also NN NN O
favours NN NN O
of NN NN O
lymphoid NNP NNP B-PROBLEM
neoplasm NNP NNP I-PROBLEM
. NN NN O

He NN NN O
then NN NN O
had NN NN O
a NNP NNP B-TEST
biopsy NNP NNP I-TEST
of NN NN O
the NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
maxillary NNP NNP I-PROBLEM
alveolar NNP NNP I-PROBLEM
ridge NNP NNP I-PROBLEM
. NN NN O

This NN NN O
was NN NN O
positive NN NN O
for NN NN O
high NNP NNP B-PROBLEM
grade NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
most NN NN O
consistent NN NN O
with NN NN O
peripheral NNP NNP B-PROBLEM
T-cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
40-year-old NN NN O
gentleman NN NN O
with NN NN O
certain NN NN O
onset NN NN O
of NN NN O
swelling NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
, NN NN O
biopsies NNP NNP B-TEST
consistent NN NN O
with NN NN O
T-cell NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

I NN NN O
plan NN NN O
at NN NN O
this NN NN O
point NN NN O
time NN NN O
is NN NN O
to NN NN O
complete NN NN O
the NN NN O
staging NN NN O
. NN NN O

He NN NN O
will NN NN O
check NN NN O
HTLV-1 NNP NNP B-TEST
serology NNP NNP I-TEST
. NN NN O

We NN NN O
will NN NN O
also NN NN O
send NN NN O
pro NN NN O
for NN NN O
blood NNP NNP B-TREATMENT
for NN NN O
flow NNP NNP B-TEST
cytometry NNP NNP I-TEST
and NN NN O
analysis NNP NNP B-TEST
for NN NN O
atypical NNP NNP B-PROBLEM
cells NNP NNP I-PROBLEM
. NN NN O

We NN NN O
will NN NN O
obtain NN NN O
a NNP NNP B-TEST
CBC NNP NNP I-TEST
, NN NN O
comprehensive NNP NNP B-TEST
metabolic NNP NNP I-TEST
panel NNP NNP I-TEST
and NN NN O
LDH NNP NNP B-TEST
. NN NN O

We NN NN O
will NN NN O
also NN NN O
send NN NN O
his NN NN O
stool NN NN O
for NN NN O
parasites NNP NNP B-PROBLEM
and NN NN O
obtain NN NN O
a NNP NNP B-TEST
PET NNP NNP I-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
. NN NN O

We NN NN O
were NN NN O
to NN NN O
preliminarily NN NN O
stage NN NN O
this NN NN O
he NN NN O
is NN NN O
at NN NN O
least NN NN O
stage NNP NNP B-PROBLEM
2 NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
axilla NNP NNP I-PROBLEM
seen NN NN O
on NN NN O
skin NN NN O
. NN NN O

On NN NN O
physical NNP NNP B-TEST
exam NNP NNP I-TEST
lymph NN NN O
nodes NN NN O
are NN NN O
palpable NN NN O
in NN NN O
inguinal NN NN O
region NN NN O
. NN NN O

He NN NN O
does NN NN O
have NN NN O
these NNP NNP B-PROBLEM
symptoms NNP NNP I-PROBLEM
with NN NN O
the NNP NNP B-PROBLEM
drenching NNP NNP I-PROBLEM
night NNP NNP I-PROBLEM
sweats NNP NNP I-PROBLEM
and NN NN O
fever NNP NNP B-PROBLEM
. NN NN O

We NN NN O
will NN NN O
also NN NN O
check NN NN O
viral NNP NNP B-TEST
load NNP NNP I-TEST
and NN NN O
hepatitis NNP NNP B-TEST
B NNP NNP I-TEST
and NN NN O
C NNP NNP B-TEST
panel NNP NNP I-TEST
. NN NN O

The NN NN O
patient NN NN O
has NN NN O
not NN NN O
established NN NN O
care NN NN O
with NN NN O
infectious NN NN O
disease NN NN O
physician NN NN O
. NN NN O

We NN NN O
will NN NN O
need NN NN O
to NN NN O
reformed NN NN O
ID NN NN O
as NN NN O
if NN NN O
he NN NN O
true NN NN O
he NN NN O
has NN NN O
HIV NNP NNP B-PROBLEM
positive NNP NNP I-PROBLEM
, NN NN O
we NN NN O
can NN NN O
do NN NN O
some NN NN O
help NN NN O
in NN NN O
coordinating NNP NNP B-TREATMENT
HIV NNP NNP I-TREATMENT
treatment NNP NNP I-TREATMENT
as NN NN O
well NN NN O
as NN NN O
treatment NNP NNP B-TREATMENT
for NN NN O
what NN NN O
appears NN NN O
to NN NN O
be NN NN O
a NNP NNP B-PROBLEM
T-cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

Once NN NN O
we NN NN O
get NN NN O
these NN NN O
preliminary NN NN O
labs NN NN O
back NN NN O
then NN NN O
we NN NN O
will NN NN O
discuss NN NN O
the NN NN O
need NN NN O
for NN NN O
bone NNP NNP B-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
and NN NN O
lumbar NNP NNP B-TEST
puncture NNP NNP I-TEST
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
t-cell NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
, NN NN O
submandibular NN NN O
, NN NN O
tooth NNP NNP B-PROBLEM
abscess NNP NNP I-PROBLEM
, NN NN O
strep NNP NNP B-PROBLEM
throat NNP NNP I-PROBLEM
, NN NN O
submandibular NNP NNP B-PROBLEM
region NNP NNP I-PROBLEM
, NN NN O
lymphoma NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Polycythemia NNP NNP B-PROBLEM
Vera NN NN O
Followup NN NN O
Description NN NN O
: NN NN O
Followup NN NN O
for NN NN O
polycythemia NNP NNP B-PROBLEM
vera NNP NNP I-PROBLEM
with NN NN O
secondary NNP NNP B-PROBLEM
myelofibrosis NNP NNP I-PROBLEM
. NN NN O

JAK-2 NNP NNP B-PROBLEM
positive NNP NNP I-PROBLEM
myeloproliferative NNP NNP I-PROBLEM
disorder NNP NNP I-PROBLEM
. NN NN O

He NN NN O
is NN NN O
not NN NN O
a NN NN O
candidate NN NN O
for NN NN O
chlorambucil NNP NNP B-DRUG
or NN NN O
radioactive NNP NNP B-DRUG
phosphorus NNP NNP I-DRUG
because NN NN O
of NN NN O
his NN NN O
young NN NN O
age NN NN O
and NN NN O
the NN NN O
concern NN NN O
for NN NN O
secondary NNP NNP B-PROBLEM
malignancy NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
DIAGNOSIS NN NN O
: NN NN O
Polycythemia NNP NNP B-PROBLEM
vera NNP NNP I-PROBLEM
with NN NN O
secondary NNP NNP B-PROBLEM
myelofibrosis NNP NNP I-PROBLEM
. NN NN O

REASON NN NN O
FOR NN NN O
VISIT NN NN O
: NN NN O
Followup NN NN O
of NN NN O
the NN NN O
above NN NN O
condition NN NN O
. NN NN O

CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
Left NNP NNP B-PROBLEM
shin NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
A NN NN O
55-year-old NN NN O
white NN NN O
male NN NN O
who NN NN O
carries NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
polycythemia NNP NNP B-PROBLEM
vera NNP NNP I-PROBLEM
with NN NN O
secondary NNP NNP B-PROBLEM
myelofibrosis NNP NNP I-PROBLEM
. NN NN O

Diagnosis NN NN O
was NN NN O
made NN NN O
some NN NN O
time NN NN O
in NN NN O
2005/2006 NNP NNP B-DATE
. NN NN O

Initially NN NN O
, NN NN O
he NN NN O
underwent NN NN O
phlebotomy NNP NNP B-TREATMENT
. NN NN O

He NN NN O
subsequently NN NN O
transferred NN NN O
his NN NN O
care NN NN O
here NN NN O
. NN NN O

In NN NN O
the NN NN O
past NN NN O
, NN NN O
he NN NN O
has NN NN O
been NN NN O
on NN NN O
hydroxyurea NNP NNP B-DRUG
and NN NN O
interferon NNP NNP B-DRUG
but NN NN O
did NN NN O
not NN NN O
tolerate NN NN O
both NN NN O
of NN NN O
them NN NN O
. NN NN O

He NN NN O
is NN NN O
JAK-2 NNP NNP B-PROBLEM
positive NNP NNP I-PROBLEM
. NN NN O

He NN NN O
does NN NN O
not NN NN O
have NN NN O
any NN NN O
siblings NN NN O
for NN NN O
a NNP NNP B-TREATMENT
match-related NNP NNP I-TREATMENT
transplant NNP NNP I-TREATMENT
. NN NN O

He NN NN O
was NN NN O
seen NN NN O
for NN NN O
consideration NN NN O
of NN NN O
a NNP NNP B-TREATMENT
MUD NNP NNP I-TREATMENT
transplant NNP NNP I-TREATMENT
, NN NN O
but NN NN O
was NN NN O
deemed NN NN O
not NN NN O
to NN NN O
be NN NN O
a NN NN O
candidate NN NN O
because NN NN O
of NN NN O
the NNP NNP B-TREATMENT
social NNP NNP I-TREATMENT
support NNP NNP I-TREATMENT
as NN NN O
well NN NN O
as NN NN O
his NN NN O
reasonably NN NN O
good NN NN O
health NN NN O
. NN NN O

At NN NN O
our NN NN O
institution NN NN O
, NN NN O
the NN NN O
patient NN NN O
received NN NN O
a NN NN O
trial NN NN O
of NN NN O
lenalidomide NNP NNP B-DRUG
and NN NN O
prednisone NNP NNP B-DRUG
for NN NN O
a NN NN O
short NN NN O
period NN NN O
. NN NN O

He NN NN O
did NN NN O
well NN NN O
with NN NN O
the NN NN O
combination NN NN O
. NN NN O

Subsequently NN NN O
, NN NN O
he NN NN O
developed NN NN O
intolerance NNP NNP B-PROBLEM
to NN NN O
lenalidomide NNP NNP B-DRUG
. NN NN O

He NN NN O
complained NN NN O
of NN NN O
severe NNP NNP B-PROBLEM
fatigue NNP NNP I-PROBLEM
and NN NN O
diarrhea NNP NNP B-PROBLEM
. NN NN O

This NN NN O
was NN NN O
subsequently NN NN O
stopped NN NN O
. NN NN O

The NN NN O
patient NN NN O
reports NN NN O
some NNP NNP B-PROBLEM
injury NNP NNP I-PROBLEM
to NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
leg NNP NNP I-PROBLEM
last NN NN O
week NN NN O
. NN NN O

His NN NN O
left NN NN O
leg NN NN O
apparently NN NN O
was NN NN O
swollen NNP NNP B-PROBLEM
. NN NN O

He NN NN O
took NN NN O
steroids NNP NNP B-DRUG
for NN NN O
about NN NN O
3 NN NN O
days NN NN O
and NN NN O
stopped NN NN O
. NN NN O

Left NNP NNP B-PROBLEM
leg NNP NNP I-PROBLEM
swelling NNP NNP I-PROBLEM
has NN NN O
disappeared NN NN O
. NN NN O

The NN NN O
patient NN NN O
denies NN NN O
any NN NN O
other NN NN O
complaints NN NN O
at NN NN O
this NN NN O
point NN NN O
in NN NN O
time NN NN O
. NN NN O

He NN NN O
admits NN NN O
to NN NN O
smoking NN NN O
marijuana NN NN O
. NN NN O

He NN NN O
says NN NN O
this NN NN O
gives NN NN O
him NN NN O
a NN NN O
great NN NN O
appetite NN NN O
and NN NN O
he NN NN O
has NN NN O
actually NN NN O
gained NN NN O
some NN NN O
weight NN NN O
. NN NN O

Performance NN NN O
status NN NN O
in NN NN O
the NN NN O
ECOG NN NN O
scale NN NN O
is NN NN O

1 NN NN O
. NN NN O
PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
He NN NN O
is NN NN O
afebrile NNP NNP B-PROBLEM
. NN NN O

Blood NNP NNP B-TEST
pressure NNP NNP I-TEST
144/85 NN NN O
, NN NN O
pulse NNP NNP B-TEST
86 NN NN O
, NN NN O
weight NNP NNP B-TEST
61.8 NN NN O
kg NN NN O
, NN NN O
and NN NN O
respiratory NNP NNP B-TEST
rate NNP NNP I-TEST
18 NN NN O
per NN NN O
minute NN NN O
. NN NN O

GENERAL NN NN O
: NN NN O
He NN NN O
is NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
There NN NN O
is NN NN O
no NN NN O
pallor NNP NNP B-PROBLEM
, NN NN O
icterus NNP NNP B-PROBLEM
or NN NN O
cervical NNP NNP B-PROBLEM
adenopathy NNP NNP I-PROBLEM
that NN NN O
is NN NN O
noted NN NN O
. NN NN O

Oral NN NN O
cavity NN NN O
is NN NN O
normal NN NN O
to NN NN O
exam NNP NNP B-TEST
. NN NN O

CHEST NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
. NN NN O

CARDIOVASCULAR NN NN O
: NN NN O
S1 NN NN O
and NN NN O
S2 NN NN O
normal NN NN O
with NN NN O
regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
and NN NN O
nontender NNP NNP B-PROBLEM
with NN NN O
no NN NN O
hepatomegaly NNP NNP B-PROBLEM
. NN NN O

Spleen NN NN O
is NN NN O
palpable NN NN O
4 NN NN O
fingerbreadths NN NN O
below NN NN O
the NN NN O
left NN NN O
costal NN NN O
margin NN NN O
. NN NN O

There NN NN O
is NN NN O
no NN NN O
guarding NNP NNP B-PROBLEM
, NN NN O
tenderness NNP NNP B-PROBLEM
, NN NN O
rebound NNP NNP B-PROBLEM
or NN NN O
rigidity NNP NNP B-PROBLEM
noted NN NN O
. NN NN O

Bowel NN NN O
sounds NN NN O
are NN NN O
present NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
Reveal NNP NNP B-TREATMENT
no NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

Palpation NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
left NNP NNP I-TEST
tibia NNP NNP I-TEST
revealed NN NN O
some NNP NNP B-PROBLEM
mild NNP NNP I-PROBLEM
tenderness NNP NNP I-PROBLEM
. NN NN O

However NN NN O
, NN NN O
I NN NN O
do NN NN O
not NN NN O
palpate NN NN O
any NNP NNP B-PROBLEM
bony NNP NNP I-PROBLEM
abnormalities NNP NNP I-PROBLEM
. NN NN O

There NN NN O
is NN NN O
no NN NN O
history NN NN O
of NN NN O
deep NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
CBC NNP NNP B-TEST
from NN NN O
today NN NN O
is NN NN O
significant NN NN O
for NN NN O
a NNP NNP B-TEST
white NNP NNP I-TEST
count NNP NNP I-TEST
of NN NN O
41,900 NN NN O
with NN NN O
an NNP NNP B-TEST
absolute NNP NNP I-TEST
neutrophil NNP NNP I-TEST
count NNP NNP I-TEST
of NN NN O
34,400 NN NN O
, NN NN O
hemoglobin NNP NNP B-TEST
14.8 NN NN O
with NN NN O
an NNP NNP B-TEST
MCV NNP NNP I-TEST
of NN NN O
56.7 NN NN O
, NN NN O
and NN NN O
platelet NNP NNP B-TEST
count NNP NNP I-TEST
235,000 NN NN O
. NN NN O

ASSESSMENT NN NN O
AND NN NN O
PLAN NN NN O
: NN NN O

1 NN NN O
. NN NN O
JAK-2 NNP NNP B-PROBLEM
positive NNP NNP I-PROBLEM
myeloproliferative NNP NNP I-PROBLEM
disorder NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
has NN NN O
failed NN NN O
pretty NN NN O
much NN NN O
all NN NN O
available NN NN O
options NN NN O
. NN NN O

He NN NN O
is NN NN O
not NN NN O
a NN NN O
candidate NN NN O
for NN NN O
chlorambucil NNP NNP B-DRUG
or NN NN O
radioactive NNP NNP B-DRUG
phosphorus NNP NNP I-DRUG
because NN NN O
of NN NN O
his NN NN O
young NN NN O
age NN NN O
and NN NN O
the NN NN O
concern NN NN O
for NN NN O
secondary NNP NNP B-PROBLEM
malignancy NNP NNP I-PROBLEM
. NN NN O

I NN NN O
have NN NN O
e-mailed NN NN O
Dr NN NN O
. NN NN O
X NN NN O
to NN NN O
see NN NN O
whether NN NN O
he NN NN O
will NN NN O
be NN NN O
a NN NN O
candidate NN NN O
for NN NN O
the NNP NNP B-TEST
LBH NNP NNP I-TEST
trial NNP NNP I-TEST
. NN NN O

Hopefully NN NN O
, NN NN O
we NN NN O
can NN NN O
get NN NN O
a NN NN O
JAK-2 NNP NNP B-DRUG
inhibitor NNP NNP I-DRUG
trial NN NN O
quickly NN NN O
on NN NN O
board NN NN O
. NN NN O

2 NN NN O
. NN NN O
I NN NN O
am NN NN O
concerned NN NN O
about NN NN O
the NN NN O
risk NN NN O
of NN NN O
thrombosis NNP NNP B-PROBLEM
with NN NN O
his NNP NNP B-PROBLEM
elevated NNP NNP I-PROBLEM
white NNP NNP I-PROBLEM
count NNP NNP I-PROBLEM
. NN NN O

He NN NN O
is NN NN O
on NN NN O
aspirin NNP NNP B-DRUG
prophylaxis NN NN O
. NN NN O

The NN NN O
patient NN NN O
has NN NN O
been NN NN O
told NN NN O
to NN NN O
call NN NN O
me NN NN O
with NN NN O
any NN NN O
complaints NN NN O
. NN NN O

3 NN NN O
. NN NN O
Left NNP NNP B-PROBLEM
shin NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

I NN NN O
have NN NN O
ordered NNP NNP B-TEST
x-rays NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
left NNP NNP I-TEST
tibia NNP NNP I-TEST
and NNP NNP I-TEST
knee NNP NNP I-TEST
today NN NN O
. NN NN O

The NN NN O
patient NN NN O
will NN NN O
return NN NN O
to NN NN O
the NN NN O
clinic NN NN O
in NN NN O
3 NN NN O
weeks NN NN O
. NN NN O

He NN NN O
is NN NN O
to NN NN O
call NN NN O
me NN NN O
in NN NN O
the NN NN O
interim NN NN O
for NN NN O
any NNP NNP B-PROBLEM
problems NNP NNP I-PROBLEM
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
jak-2 NNP NNP B-PROBLEM
positive NNP NNP I-PROBLEM
myeloproliferative NNP NNP I-PROBLEM
disorder NNP NNP I-PROBLEM
, NN NN O
secondary NN NN O
myelofibrosis NNP NNP B-PROBLEM
, NN NN O
mud NNP NNP B-TREATMENT
transplant NNP NNP I-TREATMENT
, NN NN O
ecog NNP NNP B-TREATMENT
scale NNP NNP I-TREATMENT
, NN NN O
myeloproliferative NNP NNP B-PROBLEM
disorder NNP NNP I-PROBLEM
, NN NN O
radioactive NNP NNP B-PROBLEM
phosphorus NNP NNP I-PROBLEM
, NN NN O
jak NNP NNP B-PROBLEM
positive NNP NNP I-PROBLEM
, NN NN O
polycythemia NNP NNP B-PROBLEM
vera NNP NNP I-PROBLEM
, NN NN O
thrombosis NNP NNP B-PROBLEM
, NN NN O
myelofibrosis NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
BCCa NN NN O
Excision NN NN O
- NN NN O
Canthus NN NN O
Description NN NN O
: NN NN O
Excision NNP NNP B-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NN NN O
medial NN NN O
canthus NN NN O
with NN NN O
frozen NNP NNP B-TREATMENT
section NNP NNP I-TREATMENT
, NN NN O
and NN NN O
reconstruction NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
defect NNP NNP I-TREATMENT
with NN NN O
glabellar NNP NNP B-TREATMENT
rotation NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
( NN NN O
0.8 NN NN O
cm NN NN O
diameter NN NN O
), NN NN O
right NN NN O
medial NN NN O
canthus NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
( NN NN O
0.8 NN NN O
cm NN NN O
diameter NN NN O
), NN NN O
right NN NN O
medial NN NN O
canthus NN NN O
. NN NN O

OPERATION NN NN O
: NN NN O
Excision NNP NNP B-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
( NN NN O
0.8 NN NN O
cm NN NN O
diameter NN NN O
), NN NN O
right NN NN O
medial NN NN O
canthus NN NN O
with NN NN O
frozen NN NN O
section NN NN O
, NN NN O
and NN NN O
reconstruction NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
defect NNP NNP I-TREATMENT
( NN NN O
1.2 NN NN O
cm NN NN O
diameter NN NN O
) NN NN O
with NN NN O
glabellar NNP NNP B-TREATMENT
rotation NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
. NN NN O

ANESTHESIA NNP NNP B-PROBLEM
: NN NN O
Monitored NN NN O
anesthesia NNP NNP B-DRUG
care NN NN O
. NN NN O

JUSTIFICATION NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
an NN NN O
80-year-old NN NN O
white NN NN O
female NN NN O
with NN NN O
a NNP NNP B-PROBLEM
biopsy-proven NNP NNP I-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
medial NNP NNP I-PROBLEM
canthus NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
scheduled NN NN O
for NN NN O
elective NNP NNP B-TREATMENT
excision NNP NNP I-TREATMENT
with NN NN O
frozen NNP NNP B-TREATMENT
section NNP NNP I-TREATMENT
under NN NN O
local NNP NNP B-TREATMENT
anesthesia NNP NNP I-TREATMENT
as NN NN O
an NN NN O
outpatient NN NN O
. NN NN O

PROCEDURE NN NN O
: NN NN O
With NN NN O
an NNP NNP B-TREATMENT
intravenous NNP NNP I-TREATMENT
infusing NNP NNP I-TREATMENT
and NN NN O
under NN NN O
suitable NN NN O
premedication NNP NNP B-TREATMENT
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
placed NN NN O
supine NN NN O
on NN NN O
the NN NN O
operative NN NN O
table NN NN O
. NN NN O

The NN NN O
face NN NN O
was NN NN O
prepped NN NN O
with NN NN O
pHisoHex NNP NNP B-TREATMENT
draped NNP NNP I-TREATMENT
. NN NN O

The NN NN O
right NN NN O
medial NN NN O
canthal NN NN O
region NN NN O
and NN NN O
the NN NN O
glabellar NN NN O
region NN NN O
were NN NN O
anesthetized NN NN O
with NN NN O
1% NNP NNP B-DRUG
Xylocaine NNP NNP I-DRUG
with NNP NNP I-DRUG
1:100,000 NNP NNP I-DRUG
epinephrine NNP NNP B-DRUG
. NN NN O

Under NN NN O
loupe NNP NNP B-TEST
magnification NNP NNP I-TEST
, NN NN O
the NNP NNP B-PROBLEM
lesion NNP NNP I-PROBLEM
was NN NN O
excised NN NN O
with NN NN O
2 NN NN O
mm NN NN O
margins NN NN O
, NN NN O
oriented NN NN O
with NN NN O
sutures NNP NNP B-TREATMENT
and NN NN O
submitted NN NN O
for NN NN O
frozen NNP NNP B-PROBLEM
section NNP NNP I-PROBLEM
pathology NNP NNP I-PROBLEM
. NN NN O

The NN NN O
report NN NN O
was NN NN O
" NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
with NN NN O
all NN NN O
margins NN NN O
free NN NN O
of NN NN O
tumor NNP NNP B-PROBLEM
. NN NN O

" NN NN O
Hemostasis NN NN O
was NN NN O
controlled NN NN O
with NN NN O
the NNP NNP B-TREATMENT
Bovie NNP NNP I-TREATMENT
. NN NN O

Excised NNP NNP B-TEST
lesion NNP NNP I-TEST
diameter NNP NNP I-TEST
was NN NN O
1.2 NN NN O
cm NN NN O
. NN NN O

The NNP NNP B-PROBLEM
defect NNP NNP I-PROBLEM
was NN NN O
closed NN NN O
by NN NN O
elevating NN NN O
a NNP NNP B-PROBLEM
left NNP NNP I-PROBLEM
laterally NNP NNP I-PROBLEM
based NNP NNP I-PROBLEM
rotation NNP NNP I-PROBLEM
flap NNP NNP I-PROBLEM
utilizing NN NN O
the NN NN O
glabellar NN NN O
skin NN NN O
. NN NN O

The NNP NNP B-TREATMENT
flap NNP NNP I-TREATMENT
was NN NN O
elevated NNP NNP B-PROBLEM
with NN NN O
a NNP NNP B-TREATMENT
scalpel NNP NNP I-TREATMENT
and NN NN O
Bovie NNP NNP B-TREATMENT
, NN NN O
rotated NN NN O
into NN NN O
the NNP NNP B-PROBLEM
defect NNP NNP I-PROBLEM
without NN NN O
tension NN NN O
, NN NN O
***** NN NN O
to NN NN O
the NNP NNP B-PROBLEM
defect NNP NNP I-PROBLEM
with NN NN O
scissors NNP NNP B-TREATMENT
and NN NN O
inset NNP NNP B-TREATMENT
in NNP NNP I-TREATMENT
layer NNP NNP I-TREATMENT
with NN NN O
interrupted NN NN O
5-0 NN NN O
Vicryl NNP NNP B-TREATMENT
for NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
dermis NNP NNP I-TREATMENT
and NN NN O
running NN NN O
5-0 NN NN O
Prolene NN NN O
for NN NN O
the NN NN O
skin NN NN O
. NN NN O

Donor NN NN O
site NN NN O
was NN NN O
closed NN NN O
in NN NN O
V-Y NN NN O
fashion NN NN O
with NN NN O
similar NNP NNP B-TREATMENT
suture NNP NNP I-TREATMENT
technique NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-PROBLEM
wounds NNP NNP I-PROBLEM
were NN NN O
dressed NN NN O
with NN NN O
bacitracin NNP NNP B-DRUG
ointment NNP NNP I-DRUG
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
returned NN NN O
to NN NN O
the NN NN O
recovery NN NN O
room NN NN O
in NN NN O
satisfactory NN NN O
condition NN NN O
. NN NN O

She NN NN O
tolerated NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
satisfactorily NN NN O
, NN NN O
and NN NN O
then NN NN O
no NN NN O
complications NNP NNP B-PROBLEM
. NN NN O

Blood NNP NNP B-PROBLEM
loss NNP NNP I-PROBLEM
was NN NN O
essentially NN NN O
nil NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
excision NNP NNP B-TREATMENT
, NN NN O
bacitracin NNP NNP B-TREATMENT
, NN NN O
canthal NNP NNP B-TEST
region NNP NNP I-TEST
, NNP NNP I-TEST
canthus NNP NNP I-TEST
, NN NN O
frozen NNP NNP B-TEST
section NNP NNP I-TEST
, NN NN O
glabellar NNP NNP B-TREATMENT
, NN NN O
glabellar NNP NNP B-TREATMENT
region NNP NNP I-TREATMENT
, NN NN O
loupe NNP NNP B-TEST
magnification NNP NNP I-TEST
, NN NN O
phisohex NNP NNP B-TREATMENT
, NN NN O
rotation NNP NNP B-TREATMENT
flap NNP NNP I-TREATMENT
, NN NN O
loupe NNP NNP B-TREATMENT
, NN NN O
excision NNP NNP B-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
medial NN NN O
canthus NN NN O
, NN NN O
basal NN NN O
cell NN NN O
, NN NN O
cell NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
basal NN NN O
, NN NN O
cell NN NN O
, NN NN O
carcinoma NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
MediPort NN NN O
Placement NN NN O
Description NN NN O
: NN NN O
Rhabdomyosarcoma NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
orbit NNP NNP I-PROBLEM
. NN NN O

Left NNP NNP B-TREATMENT
subclavian NNP NNP I-TREATMENT
vein NNP NNP I-TREATMENT
MediPort NNP NNP I-TREATMENT
placement NNP NNP I-TREATMENT
. NN NN O

Needs NN NN O
chemotherapy NNP NNP B-DRUG
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Rhabdomyosarcoma NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
orbit NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Rhabdomyosarcoma NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
orbit NNP NNP I-PROBLEM
. NN NN O

PROCEDURE NN NN O
: NN NN O
Left NNP NNP B-TREATMENT
subclavian NNP NNP I-TREATMENT
vein NNP NNP I-TREATMENT
MediPort NNP NNP I-TREATMENT
placement NNP NNP I-TREATMENT
( NN NN O
7.5-French NN NN O
single-lumen NN NN O
). NN NN O

INDICATIONS NN NN O
FOR NN NN O
PROCEDURE NN NN O
: NN NN O
This NN NN O
patient NN NN O
is NN NN O
a NN NN O
16-year-old NN NN O
girl NN NN O
, NN NN O
with NN NN O
newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
rhabdomyosarcoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
orbit NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
is NN NN O
being NN NN O
taken NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
for NN NN O
MediPort NNP NNP B-TREATMENT
placement NNP NNP I-TREATMENT
. NN NN O

She NN NN O
needs NN NN O
chemotherapy NNP NNP B-DRUG
. NN NN O

DESCRIPTION NN NN O
OF NN NN O
PROCEDURE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
, NN NN O
placed NN NN O
supine NN NN O
, NN NN O
put NN NN O
under NN NN O
general NN NN O
endotracheal NN NN O
anesthesia NNP NNP B-DRUG
. NN NN O

The NN NN O
patient's NN NN O
neck NN NN O
, NN NN O
chest NN NN O
, NN NN O
and NN NN O
shoulders NN NN O
were NN NN O
prepped NN NN O
and NN NN O
draped NN NN O
in NN NN O
usual NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

An NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
on NN NN O
the NN NN O
left NN NN O
shoulder NN NN O
area NN NN O
. NN NN O

The NN NN O
left NN NN O
subclavian NN NN O
vein NN NN O
was NN NN O
cannulated NN NN O
. NN NN O

The NNP NNP B-TREATMENT
wire NNP NNP I-TREATMENT
was NN NN O
passed NN NN O
, NN NN O
which NN NN O
was NN NN O
in NN NN O
good NN NN O
position NN NN O
under NN NN O
fluoro NNP NNP B-TREATMENT
, NN NN O
using NN NN O
Seldinger NNP NNP B-TREATMENT
Technique NNP NNP I-TREATMENT
. NN NN O

Near NNP NNP B-PROBLEM
wire NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
site NNP NNP I-PROBLEM
made NN NN O
a NNP NNP B-PROBLEM
pocket NNP NNP I-PROBLEM
above NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
fascia NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
sutured NNP NNP I-PROBLEM
in NN NN O
a NN NN O
size NN NN O
7.5-French NN NN O
single-lumen NNP NNP B-TREATMENT
MediPort NNP NNP I-TREATMENT
into NN NN O
the NNP NNP B-PROBLEM
pocket NNP NNP I-PROBLEM
in NN NN O
4 NN NN O
places NN NN O
using NN NN O
3-0 NNP NNP B-TREATMENT
Nurolon NNP NNP I-TREATMENT
. NN NN O

I NN NN O
then NN NN O
sized NN NN O
the NNP NNP B-TREATMENT
catheter NNP NNP I-TREATMENT
under NN NN O
fluoro NNP NNP B-TREATMENT
and NN NN O
placed NN NN O
introducer NNP NNP B-TREATMENT
and NN NN O
dilator NNP NNP B-TREATMENT
over NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
wire NNP NNP I-TREATMENT
, NN NN O
removed NN NN O
the NNP NNP B-TREATMENT
wire NNP NNP I-TREATMENT
and NN NN O
dilator NNP NNP B-TREATMENT
, NN NN O
placed NN NN O
the NNP NNP B-TREATMENT
catheter NNP NNP I-TREATMENT
through NN NN O
the NNP NNP B-TREATMENT
introducer NNP NNP I-TREATMENT
and NN NN O
removed NN NN O
the NNP NNP B-TREATMENT
introducer NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-TREATMENT
line NNP NNP I-TREATMENT
tip NNP NNP I-TREATMENT
was NN NN O
in NN NN O
good NN NN O
position NN NN O
under NN NN O
fluoro NNP NNP B-TREATMENT
. NN NN O

It NN NN O
withdrew NN NN O
and NN NN O
flushed NN NN O
well NN NN O
. NN NN O

I NN NN O
then NN NN O
closed NN NN O
the NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
using NN NN O
4-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
, NN NN O
5-0 NNP NNP B-TREATMENT
Monocryl NNP NNP I-TREATMENT
for NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
skin NNP NNP I-TREATMENT
, NN NN O
and NN NN O
dressed NN NN O
with NN NN O
Steri-Strips NNP NNP B-TREATMENT
. NN NN O

Accessed NN NN O
the NNP NNP B-TREATMENT
ports NNP NNP I-TREATMENT
with NN NN O
a NNP NNP B-TREATMENT
1-inch NNP NNP I-TREATMENT
20-gauge NNP NNP I-TREATMENT
Huber NNP NNP I-TREATMENT
needle NNP NNP I-TREATMENT
, NN NN O
and NN NN O
it NN NN O
withdrew NN NN O
and NN NN O
flushed NN NN O
well NN NN O
with NN NN O
final NN NN O
heparin NNP NNP B-DRUG
flush NN NN O
. NN NN O

We NN NN O
secured NN NN O
this NN NN O
with NN NN O
Tegaderm NNP NNP B-TREATMENT
. NN NN O

The NN NN O
patient NN NN O
is NN NN O
then NN NN O
to NN NN O
undergo NN NN O
bilateral NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
and NN NN O
lumbar NNP NNP B-TEST
puncture NNP NNP I-TEST
by NN NN O
Oncology NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
rhabdomyosarcoma NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
orbit NNP NNP I-PROBLEM
, NN NN O
single NNP NNP B-TREATMENT
lumen NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
subclavian NNP NNP I-TREATMENT
vein NNP NNP I-TREATMENT
, NN NN O
mediport NNP NNP B-TREATMENT
placement NNP NNP I-TREATMENT
, NN NN O
chemotherapy NNP NNP B-DRUG
, NN NN O
rhabdomyosarcoma NNP NNP B-PROBLEM
, NN NN O
mediport NNP NNP B-TREATMENT
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Thrombocytosis NN NN O
Followup NN NN O
Description NN NN O
: NN NN O
Essential NNP NNP B-PROBLEM
thrombocytosis NNP NNP I-PROBLEM
. NN NN O

He NN NN O
underwent NN NN O
a NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
, NN NN O
which NN NN O
showed NN NN O
essential NNP NNP B-PROBLEM
thrombocytosis NNP NNP I-PROBLEM
. NN NN O

His NNP NNP B-TEST
CBC NNP NNP I-TEST
has NN NN O
been NN NN O
very NN NN O
stable NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
Essential NNP NNP B-PROBLEM
thrombocytosis NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
This NN NN O
is NN NN O
an NN NN O
extremely NN NN O
pleasant NN NN O
64-year-old NN NN O
gentleman NN NN O
who NN NN O
I NN NN O
am NN NN O
following NN NN O
for NN NN O
essential NNP NNP B-PROBLEM
thrombocytosis NNP NNP I-PROBLEM
. NN NN O

He NN NN O
was NN NN O
first NN NN O
diagnosed NN NN O
when NN NN O
he NN NN O
first NN NN O
saw NN NN O
a NN NN O
hematologist NN NN O
on NN NN O
07/09/07 NNP NNP B-DATE
. NN NN O

At NN NN O
that NN NN O
time NN NN O
, NN NN O
his NNP NNP B-TEST
platelet NNP NNP I-TEST
count NNP NNP I-TEST
was NN NN O
1,240,000 NN NN O
. NN NN O

He NN NN O
was NN NN O
initially NN NN O
started NN NN O
on NN NN O
Hydrea NNP NNP B-DRUG
1000 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.d NN NN O
. NN NN O

On NN NN O
07/11/07 NNP NNP B-DATE
, NN NN O
he NN NN O
underwent NN NN O
a NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
, NN NN O
which NN NN O
showed NN NN O
essential NNP NNP B-PROBLEM
thrombocytosis NNP NNP I-PROBLEM
. NN NN O

He NN NN O
was NN NN O
positive NN NN O
for NN NN O
the NNP NNP B-PROBLEM
JAK-2 NNP NNP I-PROBLEM
mutation NNP NNP I-PROBLEM
. NN NN O

On NN NN O
11/06/07 NNP NNP B-DATE
, NN NN O
his NNP NNP B-TEST
platelets NNP NNP I-TEST
were NN NN O
noted NN NN O
to NN NN O
be NN NN O
766,000 NN NN O
. NN NN O

His NN NN O
current NN NN O
Hydrea NNP NNP B-DRUG
dose NN NN O
is NN NN O
now NN NN O
1500 NN NN O
mg NN NN O
on NN NN O
Mondays NNP NNP B-DATE
and NN NN O
Fridays NNP NNP B-DATE
and NN NN O
1000 NN NN O
mg NN NN O
on NN NN O
all NN NN O
other NN NN O
days NN NN O
. NN NN O

He NN NN O
moved NN NN O
to NN NN O
ABCD NNP NNP B-TREATMENT
in NN NN O
December NNP NNP B-DATE
2009 NNP NNP I-DATE
in NN NN O
an NN NN O
attempt NN NN O
to NN NN O
improve NN NN O
his NNP NNP B-PROBLEM
wife's NNP NNP I-PROBLEM
rheumatoid NNP NNP I-PROBLEM
arthritis NNP NNP I-PROBLEM
. NN NN O

Overall NN NN O
, NN NN O
he NN NN O
is NN NN O
doing NN NN O
well NN NN O
. NN NN O

He NN NN O
has NN NN O
a NN NN O
good NN NN O
energy NN NN O
level NN NN O
, NN NN O
and NN NN O
his NN NN O
ECOG NN NN O
performance NN NN O
status NN NN O
is NN NN O

0 NN NN O
. NN NN O
He NN NN O
denies NN NN O
any NN NN O
fevers NNP NNP B-PROBLEM
, NN NN O
chills NNP NNP B-PROBLEM
, NN NN O
or NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
. NN NN O

No NN NN O
lymphadenopathy NNP NNP B-PROBLEM
. NN NN O

No NN NN O
nausea NNP NNP B-PROBLEM
or NN NN O
vomiting NNP NNP B-PROBLEM
. NN NN O

No NN NN O
change NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
bowel NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
bladder NNP NNP I-PROBLEM
habits NNP NNP I-PROBLEM
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Hydrea NNP NNP B-DRUG
1500 NNP NNP I-DRUG
mg NNP NNP I-DRUG
on NN NN O
Mondays NNP NNP B-DATE
and NN NN O
Fridays NNP NNP B-DATE
and NN NN O
1000 NN NN O
mg NN NN O
the NN NN O
other NN NN O
days NN NN O
of NN NN O
the NN NN O
week NN NN O
, NN NN O
Flomax NNP NNP B-DRUG
q.d NN NN O
., NN NN O
vitamin NNP NNP B-DRUG
D NNP NNP I-DRUG
q.d NN NN O
, NN NN O
saw NN NN O
palmetto NNP NNP B-DRUG
q.d NN NN O
., NN NN O
aspirin NNP NNP B-DRUG
81 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.d NN NN O
., NN NN O
and NN NN O
vitamin NNP NNP B-DRUG
C NNP NNP I-DRUG
q.d NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
As NN NN O
per NN NN O
the NN NN O
HPI NN NN O
, NN NN O
otherwise NN NN O
negative NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O

1 NN NN O
. NN NN O
He NN NN O
is NN NN O
status NN NN O
post NN NN O
an NNP NNP B-TREATMENT
appendectomy NNP NNP I-TREATMENT
. NN NN O

2 NN NN O
. NN NN O
Status NN NN O
post NN NN O
a NNP NNP B-TREATMENT
tonsillectomy NNP NNP I-TREATMENT
and NN NN O
adenoidectomy NNP NNP B-TREATMENT
. NN NN O

3 NN NN O
. NN NN O
Status NN NN O
post NN NN O
bilateral NNP NNP B-TREATMENT
cataract NNP NNP I-TREATMENT
surgery NNP NNP I-TREATMENT
. NN NN O

4 NN NN O
. NN NN O
BPH NNP NNP B-PROBLEM
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
has NN NN O
a NN NN O
history NN NN O
of NN NN O
tobacco NN NN O
use NN NN O
, NN NN O
which NN NN O
he NN NN O
quit NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O

37 NN NN O
. NN NN O
He NN NN O
has NN NN O
one NN NN O
alcoholic NN NN O
drink NN NN O
per NN NN O
day NN NN O
. NN NN O

He NN NN O
is NN NN O
married NN NN O
. NN NN O

He NN NN O
is NN NN O
a NN NN O
retired NN NN O
lab NN NN O
manager NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
There NN NN O
is NN NN O
no NN NN O
history NN NN O
of NN NN O
solid NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
or NN NN O
hematologic NNP NNP B-PROBLEM
malignancies NNP NNP I-PROBLEM
in NN NN O
his NN NN O
family NN NN O
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
VIT NN NN O
: NN NN O
Height NNP NNP B-TEST
181 NN NN O
cm NN NN O
, NN NN O
weight NNP NNP B-TEST
72 NN NN O
kg NN NN O
, NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
116/64 NN NN O
, NN NN O
pulse NNP NNP B-TEST
62 NN NN O
, NN NN O
and NN NN O
temperature NNP NNP B-TEST
is NN NN O
96.7 NN NN O
. NN NN O

GEN NN NN O
: NN NN O
He NN NN O
is NN NN O
nontoxic NN NN O
, NN NN O
noncachectic NNP NNP B-PROBLEM
appearing NN NN O
. NN NN O

HEAD NN NN O
: NN NN O
Examined NN NN O
and NN NN O
normal NN NN O
. NN NN O

EYES NN NN O
: NN NN O
Anicteric NNP NNP B-PROBLEM
. NN NN O

ENT NN NN O
: NN NN O
No NN NN O
oropharyngeal NNP NNP B-PROBLEM
lesions NNP NNP I-PROBLEM
. NN NN O

LYMPH NN NN O
: NN NN O
No NN NN O
cervical NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

HEART NN NN O
: NN NN O
Regular NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
; NN NN O

no NN NN O
murmurs NNP NNP B-PROBLEM
, NN NN O
rubs NNP NNP B-PROBLEM
, NN NN O
or NN NN O
gallops NNP NNP B-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Nontender NN NN O
, NN NN O
nondistended NNP NNP B-PROBLEM
; NN NN O

normal NN NN O
bowel NN NN O
sounds NN NN O
; NN NN O

no NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

EXT NN NN O
: NN NN O
Reveal NNP NNP B-TREATMENT
no NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
Essential NNP NNP B-PROBLEM
thrombocytosis NNP NNP I-PROBLEM
. NN NN O

Over NN NN O
time NN NN O
, NN NN O
his NNP NNP B-TEST
CBC NNP NNP I-TEST
has NN NN O
been NN NN O
very NN NN O
stable NN NN O
. NN NN O

His NNP NNP B-TEST
most NNP NNP I-TEST
recent NNP NNP I-TEST
CBC NNP NNP I-TEST
shows NN NN O
a NNP NNP B-TEST
white NNP NNP I-TEST
blood NNP NNP I-TEST
cell NNP NNP I-TEST
count NNP NNP I-TEST
of NN NN O
6.0 NN NN O
with NN NN O
hemoglobin NNP NNP B-TEST
of NN NN O
13.7 NN NN O
and NN NN O
platelet NNP NNP B-TEST
count NNP NNP I-TEST
of NN NN O
381,000 NN NN O
. NN NN O

His NNP NNP B-TEST
MCV NNP NNP I-TEST
is NN NN O
elevated NNP NNP B-PROBLEM
at NN NN O
120.8 NN NN O
; NN NN O

however NN NN O
, NN NN O
this NN NN O
is NN NN O
a NNP NNP B-PROBLEM
known NNP NNP I-PROBLEM
side NNP NNP I-PROBLEM
effect NNP NNP I-PROBLEM
of NN NN O
hydroxyurea NNP NNP B-DRUG
. NN NN O

I NN NN O
will NN NN O
plan NN NN O
on NN NN O
checking NN NN O
his NNP NNP B-TEST
CBC NNP NNP I-TEST
again NN NN O
in NN NN O
three NN NN O
months NN NN O
and NN NN O
then NN NN O
see NN NN O
him NN NN O
again NN NN O
in NN NN O
six NN NN O
months NN NN O
with NN NN O
a NNP NNP B-TEST
CBC NNP NNP I-TEST
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
ecog NN NN O
, NN NN O
hydrea NNP NNP B-PROBLEM
, NN NN O
hematologist NN NN O
, NN NN O
platelet NNP NNP B-TEST
count NNP NNP I-TEST
, NN NN O
bone NNP NNP B-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
, NN NN O
essential NNP NNP B-PROBLEM
thrombocytosis NNP NNP I-PROBLEM
, NN NN O
lymphadenopathy NNP NNP B-PROBLEM
, NN NN O
cbc NNP NNP B-PROBLEM
, NN NN O
thrombocytosis NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Breast NN NN O
Mass NN NN O
Excision NN NN O
- NN NN O
2 NN NN O
Description NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
left NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
was NN NN O
identified NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
left NN NN O
nipple NN NN O
. NN NN O

It NN NN O
was NN NN O
freely NN NN O
mobile NN NN O
and NN NN O
it NN NN O
did NN NN O
not NN NN O
seem NN NN O
to NN NN O
hold NN NN O
the NN NN O
skin NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Breast NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
left NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Breast NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
left NN NN O
. NN NN O

PROCEDURE NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
left NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

OPERATION NN NN O
: NN NN O
After NN NN O
obtaining NN NN O
an NN NN O
informed NN NN O
consent NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
where NN NN O
he NN NN O
underwent NN NN O
general NN NN O
endotracheal NN NN O
anesthesia NNP NNP B-DRUG
. NN NN O

The NN NN O
time-out NN NN O
process NN NN O
was NN NN O
followed NN NN O
. NN NN O

Preoperative NN NN O
antibiotic NNP NNP B-DRUG
was NN NN O
given NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
prepped NNP NNP B-TREATMENT
and NNP NNP I-TREATMENT
draped NNP NNP I-TREATMENT
in NN NN O
the NN NN O
usual NN NN O
fashion NN NN O
. NN NN O

The NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
was NN NN O
identified NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
left NN NN O
nipple NN NN O
. NN NN O

It NN NN O
was NN NN O
freely NN NN O
mobile NN NN O
and NN NN O
it NN NN O
did NN NN O
not NN NN O
seem NN NN O
to NN NN O
hold NN NN O
the NN NN O
skin NN NN O
. NN NN O

An NNP NNP B-PROBLEM
elliptical NNP NNP I-PROBLEM
skin NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
over NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
and NN NN O
carried NN NN O
down NN NN O
in NN NN O
a NN NN O
pyramidal NN NN O
fashion NN NN O
towards NN NN O
the NN NN O
pectoral NN NN O
fascia NN NN O
. NN NN O

The NN NN O
whole NN NN O
of NN NN O
specimen NNP NNP B-TEST
including NN NN O
the NN NN O
skin NN NN O
, NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
and NN NN O
surrounding NN NN O
subcutaneous NN NN O
tissue NN NN O
and NN NN O
fascia NN NN O
were NN NN O
excised NNP NNP B-TREATMENT
en NNP NNP I-TREATMENT
bloc NNP NNP I-TREATMENT
. NN NN O

Hemostasis NN NN O
was NN NN O
achieved NN NN O
with NN NN O
the NNP NNP B-TREATMENT
cautery NNP NNP I-TREATMENT
. NN NN O

The NN NN O
specimen NN NN O
was NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
and NN NN O
the NN NN O
tissues NN NN O
were NN NN O
closed NN NN O
in NN NN O
layers NN NN O
including NN NN O
a NNP NNP B-TREATMENT
subcuticular NNP NNP I-TREATMENT
suture NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
Monocryl NNP NNP I-TREATMENT
. NN NN O

A NNP NNP B-TREATMENT
small NNP NNP I-TREATMENT
pressure NNP NNP I-TREATMENT
dressing NNP NNP I-TREATMENT
was NN NN O
applied NN NN O
. NN NN O

Estimated NNP NNP B-PROBLEM
blood NNP NNP I-PROBLEM
loss NNP NNP I-PROBLEM
was NN NN O
minimal NN NN O
and NN NN O
the NN NN O
patient NN NN O
who NN NN O
tolerated NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
very NN NN O
well NN NN O
was NN NN O
sent NN NN O
to NN NN O
recovery NN NN O
room NN NN O
in NN NN O
satisfactory NN NN O
condition NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
breast NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
excision NN NN O
, NN NN O
freely NN NN O
mobile NN NN O
, NN NN O
breast NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
endotracheal NN NN O
, NN NN O
fascia NN NN O
, NN NN O
specimen NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Mesothelioma NNP NNP B-PROBLEM
- NN NN O
Thoracotomy NN NN O
& NN NN O
Lobectomy NN NN O
Description NN NN O
: NN NN O
Right NNP NNP B-PROBLEM
nodular NNP NNP I-PROBLEM
malignant NNP NNP I-PROBLEM
mesothelioma NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Right NNP NNP B-PROBLEM
mesothelioma NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Right NNP NNP B-PROBLEM
lung NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
invading NN NN O
diaphragm NN NN O
and NN NN O
liver NN NN O
. NN NN O

FINDINGS NN NN O
: NN NN O
Right NNP NNP B-PROBLEM
lower NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
invading NNP NNP I-PROBLEM
diaphragm NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
liver NNP NNP I-PROBLEM
. NN NN O

PROCEDURES NN NN O
: NN NN O

1 NN NN O
. NN NN O
Right NNP NNP B-TREATMENT
thoracotomy NNP NNP I-TREATMENT
. NN NN O

2 NN NN O
. NN NN O
Right NNP NNP B-TREATMENT
lower NNP NNP I-TREATMENT
lobectomy NNP NNP I-TREATMENT
with NN NN O
en NNP NNP B-TREATMENT
bloc NNP NNP I-TREATMENT
resection NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
diaphragm NNP NNP I-TREATMENT
and NN NN O
portion NN NN O
of NN NN O
liver NN NN O
. NN NN O

SPECIMENS NN NN O
: NN NN O
Right NNP NNP B-TREATMENT
lower NNP NNP I-TREATMENT
lobectomy NNP NNP I-TREATMENT
with NN NN O
en NNP NNP B-TREATMENT
bloc NNP NNP I-TREATMENT
resection NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
diaphragm NNP NNP I-TREATMENT
and NNP NNP I-TREATMENT
portion NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
liver NNP NNP I-TREATMENT
. NN NN O

BLOOD NN NN O
LOSS NN NN O
: NN NN O
600 NN NN O
mL NN NN O
. NN NN O

FLUIDS NN NN O
: NN NN O
Crystalloid NNP NNP B-DRUG
2.7 NNP NNP I-DRUG
L NNP NNP I-DRUG
and NNP NNP I-DRUG
1 NNP NNP I-DRUG
unit NNP NNP I-DRUG
packed NNP NNP I-DRUG
red NNP NNP I-DRUG
blood NNP NNP I-DRUG
cells NNP NNP I-DRUG
. NN NN O

ANESTHESIA NNP NNP B-PROBLEM
: NN NN O
Double-lumen NNP NNP B-TREATMENT
endotracheal NNP NNP I-TREATMENT
tube NNP NNP I-TREATMENT
. NN NN O

CONDITION NN NN O
: NN NN O
Stable NN NN O
, NN NN O
extubated NNP NNP B-TREATMENT
, NN NN O
to NN NN O
PACU NN NN O
. NN NN O

PROCEDURE NN NN O
IN NN NN O
DETAIL NN NN O
: NN NN O
Briefly NN NN O
, NN NN O
this NN NN O
is NN NN O
a NN NN O
gentleman NN NN O
who NN NN O
was NN NN O
diagnosed NN NN O
with NN NN O
a NNP NNP B-PROBLEM
B-cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
and NN NN O
then NN NN O
subsequently NN NN O
on NN NN O
workup NNP NNP B-TEST
noted NN NN O
to NN NN O
have NN NN O
a NNP NNP B-PROBLEM
right-sided NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
seeming NN NN O
to NN NN O
arise NN NN O
from NN NN O
the NN NN O
right NN NN O
diaphragm NN NN O
. NN NN O

He NN NN O
was NN NN O
presented NN NN O
at NN NN O
Tumor NN NN O
Board NN NN O
where NN NN O
it NN NN O
was NN NN O
thought NN NN O
upon NN NN O
review NN NN O
that NN NN O
day NN NN O
that NN NN O
he NN NN O
had NN NN O
a NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
nodular NNP NNP I-PROBLEM
malignant NNP NNP I-PROBLEM
mesothelioma NNP NNP I-PROBLEM
. NN NN O

Thus NN NN O
, NN NN O
he NN NN O
was NN NN O
offered NN NN O
a NNP NNP B-TREATMENT
right NNP NNP I-TREATMENT
thoracotomy NNP NNP I-TREATMENT
and NN NN O
excision NNP NNP B-TREATMENT
of NN NN O
mass NNP NNP B-PROBLEM
with NN NN O
possible NN NN O
reconstruction NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
diaphragm NNP NNP I-TREATMENT
. NN NN O

He NN NN O
was NN NN O
explained NN NN O
the NN NN O
risks NN NN O
, NN NN O
benefits NN NN O
, NN NN O
and NN NN O
alternatives NN NN O
to NN NN O
this NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
. NN NN O

He NN NN O
wished NN NN O
to NN NN O
proceed NN NN O
, NN NN O
so NN NN O
he NN NN O
was NN NN O
brought NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
. NN NN O

An NNP NNP B-TREATMENT
epidural NNP NNP I-TREATMENT
catheter NNP NNP I-TREATMENT
was NN NN O
placed NN NN O
. NN NN O

He NN NN O
was NN NN O
put NN NN O
in NN NN O
a NN NN O
supine NN NN O
position NN NN O
where NN NN O
SCDs NNP NNP B-TREATMENT
and NN NN O
Foley NNP NNP B-TREATMENT
catheter NNP NNP I-TREATMENT
were NN NN O
placed NN NN O
. NN NN O

He NN NN O
was NN NN O
put NN NN O
under NN NN O
general NNP NNP B-TREATMENT
endotracheal NNP NNP I-TREATMENT
anesthesia NNP NNP I-TREATMENT
with NN NN O
a NNP NNP B-TREATMENT
double-lumen NNP NNP I-TREATMENT
endotracheal NNP NNP I-TREATMENT
tube NNP NNP I-TREATMENT
. NN NN O

He NN NN O
was NN NN O
given NN NN O
preoperative NN NN O
antibiotics NNP NNP B-DRUG
, NN NN O
then NN NN O
he NN NN O
was NN NN O
placed NN NN O
in NN NN O
the NN NN O
left NN NN O
decubitus NN NN O
position NN NN O
, NN NN O
and NN NN O
the NN NN O
area NN NN O
was NN NN O
prepped NNP NNP B-TREATMENT
and NN NN O
draped NN NN O
in NN NN O
the NN NN O
usual NN NN O
fashion NN NN O
. NN NN O

A NNP NNP B-TREATMENT
low NNP NNP I-TREATMENT
thoracotomy NNP NNP I-TREATMENT
in NN NN O
the NN NN O
7th NN NN O
interspace NN NN O
was NN NN O
made NN NN O
using NN NN O
the NNP NNP B-TREATMENT
skin NNP NNP I-TREATMENT
knife NNP NNP I-TREATMENT
and NN NN O
then NN NN O
Bovie NNP NNP B-TREATMENT
cautery NNP NNP I-TREATMENT
onto NN NN O
the NN NN O
middle NN NN O
of NN NN O
the NN NN O
rib NN NN O
and NN NN O
then NN NN O
with NN NN O
the NN NN O
Alexander NN NN O
instrument NN NN O
, NN NN O
the NN NN O
chest NN NN O
was NN NN O
entered NN NN O
. NN NN O

Upon NN NN O
entering NN NN O
the NN NN O
chest NN NN O
, NN NN O
the NNP NNP B-TREATMENT
chest NNP NNP I-TREATMENT
wall NNP NNP I-TREATMENT
retractor NNP NNP I-TREATMENT
was NN NN O
inserted NN NN O
and NN NN O
the NN NN O
cavity NN NN O
inspected NN NN O
. NN NN O

It NN NN O
appeared NN NN O
that NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
actually NN NN O
arose NN NN O
more NN NN O
from NN NN O
the NN NN O
right NN NN O
lower NN NN O
lobe NN NN O
and NN NN O
was NN NN O
involving NN NN O
the NN NN O
diaphragm NN NN O
. NN NN O

He NN NN O
also NN NN O
had NN NN O
some NNP NNP B-PROBLEM
marked NNP NNP I-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

With NN NN O
these NN NN O
findings NN NN O
, NN NN O
which NN NN O
were NN NN O
thought NN NN O
at NN NN O
that NN NN O
time NN NN O
to NN NN O
be NN NN O
more NN NN O
consistent NN NN O
with NN NN O
a NNP NNP B-PROBLEM
bronchogenic NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
we NN NN O
proceeded NN NN O
with NN NN O
the NN NN O
intent NN NN O
to NN NN O
perform NN NN O
a NNP NNP B-TREATMENT
right NNP NNP I-TREATMENT
lower NNP NNP I-TREATMENT
lobectomy NNP NNP I-TREATMENT
and NN NN O
en NNP NNP B-TREATMENT
bloc NNP NNP I-TREATMENT
diaphragmatic NNP NNP I-TREATMENT
resection NNP NNP I-TREATMENT
. NN NN O

Thus NN NN O
, NN NN O
we NN NN O
mobilized NN NN O
the NN NN O
inferior NN NN O
pulmonary NN NN O
ligament NN NN O
and NN NN O
made NN NN O
our NN NN O
way NN NN O
around NN NN O
the NN NN O
hilum NN NN O
anteriorly NN NN O
and NN NN O
posteriorly NN NN O
. NN NN O

We NN NN O
also NN NN O
worked NN NN O
to NN NN O
open NN NN O
the NN NN O
fissure NN NN O
and NN NN O
tried NN NN O
to NN NN O
identify NN NN O
the NN NN O
arteries NN NN O
going NN NN O
to NN NN O
the NN NN O
superior NN NN O
portion NN NN O
of NN NN O
the NN NN O
right NN NN O
lower NN NN O
lobe NN NN O
and NN NN O
basilar NN NN O
arteries NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
artery NN NN O
going NN NN O
to NN NN O
the NN NN O
right NN NN O
middle NN NN O
lobe NN NN O
. NN NN O

The NN NN O
posterior NN NN O
portion NN NN O
of NN NN O
the NN NN O
fissure NN NN O
ultimately NN NN O
divided NN NN O
with NN NN O
the NN NN O
single NN NN O
firing NN NN O
of NN NN O
a NNP NNP B-TREATMENT
GIA NNP NNP I-TREATMENT
stapler NNP NNP I-TREATMENT
with NN NN O
a NNP NNP B-TREATMENT
blue NNP NNP I-TREATMENT
load NNP NNP I-TREATMENT
and NN NN O
with NN NN O
the NN NN O
final NN NN O
portion NN NN O
being NN NN O
divided NN NN O
between NN NN O
2-0 NN NN O
ties NN NN O
. NN NN O

Once NN NN O
we NN NN O
had NN NN O
clearly NN NN O
delineated NN NN O
the NN NN O
arterial NN NN O
anatomy NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
pass NN NN O
a NN NN O
right NN NN O
angle NN NN O
around NN NN O
the NN NN O
artery NN NN O
going NN NN O
to NN NN O
the NN NN O
superior NN NN O
segment NN NN O
. NN NN O

This NN NN O
was NN NN O
ligated NN NN O
in NN NN O
continuity NN NN O
with NN NN O
an NNP NNP B-TREATMENT
additional NNP NNP I-TREATMENT
stick NNP NNP I-TREATMENT
tie NNP NNP I-TREATMENT
in NN NN O
the NN NN O
proximal NN NN O
portion NN NN O
of NN NN O
3-0 NNP NNP B-TREATMENT
silk NNP NNP I-TREATMENT
. NN NN O

This NN NN O
was NN NN O
divided NN NN O
thus NN NN O
revealing NN NN O
a NNP NNP B-PROBLEM
branched NNP NNP I-PROBLEM
artery NNP NNP I-PROBLEM
going NNP NNP I-PROBLEM
to NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
basilar NNP NNP I-PROBLEM
portion NNP NNP I-PROBLEM
of NN NN O
the NN NN O
right NN NN O
lower NN NN O
lobe NN NN O
. NN NN O

This NN NN O
was NN NN O
also NN NN O
ligated NN NN O
in NN NN O
continuity NN NN O
and NN NN O
actually NN NN O
doubly NN NN O
ligated NN NN O
. NN NN O

Care NN NN O
was NN NN O
taken NN NN O
to NN NN O
preserve NN NN O
the NN NN O
artery NN NN O
to NN NN O
the NN NN O
right NN NN O
and NN NN O
middle NN NN O
lobe NN NN O
. NN NN O

We NN NN O
then NN NN O
turned NN NN O
our NN NN O
attention NN NN O
once NN NN O
again NN NN O
to NN NN O
the NN NN O
hilum NN NN O
to NN NN O
dissect NN NN O
out NN NN O
the NN NN O
inferior NN NN O
pulmonary NN NN O
vein NN NN O
. NN NN O

The NN NN O
superior NN NN O
pulmonary NN NN O
vein NN NN O
was NN NN O
visualized NN NN O
as NN NN O
well NN NN O
. NN NN O

The NN NN O
right NN NN O
angle NN NN O
was NN NN O
passed NN NN O
around NN NN O
the NN NN O
inferior NN NN O
pulmonary NN NN O
vein NN NN O
, NN NN O
and NN NN O
this NN NN O
was NN NN O
ligated NN NN O
in NN NN O
continuity NN NN O
with NN NN O
2-0 NNP NNP B-TREATMENT
silk NNP NNP I-TREATMENT
and NN NN O
a NNP NNP B-TREATMENT
3-0 NNP NNP I-TREATMENT
stick NNP NNP I-TREATMENT
tie NNP NNP I-TREATMENT
. NN NN O

Upon NN NN O
division NN NN O
of NN NN O
this NN NN O
portion NN NN O
, NN NN O
the NN NN O
specimen NN NN O
site NN NN O
had NN NN O
some NNP NNP B-PROBLEM
bleeding NNP NNP I-PROBLEM
, NN NN O
which NN NN O
was NN NN O
eventually NN NN O
controlled NN NN O
using NN NN O
several NNP NNP B-TREATMENT
3-0 NNP NNP I-TREATMENT
silk NNP NNP I-TREATMENT
sutures NNP NNP I-TREATMENT
. NN NN O

The NN NN O
bronchial NN NN O
anatomy NN NN O
was NN NN O
defined NN NN O
. NN NN O

Next NN NN O
, NN NN O
we NN NN O
identified NN NN O
the NN NN O
bronchus NN NN O
going NN NN O
to NN NN O
the NN NN O
right NN NN O
lower NN NN O
lobe NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
right NN NN O
middle NN NN O
lobe NN NN O
. NN NN O

A NNP NNP B-TREATMENT
TA-30 NNP NNP I-TREATMENT
4.8 NN NN O
stapler NNP NNP B-TREATMENT
was NN NN O
then NN NN O
closed NN NN O
. NN NN O

The NN NN O
lung NN NN O
insufflated NN NN O
. NN NN O

The NN NN O
right NN NN O
middle NN NN O
lobe NN NN O
and NN NN O
right NN NN O
upper NN NN O
lobe NN NN O
were NN NN O
noted NN NN O
to NN NN O
inflate NN NN O
well NN NN O
. NN NN O

The NNP NNP B-TREATMENT
stapler NNP NNP I-TREATMENT
was NN NN O
fired NN NN O
, NN NN O
and NN NN O
the NN NN O
bronchus NN NN O
was NN NN O
cut NN NN O
with NN NN O
a NNP NNP B-TREATMENT
10-blade NNP NNP I-TREATMENT
. NN NN O

We NN NN O
then NN NN O
turned NN NN O
our NN NN O
attention NN NN O
to NN NN O
the NN NN O
diaphragm NN NN O
. NN NN O

There NN NN O
was NN NN O
a NNP NNP B-PROBLEM
small NNP NNP I-PROBLEM
portion NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
diaphragm NNP NNP I-PROBLEM
of NN NN O
approximately NN NN O
4 NN NN O
to NN NN O
5 NN NN O
cm NN NN O
has NN NN O
involved NN NN O
with NN NN O
tumor NNP NNP B-PROBLEM
, NN NN O
and NN NN O
we NN NN O
bovied NN NN O
around NN NN O
this NN NN O
with NN NN O
at NN NN O
least NN NN O
1 NN NN O
cm NN NN O
margin NN NN O
. NN NN O

Upon NN NN O
going NN NN O
through NN NN O
the NN NN O
diaphragm NN NN O
, NN NN O
it NN NN O
became NN NN O
clear NN NN O
that NN NN O
the NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
was NN NN O
also NN NN O
involving NN NN O
the NN NN O
dome NN NN O
of NN NN O
the NN NN O
liver NN NN O
, NN NN O
so NN NN O
after NN NN O
going NN NN O
around NN NN O
the NN NN O
diaphragm NN NN O
in NN NN O
its NN NN O
entirety NN NN O
, NN NN O
we NN NN O
proceeded NN NN O
to NN NN O
wedge NN NN O
out NN NN O
the NN NN O
portion NN NN O
of NN NN O
liver NN NN O
that NN NN O
was NN NN O
involved NN NN O
. NN NN O

It NN NN O
seemed NN NN O
that NN NN O
it NN NN O
would NN NN O
be NN NN O
a NNP NNP B-PROBLEM
mucoid NNP NNP I-PROBLEM
shallow NNP NNP I-PROBLEM
portion NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-TREATMENT
Bovie NNP NNP I-TREATMENT
was NN NN O
set NN NN O
to NN NN O
high NNP NNP B-TREATMENT
cautery NNP NNP I-TREATMENT
. NN NN O

The NN NN O
capsule NN NN O
was NN NN O
entered NN NN O
, NN NN O
and NN NN O
then NN NN O
using NN NN O
Bovie NNP NNP B-TREATMENT
cautery NNP NNP I-TREATMENT
, NN NN O
we NN NN O
wedged NN NN O
out NN NN O
the NN NN O
remaining NN NN O
portion NN NN O
of NN NN O
the NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
with NN NN O
a NN NN O
margin NN NN O
of NN NN O
normal NN NN O
liver NN NN O
. NN NN O

It NN NN O
did NN NN O
leave NN NN O
quite NN NN O
a NNP NNP B-PROBLEM
shallow NNP NNP I-PROBLEM
defect NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
liver NNP NNP I-PROBLEM
. NN NN O

Hemostasis NN NN O
was NN NN O
achieved NN NN O
with NN NN O
Bovie NNP NNP B-TREATMENT
cautery NNP NNP I-TREATMENT
and NN NN O
gentle NNP NNP B-TREATMENT
pressure NNP NNP I-TREATMENT
. NN NN O

The NN NN O
specimen NN NN O
was NN NN O
then NN NN O
taken NN NN O
off NN NN O
the NN NN O
table NN NN O
and NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
for NN NN O
permanent NN NN O
. NN NN O

The NN NN O
area NN NN O
was NN NN O
inspected NN NN O
for NN NN O
hemostasis NNP NNP B-TEST
. NN NN O

A NNP NNP B-TREATMENT
10-flat NNP NNP I-TREATMENT
JP NNP NNP I-TREATMENT
was NN NN O
placed NN NN O
in NN NN O
the NN NN O
abdomen NN NN O
at NN NN O
the NN NN O
portion NN NN O
of NN NN O
the NNP NNP B-TREATMENT
wedge NNP NNP I-TREATMENT
resection NNP NNP I-TREATMENT
, NN NN O
and NN NN O
0 NN NN O
Prolene NNP NNP B-TREATMENT
was NN NN O
used NN NN O
to NN NN O
close NN NN O
the NNP NNP B-PROBLEM
diaphragmatic NNP NNP I-PROBLEM
defect NNP NNP I-PROBLEM
, NN NN O
which NN NN O
was NN NN O
under NN NN O
very NNP NNP B-PROBLEM
little NNP NNP I-PROBLEM
tension NNP NNP I-PROBLEM
. NN NN O

A NNP NNP B-TREATMENT
single NNP NNP I-TREATMENT
32 NNP NNP I-TREATMENT
straight NNP NNP I-TREATMENT
chest NNP NNP I-TREATMENT
tube NNP NNP I-TREATMENT
was NN NN O
also NN NN O
placed NN NN O
. NN NN O

The NN NN O
lung NN NN O
was NN NN O
seen NN NN O
to NN NN O
expand NN NN O
. NN NN O

We NN NN O
also NN NN O
noted NN NN O
that NN NN O
the NNP NNP B-PROBLEM
incomplete NNP NNP I-PROBLEM
fissure NNP NNP I-PROBLEM
between NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
middle NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
lobes NNP NNP I-PROBLEM
would NN NN O
prevent NN NN O
torsion NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
middle NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
. NN NN O

Hemostasis NN NN O
was NN NN O
observed NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
case NN NN O
. NN NN O

The NNP NNP B-TREATMENT
chest NNP NNP I-TREATMENT
tube NNP NNP I-TREATMENT
was NN NN O
irrigated NN NN O
with NN NN O
sterile NNP NNP B-TREATMENT
water NNP NNP I-TREATMENT
, NN NN O
and NN NN O
there NN NN O
was NN NN O
no NN NN O
air NNP NNP B-PROBLEM
leak NNP NNP I-PROBLEM
observed NN NN O
from NN NN O
the NN NN O
bronchial NN NN O
stump NN NN O
. NN NN O

The NN NN O
chest NN NN O
was NN NN O
then NN NN O
closed NN NN O
with NN NN O
Vicryl NNP NNP B-TREATMENT
at NN NN O
the NN NN O
level NN NN O
of NN NN O
the NN NN O
intercostal NN NN O
muscles NN NN O
, NN NN O
staying NN NN O
above NN NN O
the NN NN O
ribs NN NN O
. NN NN O

The NNP NNP B-TREATMENT
2-0 NNP NNP I-TREATMENT
Vicryl NNP NNP I-TREATMENT
was NN NN O
used NN NN O
for NN NN O
the NN NN O
latissimus NN NN O
dorsi NN NN O
layer NN NN O
and NN NN O
the NN NN O
subcutaneous NN NN O
layer NN NN O
, NN NN O
and NN NN O
4-0 NNP NNP B-TREATMENT
Monocryl NNP NNP I-TREATMENT
was NN NN O
used NN NN O
to NN NN O
close NN NN O
the NN NN O
skin NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
then NN NN O
brought NN NN O
to NN NN O
supine NN NN O
position NN NN O
, NN NN O
extubated NNP NNP B-TREATMENT
, NN NN O
and NN NN O
brought NN NN O
to NN NN O
the NN NN O
recovery NN NN O
room NN NN O
in NN NN O
stable NN NN O
condition NN NN O
. NN NN O

Dr NN NN O
. NN NN O
X NN NN O
was NN NN O
present NN NN O
for NN NN O
the NN NN O
entirety NN NN O
of NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
, NN NN O
which NN NN O
was NN NN O
a NNP NNP B-TREATMENT
right NNP NNP I-TREATMENT
thoracotomy NNP NNP I-TREATMENT
, NN NN O
right NNP NNP B-TREATMENT
lower NNP NNP I-TREATMENT
lobectomy NNP NNP I-TREATMENT
with NN NN O
en NNP NNP B-TREATMENT
bloc NNP NNP I-TREATMENT
resection NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
diaphragm NNP NNP I-TREATMENT
and NN NN O
a NN NN O
portion NN NN O
of NN NN O
liver NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
double NNP NNP B-TREATMENT
lumen NNP NNP I-TREATMENT
endotracheal NNP NNP I-TREATMENT
, NN NN O
en NNP NNP B-TREATMENT
bloc NNP NNP I-TREATMENT
resection NNP NNP I-TREATMENT
, NN NN O
malignant NNP NNP B-PROBLEM
mesothelioma NNP NNP I-PROBLEM
, NN NN O
lung NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
endotracheal NNP NNP B-TREATMENT
tube NNP NNP I-TREATMENT
, NN NN O
chest NNP NNP B-TREATMENT
tube NNP NNP I-TREATMENT
, NN NN O
bovie NNP NNP B-TREATMENT
cautery NNP NNP I-TREATMENT
, NN NN O
en NNP NNP B-TREATMENT
bloc NNP NNP I-TREATMENT
, NN NN O
diaphragm NNP NNP B-TREATMENT
, NN NN O
lobectomy NNP NNP B-TREATMENT
, NN NN O
mesothelioma NNP NNP B-TREATMENT
, NN NN O
thoracotomy NNP NNP B-TREATMENT
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
MGUS NN NN O
Followup NN NN O
Description NN NN O
: NN NN O
MGUS NNP NNP B-PROBLEM
. NN NN O

His NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
showed NN NN O
a NN NN O
normal NN NN O
cellular NN NN O
bone NN NN O
marrow NN NN O
; NN NN O

however NN NN O
, NN NN O
there NN NN O
were NN NN O
10% NNP NNP B-TEST
plasma NNP NNP I-TEST
cells NNP NNP I-TEST
and NN NN O
we NN NN O
proceeded NN NN O
with NN NN O
the NNP NNP B-TEST
workup NNP NNP I-TEST
for NN NN O
a NNP NNP B-PROBLEM
plasma NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
dyscrasia NNP NNP I-PROBLEM
. NN NN O

All NN NN O
his NNP NNP B-TEST
tests NNP NNP I-TEST
came NN NN O
back NN NN O
as NN NN O
consistent NN NN O
with NN NN O
an NNP NNP B-PROBLEM
MGUS NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
MGUS NNP NNP B-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
This NN NN O
is NN NN O
an NN NN O
extremely NN NN O
pleasant NN NN O
86-year-old NN NN O
gentleman NN NN O
, NN NN O
who NN NN O
I NN NN O
follow NN NN O
for NN NN O
his NNP NNP B-PROBLEM
MGUS NNP NNP I-PROBLEM
. NN NN O

I NN NN O
initially NN NN O
saw NN NN O
him NN NN O
for NN NN O
thrombocytopenia NNP NNP B-PROBLEM
when NN NN O
his NNP NNP B-TEST
ANC NNP NNP I-TEST
was NN NN O
1300 NN NN O
. NN NN O

A NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
was NN NN O
obtained NN NN O
. NN NN O

Interestingly NN NN O
enough NN NN O
, NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
his NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
, NN NN O
his NNP NNP B-TEST
hemoglobin NNP NNP I-TEST
was NN NN O
13.0 NN NN O
and NN NN O
his NNP NNP B-TEST
white NNP NNP I-TEST
blood NNP NNP I-TEST
cell NNP NNP I-TEST
count NNP NNP I-TEST
was NN NN O
6.5 NN NN O
with NN NN O
a NNP NNP B-TEST
platelet NNP NNP I-TEST
count NNP NNP I-TEST
of NN NN O
484,000 NN NN O
. NN NN O

His NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
showed NN NN O
a NN NN O
normal NN NN O
cellular NN NN O
bone NN NN O
marrow NN NN O
; NN NN O

however NN NN O
, NN NN O
there NN NN O
were NN NN O
10% NNP NNP B-TEST
plasma NNP NNP I-TEST
cells NNP NNP I-TEST
and NN NN O
we NN NN O
proceeded NN NN O
with NN NN O
the NNP NNP B-TEST
workup NNP NNP I-TEST
for NN NN O
a NNP NNP B-PROBLEM
plasma NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
dyscrasia NNP NNP I-PROBLEM
. NN NN O

All NN NN O
his NNP NNP B-TEST
tests NNP NNP I-TEST
came NN NN O
back NN NN O
as NN NN O
consistent NN NN O
with NN NN O
an NNP NNP B-PROBLEM
MGUS NNP NNP I-PROBLEM
. NN NN O

Overall NN NN O
, NN NN O
he NN NN O
is NN NN O
doing NN NN O
well NN NN O
. NN NN O

Since NN NN O
I NN NN O
last NN NN O
saw NN NN O
him NN NN O
, NN NN O
he NN NN O
tells NN NN O
me NN NN O
that NN NN O
he NN NN O
has NN NN O
had NN NN O
onset NN NN O
of NN NN O
atrial NNP NNP B-PROBLEM
fibrillation NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
now NN NN O
started NN NN O
going NN NN O
to NN NN O
the NN NN O
gym NN NN O
two NN NN O
times NN NN O
per NN NN O
week NN NN O
, NN NN O
and NN NN O
has NN NN O
lost NN NN O
over NN NN O
10 NN NN O
pounds NN NN O
. NN NN O

He NN NN O
has NN NN O
a NN NN O
good NN NN O
energy NN NN O
level NN NN O
and NN NN O
his NN NN O
ECOG NN NN O
performance NN NN O
status NN NN O
is NN NN O

0 NN NN O
. NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
fever NNP NNP I-PROBLEM
, NN NN O
chills NNP NNP B-PROBLEM
, NN NN O
or NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
. NN NN O

No NN NN O
lymphadenopathy NNP NNP B-PROBLEM
. NN NN O

No NN NN O
nausea NNP NNP B-PROBLEM
or NN NN O
vomiting NNP NNP B-PROBLEM
. NN NN O

No NN NN O
change NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
bowel NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
bladder NNP NNP I-PROBLEM
habits NNP NNP I-PROBLEM
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Multivitamin NNP NNP B-DRUG
q.d NN NN O
., NN NN O
aspirin NNP NNP B-DRUG
one NNP NNP I-DRUG
tablet NNP NNP I-DRUG
q.d NN NN O
., NN NN O
Lupron NNP NNP B-TREATMENT
q NN NN O
. NN NN O

three NN NN O
months NN NN O
, NN NN O
Flomax NNP NNP B-DRUG
0.4 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.d NN NN O
., NN NN O
and NN NN O
Warfarin NNP NNP B-DRUG
2.5 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.d NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
As NN NN O
per NN NN O
the NN NN O
HPI NN NN O
, NN NN O
otherwise NN NN O
negative NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O

1 NN NN O
. NN NN O
He NN NN O
is NN NN O
status NN NN O
post NN NN O
left NNP NNP B-TREATMENT
inguinal NNP NNP I-TREATMENT
hernia NNP NNP I-TREATMENT
repair NNP NNP I-TREATMENT
. NN NN O

2 NN NN O
. NN NN O
Prostate NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
diagnosed NN NN O
in NN NN O
December NNP NNP B-DATE
2004 NNP NNP I-DATE
, NN NN O
which NN NN O
was NN NN O
a NN NN O
Gleason NN NN O
3+4 NN NN O
. NN NN O

He NN NN O
is NN NN O
now NN NN O
receiving NN NN O
Lupron NNP NNP B-DRUG
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
has NN NN O
a NN NN O
very NN NN O
remote NN NN O
history NN NN O
of NN NN O
tobacco NN NN O
use NN NN O
. NN NN O

He NN NN O
has NN NN O
one NN NN O
to NN NN O
two NN NN O
alcoholic NN NN O
drinks NN NN O
per NN NN O
day NN NN O
. NN NN O

He NN NN O
is NN NN O
married NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
His NN NN O
brother NN NN O
had NN NN O
prostate NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
VIT NN NN O
: NN NN O
Height NNP NNP B-TEST
175 NN NN O
cm NN NN O
, NN NN O
weight NNP NNP B-TEST
77 NN NN O
kg NN NN O
, NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
138/76 NN NN O
, NN NN O
pulse NNP NNP B-TEST
is NN NN O
58 NN NN O
, NN NN O
and NN NN O
temperature NNP NNP B-TEST
is NN NN O
97.0 NN NN O
. NN NN O

GEN NN NN O
: NN NN O
He NN NN O
is NN NN O
nontoxic NN NN O
, NN NN O
noncachectic NNP NNP B-PROBLEM
appearing NN NN O
. NN NN O

HEAD NN NN O
: NN NN O
Examined NN NN O
and NN NN O
normal NN NN O
. NN NN O

EYES NN NN O
: NN NN O
Anicteric NNP NNP B-PROBLEM
. NN NN O

ENT NN NN O
: NN NN O
No NN NN O
oropharyngeal NNP NNP B-PROBLEM
lesions NNP NNP I-PROBLEM
. NN NN O

LYMPH NN NN O
: NN NN O
No NN NN O
cervical NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

HEART NN NN O
: NN NN O
Regular NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
; NN NN O

no NN NN O
murmurs NNP NNP B-PROBLEM
, NN NN O
rubs NNP NNP B-PROBLEM
, NN NN O
or NN NN O
gallops NNP NNP B-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Nontender NNP NNP B-PROBLEM
, NN NN O
nondistended NNP NNP B-PROBLEM
. NN NN O

Normal NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

EXT NN NN O
: NN NN O
Reveal NNP NNP B-TREATMENT
no NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
MGUS NNP NNP B-PROBLEM
. NN NN O

His NNP NNP B-TEST
serum NNP NNP I-TEST
protein NNP NNP I-TEST
electrophoresis NNP NNP I-TEST
showed NN NN O
that NN NN O
his NN NN O
M-spike NN NN O
overall NN NN O
is NN NN O
stable NN NN O
at NN NN O
0.5 NN NN O
. NN NN O

He NN NN O
is NN NN O
doing NN NN O
well NN NN O
and NN NN O
I NN NN O
will NN NN O
see NN NN O
him NN NN O
again NN NN O
with NN NN O
repeat NNP NNP B-TEST
laboratory NNP NNP I-TEST
studies NNP NNP I-TEST
in NN NN O
six NN NN O
months NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
anc NN NN O
, NN NN O
thrombocytopenia NNP NNP B-PROBLEM
, NN NN O
bone NNP NNP B-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
, NN NN O
platelet NNP NNP B-TEST
count NNP NNP I-TEST
, NN NN O
blood NNP NNP B-TEST
cell NNP NNP I-TEST
count NNP NNP I-TEST
, NN NN O
dyscrasia NNP NNP B-PROBLEM
, NN NN O
ecog NNP NNP B-TEST
, NN NN O
prostate NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
plasma NNP NNP B-PROBLEM
cells NNP NNP I-PROBLEM
, NN NN O
bone NNP NNP B-PROBLEM
marrow NNP NNP I-PROBLEM
, NN NN O
mgus NNP NNP B-PROBLEM
, NN NN O
hemoglobin NNP NNP B-TEST
, NN NN O
lymphadenopathy NNP NNP B-PROBLEM
, NN NN O
cellular NNP NNP B-TEST
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Craniopharyngioma NNP NNP B-PROBLEM
- NN NN O
Postop NN NN O
Description NN NN O
: NN NN O
Postoperative NN NN O
visit NN NN O
for NN NN O
craniopharyngioma NNP NNP B-PROBLEM
with NN NN O
residual NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

According NN NN O
to NN NN O
him NN NN O
, NN NN O
he NN NN O
is NN NN O
doing NN NN O
well NN NN O
, NN NN O
back NN NN O
at NN NN O
school NN NN O
without NN NN O
any NNP NNP B-PROBLEM
difficulties NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
some NNP NNP B-PROBLEM
occasional NNP NNP I-PROBLEM
headaches NNP NNP I-PROBLEM
and NN NN O
tinnitus NNP NNP B-PROBLEM
, NN NN O
but NN NN O
his NN NN O
vision NN NN O
is NN NN O
much NN NN O
improved NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
VISIT NN NN O
: NN NN O
Postoperative NN NN O
visit NN NN O
for NN NN O
craniopharyngioma NNP NNP B-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
Briefly NN NN O
, NN NN O
a NN NN O
16-year-old NN NN O
right-handed NN NN O
boy NN NN O
who NN NN O
is NN NN O
in NN NN O
eleventh NN NN O
grade NN NN O
, NN NN O
who NN NN O
presents NN NN O
with NN NN O
some NNP NNP B-PROBLEM
blurred NNP NNP I-PROBLEM
vision NNP NNP I-PROBLEM
and NN NN O
visual NNP NNP B-PROBLEM
acuity NNP NNP I-PROBLEM
difficulties NNP NNP I-PROBLEM
, NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NNP NNP B-PROBLEM
suprasellar NNP NNP I-PROBLEM
tumor NNP NNP I-PROBLEM
. NN NN O

He NN NN O
was NN NN O
brought NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
on NN NN O
01/04/07 NNP NNP B-DATE
, NN NN O
underwent NN NN O
a NNP NNP B-TREATMENT
transsphenoidal NNP NNP I-TREATMENT
resection NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
tumor NNP NNP I-TREATMENT
. NN NN O

Histology NNP NNP B-TEST
returned NN NN O
as NN NN O
craniopharyngioma NNP NNP B-PROBLEM
. NN NN O

There NN NN O
is NN NN O
some NNP NNP B-PROBLEM
residual NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
; NN NN O

however NN NN O
, NN NN O
the NN NN O
visual NN NN O
apparatus NN NN O
was NN NN O
decompressed NNP NNP B-TREATMENT
. NN NN O

According NN NN O
to NN NN O
him NN NN O
, NN NN O
he NN NN O
is NN NN O
doing NN NN O
well NN NN O
, NN NN O
back NN NN O
at NN NN O
school NN NN O
without NN NN O
any NNP NNP B-PROBLEM
difficulties NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
some NNP NNP B-PROBLEM
occasional NNP NNP I-PROBLEM
headaches NNP NNP I-PROBLEM
and NN NN O
tinnitus NNP NNP B-PROBLEM
, NN NN O
but NN NN O
his NN NN O
vision NN NN O
is NN NN O
much NN NN O
improved NN NN O
. NN NN O

MEDICATIONS NN NN O
: NN NN O
Synthroid NNP NNP B-DRUG
100 NNP NNP I-DRUG
mcg NNP NNP I-DRUG
per NN NN O
day NN NN O
. NN NN O

FINDINGS NN NN O
: NN NN O
On NN NN O
exam NNP NNP B-TEST
, NN NN O
he NN NN O
is NN NN O
awake NN NN O
, NN NN O
alert NN NN O
and NN NN O
oriented NN NN O
x NN NN O

3 NN NN O
. NN NN O
Pupils NN NN O
are NN NN O
equal NN NN O
and NN NN O
reactive NN NN O
. NN NN O

EOMs NN NN O
are NN NN O
full NN NN O
. NN NN O

His NNP NNP B-TEST
visual NNP NNP I-TEST
acuity NNP NNP I-TEST
is NN NN O
20/25 NN NN O
in NN NN O
the NN NN O
right NN NN O
( NN NN O
improved NN NN O
from NN NN O
20/200 NN NN O
) NN NN O
and NN NN O
the NN NN O
left NN NN O
is NN NN O
20/200 NN NN O
improved NN NN O
from NN NN O
20/400 NN NN O
. NN NN O

He NN NN O
has NN NN O
a NNP NNP B-PROBLEM
bitemporal NNP NNP I-PROBLEM
hemianopsia NNP NNP I-PROBLEM
, NN NN O
which NN NN O
is NN NN O
significantly NN NN O
improved NN NN O
and NN NN O
wider NN NN O
. NN NN O

His NN NN O
motor NN NN O
is NN NN O
5 NN NN O
out NN NN O
of NN NN O

5 NN NN O
. NN NN O
There NN NN O
are NN NN O
no NN NN O
focal NNP NNP B-PROBLEM
motor NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
sensory NNP NNP I-PROBLEM
deficits NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
abdominal NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
is NN NN O
well NN NN O
healed NN NN O
. NN NN O

There NN NN O
is NN NN O
no NN NN O
evidence NN NN O
of NN NN O
erythema NNP NNP B-PROBLEM
or NN NN O
collection NNP NNP B-PROBLEM
. NN NN O

The NNP NNP B-TREATMENT
lumbar NNP NNP I-TREATMENT
drain NNP NNP I-TREATMENT
was NN NN O
also NN NN O
well NN NN O
healed NN NN O
. NN NN O

The NNP NNP B-TEST
postoperative NNP NNP I-TEST
MRI NNP NNP I-TEST
demonstrates NN NN O
small NNP NNP B-PROBLEM
residual NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

Histology NNP NNP B-TEST
returned NN NN O
as NN NN O
craniopharyngioma NNP NNP B-PROBLEM
. NN NN O

ASSESSMENT NN NN O
: NN NN O
Postoperative NN NN O
visit NN NN O
for NN NN O
craniopharyngioma NNP NNP B-PROBLEM
with NN NN O
residual NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

PLANS NN NN O
: NN NN O
I NN NN O
have NN NN O
recommended NN NN O
that NN NN O
he NN NN O
call NN NN O
. NN NN O

I NN NN O
discussed NN NN O
the NN NN O
options NN NN O
with NN NN O
our NN NN O
radiation NN NN O
oncologist NN NN O
, NN NN O
Dr NN NN O
. NN NN O
X NN NN O
. NN NN O
They NN NN O
will NN NN O
schedule NN NN O
the NN NN O
appointment NN NN O
to NN NN O
see NN NN O
him NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
he NN NN O
probably NN NN O
will NN NN O
need NN NN O
an NNP NNP B-TEST
MRI NNP NNP I-TEST
prior NN NN O
to NN NN O
any NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
, NN NN O
to NN NN O
follow NN NN O
the NNP NNP B-PROBLEM
residual NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
visual NN NN O
acuity NN NN O
, NN NN O
blurred NNP NNP B-PROBLEM
vision NNP NNP I-PROBLEM
, NN NN O
tinnitus NNP NNP B-PROBLEM
, NN NN O
headaches NNP NNP B-PROBLEM
, NN NN O
residual NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
tumor NNP NNP B-PROBLEM
, NN NN O
histology NNP NNP B-PROBLEM
, NN NN O
craniopharyngioma NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Aplastic NNP NNP B-PROBLEM
Anemia NNP NNP I-PROBLEM
Followup NN NN O
Description NN NN O
: NN NN O
Aplastic NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

After NN NN O
several NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsies NNP NNP I-TEST
, NN NN O
she NN NN O
was NN NN O
diagnosed NN NN O
with NN NN O
aplastic NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

She NN NN O
started NN NN O
cyclosporine NNP NNP B-DRUG
and NN NN O
prednisone NNP NNP B-DRUG
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
Aplastic NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
72-year-old NN NN O
woman NN NN O
, NN NN O
who NN NN O
I NN NN O
have NN NN O
been NN NN O
following NN NN O
for NN NN O
her NNP NNP B-PROBLEM
pancytopenia NNP NNP I-PROBLEM
. NN NN O

After NN NN O
several NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsies NNP NNP I-TEST
, NN NN O
she NN NN O
was NN NN O
diagnosed NN NN O
with NN NN O
aplastic NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

She NN NN O
started NN NN O
cyclosporine NNP NNP B-DRUG
and NN NN O
prednisone NNP NNP B-DRUG
on NN NN O
03/30/10 NNP NNP B-DATE
. NN NN O

She NN NN O
was NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
from NN NN O
07/11/10 NNP NNP B-DATE
to NN NN O
07/14/10 NNP NNP B-DATE
with NN NN O
acute NNP NNP B-PROBLEM
kidney NNP NNP I-PROBLEM
injury NNP NNP I-PROBLEM
. NN NN O

Her NN NN O
cyclosporine NNP NNP B-DRUG
level NN NN O
was NN NN O
555 NN NN O
. NN NN O

It NN NN O
was NN NN O
thought NN NN O
that NN NN O
her NNP NNP B-PROBLEM
acute NNP NNP I-PROBLEM
kidney NNP NNP I-PROBLEM
injury NNP NNP I-PROBLEM
was NN NN O
due NN NN O
to NN NN O
cyclosporine NNP NNP B-DRUG
toxicity NN NN O
and NN NN O
therefore NN NN O
that NN NN O
was NN NN O
held NN NN O
. NN NN O

Overall NN NN O
, NN NN O
she NN NN O
tells NN NN O
me NN NN O
that NN NN O
now NN NN O
she NN NN O
feels NN NN O
quite NN NN O
well NN NN O
since NN NN O
leaving NN NN O
the NN NN O
hospital NN NN O
. NN NN O

She NN NN O
was NN NN O
transfused NN NN O
2 NNP NNP B-DRUG
units NNP NNP I-DRUG
of NNP NNP I-DRUG
packed NNP NNP I-DRUG
red NNP NNP I-DRUG
blood NNP NNP I-DRUG
cells NNP NNP I-DRUG
while NN NN O
in NN NN O
the NN NN O
hospital NN NN O
. NN NN O

Repeat NNP NNP B-TEST
CBC NNP NNP I-TEST
from NN NN O
07/26/10 NNP NNP B-DATE
showed NN NN O
white NNP NNP B-TEST
blood NNP NNP I-TEST
cell NNP NNP I-TEST
count NNP NNP I-TEST
of NN NN O
3.4 NN NN O
with NN NN O
a NNP NNP B-TEST
hemoglobin NNP NNP I-TEST
of NN NN O
10.7 NN NN O
and NN NN O
platelet NNP NNP B-TEST
count NNP NNP I-TEST
of NN NN O
49,000 NN NN O
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Folic NNP NNP B-DRUG
acid NNP NNP I-DRUG
, NN NN O
Aciphex NNP NNP B-DRUG
, NN NN O
MiraLax NNP NNP B-DRUG
, NN NN O
trazodone NNP NNP B-DRUG
, NN NN O
prednisone NNP NNP B-DRUG
for NN NN O
5 NN NN O
days NN NN O
every NN NN O
4 NN NN O
weeks NN NN O
, NN NN O
Bactrim NNP NNP B-DRUG
double NN NN O
strength NN NN O
1 NN NN O
tablet NN NN O
b.i.d NN NN O
. NN NN O
on NN NN O
Mondays NNP NNP B-DATE
, NN NN O
Wednesdays NNP NNP B-DATE
and NN NN O
Fridays NNP NNP B-DATE
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
As NN NN O
per NN NN O
the NN NN O
HPI NN NN O
, NN NN O
otherwise NN NN O
negative NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O

1 NN NN O
. NN NN O
Hypertension NNP NNP B-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
GERD NNP NNP B-PROBLEM
. NN NN O

3 NN NN O
. NN NN O
Osteoarthritis NNP NNP B-PROBLEM
. NN NN O

4 NN NN O
. NN NN O
Status NN NN O
post NN NN O
tonsillectomy NNP NNP B-TREATMENT
. NN NN O

5 NN NN O
. NN NN O
Status NN NN O
post NN NN O
hysterectomy NNP NNP B-TREATMENT
. NN NN O

6 NN NN O
. NN NN O
Status NN NN O
post NN NN O
bilateral NNP NNP B-TREATMENT
cataract NNP NNP I-TREATMENT
surgery NNP NNP I-TREATMENT
. NN NN O

7 NN NN O
. NN NN O
Esophageal NNP NNP B-PROBLEM
stricture NNP NNP I-PROBLEM
status NN NN O
post NN NN O
dilatation NNP NNP B-TREATMENT
approximately NN NN O
four NN NN O
times NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
has NN NN O
no NN NN O
tobacco NN NN O
use NN NN O
. NN NN O

She NN NN O
has NN NN O
rare NN NN O
alcohol NN NN O
use NN NN O
. NN NN O

She NN NN O
has NN NN O
three NN NN O
children NN NN O
and NN NN O
is NN NN O
a NN NN O
widow NN NN O
. NN NN O

Her NN NN O
husband NN NN O
died NN NN O
after NN NN O
they NN NN O
were NN NN O
married NN NN O
only NN NN O
eight NN NN O
years NN NN O
. NN NN O

She NN NN O
is NN NN O
retired NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Her NN NN O
sister NN NN O
had NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
VIT NN NN O
: NN NN O
Height NNP NNP B-TEST
167 NN NN O
cm NN NN O
, NN NN O
weight NNP NNP B-TEST
66 NN NN O
kg NN NN O
, NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
122/70 NN NN O
, NN NN O
pulse NNP NNP B-TEST
84 NN NN O
, NN NN O
and NN NN O
temperature NNP NNP B-TEST
is NN NN O
98.9 NN NN O
. NN NN O

GEN NN NN O
: NN NN O
She NN NN O
is NN NN O
nontoxic NN NN O
, NN NN O
noncachectic NNP NNP B-PROBLEM
appearing NN NN O
. NN NN O

HEAD NN NN O
: NN NN O
Examined NN NN O
and NN NN O
normal NN NN O
. NN NN O

EYES NN NN O
: NN NN O
Anicteric NNP NNP B-PROBLEM
. NN NN O

ENT NN NN O
: NN NN O
No NN NN O
oropharyngeal NNP NNP B-PROBLEM
lesions NNP NNP I-PROBLEM
. NN NN O

LYMPH NN NN O
: NN NN O
No NN NN O
cervical NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

HEART NN NN O
: NN NN O
Regular NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
; NN NN O

no NN NN O
murmurs NNP NNP B-PROBLEM
, NN NN O
rubs NNP NNP B-PROBLEM
, NN NN O
or NN NN O
gallops NNP NNP B-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Nontender NN NN O
, NN NN O
nondistended NNP NNP B-PROBLEM
; NN NN O

normal NN NN O
bowel NN NN O
sounds NN NN O
; NN NN O

no NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

EXT NN NN O
: NN NN O
Reveal NNP NNP B-TREATMENT
no NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
Aplastic NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

I NN NN O
am NN NN O
going NN NN O
to NN NN O
repeat NN NN O
her NN NN O
CMP NN NN O
today NN NN O
to NN NN O
assess NN NN O
her NN NN O
kidney NN NN O
function NN NN O
. NN NN O

It NN NN O
is NN NN O
possible NN NN O
that NN NN O
I NN NN O
may NN NN O
resume NN NN O
the NN NN O
cyclosporine NNP NNP B-DRUG
, NN NN O
but NN NN O
at NN NN O
50% NNP NNP B-TREATMENT
dose NNP NNP I-TREATMENT
reduction NNP NNP I-TREATMENT
. NN NN O

She NN NN O
was NN NN O
supratherapeutic NNP NNP B-PROBLEM
when NN NN O
her NN NN O
cyclosporine NNP NNP B-DRUG
level NN NN O
was NN NN O
drawn NN NN O
in NN NN O
the NN NN O
hospital NN NN O
. NN NN O

Her NNP NNP B-TEST
values NNP NNP I-TEST
were NN NN O
555 NN NN O
and NN NN O
the NNP NNP B-TEST
trough NNP NNP I-TEST
should NN NN O
be NN NN O
100 NN NN O
to NN NN O
400 NN NN O
. NN NN O

We NN NN O
will NN NN O
continue NN NN O
with NN NN O
monthly NNP NNP B-TEST
CBCs NNP NNP I-TEST
for NN NN O
now NN NN O
and NN NN O
I NN NN O
will NN NN O
see NN NN O
her NN NN O
again NN NN O
in NN NN O
one NN NN O
month NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
pancytopenia NNP NNP B-PROBLEM
, NN NN O
bone NNP NNP B-TEST
marrow NNP NNP I-TEST
biopsies NNP NNP I-TEST
, NN NN O
cbc NN NN O
, NN NN O
cmp NN NN O
, NN NN O
acute NNP NNP B-PROBLEM
kidney NNP NNP I-PROBLEM
injury NNP NNP I-PROBLEM
, NN NN O
kidney NNP NNP B-PROBLEM
injury NNP NNP I-PROBLEM
, NN NN O
cyclosporine NNP NNP B-DRUG
level NN NN O
, NN NN O
aplastic NNP NNP B-PROBLEM
anemia NNP NNP I-PROBLEM
, NN NN O
oropharyngeal NNP NNP B-PROBLEM
, NN NN O
anemia NNP NNP B-PROBLEM
, NN NN O
cyclosporine NNP NNP B-DRUG
, NN NN O
aplastic NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Thyroid NN NN O
Mass NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Thyroid NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
diagnosed NN NN O
as NN NN O
papillary NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
is NN NN O
a NN NN O
16-year-old NN NN O
young NN NN O
lady NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
thyroid NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
that NN NN O
is NN NN O
now NN NN O
biopsy NNP NNP B-TEST
proven NN NN O
as NN NN O
papillary NNP NNP B-PROBLEM
. NN NN O

The NN NN O
pattern NN NN O
of NN NN O
miliary NNP NNP B-PROBLEM
metastatic NNP NNP I-PROBLEM
lesions NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
chest NNP NNP I-PROBLEM
is NN NN O
consistent NN NN O
with NN NN O
this NN NN O
diagnosis NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULTATION NN NN O
: NN NN O
Thyroid NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
diagnosed NN NN O
as NN NN O
papillary NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
16-year-old NN NN O
young NN NN O
lady NN NN O
, NN NN O
who NN NN O
was NN NN O
referred NN NN O
from NN NN O
the NN NN O
Pediatric NN NN O
Endocrinology NN NN O
Department NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
for NN NN O
evaluation NNP NNP B-TEST
and NN NN O
surgical NN NN O
recommendations NN NN O
regarding NN NN O
treatment NNP NNP B-TREATMENT
of NN NN O
a NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
thyroid NNP NNP I-PROBLEM
, NN NN O
which NN NN O
has NN NN O
now NN NN O
been NN NN O
proven NN NN O
to NN NN O
be NN NN O
papillary NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
on NN NN O
fine NNP NNP B-TEST
needle NNP NNP I-TEST
aspiration NNP NNP I-TEST
biopsy NNP NNP I-TEST
. NN NN O

The NN NN O
patient's NN NN O
parents NN NN O
relayed NN NN O
that NN NN O
they NN NN O
first NN NN O
noted NN NN O
a NNP NNP B-PROBLEM
relatively NNP NNP I-PROBLEM
small NNP NNP I-PROBLEM
but NNP NNP I-PROBLEM
noticeable NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
in NN NN O
the NN NN O
middle NN NN O
portion NN NN O
of NN NN O
her NN NN O
thyroid NN NN O
gland NN NN O
about NN NN O
2004 NNP NNP B-DATE
. NN NN O

An NNP NNP B-TEST
ultrasound NNP NNP I-TEST
examination NNP NNP I-TEST
had NN NN O
reportedly NN NN O
been NN NN O
done NN NN O
in NN NN O
the NN NN O
past NN NN O
and NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
is NN NN O
being NN NN O
observed NN NN O
. NN NN O

When NN NN O
it NN NN O
began NN NN O
to NN NN O
enlarge NN NN O
recently NN NN O
, NN NN O
she NN NN O
was NN NN O
referred NN NN O
to NN NN O
the NN NN O
Pediatric NN NN O
Endocrinology NN NN O
Department NN NN O
and NN NN O
had NN NN O
an NNP NNP B-TEST
evaluation NNP NNP I-TEST
there NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
referred NN NN O
for NN NN O
fine NNP NNP B-PROBLEM
needle NNP NNP I-PROBLEM
aspiration NNP NNP I-PROBLEM
and NN NN O
the NN NN O
reports NN NN O
recently NN NN O
returned NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
papillary NNP NNP B-PROBLEM
thyroid NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
has NN NN O
not NN NN O
had NN NN O
any NNP NNP B-PROBLEM
hoarseness NNP NNP I-PROBLEM
, NN NN O
difficulty NNP NNP B-PROBLEM
swallowing NNP NNP I-PROBLEM
, NN NN O
or NN NN O
any NN NN O
symptoms NN NN O
of NN NN O
endocrine NNP NNP B-PROBLEM
dysfunction NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
no NN NN O
weight NNP NNP B-PROBLEM
changes NNP NNP I-PROBLEM
consistent NN NN O
with NN NN O
either NN NN O
hyper NNP NNP B-PROBLEM
or NN NN O
hypothyroidism NNP NNP B-PROBLEM
. NN NN O

There NN NN O
is NN NN O
no NN NN O
family NN NN O
history NN NN O
of NN NN O
thyroid NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
in NN NN O
her NN NN O
family NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
notable NNP NNP B-PROBLEM
discomfort NNP NNP I-PROBLEM
with NN NN O
this NNP NNP B-PROBLEM
lesion NNP NNP I-PROBLEM
. NN NN O

There NN NN O
have NN NN O
been NN NN O
no NN NN O
skin NNP NNP B-PROBLEM
changes NNP NNP I-PROBLEM
. NN NN O

Historically NN NN O
, NN NN O
she NN NN O
does NN NN O
not NN NN O
have NN NN O
a NN NN O
history NN NN O
of NN NN O
any NNP NNP B-TREATMENT
prior NNP NNP I-TREATMENT
head NNP NNP I-TREATMENT
and NNP NNP I-TREATMENT
neck NNP NNP I-TREATMENT
radiation NNP NNP I-TREATMENT
or NN NN O
treatment NNP NNP B-TREATMENT
of NN NN O
any NNP NNP B-PROBLEM
unusual NNP NNP I-PROBLEM
endocrinopathy NNP NNP I-PROBLEM
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Essentially NN NN O
unremarkable NN NN O
. NN NN O

The NN NN O
patient NN NN O
has NN NN O
never NN NN O
been NN NN O
hospitalized NN NN O
in NN NN O
the NN NN O
past NN NN O
for NN NN O
any NNP NNP B-PROBLEM
major NNP NNP I-PROBLEM
illnesses NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
had NN NN O
no NN NN O
prior NNP NNP B-TREATMENT
surgical NNP NNP I-TREATMENT
procedures NNP NNP I-TREATMENT
. NN NN O

IMMUNIZATIONS NN NN O
: NN NN O
Current NN NN O
and NN NN O
up NN NN O
to NN NN O
date NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
She NN NN O
has NN NN O
no NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Currently NN NN O
taking NN NN O
no NN NN O
routine NNP NNP B-TREATMENT
medications NNP NNP I-TREATMENT
. NN NN O

She NN NN O
describes NN NN O
her NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
level NNP NNP I-PROBLEM
currently NN NN O
as NN NN O
zero NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
There NN NN O
is NN NN O
no NN NN O
significant NN NN O
family NN NN O
history NN NN O
, NN NN O
although NN NN O
the NN NN O
patient's NN NN O
father NN NN O
does NN NN O
note NN NN O
that NN NN O
his NN NN O
mother NN NN O
had NN NN O
a NNP NNP B-TREATMENT
thyroid NNP NNP I-TREATMENT
surgery NNP NNP I-TREATMENT
at NN NN O
some NN NN O
point NN NN O
in NN NN O
life NN NN O
, NN NN O
but NN NN O
it NN NN O
was NN NN O
not NN NN O
known NN NN O
whether NN NN O
this NN NN O
was NN NN O
for NN NN O
cancer NNP NNP B-PROBLEM
, NN NN O
but NN NN O
he NN NN O
suspects NN NN O
it NN NN O
might NN NN O
have NN NN O
been NN NN O
for NN NN O
goiter NNP NNP B-PROBLEM
. NN NN O

This NN NN O
was NN NN O
done NN NN O
in NN NN O
Tijuana NN NN O
. NN NN O

His NN NN O
mom NN NN O
is NN NN O
from NN NN O
central NN NN O
portion NN NN O
of NN NN O
Mexico NN NN O
. NN NN O

There NN NN O
is NN NN O
no NN NN O
family NN NN O
history NN NN O
of NN NN O
multiple NNP NNP B-PROBLEM
endocrine NNP NNP I-PROBLEM
neoplasia NNP NNP I-PROBLEM
syndromes NNP NNP I-PROBLEM
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
junior NN NN O
at NN NN O
Hoover NN NN O
High NN NN O
School NN NN O
. NN NN O

She NN NN O
lives NN NN O
with NN NN O
her NN NN O
mom NN NN O
in NN NN O
Fresno NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
A NNP NNP B-TEST
careful NNP NNP I-TEST
12-system NNP NNP I-TEST
review NNP NNP I-TEST
was NN NN O
completely NN NN O
normal NN NN O
except NN NN O
for NN NN O
the NNP NNP B-PROBLEM
problems NNP NNP I-PROBLEM
related NN NN O
to NN NN O
the NNP NNP B-PROBLEM
thyroid NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
GENERAL NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
55.7 NN NN O
kg NN NN O
, NN NN O
nondysmorphic NN NN O
, NN NN O
quiet NN NN O
, NN NN O
and NN NN O
perhaps NN NN O
slightly NN NN O
apprehensive NN NN O
young NN NN O
lady NN NN O
, NN NN O
who NN NN O
was NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
alert NN NN O
and NN NN O
oriented NN NN O
x3 NN NN O
and NN NN O
had NN NN O
an NN NN O
appropriate NN NN O
affect NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
The NNP NNP B-TEST
head NNP NNP I-TEST
and NNP NNP I-TEST
neck NNP NNP I-TEST
examination NNP NNP I-TEST
is NN NN O
most NN NN O
significant NN NN O
. NN NN O

There NN NN O
is NN NN O
mild NN NN O
amount NN NN O
of NN NN O
facial NNP NNP B-PROBLEM
acne NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient's NN NN O
head NN NN O
, NN NN O
eyes NN NN O
, NN NN O
ears NN NN O
, NN NN O
nose NN NN O
, NN NN O
and NN NN O
throat NN NN O
appeared NN NN O
to NN NN O
be NN NN O
grossly NN NN O
normal NN NN O
. NN NN O

NECK NN NN O
: NN NN O
There NN NN O
is NN NN O
a NNP NNP B-PROBLEM
slightly NNP NNP I-PROBLEM
visible NNP NNP I-PROBLEM
midline NNP NNP I-PROBLEM
bulge NNP NNP I-PROBLEM
in NN NN O
the NN NN O
region NN NN O
of NN NN O
the NN NN O
thyroid NN NN O
isthmus NN NN O
. NN NN O

A NNP NNP B-PROBLEM
firm NNP NNP I-PROBLEM
nodule NNP NNP I-PROBLEM
is NN NN O
present NN NN O
there NN NN O
, NN NN O
and NN NN O
there NN NN O
is NN NN O
also NN NN O
some NNP NNP B-PROBLEM
nodularity NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
of NN NN O
the NN NN O
thyroid NN NN O
. NN NN O

This NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
is NN NN O
relatively NNP NNP B-PROBLEM
hard NNP NNP I-PROBLEM
, NN NN O
slightly NN NN O
fixed NN NN O
, NN NN O
but NN NN O
not NN NN O
tethered NN NN O
to NN NN O
surrounding NN NN O
tissues NN NN O
, NN NN O
skin NN NN O
, NN NN O
or NN NN O
muscles NN NN O
that NN NN O
I NN NN O
can NN NN O
determine NN NN O
. NN NN O

There NN NN O
are NN NN O
some NNP NNP B-PROBLEM
shotty NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
area NNP NNP I-PROBLEM
. NN NN O

No NN NN O
supraclavicular NNP NNP B-PROBLEM
nodes NNP NNP I-PROBLEM
were NN NN O
noted NN NN O
. NN NN O

CHEST NN NN O
: NN NN O
Excursions NN NN O
are NN NN O
symmetric NN NN O
with NN NN O
good NN NN O
air NN NN O
entry NN NN O
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
. NN NN O

CARDIOVASCULAR NN NN O
: NN NN O
Normal NN NN O
. NN NN O

There NN NN O
is NN NN O
no NN NN O
tachycardia NNP NNP B-PROBLEM
or NN NN O
murmur NNP NNP B-PROBLEM
noted NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Benign NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
Extremities NN NN O
are NN NN O
anatomically NN NN O
correct NN NN O
with NN NN O
full NN NN O
range NN NN O
of NN NN O
motion NN NN O
. NN NN O

GENITOURINARY NN NN O
: NN NN O
External NNP NNP B-TEST
genitourinary NNP NNP I-TEST
exam NNP NNP I-TEST
was NN NN O
deferred NN NN O
at NN NN O
this NN NN O
time NN NN O
and NN NN O
can NN NN O
be NN NN O
performed NN NN O
later NN NN O
during NN NN O
anesthesia NNP NNP B-DRUG
. NN NN O

This NN NN O
is NN NN O
same NN NN O
as NN NN O
too NN NN O
for NN NN O
her NNP NNP B-TEST
rectal NNP NNP I-TEST
examination NNP NNP I-TEST
. NN NN O

SKIN NN NN O
: NN NN O
There NN NN O
is NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
rash NNP NNP I-PROBLEM
, NN NN O
purpura NNP NNP B-PROBLEM
, NN NN O
or NN NN O
petechiae NNP NNP B-PROBLEM
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Normal NN NN O
and NN NN O
no NN NN O
focal NNP NNP B-PROBLEM
deficits NNP NNP I-PROBLEM
. NN NN O

Her NN NN O
voice NN NN O
is NN NN O
strong NN NN O
and NN NN O
clear NN NN O
. NN NN O

There NN NN O
is NN NN O
no NN NN O
evidence NN NN O
of NN NN O
dysphonia NNP NNP B-PROBLEM
or NN NN O
vocal NNP NNP B-PROBLEM
cord NNP NNP I-PROBLEM
malfunction NNP NNP I-PROBLEM
. NN NN O

DIAGNOSTIC NN NN O
STUDIES NN NN O
: NN NN O
I NN NN O
reviewed NN NN O
laboratory NN NN O
data NN NN O
from NN NN O
the NN NN O
Diagnostics NN NN O
Lab NN NN O
, NN NN O
which NN NN O
included NN NN O
a NNP NNP B-PROBLEM
mild NNP NNP I-PROBLEM
abnormality NNP NNP I-PROBLEM
in NN NN O
the NNP NNP B-TEST
AST NNP NNP I-TEST
at NN NN O
11 NN NN O
, NN NN O
which NN NN O
is NN NN O
slightly NN NN O
lower NN NN O
than NN NN O
the NN NN O
normal NN NN O
range NN NN O
. NN NN O

T4 NNP NNP B-TEST
and NNP NNP I-TEST
TSH NNP NNP I-TEST
levels NNP NNP I-TEST
were NN NN O
recorded NN NN O
as NN NN O
normal NN NN O
. NN NN O

Free NNP NNP B-TEST
thyroxine NNP NNP I-TEST
was NN NN O
normal NN NN O
, NN NN O
and NN NN O
the NNP NNP B-TEST
serum NNP NNP I-TEST
pregnancy NNP NNP I-TEST
test NNP NNP I-TEST
was NN NN O
negative NN NN O
. NN NN O

There NN NN O
was NN NN O
no NN NN O
level NN NN O
of NN NN O
thyroglobulin NNP NNP B-DRUG
recorded NN NN O
on NN NN O
this NN NN O
. NN NN O

A NNP NNP B-TEST
urinalysis NNP NNP I-TEST
and NN NN O
comprehensive NNP NNP B-TEST
metabolic NNP NNP I-TEST
panel NNP NNP I-TEST
was NN NN O
unremarkable NN NN O
. NN NN O

A NNP NNP B-TEST
chest NNP NNP I-TEST
x-ray NNP NNP I-TEST
was NN NN O
obtained NN NN O
, NN NN O
which NN NN O
I NN NN O
personally NN NN O
reviewed NN NN O
. NN NN O

There NN NN O
is NN NN O
a NN NN O
diffuse NN NN O
pattern NN NN O
of NN NN O
tiny NNP NNP B-PROBLEM
nodules NNP NNP I-PROBLEM
in NN NN O
both NN NN O
lungs NN NN O
typical NN NN O
of NN NN O
miliary NNP NNP B-PROBLEM
metastatic NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
that NN NN O
is NN NN O
often NN NN O
seen NN NN O
in NN NN O
patients NN NN O
with NN NN O
metastatic NNP NNP B-PROBLEM
thyroid NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

IMPRESSION/PLAN NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
16-year-old NN NN O
young NN NN O
lady NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
thyroid NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
that NN NN O
is NN NN O
now NN NN O
biopsy NNP NNP B-TEST
proven NN NN O
as NN NN O
papillary NNP NNP B-PROBLEM
. NN NN O

The NN NN O
pattern NN NN O
of NN NN O
miliary NNP NNP B-PROBLEM
metastatic NNP NNP I-PROBLEM
lesions NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
chest NNP NNP I-PROBLEM
is NN NN O
consistent NN NN O
with NN NN O
this NN NN O
diagnosis NN NN O
and NN NN O
is NN NN O
unfortunate NN NN O
in NN NN O
that NN NN O
it NN NN O
generally NN NN O
means NN NN O
a NN NN O
more NN NN O
advanced NN NN O
stage NN NN O
of NN NN O
disease NNP NNP B-PROBLEM
. NN NN O

I NN NN O
spent NN NN O
approximately NN NN O
30 NN NN O
minutes NN NN O
with NN NN O
the NN NN O
patient NN NN O
and NN NN O
her NN NN O
family NN NN O
today NN NN O
discussing NN NN O
the NN NN O
surgical NN NN O
aspects NN NN O
of NN NN O
the NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
of NN NN O
this NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

During NN NN O
this NN NN O
time NN NN O
, NN NN O
we NN NN O
talked NN NN O
about NN NN O
performing NN NN O
a NNP NNP B-TREATMENT
total NNP NNP I-TREATMENT
thyroidectomy NNP NNP I-TREATMENT
to NN NN O
eradicate NN NN O
as NN NN O
much NN NN O
of NN NN O
the NN NN O
native NN NN O
thyroid NN NN O
tissue NN NN O
and NN NN O
remove NN NN O
the NN NN O
primary NN NN O
source NN NN O
of NN NN O
the NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
in NN NN O
anticipation NN NN O
of NN NN O
radioactive NNP NNP B-DRUG
iodine NNP NNP I-DRUG
therapy NN NN O
. NN NN O

We NN NN O
talked NN NN O
about NN NN O
sentinel NNP NNP B-TREATMENT
node NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
, NN NN O
and NN NN O
we NN NN O
spent NN NN O
significant NN NN O
amount NN NN O
of NN NN O
time NN NN O
talking NN NN O
about NN NN O
the NN NN O
possibility NN NN O
of NN NN O
hypoparathyroidism NNP NNP B-PROBLEM
if NN NN O
all NN NN O
four NN NN O
of NN NN O
the NN NN O
parathyroid NN NN O
glands NN NN O
were NN NN O
damaged NNP NNP B-PROBLEM
during NN NN O
this NNP NNP B-TREATMENT
operation NNP NNP I-TREATMENT
. NN NN O

We NN NN O
also NN NN O
discussed NN NN O
the NN NN O
recurrent NN NN O
laryngeal NN NN O
and NN NN O
external NN NN O
laryngeal NN NN O
branches NN NN O
of NN NN O
the NN NN O
nerve NN NN O
supplying NN NN O
the NN NN O
vocal NN NN O
cord NN NN O
function NN NN O
and NN NN O
how NN NN O
they NN NN O
cane NNP NNP B-TREATMENT
be NN NN O
damaged NN NN O
during NN NN O
the NNP NNP B-TREATMENT
thyroidectomy NNP NNP I-TREATMENT
as NN NN O
well NN NN O
. NN NN O

I NN NN O
answered NN NN O
as NN NN O
many NN NN O
of NN NN O
the NN NN O
family's NN NN O
questions NN NN O
as NN NN O
they NN NN O
could NN NN O
mount NN NN O
during NN NN O
this NN NN O
stressful NN NN O
time NN NN O
with NN NN O
this NN NN O
recent NN NN O
information NN NN O
supplied NN NN O
to NN NN O
them NN NN O
. NN NN O

I NN NN O
also NN NN O
did NN NN O
talk NN NN O
to NN NN O
them NN NN O
about NN NN O
the NNP NNP B-TEST
chest NNP NNP I-TEST
x-ray NNP NNP I-TEST
pattern NNP NNP I-TEST
, NN NN O
which NN NN O
was NN NN O
complete NN NN O
__________ NN NN O
as NN NN O
the NNP NNP B-TEST
film NNP NNP I-TEST
was NN NN O
just NN NN O
on NN NN O
the NN NN O
day NN NN O
prior NN NN O
to NN NN O
my NN NN O
clinic NN NN O
visit NN NN O
. NN NN O

This NN NN O
will NN NN O
have NN NN O
some NN NN O
impact NN NN O
on NN NN O
the NNP NNP B-TREATMENT
postoperative NNP NNP I-TREATMENT
adjunctive NNP NNP I-TREATMENT
therapy NNP NNP I-TREATMENT
. NN NN O

The NN NN O
radiologist NN NN O
commented NN NN O
about NN NN O
the NN NN O
risk NN NN O
of NN NN O
pulmonary NNP NNP B-PROBLEM
fibrosis NNP NNP I-PROBLEM
and NN NN O
the NN NN O
use NN NN O
of NN NN O
radioactive NNP NNP B-DRUG
iodine NNP NNP I-DRUG
in NN NN O
this NN NN O
situation NN NN O
, NN NN O
but NN NN O
it NN NN O
seems NN NN O
likely NN NN O
that NN NN O
is NN NN O
going NN NN O
to NN NN O
be NN NN O
necessary NN NN O
to NN NN O
attempt NN NN O
to NN NN O
treat NN NN O
this NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
in NN NN O
the NN NN O
patient's NN NN O
case NN NN O
. NN NN O

I NN NN O
did NN NN O
discuss NN NN O
with NN NN O
them NN NN O
the NN NN O
possibility NN NN O
of NN NN O
having NN NN O
to NN NN O
take NN NN O
large NN NN O
doses NN NN O
of NN NN O
calcium NNP NNP B-DRUG
and NN NN O
vitamin NNP NNP B-DRUG
D NNP NNP I-DRUG
in NN NN O
the NN NN O
event NN NN O
of NN NN O
hypoparathyroidism NNP NNP B-PROBLEM
if NN NN O
that NN NN O
does NN NN O
happen NN NN O
, NN NN O
and NN NN O
we NN NN O
also NN NN O
talked NN NN O
about NN NN O
possibly NN NN O
sparing NNP NNP B-PROBLEM
parathyroid NNP NNP I-PROBLEM
tissue NNP NNP I-PROBLEM
and NN NN O
reimplanting NN NN O
it NN NN O
in NN NN O
a NN NN O
muscle NN NN O
belly NN NN O
either NN NN O
in NN NN O
the NN NN O
neck NN NN O
or NN NN O
forearm NN NN O
if NN NN O
that NN NN O
becomes NN NN O
a NN NN O
necessity NN NN O
. NN NN O

All NN NN O
of NN NN O
the NN NN O
family's NN NN O
questions NN NN O
have NN NN O
been NN NN O
answered NN NN O
. NN NN O

This NN NN O
is NN NN O
a NNP NNP B-PROBLEM
very NNP NNP I-PROBLEM
anxious NNP NNP I-PROBLEM
and NN NN O
anxiety NNP NNP B-PROBLEM
provoking NN NN O
time NN NN O
in NN NN O
the NN NN O
family NN NN O
. NN NN O

I NN NN O
have NN NN O
made NN NN O
every NN NN O
effort NN NN O
to NN NN O
get NN NN O
the NN NN O
patient NN NN O
under NN NN O
schedule NN NN O
within NN NN O
the NN NN O
next NN NN O
48 NN NN O
hours NN NN O
to NN NN O
have NN NN O
this NNP NNP B-TREATMENT
operation NNP NNP I-TREATMENT
done NN NN O
. NN NN O

We NN NN O
are NN NN O
tentatively NN NN O
planning NN NN O
on NN NN O
proceeding NN NN O
this NN NN O
upcoming NN NN O
Friday NNP NNP B-DATE
afternoon NN NN O
with NN NN O
total NNP NNP B-TREATMENT
thyroidectomy NNP NNP I-TREATMENT
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
papillary NN NN O
, NN NN O
thyroid NN NN O
, NN NN O
carcinoma NNP NNP B-PROBLEM
, NN NN O
biopsy NNP NNP B-TEST
proven NN NN O
, NN NN O
metastatic NNP NNP B-PROBLEM
lesions NNP NNP I-PROBLEM
, NN NN O
endocrinology NN NN O
department NN NN O
, NN NN O
needle NNP NNP B-PROBLEM
aspiration NNP NNP I-PROBLEM
, NN NN O
thyroid NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
vocal NNP NNP B-PROBLEM
cord NNP NNP I-PROBLEM
, NN NN O
papillary NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
thyroid NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
cancer NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Breast NN NN O
Cancer NN NN O
Followup NN NN O
Description NN NN O
: NN NN O
A NN NN O
nurse NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
enrolled NN NN O
is NN NN O
clinical NN NN O
trial NN NN O
C40502 NNP NNP B-DRUG
. NN NN O

Her NNP NNP B-TREATMENT
previous NNP NNP I-TREATMENT
treatments NNP NNP I-TREATMENT
included NN NN O
Zometa NNP NNP B-DRUG
, NN NN O
Faslodex NNP NNP B-DRUG
, NN NN O
and NN NN O
Aromasin NNP NNP B-DRUG
. NN NN O

She NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
disease NNP NNP B-PROBLEM
progression NNP NNP I-PROBLEM
first NN NN O
noted NN NN O
by NN NN O
rising NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
markers NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O

1 NN NN O
. NN NN O
Metastatic NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
Enrolled NN NN O
is NN NN O
clinical NN NN O
trial NN NN O
C40502 NNP NNP B-DRUG
. NN NN O

3 NN NN O
. NN NN O
Sinus NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
She NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
59-year-old NN NN O
nurse NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
initially NN NN O
diagnosed NN NN O
in NN NN O
June NNP NNP B-DATE
1994 NNP NNP I-DATE
. NN NN O

Her NNP NNP B-TREATMENT
previous NNP NNP I-TREATMENT
treatments NNP NNP I-TREATMENT
included NN NN O
Zometa NNP NNP B-DRUG
, NN NN O
Faslodex NNP NNP B-DRUG
, NN NN O
and NN NN O
Aromasin NNP NNP B-DRUG
. NN NN O

She NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
disease NNP NNP B-PROBLEM
progression NNP NNP I-PROBLEM
first NN NN O
noted NN NN O
by NN NN O
rising NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
markers NNP NNP I-PROBLEM
. NN NN O

PET/CT NNP NNP B-TEST
scan NNP NNP I-TEST
revealed NN NN O
metastatic NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
and NN NN O
she NN NN O
was NN NN O
enrolled NN NN O
in NN NN O
clinical NN NN O
trial NN NN O
of NN NN O
CTSU/C40502 NNP NNP B-DRUG
. NN NN O

She NN NN O
was NN NN O
randomized NN NN O
to NN NN O
the NN NN O
ixabepilone NNP NNP B-DRUG
plus NN NN O
Avastin NNP NNP B-DRUG
. NN NN O

She NN NN O
experienced NN NN O
dose-limiting NNP NNP B-PROBLEM
toxicity NNP NNP I-PROBLEM
with NN NN O
the NN NN O
fourth NN NN O
cycle NN NN O
. NN NN O

The NN NN O
Ixempra NNP NNP B-DRUG
was NN NN O
skipped NN NN O
on NN NN O
day NN NN O
1 NN NN O
and NN NN O
day NN NN O

8 NN NN O
. NN NN O
She NN NN O
then NN NN O
had NN NN O
a NNP NNP B-TREATMENT
dose NNP NNP I-TREATMENT
reduction NNP NNP I-TREATMENT
and NN NN O
has NN NN O
been NN NN O
tolerating NN NN O
treatment NNP NNP B-TREATMENT
well NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
progressive NNP NNP B-PROBLEM
neuropathy NNP NNP I-PROBLEM
. NN NN O

Early NN NN O
in NN NN O
the NN NN O
month NN NN O
she NN NN O
had NN NN O
concerned NN NN O
about NN NN O
possible NN NN O
perforated NNP NNP B-PROBLEM
septum NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
seen NN NN O
by NN NN O
ENT NN NN O
urgently NN NN O
. NN NN O

She NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
nasal NN NN O
septum NN NN O
intact NN NN O
. NN NN O

She NN NN O
comes NN NN O
into NN NN O
clinic NN NN O
today NN NN O
for NN NN O
day NN NN O
eight NN NN O
Ixempra NN NN O
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Zometa NNP NNP B-DRUG
monthly NN NN O
, NN NN O
calcium NNP NNP B-DRUG
with NN NN O
Vitamin NNP NNP B-DRUG
D NNP NNP I-DRUG
q.d NN NN O
., NN NN O
multivitamin NNP NNP B-DRUG
q.d NN NN O
., NN NN O
Ambien NNP NNP B-DRUG
5 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.h.s NN NN O
., NN NN O
Pepcid NNP NNP B-DRUG
AC NNP NNP I-DRUG
20 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.d NN NN O
., NN NN O
Effexor NNP NNP B-DRUG
112 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.d NN NN O
., NN NN O
Lyrica NNP NNP B-DRUG
100 NNP NNP I-DRUG
mg NNP NNP I-DRUG
at NN NN O
bedtime NN NN O
, NN NN O
Tylenol NNP NNP B-DRUG
p.r.n NN NN O
., NN NN O
Ultram NNP NNP B-DRUG
p.r.n NN NN O
., NN NN O
Mucinex NNP NNP B-TREATMENT
one NN NN O
to NN NN O
two NN NN O
tablets NN NN O
b.i.d NN NN O
., NN NN O
Neosporin NNP NNP B-DRUG
applied NN NN O
to NN NN O
the NN NN O
nasal NN NN O
mucosa NN NN O
b.i.d NN NN O
. NN NN O
nasal NNP NNP B-TREATMENT
rinse NNP NNP I-TREATMENT
daily NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
Compazine NNP NNP B-DRUG
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
comfort NN NN O
in NN NN O
knowing NN NN O
that NN NN O
she NN NN O
does NN NN O
not NN NN O
have NN NN O
a NNP NNP B-PROBLEM
septal NNP NNP I-PROBLEM
perforation NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
progressive NNP NNP B-PROBLEM
neuropathy NNP NNP I-PROBLEM
and NN NN O
decreased NNP NNP B-PROBLEM
sensation NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
fingertips NNP NNP I-PROBLEM
. NN NN O

She NN NN O
makes NN NN O
many NNP NNP B-PROBLEM
errors NNP NNP I-PROBLEM
when NN NN O
keyboarding NN NN O
. NN NN O

I NN NN O
would NN NN O
rate NN NN O
her NNP NNP B-PROBLEM
neuropathy NNP NNP I-PROBLEM
as NN NN O
grade NN NN O

2 NN NN O
. NN NN O
She NN NN O
continues NN NN O
to NN NN O
have NN NN O
headaches NNP NNP B-PROBLEM
respond NN NN O
to NN NN O
Ultram NNP NNP B-DRUG
which NN NN O
she NN NN O
takes NN NN O
as NN NN O
needed NN NN O
. NN NN O

She NN NN O
occasionally NN NN O
reports NN NN O
pain NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
quadrant NNP NNP I-PROBLEM
as NN NN O
well NN NN O
as NN NN O
right NN NN O
sternum NN NN O
. NN NN O

He NN NN O
denies NN NN O
any NN NN O
fevers NNP NNP B-PROBLEM
, NN NN O
chills NNP NNP B-PROBLEM
, NN NN O
or NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
. NN NN O

Her NNP NNP B-PROBLEM
diarrhea NNP NNP I-PROBLEM
has NN NN O
finally NN NN O
resolved NN NN O
and NN NN O
her NN NN O
bowels NN NN O
are NN NN O
back NN NN O
to NN NN O
normal NN NN O
. NN NN O

The NN NN O
rest NN NN O
of NN NN O
her NNP NNP B-TEST
review NNP NNP I-TEST
of NNP NNP I-TEST
systems NNP NNP I-TEST
is NN NN O
negative NN NN O
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
VITALS NN NN O
: NN NN O
BP NNP NNP B-TEST
: NN NN O
113/63 NN NN O
. NN NN O

HEART NN NN O
RATE NN NN O
: NN NN O

84 NN NN O
. NN NN O
TEMP NN NN O
: NN NN O

99 NN NN O
. NN NN O
Weight NNP NNP B-TEST
: NN NN O
67.8 NN NN O
kg NN NN O
. NN NN O

Her NN NN O
performance NN NN O
status NN NN O
is NN NN O

1 NN NN O
. NN NN O
GEN NN NN O
: NN NN O
She NN NN O
looks NN NN O
well NN NN O
, NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
Pupils NN NN O
are NN NN O
equal NN NN O
, NN NN O
round NN NN O
, NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O

Sclerae NN NN O
are NN NN O
anicteric NNP NNP B-PROBLEM
. NN NN O

Her NN NN O
oropharynx NN NN O
is NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
cervical NNP NNP B-PROBLEM
or NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

CV NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
; NN NN O

normal NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
, NN NN O
no NN NN O
murmurs NNP NNP B-PROBLEM
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
. NN NN O

She NN NN O
has NN NN O
positive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

EXT NN NN O
: NN NN O
Lower NN NN O
extremities NN NN O
are NN NN O
without NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
White NNP NNP B-TEST
blood NNP NNP I-TEST
cell NNP NNP I-TEST
count NNP NNP I-TEST
is NN NN O
7.6 NN NN O
, NN NN O
hemoglobin NNP NNP B-TEST
12.6 NN NN O
, NN NN O
hematocrit NNP NNP B-TEST
37.5 NN NN O
, NN NN O
and NN NN O
platelets NNP NNP B-TEST
287,000 NN NN O
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
59-year-old NN NN O
female NN NN O
with NN NN O
metastatic NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

She NN NN O
is NN NN O
enrolled NN NN O
in NN NN O
clinical NN NN O
trial NN NN O
C40502 NNP NNP B-DRUG
. NN NN O

She NN NN O
has NN NN O
completed NN NN O
nine NN NN O
cycles NN NN O
of NN NN O
chemotherapy NNP NNP B-DRUG
with NN NN O
Ixempra NNP NNP B-DRUG
plus NN NN O
Avastin NNP NNP B-DRUG
. NN NN O

First NN NN O
we NN NN O
thought NN NN O
she NN NN O
might NN NN O
suffered NN NN O
a NNP NNP B-PROBLEM
perforated NNP NNP I-PROBLEM
septum NNP NNP I-PROBLEM
which NN NN O
would NN NN O
bring NN NN O
up NN NN O
concerns NN NN O
with NN NN O
the NN NN O
Avastin NNP NNP B-DRUG
. NN NN O

There NN NN O
have NN NN O
been NN NN O
isolated NN NN O
cases NN NN O
reported NN NN O
of NN NN O
nasal NNP NNP B-PROBLEM
septum NNP NNP I-PROBLEM
perforation NNP NNP I-PROBLEM
that NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
Avastin NNP NNP B-DRUG
. NN NN O

She NN NN O
was NN NN O
noted NN NN O
to NN NN O
have NN NN O
a NNP NNP B-PROBLEM
thin NNP NNP I-PROBLEM
septum NNP NNP I-PROBLEM
but NN NN O
it NN NN O
is NN NN O
intact NN NN O
. NN NN O

We NN NN O
will NN NN O
continue NN NN O
her NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
as NN NN O
planned NN NN O
. NN NN O

I NN NN O
will NN NN O
see NN NN O
her NN NN O
clinic NN NN O
in NN NN O
four NN NN O
weeks NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
zometa NNP NNP B-DRUG
, NN NN O
faslodex NNP NNP B-DRUG
, NN NN O
aromasin NNP NNP B-DRUG
, NN NN O
dose-limiting NNP NNP B-PROBLEM
toxicity NNP NNP I-PROBLEM
, NN NN O
metastatic NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
perforated NNP NNP B-PROBLEM
septum NNP NNP I-PROBLEM
, NN NN O
nasal NNP NNP B-PROBLEM
septum NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
clinical NNP NNP I-PROBLEM
trial NNP NNP I-PROBLEM
, NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
disease NNP NNP B-PROBLEM
, NN NN O
metastatic NNP NNP B-PROBLEM
, NN NN O
breast NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Prostate NN NN O
Brachytherapy NN NN O
Description NN NN O
: NN NN O
Prostate NNP NNP B-TREATMENT
Brachytherapy NNP NNP I-TREATMENT
- NNP NNP I-TREATMENT
Prostate NNP NNP I-TREATMENT
I-125 NNP NNP I-TREATMENT
Implantation NNP NNP I-TREATMENT
( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PROSTATE NNP NNP B-TREATMENT
BRACHYTHERAPY NNP NNP I-TREATMENT
- NNP NNP I-TREATMENT
PROSTATE NNP NNP I-TREATMENT
I-125 NNP NNP I-TREATMENT
IMPLANTATION NNP NNP I-TREATMENT
This NN NN O
patient NN NN O
will NN NN O
be NN NN O
treated NN NN O
to NN NN O
the NN NN O
prostate NN NN O
with NN NN O
ultrasound-guided NNP NNP B-TREATMENT
I-125 NNP NNP I-TREATMENT
seed NNP NNP I-TREATMENT
implantation NNP NNP I-TREATMENT
. NN NN O

The NN NN O
original NN NN O
consultation NN NN O
and NN NN O
treatment NN NN O
planning NN NN O
will NN NN O
be NN NN O
separately NN NN O
performed NN NN O
. NN NN O

At NN NN O
the NN NN O
time NN NN O
of NN NN O
the NNP NNP B-TREATMENT
implantation NNP NNP I-TREATMENT
, NN NN O
special NN NN O
coordination NN NN O
will NN NN O
be NN NN O
required NN NN O
. NN NN O

Stepping NNP NNP B-TEST
ultrasound NNP NNP I-TEST
will NN NN O
be NN NN O
performed NN NN O
and NN NN O
utilized NN NN O
in NN NN O
the NN NN O
pre-planning NN NN O
process NN NN O
. NN NN O

Some NNP NNP B-PROBLEM
discrepancies NNP NNP I-PROBLEM
are NN NN O
frequently NN NN O
identified NN NN O
, NN NN O
based NN NN O
on NN NN O
the NN NN O
positioning NN NN O
, NN NN O
edema NNP NNP B-PROBLEM
, NN NN O
and/or NN NN O
change NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
tumor NNP NNP I-PROBLEM
since NN NN O
the NNP NNP B-PROBLEM
pre-planning NNP NNP I-PROBLEM
process NNP NNP I-PROBLEM
. NN NN O

Re-assessment NNP NNP B-TREATMENT
is NN NN O
required NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
surgery NNP NNP B-TREATMENT
, NN NN O
evaluating NN NN O
the NNP NNP B-TEST
pre-plan NNP NNP I-TEST
and NN NN O
comparing NN NN O
to NN NN O
the NNP NNP B-TEST
stepping NNP NNP I-TEST
ultrasound NNP NNP I-TEST
. NN NN O

Modifications NNP NNP B-TREATMENT
will NN NN O
be NN NN O
made NN NN O
in NN NN O
real NN NN O
time NN NN O
to NN NN O
add NN NN O
or NN NN O
subtract NN NN O
needles NNP NNP B-TREATMENT
and NN NN O
seeds NN NN O
as NN NN O
required NN NN O
. NN NN O

This NN NN O
may NN NN O
be NN NN O
integrated NN NN O
with NN NN O
the NN NN O
loading NN NN O
of NN NN O
the NNP NNP B-TREATMENT
seeds NNP NNP I-TREATMENT
performed NN NN O
by NN NN O
the NN NN O
brachytherapist NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
coordinated NN NN O
with NN NN O
the NN NN O
urologist NN NN O
, NN NN O
dosimetrist NN NN O
or NN NN O
physicist NN NN O
. NN NN O

The NNP NNP B-TREATMENT
brachytherapy NNP NNP I-TREATMENT
must NN NN O
be NN NN O
customized NN NN O
to NN NN O
fit NN NN O
the NNP NNP B-PROBLEM
individual's NNP NNP I-PROBLEM
tumor NNP NNP I-PROBLEM
and NN NN O
prostate NN NN O
. NN NN O

Attention NN NN O
is NN NN O
given NN NN O
both NN NN O
preoperatively NN NN O
and NN NN O
intraoperatively NN NN O
to NN NN O
avoid NN NN O
overdosage NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
rectum NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
bladder NNP NNP I-PROBLEM
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
i-125 NNP NNP B-TREATMENT
implantation NNP NNP I-TREATMENT
, NN NN O
tumor NNP NNP B-TREATMENT
, NN NN O
prostate NNP NNP B-TREATMENT
, NNP NNP I-TREATMENT
prostate NNP NNP I-TREATMENT
brachytherapy NNP NNP I-TREATMENT
, NN NN O
implantation NNP NNP B-TREATMENT
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Discharge NN NN O
Summary NN NN O
- NN NN O
Mesothelioma NN NN O
Description NN NN O
: NN NN O
A NN NN O
patient NN NN O
with NN NN O
preoperative NN NN O
diagnosis NN NN O
of NN NN O
right NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
and NN NN O
postoperative NN NN O
diagnosis NN NN O
of NN NN O
mesothelioma NNP NNP B-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Right NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Mesothelioma NNP NNP B-PROBLEM
. NN NN O

PROCEDURES NN NN O
PERFORMED NN NN O
: NN NN O

1 NN NN O
. NN NN O
Flexible NNP NNP B-TEST
bronchoscopy NNP NNP I-TEST
. NN NN O

2 NN NN O
. NN NN O
Mediastinoscopy NNP NNP B-TEST
. NN NN O

3 NN NN O
. NN NN O
Right NNP NNP B-TREATMENT
thoracotomy NNP NNP I-TREATMENT
. NN NN O

4 NN NN O
. NN NN O
Parietal NNP NNP B-TEST
pleural NNP NNP I-TEST
biopsy NNP NNP I-TEST
. NN NN O

CONSULTS NN NN O
: NN NN O
Consults NN NN O
obtained NN NN O
during NN NN O
this NN NN O
hospitalization NN NN O
included NN NN O
: NN NN O

1 NN NN O
. NN NN O
Radiation NN NN O
Oncology NN NN O
. NN NN O

2 NN NN O
. NN NN O
Pulmonary NN NN O
Medicine NN NN O
. NN NN O

3 NN NN O
. NN NN O
Medical NN NN O
Oncology NN NN O
. NN NN O

4 NN NN O
. NN NN O
Cancer NN NN O
Center NN NN O
Team NN NN O
consult NN NN O
. NN NN O

5 NN NN O
. NN NN O
Massage NN NN O
therapy NN NN O
consult NN NN O
. NN NN O

HOSPITAL NN NN O
COURSE NN NN O
: NN NN O
The NN NN O
patient's NN NN O
hospital NN NN O
course NN NN O
was NN NN O
unremarkable NN NN O
. NN NN O

Her NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
was NN NN O
well NN NN O
controlled NN NN O
with NN NN O
an NNP NNP B-TREATMENT
epidural NNP NNP I-TREATMENT
that NN NN O
was NN NN O
placed NN NN O
by NN NN O
Anesthesia NNP NNP B-DRUG
. NN NN O

At NN NN O
the NN NN O
time NN NN O
of NN NN O
discharge NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
ambulatory NN NN O
. NN NN O

She NN NN O
was NN NN O
discharged NN NN O
with NN NN O
home NN NN O
oxygen NNP NNP B-DRUG
available NN NN O
. NN NN O

She NN NN O
was NN NN O
discharged NN NN O
with NN NN O
albuterol NNP NNP B-DRUG
nebulizer NNP NNP I-DRUG
treatments NN NN O
, NN NN O
treatments NNP NNP B-TREATMENT
were NN NN O
to NN NN O
be NN NN O
q.i.d NN NN O
. NN NN O

She NN NN O
was NN NN O
discharged NN NN O
with NN NN O
a NN NN O
prescription NN NN O
for NN NN O
Vicodin NNP NNP B-DRUG
for NN NN O
pain NNP NNP B-TREATMENT
control NNP NNP I-TREATMENT
. NN NN O

She NN NN O
is NN NN O
to NN NN O
follow NN NN O
up NN NN O
with NN NN O
Dr NN NN O
. NN NN O
X NN NN O
in NN NN O
the NN NN O
office NN NN O
in NN NN O
one NN NN O
week NN NN O
with NN NN O
a NNP NNP B-TEST
chest NNP NNP I-TEST
x-ray NNP NNP I-TEST
. NN NN O

She NN NN O
is NN NN O
instructed NN NN O
not NN NN O
to NN NN O
lift NN NN O
, NN NN O
push NN NN O
or NN NN O
pull NN NN O
anything NN NN O
greater NN NN O
than NN NN O
10 NN NN O
pounds NN NN O
. NN NN O

She NN NN O
is NN NN O
instructed NN NN O
not NN NN O
to NN NN O
drive NN NN O
until NN NN O
after NN NN O
she NN NN O
sees NN NN O
us NN NN O
in NN NN O
the NN NN O
office NN NN O
and NN NN O
is NN NN O
off NN NN O
her NNP NNP B-TREATMENT
pain NNP NNP I-TREATMENT
medications NNP NNP I-TREATMENT
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
flexible NNP NNP B-TEST
bronchoscopy NNP NNP I-TEST
, NN NN O
mediastinoscopy NNP NNP B-TEST
, NN NN O
right NNP NNP B-TREATMENT
thoracotomy NNP NNP I-TREATMENT
, NN NN O
pleural NNP NNP B-TEST
biopsy NNP NNP I-TEST
, NN NN O
pleural NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
mesothelioma NNP NNP B-PROBLEM
, NN NN O
oncology NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Axillary NN NN O
Dissection NN NN O
& NN NN O
Mass NN NN O
Excision NN NN O
Description NN NN O
: NN NN O
Left NNP NNP B-TREATMENT
axillary NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
with NN NN O
incision NNP NNP B-PROBLEM
and NN NN O
drainage NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

Right NNP NNP B-TREATMENT
axillary NNP NNP I-TREATMENT
mass NNP NNP I-TREATMENT
excision NNP NNP I-TREATMENT
and NN NN O
incision NNP NNP B-PROBLEM
and NN NN O
drainage NNP NNP B-TREATMENT
. NN NN O

Bilateral NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
masses NNP NNP I-PROBLEM
, NN NN O
rule NN NN O
out NN NN O
recurrent NNP NNP B-PROBLEM
Hodgkin's NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Bilateral NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
masses NNP NNP I-PROBLEM
, NN NN O
rule NN NN O
out NN NN O
recurrent NNP NNP B-PROBLEM
Hodgkin's NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Bilateral NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
masses NNP NNP I-PROBLEM
, NN NN O
rule NN NN O
out NN NN O
recurrent NNP NNP B-PROBLEM
Hodgkin's NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

PROCEDURE NN NN O
PERFORMED NN NN O
: NN NN O

1 NN NN O
. NN NN O
Left NNP NNP B-TREATMENT
axillary NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
with NN NN O
incision NNP NNP B-PROBLEM
and NN NN O
drainage NNP NNP B-TREATMENT
of NN NN O
left NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
Right NNP NNP B-TREATMENT
axillary NNP NNP I-TREATMENT
mass NNP NNP I-TREATMENT
excision NNP NNP I-TREATMENT
and NN NN O
incision NNP NNP B-PROBLEM
and NN NN O
drainage NNP NNP B-TREATMENT
. NN NN O

ANESTHESIA NN NN O
: NN NN O
LMA NNP NNP B-TREATMENT
. NN NN O

SPECIMENS NN NN O
: NN NN O
Left NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
with NN NN O
nodes NNP NNP B-PROBLEM
and NN NN O
right NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

ESTIMATED NN NN O
BLOOD NN NN O
LOSS NN NN O
: NN NN O
Less NN NN O
than NN NN O
30 NN NN O
cc NN NN O
. NN NN O

INDICATION NN NN O
: NN NN O
This NN NN O
56-year-old NN NN O
male NN NN O
presents NN NN O
to NN NN O
surgical NN NN O
office NN NN O
with NN NN O
history NN NN O
of NN NN O
bilateral NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
masses NNP NNP I-PROBLEM
. NN NN O

Upon NN NN O
evaluation NNP NNP B-TEST
, NN NN O
it NN NN O
was NN NN O
noted NN NN O
that NN NN O
the NN NN O
patient NN NN O
has NN NN O
draining NNP NNP B-PROBLEM
bilateral NNP NNP I-PROBLEM
masses NNP NNP I-PROBLEM
with NN NN O
the NNP NNP B-PROBLEM
left NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
being NN NN O
approximately NN NN O
8 NN NN O
cm NN NN O
in NN NN O
diameter NN NN O
upon NN NN O
palpation NNP NNP B-TEST
and NN NN O
the NN NN O
right NN NN O
being NN NN O
approximately NN NN O
4 NN NN O
cm NN NN O
in NN NN O
diameter NN NN O
. NN NN O

The NN NN O
patient NN NN O
had NN NN O
been NN NN O
continued NN NN O
on NN NN O
antibiotics NNP NNP B-DRUG
preoperatively NN NN O
. NN NN O

The NN NN O
patient NN NN O
with NN NN O
history NN NN O
of NN NN O
Hodgkin's NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
approximately NN NN O
18 NN NN O
years NN NN O
ago NN NN O
and NN NN O
underwent NN NN O
therapy NNP NNP B-TREATMENT
at NN NN O
that NN NN O
time NN NN O
and NN NN O
he NN NN O
was NN NN O
declared NN NN O
free NN NN O
of NN NN O
disease NNP NNP B-PROBLEM
since NN NN O
that NN NN O
time NN NN O
. NN NN O

Consent NN NN O
for NN NN O
possible NN NN O
recurrence NNP NNP B-PROBLEM
of NN NN O
Hodgkin's NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
warranted NN NN O
exploration NNP NNP B-TEST
and NN NN O
excision NNP NNP B-TREATMENT
of NN NN O
these NNP NNP B-PROBLEM
masses NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
explained NN NN O
the NN NN O
risks NN NN O
and NN NN O
benefits NN NN O
of NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
and NN NN O
informed NN NN O
consent NN NN O
was NN NN O
obtained NN NN O
. NN NN O

GROSS NN NN O
FINDINGS NN NN O
: NN NN O
Upon NN NN O
dissection NNP NNP B-TREATMENT
of NN NN O
the NNP NNP B-PROBLEM
left NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
was NN NN O
removed NN NN O
in NN NN O
toto NN NN O
and NN NN O
noted NN NN O
to NN NN O
have NN NN O
a NN NN O
cavity NN NN O
within NN NN O
it NN NN O
consistent NN NN O
with NN NN O
an NNP NNP B-PROBLEM
abscess NNP NNP I-PROBLEM
. NN NN O

No NN NN O
loose NNP NNP B-PROBLEM
structures NNP NNP I-PROBLEM
were NN NN O
identified NN NN O
and NN NN O
sent NN NN O
for NN NN O
frozen NNP NNP B-TEST
section NNP NNP I-TEST
, NN NN O
which NN NN O
upon NN NN O
intraoperative NN NN O
consultation NN NN O
with NN NN O
Pathology NN NN O
Department NN NN O
revealed NN NN O
no NN NN O
obvious NN NN O
evidence NN NN O
of NN NN O
lymphoma NNP NNP B-PROBLEM
, NN NN O
however NN NN O
, NN NN O
the NN NN O
confirmed NN NN O
pathology NN NN O
report NN NN O
is NN NN O
pending NN NN O
at NN NN O
this NN NN O
time NN NN O
. NN NN O

The NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
was NN NN O
excised NNP NNP B-TREATMENT
without NN NN O
difficulty NN NN O
without NN NN O
requiring NN NN O
full NNP NNP B-TREATMENT
axillary NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
. NN NN O

PROCEDURE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
placed NN NN O
in NN NN O
supine NN NN O
position NN NN O
after NN NN O
appropriate NN NN O
anesthesia NNP NNP B-DRUG
was NN NN O
obtained NN NN O
and NN NN O
a NNP NNP B-TREATMENT
sterile NNP NNP I-TREATMENT
prep NNP NNP I-TREATMENT
and NN NN O
drape NNP NNP B-TREATMENT
complete NN NN O
. NN NN O

A NNP NNP B-TREATMENT
#10 NNP NNP I-TREATMENT
blade NNP NNP I-TREATMENT
scalpel NNP NNP I-TREATMENT
was NN NN O
used NN NN O
to NN NN O
make NN NN O
an NNP NNP B-PROBLEM
elliptical NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
about NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
itself NN NN O
extending NN NN O
this NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
further NN NN O
to NN NN O
aid NN NN O
in NN NN O
the NN NN O
mobilization NN NN O
of NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

Sharp NNP NNP B-TREATMENT
dissection NNP NNP I-TREATMENT
was NN NN O
utilized NN NN O
with NN NN O
Metzenbaum NNP NNP B-TREATMENT
scissors NNP NNP I-TREATMENT
about NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
to NN NN O
maintain NN NN O
the NNP NNP B-PROBLEM
injury NNP NNP I-PROBLEM
to NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
skin NNP NNP I-PROBLEM
structure NNP NNP I-PROBLEM
and NN NN O
upon NN NN O
showing NN NN O
out NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
Bovie NNP NNP B-TREATMENT
electrocautery NNP NNP I-TREATMENT
was NN NN O
utilized NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
wall NN NN O
structure NN NN O
to NN NN O
maintain NN NN O
hemostasis NNP NNP B-TEST
. NN NN O

Identification NN NN O
of NN NN O
the NN NN O
axillary NN NN O
anatomy NN NN O
was NN NN O
made NN NN O
and NN NN O
care NN NN O
was NN NN O
made NN NN O
to NN NN O
avoid NN NN O
injury NNP NNP B-PROBLEM
to NNP NNP I-PROBLEM
nerve NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
vessel NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
musculature NNP NNP I-PROBLEM
. NN NN O

Once NN NN O
this NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
was NN NN O
removed NN NN O
in NN NN O
toto NN NN O
, NN NN O
lymph NN NN O
node NN NN O
structures NN NN O
were NN NN O
as NN NN O
well NN NN O
delivered NN NN O
with NN NN O
this NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
and NN NN O
sent NN NN O
to NN NN O
frozen NNP NNP B-TEST
section NNP NNP I-TEST
as NN NN O
well NN NN O
the NNP NNP B-TEST
specimen NNP NNP I-TEST
was NN NN O
sent NN NN O
to NN NN O
gram NNP NNP B-TEST
stain NNP NNP I-TEST
and NN NN O
culture NNP NNP B-TEST
. NN NN O

Upon NN NN O
revaluation NNP NNP B-TEST
of NN NN O
the NNP NNP B-PROBLEM
incisional NNP NNP I-PROBLEM
site NNP NNP I-PROBLEM
, NN NN O
it NN NN O
was NN NN O
noted NN NN O
to NN NN O
be NN NN O
hemostatic NN NN O
. NN NN O

Warm NNP NNP B-TREATMENT
lap NNP NNP I-TREATMENT
sponge NNP NNP I-TREATMENT
was NN NN O
then NN NN O
left NN NN O
in NN NN O
place NN NN O
at NN NN O
this NN NN O
site NN NN O
. NN NN O

Next NN NN O
, NN NN O
attention NN NN O
was NN NN O
turned NN NN O
to NN NN O
the NN NN O
right NN NN O
axilla NN NN O
where NN NN O
a NNP NNP B-TREATMENT
#10 NNP NNP I-TREATMENT
blade NNP NNP I-TREATMENT
scalpel NNP NNP I-TREATMENT
was NN NN O
used NN NN O
to NN NN O
make NN NN O
a NNP NNP B-PROBLEM
4 NNP NNP I-PROBLEM
cm NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
about NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
including NN NN O
the NNP NNP B-PROBLEM
cutaneous NNP NNP I-PROBLEM
structures NNP NNP I-PROBLEM
involved NN NN O
with NN NN O
the NNP NNP B-PROBLEM
erythematous NNP NNP I-PROBLEM
reaction NNP NNP I-PROBLEM
. NN NN O

This NN NN O
was NN NN O
as NN NN O
well NN NN O
removed NN NN O
in NN NN O
toto NN NN O
and NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
for NN NN O
gram NNP NNP B-TEST
stain NNP NNP I-TEST
and NN NN O
culture NNP NNP B-TEST
as NN NN O
well NN NN O
as NN NN O
pathologic NNP NNP B-TEST
evaluation NNP NNP I-TEST
. NN NN O

This NN NN O
site NN NN O
was NN NN O
then NN NN O
made NN NN O
hemostatic NN NN O
as NN NN O
well NN NN O
with NN NN O
the NN NN O
aid NN NN O
of NN NN O
Bovie NNP NNP B-TREATMENT
electrocautery NNP NNP I-TREATMENT
and NN NN O
approximation NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
deep NNP NNP I-TREATMENT
dermal NNP NNP I-TREATMENT
tissues NNP NNP I-TREATMENT
after NN NN O
irrigation NNP NNP B-TREATMENT
with NN NN O
warm NNP NNP B-TREATMENT
saline NNP NNP I-TREATMENT
was NN NN O
then NN NN O
done NN NN O
with NN NN O
#3-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
suture NNP NNP I-TREATMENT
followed NN NN O
by NN NN O
#4-0 NN NN O
Vicryl NNP NNP B-TREATMENT
running NN NN O
subcuticular NNP NNP B-TREATMENT
stitch NNP NNP I-TREATMENT
. NN NN O

Steri-Strips NNP NNP B-TREATMENT
were NN NN O
applied NN NN O
. NN NN O

Attention NN NN O
was NN NN O
returned NN NN O
back NN NN O
left NN NN O
axilla NN NN O
, NN NN O
which NN NN O
upon NN NN O
re-exploration NNP NNP B-TEST
was NN NN O
noted NN NN O
to NN NN O
be NN NN O
hemostatic NN NN O
and NN NN O
a NNP NNP B-TREATMENT
#7 NNP NNP I-TREATMENT
mm NNP NNP I-TREATMENT
JP NNP NNP I-TREATMENT
was NN NN O
then NN NN O
introduced NN NN O
making NN NN O
a NNP NNP B-PROBLEM
skin NNP NNP I-PROBLEM
stab NNP NNP I-PROBLEM
inferior NN NN O
to NN NN O
the NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
and NN NN O
bringing NN NN O
the NN NN O
end NN NN O
of NN NN O
the NNP NNP B-TREATMENT
drain NNP NNP I-TREATMENT
through NN NN O
this NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
. NN NN O

This NN NN O
was NN NN O
placed NN NN O
within NN NN O
the NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
site NNP NNP I-PROBLEM
, NN NN O
________ NN NN O
drainage NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
potential NNP NNP I-PROBLEM
space NNP NNP I-PROBLEM
. NN NN O

Approximation NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
deep NNP NNP I-TREATMENT
dermal NNP NNP I-TREATMENT
tissues NNP NNP I-TREATMENT
were NN NN O
then NN NN O
done NN NN O
with NN NN O
#3-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
in NN NN O
an NN NN O
interrupted NN NN O
technique NN NN O
followed NN NN O
by NN NN O
#4-0 NN NN O
Vicryl NNP NNP B-TREATMENT
with NN NN O
running NN NN O
subcuticular NN NN O
technique NN NN O
. NN NN O

Steri-Strips NNP NNP B-TREATMENT
and NN NN O
sterile NNP NNP B-TREATMENT
dressings NNP NNP I-TREATMENT
were NN NN O
applied NN NN O
. NN NN O

JP NNP NNP B-TREATMENT
bulb NNP NNP I-TREATMENT
was NN NN O
then NN NN O
placed NN NN O
to NN NN O
suction NNP NNP B-TREATMENT
and NN NN O
sterile NNP NNP B-TREATMENT
dressings NNP NNP I-TREATMENT
were NN NN O
applied NN NN O
to NN NN O
both NN NN O
axilla NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
well NN NN O
and NN NN O
sent NN NN O
to NN NN O
postanesthesia NN NN O
care NN NN O
unit NN NN O
in NN NN O
a NN NN O
stable NN NN O
condition NN NN O
. NN NN O

He NN NN O
will NN NN O
be NN NN O
discharged NN NN O
to NN NN O
home NN NN O
upon NN NN O
ability NN NN O
of NN NN O
the NN NN O
patient NN NN O
to NN NN O
have NN NN O
pain NNP NNP B-PROBLEM
tolerance NNP NNP I-PROBLEM
with NN NN O
Vicodin NNP NNP B-DRUG
1-2 NN NN O
as NN NN O
needed NN NN O
every NN NN O
six NN NN O
hours NN NN O
for NN NN O
pain NNP NNP B-PROBLEM
and NN NN O
continue NN NN O
on NN NN O
Keflex NNP NNP B-DRUG
antibiotics NNP NNP I-DRUG
until NN NN O
gram NNP NNP B-TEST
stain NNP NNP I-TEST
culture NNP NNP I-TEST
proves NN NN O
otherwise NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
incision NNP NNP B-PROBLEM
and NN NN O
drainage NNP NNP B-TREATMENT
, NN NN O
axillary NNP NNP B-TREATMENT
mass NNP NNP I-TREATMENT
excision NNP NNP I-TREATMENT
, NN NN O
axillary NNP NNP B-TREATMENT
dissection NNP NNP I-TREATMENT
, NN NN O
hodgkin's NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
axillary NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
mass NNP NNP B-PROBLEM
, NN NN O
incision NNP NNP B-PROBLEM
, NN NN O
axillary NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Breast NN NN O
Mass NN NN O
Excision NN NN O
Description NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
right NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

Right NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
with NN NN O
atypical NNP NNP B-PROBLEM
proliferative NNP NNP I-PROBLEM
cells NNP NNP I-PROBLEM
on NN NN O
fine-needle NNP NNP B-TEST
aspiration NNP NNP I-TEST
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Right NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
with NN NN O
atypical NNP NNP B-PROBLEM
proliferative NNP NNP I-PROBLEM
cells NNP NNP I-PROBLEM
on NN NN O
fine-needle NNP NNP B-TEST
aspiration NNP NNP I-TEST
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Benign NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

ANESTHESIA NN NN O
: NN NN O
General NN NN O
NAME NN NN O
OF NN NN O
OPERATION NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
right NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

PROCEDURE NN NN O
: NN NN O
With NN NN O
the NN NN O
patient NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
, NN NN O
the NN NN O
right NN NN O
breast NN NN O
was NN NN O
prepped NNP NNP B-TREATMENT
and NN NN O
draped NN NN O
in NN NN O
a NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

A NNP NNP B-PROBLEM
curvilinear NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
directly NN NN O
over NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
in NN NN O
the NN NN O
upper-outer NN NN O
quadrant NN NN O
of NN NN O
the NN NN O
right NN NN O
breast NN NN O
. NN NN O

Dissection NNP NNP B-TREATMENT
was NN NN O
carried NN NN O
out NN NN O
around NN NN O
a NNP NNP B-PROBLEM
firm NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
which NN NN O
was NN NN O
dissected NN NN O
with NN NN O
surrounding NNP NNP B-TREATMENT
margins NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
breast NNP NNP I-TREATMENT
tissue NNP NNP I-TREATMENT
. NN NN O

Hemostasis NN NN O
was NN NN O
obtained NN NN O
using NN NN O
electrocautery NNP NNP B-TREATMENT
. NN NN O

Frozen NNP NNP B-TEST
section NNP NNP I-TEST
exam NNP NNP I-TEST
showed NN NN O
a NNP NNP B-PROBLEM
fibroadenoma NNP NNP I-PROBLEM
with NN NN O
some NNP NNP B-PROBLEM
proliferative NNP NNP I-PROBLEM
hyperplasia NNP NNP I-PROBLEM
within NN NN O
the NNP NNP B-PROBLEM
fibroadenoma NNP NNP I-PROBLEM
, NN NN O
but NN NN O
appeared NN NN O
benign NN NN O
. NN NN O

The NN NN O
breast NN NN O
tissues NN NN O
were NN NN O
approximated NN NN O
using NN NN O
4-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
. NN NN O

The NN NN O
skin NN NN O
was NN NN O
closed NN NN O
using NN NN O
5-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
running NN NN O
subcuticular NNP NNP B-TREATMENT
stitches NNP NNP I-TREATMENT
. NN NN O

A NNP NNP B-TREATMENT
sterile NNP NNP I-TREATMENT
bandage NNP NNP I-TREATMENT
was NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
well NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
atypical NNP NNP B-PROBLEM
proliferative NNP NNP I-PROBLEM
cells NNP NNP I-PROBLEM
, NN NN O
fine NNP NNP B-PROBLEM
needle NNP NNP I-PROBLEM
aspiration NNP NNP I-PROBLEM
, NN NN O
proliferative NNP NNP B-PROBLEM
cells NNP NNP I-PROBLEM
, NN NN O
breast NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
breast NNP NNP B-PROBLEM
, NN NN O
needle NNP NNP B-PROBLEM
, NN NN O
aspiration NNP NNP B-PROBLEM
, NN NN O
fibroadenoma NNP NNP B-PROBLEM
, NN NN O
excision NNP NNP B-PROBLEM
, NN NN O
proliferative NN NN O
, NN NN O
mass NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Lymphoblastic NN NN O
Leukemia NN NN O
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
high-risk NNP NNP I-PROBLEM
acute NNP NNP I-PROBLEM
lymphoblastic NNP NNP I-PROBLEM
leukemia NNP NNP I-PROBLEM
; NN NN O

extensive NNP NNP B-PROBLEM
deep NNP NNP I-PROBLEM
vein NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
, NN NN O
and NN NN O
pharmacologic NNP NNP B-TREATMENT
thrombolysis NNP NNP I-TREATMENT
following NN NN O
placement NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
a NNP NNP I-TREATMENT
vena NNP NNP I-TREATMENT
caval NNP NNP I-TREATMENT
filter NNP NNP I-TREATMENT
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
high-risk NNP NNP I-PROBLEM
acute NNP NNP I-PROBLEM
lymphoblastic NNP NNP I-PROBLEM
leukemia NNP NNP I-PROBLEM
; NN NN O

extensive NNP NNP B-PROBLEM
deep NNP NNP I-PROBLEM
vein NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
, NN NN O
right NNP NNP B-PROBLEM
iliac NNP NNP I-PROBLEM
vein NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
inferior NNP NNP I-PROBLEM
vena NNP NNP I-PROBLEM
cava NNP NNP I-PROBLEM
( NNP NNP I-PROBLEM
IVC NNP NNP I-PROBLEM
), NN NN O
status NN NN O
post NN NN O
balloon NNP NNP B-TREATMENT
angioplasty NNP NNP I-TREATMENT
, NN NN O
and NN NN O
mechanical NNP NNP B-TREATMENT
and NN NN O
pharmacologic NNP NNP B-TREATMENT
thrombolysis NNP NNP I-TREATMENT
following NN NN O
placement NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
a NNP NNP I-TREATMENT
vena NNP NNP I-TREATMENT
caval NNP NNP I-TREATMENT
filter NNP NNP I-TREATMENT
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
transferred NN NN O
here NN NN O
the NN NN O
evening NN NN O
of NN NN O
02/23/2007 NNP NNP B-DATE
from NN NN O
Hospital NN NN O
with NN NN O
a NN NN O
new NN NN O
diagnosis NN NN O
of NN NN O
high-risk NNP NNP B-PROBLEM
acute NNP NNP I-PROBLEM
lymphoblastic NNP NNP I-PROBLEM
leukemia NNP NNP I-PROBLEM
based NN NN O
on NN NN O
confirmation NN NN O
by NN NN O
flow NNP NNP B-TEST
cytometry NNP NNP I-TEST
of NN NN O
peripheral NNP NNP B-TEST
blood NNP NNP I-TEST
lymphoblasts NNP NNP I-TEST
that NN NN O
afternoon NN NN O
. NN NN O

History NN NN O
related NN NN O
to NN NN O
this NNP NNP B-PROBLEM
illness NNP NNP I-PROBLEM
probably NN NN O
dates NN NN O
back NN NN O
to NN NN O
October NNP NNP B-DATE
of NNP NNP I-DATE
2006 NNP NNP I-DATE
when NN NN O
he NN NN O
had NN NN O
onset NN NN O
of NN NN O
swelling NNP NNP B-PROBLEM
and NN NN O
discomfort NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
testicle NNP NNP I-PROBLEM
with NN NN O
what NN NN O
he NN NN O
described NN NN O
as NN NN O
a NNP NNP B-PROBLEM
residual NNP NNP I-PROBLEM
" NNP NNP I-PROBLEM
lump NNP NNP I-PROBLEM
" NNP NNP I-PROBLEM
posteriorly NNP NNP I-PROBLEM
. NN NN O

The NN NN O
left NN NN O
testicle NN NN O
has NN NN O
continued NN NN O
to NN NN O
be NN NN O
painful NNP NNP B-PROBLEM
off NN NN O
and NN NN O
on NN NN O
since NN NN O
. NN NN O

In NN NN O
early NN NN O
November NNP NNP B-DATE
, NN NN O
he NN NN O
developed NN NN O
pain NNP NNP B-PROBLEM
in NN NN O
the NN NN O
posterior NN NN O
part NN NN O
of NN NN O
his NN NN O
upper NN NN O
right NN NN O
leg NN NN O
, NN NN O
which NN NN O
he NN NN O
initially NN NN O
thought NN NN O
was NN NN O
related NN NN O
to NN NN O
skateboarding NNP NNP B-PROBLEM
and NNP NNP I-PROBLEM
muscle NNP NNP I-PROBLEM
strain NNP NNP I-PROBLEM
. NN NN O

Physical NNP NNP B-TREATMENT
therapy NNP NNP I-TREATMENT
was NN NN O
prescribed NN NN O
and NN NN O
the NNP NNP B-PROBLEM
discomfort NNP NNP I-PROBLEM
temporarily NN NN O
improved NN NN O
. NN NN O

In NN NN O
December NNP NNP B-DATE
, NN NN O
he NN NN O
noted NN NN O
onset NN NN O
of NN NN O
increasing NNP NNP B-PROBLEM
fatigue NNP NNP I-PROBLEM
. NN NN O

He NN NN O
used NN NN O
to NN NN O
work NN NN O
out NN NN O
regularly NN NN O
, NN NN O
lifting NN NN O
lifts NN NN O
, NN NN O
doing NN NN O
abdominal NN NN O
exercises NN NN O
, NN NN O
and NN NN O
playing NN NN O
basketball NN NN O
and NN NN O
found NN NN O
he NN NN O
did NN NN O
not NN NN O
have NN NN O
energy NN NN O
to NN NN O
pursue NN NN O
these NN NN O
activities NN NN O
. NN NN O

He NN NN O
has NN NN O
lost NNP NNP B-PROBLEM
10 NNP NNP I-PROBLEM
pounds NNP NNP I-PROBLEM
since NN NN O
December NNP NNP B-DATE
and NN NN O
feels NN NN O
his NN NN O
appetite NN NN O
has NN NN O
decreased NN NN O
. NN NN O

Night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
and NN NN O
cough NNP NNP B-PROBLEM
began NN NN O
in NN NN O
December NNP NNP B-DATE
, NN NN O
for NN NN O
which NN NN O
he NN NN O
was NN NN O
treated NN NN O
with NN NN O
a NN NN O
course NN NN O
of NN NN O
Augmentin NNP NNP B-DRUG
. NN NN O

However NN NN O
, NN NN O
both NN NN O
of NN NN O
these NNP NNP B-PROBLEM
problems NNP NNP I-PROBLEM
have NN NN O
continued NN NN O
. NN NN O

He NN NN O
also NN NN O
began NN NN O
taking NN NN O
Accutane NNP NNP B-DRUG
for NN NN O
persistent NNP NNP B-PROBLEM
acne NNP NNP I-PROBLEM
in NN NN O
December NNP NNP B-DATE
( NN NN O
this NNP NNP B-TREATMENT
agent NNP NNP I-TREATMENT
was NN NN O
stopped NN NN O
on NN NN O
02/19/2007 NNP NNP B-DATE
). NN NN O

Despite NN NN O
increasing NNP NNP B-PROBLEM
fatigue NNP NNP I-PROBLEM
and NN NN O
lethargy NNP NNP B-PROBLEM
, NN NN O
he NN NN O
continues NN NN O
his NNP NNP B-TEST
studies NNP NNP I-TEST
at NN NN O
University NN NN O
of NN NN O
Denver NN NN O
, NN NN O
has NN NN O
a NN NN O
biology NN NN O
major NN NN O
( NN NN O
he NN NN O
aspires NN NN O
to NN NN O
be NN NN O
an NN NN O
ophthalmologist NN NN O
). NN NN O

The NN NN O
morning NN NN O
of NN NN O
02/19/2007 NNP NNP B-DATE
, NN NN O
he NN NN O
awakened NN NN O
with NN NN O
severe NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
inguinal NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
quadrant NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

He NN NN O
was NN NN O
seen NN NN O
in NN NN O
Emergency NN NN O
Room NN NN O
where NN NN O
it NN NN O
was NN NN O
noted NN NN O
that NN NN O
he NN NN O
had NN NN O
an NNP NNP B-PROBLEM
elevated NNP NNP I-PROBLEM
WBC NNP NNP I-PROBLEM
of NN NN O
18,000 NN NN O
. NN NN O

CT NNP NNP B-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
abdomen NNP NNP I-TEST
was NN NN O
obtained NN NN O
to NN NN O
rule NN NN O
out NN NN O
possible NN NN O
appendicitis NNP NNP B-PROBLEM
and NN NN O
on NN NN O
that NNP NNP B-TEST
CT NNP NNP I-TEST
, NN NN O
a NNP NNP B-PROBLEM
large NNP NNP I-PROBLEM
clot NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
inferior NNP NNP I-PROBLEM
vena NNP NNP I-PROBLEM
cava NNP NNP I-PROBLEM
extending NN NN O
to NN NN O
the NN NN O
right NN NN O
iliac NN NN O
and NN NN O
femoral NN NN O
veins NN NN O
was NN NN O
found NN NN O
. NN NN O

He NN NN O
promptly NN NN O
underwent NN NN O
appropriate NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
in NN NN O
interventional NN NN O
radiology NN NN O
with NN NN O
the NNP NNP B-TREATMENT
above-noted NNP NNP I-TREATMENT
angioplasty NNP NNP I-TREATMENT
and NN NN O
placement NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
a NNP NNP I-TREATMENT
vena NNP NNP I-TREATMENT
caval NNP NNP I-TREATMENT
filter NNP NNP I-TREATMENT
followed NN NN O
by NN NN O
mechanical NNP NNP B-TREATMENT
and NN NN O
pharmacologic NNP NNP B-TREATMENT
thrombolysis NNP NNP I-TREATMENT
. NN NN O

Repeat NNP NNP B-TEST
ultrasound NNP NNP I-TEST
there NN NN O
on NN NN O
02/20/2007 NNP NNP B-DATE
showed NN NN O
no NN NN O
evidence NN NN O
of NN NN O
deep NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
( NN NN O
DVT NNP NNP B-PROBLEM
). NN NN O

Continuous NN NN O
intravenous NNP NNP B-DRUG
unfractionated NNP NNP I-DRUG
heparin NNP NNP I-DRUG
infusion NNP NNP I-DRUG
was NN NN O
continued NN NN O
. NN NN O

Because NN NN O
there NN NN O
was NN NN O
no NN NN O
obvious NN NN O
cause NN NN O
of NN NN O
this NNP NNP B-PROBLEM
extensive NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
, NN NN O
occult NNP NNP B-PROBLEM
malignancy NNP NNP I-PROBLEM
was NN NN O
suspected NN NN O
. NN NN O

Appropriate NNP NNP B-TEST
blood NNP NNP I-TEST
studies NNP NNP I-TEST
were NN NN O
obtained NN NN O
and NN NN O
he NN NN O
underwent NN NN O
a NNP NNP B-TEST
PET/CT NNP NNP I-TEST
scan NNP NNP I-TEST
as NN NN O
part NN NN O
of NN NN O
his NNP NNP B-TEST
diagnostic NNP NNP I-TEST
evaluation NNP NNP I-TEST
. NN NN O

This NNP NNP B-TEST
study NNP NNP I-TEST
showed NN NN O
moderately NNP NNP B-PROBLEM
increased NNP NNP I-PROBLEM
diffuse NNP NNP I-PROBLEM
bone NNP NNP I-PROBLEM
marrow NNP NNP I-PROBLEM
metabolic NNP NNP I-PROBLEM
activity NNP NNP I-PROBLEM
. NN NN O

Because NN NN O
the NNP NNP B-TEST
WBC NNP NNP I-TEST
continued NN NN O
to NN NN O
rise NN NN O
and NN NN O
showed NN NN O
a NN NN O
preponderance NN NN O
of NN NN O
lymphocytes NN NN O
, NN NN O
the NNP NNP B-TEST
smear NNP NNP I-TEST
was NN NN O
reviewed NN NN O
by NN NN O
pathologist NN NN O
, NN NN O
Sheryl NNP NNP B-NAME
Asplund NNP NNP I-NAME
, NN NN O
M.D NN NN O
., NN NN O
and NN NN O
flow NNP NNP B-TEST
cytometry NNP NNP I-TEST
was NN NN O
performed NN NN O
on NN NN O
the NNP NNP B-TEST
peripheral NNP NNP I-TEST
blood NNP NNP I-TEST
. NN NN O

These NNP NNP B-TEST
studies NNP NNP I-TEST
became NN NN O
available NN NN O
the NN NN O
afternoon NN NN O
of NN NN O
02/23/2007 NNP NNP B-DATE
, NN NN O
and NN NN O
confirmed NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
precursor-B NNP NNP B-PROBLEM
acute NNP NNP I-PROBLEM
lymphoblastic NNP NNP I-PROBLEM
leukemia NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
transferred NN NN O
here NN NN O
after NN NN O
stopping NN NN O
of NN NN O
the NN NN O
continuous NN NN O
infusion NN NN O
heparin NNP NNP B-DRUG
and NN NN O
receiving NN NN O
a NN NN O
dose NN NN O
of NN NN O
Lovenox NNP NNP B-DRUG
60 NNP NNP I-DRUG
mg NNP NNP I-DRUG
subcutaneously NNP NNP I-DRUG
for NN NN O
further NNP NNP B-TEST
diagnostic NNP NNP I-TEST
evaluation NNP NNP I-TEST
and NN NN O
management NNP NNP B-TREATMENT
of NN NN O
the NNP NNP B-PROBLEM
acute NNP NNP I-PROBLEM
lymphoblastic NNP NNP I-PROBLEM
leukemia NNP NNP I-PROBLEM
( NN NN O
ALL NN NN O
). NN NN O

ALLERGIES NN NN O
: NN NN O
NO NN NN O
KNOWN NNP NNP B-PROBLEM
DRUG NNP NNP I-PROBLEM
ALLERGIES NNP NNP I-PROBLEM
. NN NN O

HE NN NN O
DOES NN NN O
SEEM NN NN O
TO NN NN O
REACT NN NN O
TO NN NN O
CERTAIN NNP NNP B-TREATMENT
ADHESIVES NNP NNP I-TREATMENT
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O

1 NN NN O
. NN NN O
Lovenox NNP NNP B-TREATMENT
60 NN NN O
mg NN NN O
subcutaneously NN NN O
q.12h NN NN O
. NN NN O

initiated NN NN O
. NN NN O

2 NN NN O
. NN NN O
Coumadin NNP NNP B-DRUG
5 NNP NNP I-DRUG
mg NNP NNP I-DRUG
p.o NNP NNP I-DRUG
. NN NN O

, NN NN O
was NN NN O
administered NN NN O
on NN NN O
02/19/2007 NNP NNP B-DATE
and NN NN O
02/22/2007 NNP NNP B-DATE
. NN NN O

3 NN NN O
. NN NN O
Protonix NNP NNP B-DRUG
40 NNP NNP I-DRUG
mg NNP NNP I-DRUG
intravenous NNP NNP I-DRUG
( NNP NNP I-DRUG
IV NNP NNP I-DRUG
) NN NN O
daily NN NN O
. NN NN O

4 NN NN O
. NN NN O
Vicodin NNP NNP B-DRUG
p.r.n NN NN O
. NN NN O

5 NN NN O
. NN NN O
Levaquin NNP NNP B-DRUG
750 NNP NNP I-DRUG
mg NNP NNP I-DRUG
IV NNP NNP I-DRUG
on NN NN O
02/23/2007 NNP NNP B-DATE
. NN NN O

IMMUNIZATIONS NN NN O
: NN NN O
Up-to-date NN NN O
. NN NN O

PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O
: NN NN O
The NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
of NN NN O
the NNP NNP B-PROBLEM
thrombosis NNP NNP I-PROBLEM
as NN NN O
noted NN NN O
above NN NN O
on NN NN O
02/19/2007 NNP NNP B-DATE
and NN NN O
02/20/2007 NNP NNP B-DATE
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Two NN NN O
half-brothers NN NN O
, NN NN O
ages NN NN O
26 NN NN O
and NN NN O
28 NN NN O
, NN NN O
both NN NN O
in NN NN O
good NN NN O
health NN NN O
. NN NN O

Parents NN NN O
are NN NN O
in NN NN O
good NN NN O
health NN NN O
. NN NN O

A NN NN O
maternal NN NN O
great-grandmother NN NN O
had NN NN O
a NNP NNP B-PROBLEM
deep NNP NNP I-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
( NN NN O
DVT NNP NNP B-PROBLEM
) NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
leg NNP NNP I-PROBLEM
in NN NN O
her NN NN O
40s NN NN O
. NN NN O

A NN NN O
maternal NN NN O
great-uncle NN NN O
developed NN NN O
leukemia NNP NNP B-PROBLEM
around NN NN O
age NN NN O

50 NN NN O
. NN NN O
A NN NN O
maternal NN NN O
great-grandfather NN NN O
had NN NN O
bone NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
around NN NN O
age NN NN O

80 NN NN O
. NN NN O
His NN NN O
paternal NN NN O
grandfather NN NN O
died NN NN O
of NN NN O
colon NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
at NN NN O
age NN NN O
73 NN NN O
, NN NN O
which NN NN O
he NN NN O
had NN NN O
had NN NN O
since NN NN O
age NN NN O

68 NN NN O
. NN NN O
Adult-onset NNP NNP B-PROBLEM
diabetes NNP NNP I-PROBLEM
is NN NN O
present NN NN O
in NN NN O
distant NN NN O
relatives NN NN O
on NN NN O
both NN NN O
sides NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
student NN NN O
at NN NN O
the NN NN O
University NN NN O
majoring NN NN O
in NN NN O
biology NN NN O
. NN NN O

He NN NN O
lives NN NN O
in NN NN O
a NN NN O
dorm NN NN O
there NN NN O
. NN NN O

His NN NN O
parents NN NN O
live NN NN O
in NN NN O
Breckenridge NN NN O
. NN NN O

He NN NN O
admits NN NN O
to NN NN O
having NN NN O
smoked NN NN O
marijuana NN NN O
off NN NN O
and NN NN O
on NN NN O
with NN NN O
friends NN NN O
and NN NN O
drinking NN NN O
beer NN NN O
off NN NN O
and NN NN O
on NN NN O
as NN NN O
well NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
He NN NN O
has NN NN O
had NN NN O
emesis NNP NNP B-PROBLEM
off NN NN O
and NN NN O
on NN NN O
related NN NN O
to NN NN O
Vicodin NNP NNP B-DRUG
and NN NN O
constipation NNP NNP B-PROBLEM
since NN NN O
02/19/2007 NNP NNP B-DATE
, NN NN O
also NN NN O
related NN NN O
to NN NN O
pain NNP NNP B-TREATMENT
medication NNP NNP I-TREATMENT
. NN NN O

He NN NN O
has NN NN O
had NN NN O
acne NNP NNP B-PROBLEM
for NN NN O
about NN NN O
two NN NN O
years NN NN O
, NN NN O
which NN NN O
he NN NN O
describes NN NN O
as NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
. NN NN O

He NN NN O
denied NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
, NN NN O
chest NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
hemoptysis NNP NNP B-PROBLEM
, NN NN O
dyspnea NNP NNP B-PROBLEM
, NN NN O
headaches NNP NNP B-PROBLEM
, NN NN O
joint NNP NNP B-PROBLEM
pains NNP NNP I-PROBLEM
, NN NN O
rashes NNP NNP B-PROBLEM
, NN NN O
except NN NN O
where NN NN O
he NN NN O
has NN NN O
had NN NN O
dressings NNP NNP B-TREATMENT
applied NN NN O
, NN NN O
and NN NN O
extremity NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
except NN NN O
for NN NN O
the NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
leg NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
noted NN NN O
above NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
GENERAL NN NN O
: NN NN O
Alert NN NN O
, NN NN O
cooperative NN NN O
, NN NN O
moderately NN NN O
ill-appearing NN NN O
young NN NN O
man NN NN O
. NN NN O

VITAL NN NN O
SIGNS NN NN O
: NN NN O
At NN NN O
the NN NN O
time NN NN O
of NN NN O
admission NN NN O
, NN NN O
pulse NNP NNP B-TEST
was NN NN O
94 NN NN O
, NN NN O
respirations NNP NNP B-TEST
20 NN NN O
, NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
120/62 NN NN O
, NN NN O
temperature NNP NNP B-TEST
98.7 NN NN O
, NN NN O
height NNP NNP B-TEST
171.5 NN NN O
cm NN NN O
, NN NN O
weight NNP NNP B-TEST
63.04 NN NN O
kg NN NN O
, NN NN O
and NN NN O
pulse NNP NNP B-TEST
oximetry NNP NNP I-TEST
on NNP NNP I-TEST
room NNP NNP I-TEST
air NNP NNP I-TEST
95% NN NN O
. NN NN O

HAIR NN NN O
AND NN NN O
SKIN NN NN O
: NN NN O
Mild NNP NNP B-PROBLEM
facial NNP NNP I-PROBLEM
acne NNP NNP I-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
Extraocular NN NN O
muscles NN NN O
( NN NN O
EOMs NN NN O
) NN NN O
intact NN NN O
. NN NN O

Pupils NN NN O
equal NN NN O
, NN NN O
round NN NN O
, NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
and NN NN O
accommodation NN NN O
( NN NN O
PERRLA NN NN O
), NN NN O
fundi NN NN O
normal NN NN O
. NN NN O

CARDIOVASCULAR NN NN O
: NN NN O
A NNP NNP B-PROBLEM
2/6 NNP NNP I-PROBLEM
systolic NNP NNP I-PROBLEM
ejection NNP NNP I-PROBLEM
murmur NNP NNP I-PROBLEM
( NNP NNP I-PROBLEM
SEM NNP NNP I-PROBLEM
), NN NN O
regular NN NN O
sinus NN NN O
rhythm NN NN O
( NN NN O
RSR NN NN O
). NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
with NN NN O
an NNP NNP B-PROBLEM
occasional NNP NNP I-PROBLEM
productive NNP NNP I-PROBLEM
cough NNP NNP I-PROBLEM
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
with NN NN O
mild NNP NNP B-PROBLEM
lower NNP NNP I-PROBLEM
quadrant NNP NNP I-PROBLEM
tenderness NNP NNP I-PROBLEM
, NN NN O
right NN NN O
more NN NN O
so NN NN O
than NN NN O
left NN NN O
; NN NN O

liver NN NN O
and NN NN O
spleen NN NN O
each NN NN O
decreased NN NN O
4 NN NN O
cm NN NN O
below NN NN O
their NN NN O
respective NN NN O
costal NN NN O
margins NN NN O
. NN NN O

MUSCULOSKELETAL NN NN O
: NN NN O
Mild NNP NNP B-PROBLEM
swelling NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
dorsal NNP NNP I-PROBLEM
aspect NNP NNP I-PROBLEM
of NN NN O
the NN NN O
right NN NN O
foot NN NN O
and NN NN O
distal NN NN O
right NN NN O
leg NN NN O
. NN NN O

Mild NNP NNP B-PROBLEM
tenderness NNP NNP I-PROBLEM
over NN NN O
the NNP NNP B-TREATMENT
prior NNP NNP I-TREATMENT
catheter NNP NNP I-TREATMENT
entrance NN NN O
site NN NN O
in NN NN O
the NN NN O
right NN NN O
popliteal NN NN O
fossa NN NN O
and NN NN O
mild NNP NNP B-PROBLEM
tenderness NNP NNP I-PROBLEM
over NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
medial NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
thigh NNP NNP I-PROBLEM
. NN NN O

GENITOURINARY NN NN O
: NN NN O
Testicle NNP NNP B-TEST
exam NNP NNP I-TEST
disclosed NN NN O
no NN NN O
firm NNP NNP B-PROBLEM
swelling NNP NNP I-PROBLEM
with NN NN O
mild NNP NNP B-PROBLEM
nondiscrete NNP NNP I-PROBLEM
fullness NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
posterior NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
testicle NNP NNP I-PROBLEM
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Exam NNP NNP B-TEST
showed NN NN O
him NN NN O
to NN NN O
be NN NN O
oriented NN NN O
x4 NN NN O
. NN NN O

Normal NN NN O
fundi NN NN O
, NN NN O
intact NN NN O
cranial NN NN O
nerves NN NN O
II NN NN O
through NN NN O
XII NN NN O
with NN NN O
downgoing NN NN O
toes NN NN O
, NN NN O
symmetric NN NN O
muscle NN NN O
strength NN NN O
, NN NN O
and NN NN O
decreased NNP NNP B-PROBLEM
patellar NNP NNP I-PROBLEM
deep NNP NNP I-PROBLEM
tendon NNP NNP I-PROBLEM
reflexes NNP NNP I-PROBLEM
( NN NN O
DTRs NN NN O
). NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
White NNP NNP B-TEST
count NNP NNP I-TEST
25,500 NN NN O
( NN NN O
26 NN NN O
neutrophils NNP NNP B-TEST
, NN NN O
1 NN NN O
band NNP NNP B-TEST
, NN NN O
7 NN NN O
lymphocytes NNP NNP B-TEST
, NN NN O
1 NN NN O
monocyte NNP NNP B-TEST
, NN NN O
1 NN NN O
myelocyte NNP NNP B-TEST
, NN NN O
64 NN NN O
blasts NNP NNP B-TEST
), NN NN O
hemoglobin NNP NNP B-TEST
13.3 NN NN O
, NN NN O
hematocrit NNP NNP B-TEST
38.8 NN NN O
, NN NN O
and NN NN O
312,000 NN NN O
platelets NNP NNP B-TEST
. NN NN O

Electrolytes NNP NNP B-TEST
, NN NN O
BUN NNP NNP B-TEST
, NN NN O
creatinine NNP NNP B-TEST
, NN NN O
phosphorus NNP NNP B-TEST
, NN NN O
uric NNP NNP B-TEST
acid NNP NNP I-TEST
, NN NN O
AST NNP NNP B-TEST
, NN NN O
ALT NNP NNP B-TEST
, NN NN O
alkaline NNP NNP B-TEST
phosphatase NNP NNP I-TEST
, NN NN O
and NN NN O
magnesium NNP NNP B-TEST
were NN NN O
all NN NN O
normal NN NN O
. NN NN O

LDH NNP NNP B-TEST
was NN NN O
elevated NNP NNP B-PROBLEM
to NN NN O
1925 NN NN O
units/L NN NN O
( NN NN O
upper NN NN O
normal NN NN O
670 NN NN O
), NN NN O
and NN NN O
total NNP NNP B-TEST
protein NNP NNP I-TEST
and NN NN O
albumin NNP NNP B-DRUG
were NN NN O
both NN NN O
low NN NN O
at NN NN O
6.2 NN NN O
and NN NN O
3.4 NN NN O
g/dL NNP NNP B-TEST
respectively NN NN O
. NN NN O

Calcium NNP NNP B-TEST
was NN NN O
also NN NN O
slightly NNP NNP B-PROBLEM
low NNP NNP I-PROBLEM
at NN NN O
8.8 NN NN O
mg/dL NN NN O
. NN NN O

Low NNP NNP B-PROBLEM
molecular NNP NNP I-PROBLEM
weight NNP NNP I-PROBLEM
heparin NNP NNP B-DRUG
test NN NN O
was NN NN O
low NN NN O
at NN NN O
0.27 NN NN O
units/mL NN NN O
. NN NN O

PT NNP NNP B-TEST
was NN NN O
11.8 NN NN O
, NN NN O
INR NNP NNP B-TEST
1.2 NN NN O
, NN NN O
and NN NN O
fibrinogen NNP NNP B-TEST
374 NN NN O
. NN NN O

Urinalysis NNP NNP B-TEST
was NN NN O
normal NN NN O
. NN NN O

ASSESSMENT NN NN O
: NN NN O

1 NN NN O
. NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
high-risk NNP NNP I-PROBLEM
acute NNP NNP I-PROBLEM
lymphoblastic NNP NNP I-PROBLEM
leukemia NNP NNP I-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
Deep NNP NNP B-PROBLEM
vein NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
distal NNP NNP I-PROBLEM
iliac NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
common NNP NNP I-PROBLEM
femoral/right NNP NNP I-PROBLEM
femoral NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
iliac NNP NNP I-PROBLEM
veins NNP NNP I-PROBLEM
, NN NN O
status NN NN O
post NN NN O
vena NNP NNP B-TREATMENT
caval NNP NNP I-TREATMENT
filter NNP NNP I-TREATMENT
placement NNP NNP I-TREATMENT
and NN NN O
mechanical NNP NNP B-TREATMENT
and NN NN O
thrombolytic NNP NNP B-TREATMENT
therapy NNP NNP I-TREATMENT
, NN NN O
on NN NN O
continued NN NN O
anticoagulation NNP NNP B-DRUG
. NN NN O

3 NN NN O
. NN NN O
Probable NN NN O
chronic NNP NNP B-PROBLEM
left NNP NNP I-PROBLEM
epididymitis NNP NNP I-PROBLEM
. NN NN O

PLAN NN NN O
: NN NN O

1 NN NN O
. NN NN O
Proceed NN NN O
with NN NN O
diagnostic NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
aspirate/biopsy NNP NNP I-TEST
and NN NN O
lumbar NNP NNP B-TEST
puncture NNP NNP I-TEST
( NN NN O
using NN NN O
a NNP NNP B-TREATMENT
#27-gauge NNP NNP I-TREATMENT
pencil-tip NNP NNP I-TREATMENT
needle NNP NNP I-TREATMENT
for NN NN O
minimal NNP NNP B-PROBLEM
trauma NNP NNP I-PROBLEM
) NN NN O
as NN NN O
soon NN NN O
as NN NN O
these NNP NNP B-TREATMENT
procedures NNP NNP I-TREATMENT
can NN NN O
be NN NN O
safely NN NN O
done NN NN O
with NN NN O
regard NN NN O
to NN NN O
the NN NN O
anticoagulation NNP NNP B-DRUG
status NN NN O
. NN NN O

2 NN NN O
. NN NN O
Prompt NNP NNP B-TEST
reassessment NNP NNP I-TEST
of NN NN O
the NN NN O
status NN NN O
of NN NN O
the NNP NNP B-PROBLEM
deep NNP NNP I-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
with NN NN O
Doppler NNP NNP B-TEST
studies NNP NNP I-TEST
. NN NN O

3 NN NN O
. NN NN O
Ultrasound/Doppler NNP NNP B-TREATMENT
of NN NN O
the NN NN O
testicles NN NN O
. NN NN O

4 NN NN O
. NN NN O
Maintain NN NN O
therapeutic NN NN O
anticoagulation NNP NNP B-DRUG
as NN NN O
soon NN NN O
as NN NN O
the NNP NNP B-TREATMENT
diagnostic NNP NNP I-TREATMENT
procedures NNP NNP I-TREATMENT
for NN NN O
ALL NNP NNP B-PROBLEM
can NN NN O
be NN NN O
completed NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
accutane NN NN O
, NN NN O
inferior NN NN O
vena NN NN O
cava NN NN O
, NN NN O
deep NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
, NN NN O
vena NNP NNP B-TREATMENT
caval NNP NNP I-TREATMENT
filter NNP NNP I-TREATMENT
, NN NN O
acute NNP NNP B-PROBLEM
lymphoblastic NNP NNP I-PROBLEM
leukemia NNP NNP I-PROBLEM
, NN NN O
pharmacologic NNP NNP B-TREATMENT
thrombolysis NNP NNP I-TREATMENT
, NN NN O
venous NNP NNP B-PROBLEM
thrombosis NNP NNP I-PROBLEM
, NN NN O
lymphoblastic NNP NNP B-PROBLEM
leukemia NNP NNP I-PROBLEM
, NN NN O
anticoagulation NNP NNP B-TREATMENT
, NN NN O
pharmacologic NNP NNP B-TREATMENT
, NN NN O
vena NNP NNP B-TREATMENT
, NNP NNP I-TREATMENT
caval NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
lymphoblastic NNP NNP I-TREATMENT
, NN NN O
leukemia NNP NNP B-PROBLEM
, NN NN O
thrombosis NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Symes NN NN O
Amputation NN NN O
- NN NN O
Hallux NN NN O
Description NN NN O
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
mass NNP NNP B-PROBLEM
, NN NN O
left NNP NNP B-TREATMENT
second NNP NNP I-TREATMENT
toe NNP NNP I-TREATMENT
and NNP NNP I-TREATMENT
distal NNP NNP I-TREATMENT
Symes NNP NNP I-TREATMENT
amputation NNP NNP I-TREATMENT
, NN NN O
left NN NN O
hallux NN NN O
with NN NN O
excisional NNP NNP B-TEST
biopsy NNP NNP I-TEST
. NN NN O

Mass NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
second NNP NNP I-PROBLEM
toe NNP NNP I-PROBLEM
. NN NN O

Tumor NNP NNP B-PROBLEM
. NN NN O

Left NNP NNP B-PROBLEM
hallux NNP NNP I-PROBLEM
bone NNP NNP I-PROBLEM
invasion NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
distal NNP NNP I-PROBLEM
phalanx NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSES NN NN O
: NN NN O

1 NN NN O
. NN NN O
Mass NNP NNP B-PROBLEM
, NN NN O
left NN NN O
second NN NN O
toe NN NN O
. NN NN O

2 NN NN O
. NN NN O
Tumor NNP NNP B-PROBLEM
. NN NN O

3 NN NN O
. NN NN O
Left NNP NNP B-PROBLEM
hallux NNP NNP I-PROBLEM
bone NNP NNP I-PROBLEM
invasion NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
distal NNP NNP I-PROBLEM
phalanx NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSES NN NN O
: NN NN O

1 NN NN O
. NN NN O
Mass NNP NNP B-PROBLEM
, NN NN O
left NN NN O
second NN NN O
toe NN NN O
. NN NN O

2 NN NN O
. NN NN O
Tumor NNP NNP B-PROBLEM
. NN NN O

3 NN NN O
. NN NN O
Left NN NN O
hallux NN NN O
with NN NN O
bone NNP NNP B-PROBLEM
invasion NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
distal NNP NNP I-PROBLEM
phalanx NNP NNP I-PROBLEM
. NN NN O

PROCEDURE NN NN O
PERFORMED NN NN O
: NN NN O

1 NN NN O
. NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
mass NNP NNP B-PROBLEM
, NN NN O
left NN NN O
second NN NN O
toe NN NN O
. NN NN O

2 NN NN O
. NN NN O
Distal NNP NNP B-TREATMENT
Syme's NNP NNP I-TREATMENT
amputation NNP NNP I-TREATMENT
, NN NN O
left NNP NNP B-TREATMENT
hallux NNP NNP I-TREATMENT
with NN NN O
excisional NNP NNP B-TEST
biopsy NNP NNP I-TEST
. NN NN O

HISTORY NN NN O
: NN NN O
This NN NN O
47-year-old NN NN O
Caucasian NN NN O
male NN NN O
presents NN NN O
to NN NN O
ABCD NN NN O
General NN NN O
Hospital NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
tissue NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
on NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
foot NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
states NN NN O
that NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
has NN NN O
been NN NN O
present NN NN O
for NN NN O
approximately NN NN O
two NN NN O
weeks NN NN O
and NN NN O
has NN NN O
been NN NN O
rapidly NN NN O
growing NN NN O
in NN NN O
size NN NN O
. NN NN O

The NN NN O
patient NN NN O
also NN NN O
has NN NN O
history NN NN O
of NN NN O
shave NNP NNP B-TEST
biopsy NNP NNP I-TEST
in NN NN O
the NN NN O
past NN NN O
. NN NN O

The NN NN O
patient NN NN O
does NN NN O
state NN NN O
that NN NN O
he NN NN O
desires NN NN O
surgical NNP NNP B-TREATMENT
excision NNP NNP I-TREATMENT
at NN NN O
this NN NN O
time NN NN O
. NN NN O

PROCEDURE NN NN O
IN NN NN O
DETAIL NN NN O
: NN NN O
An NNP NNP B-TREATMENT
IV NNP NNP I-TREATMENT
was NN NN O
instituted NN NN O
by NN NN O
the NN NN O
Department NN NN O
of NN NN O
Anesthesia NNP NNP B-DRUG
in NN NN O
the NN NN O
preoperative NN NN O
holding NN NN O
area NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
transported NN NN O
from NN NN O
the NN NN O
operating NN NN O
room NN NN O
and NN NN O
placed NN NN O
on NN NN O
the NN NN O
operating NN NN O
room NN NN O
table NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
with NN NN O
the NN NN O
safety NN NN O
belt NN NN O
across NN NN O
his NN NN O
lap NN NN O
. NN NN O

Copious NN NN O
amount NN NN O
of NN NN O
Webril NN NN O
was NN NN O
placed NN NN O
around NN NN O
the NN NN O
left NN NN O
ankle NN NN O
followed NN NN O
by NN NN O
a NNP NNP B-TEST
blood NNP NNP I-TEST
pressure NNP NNP I-TEST
cuff NNP NNP I-TEST
. NN NN O

After NN NN O
adequate NNP NNP B-TREATMENT
sedation NNP NNP I-TREATMENT
by NN NN O
the NN NN O
Department NN NN O
of NN NN O
Anesthesia NNP NNP B-DRUG
, NN NN O
a NN NN O
total NN NN O
of NN NN O
6 NN NN O
cc NN NN O
mixed NN NN O
with NN NN O
1% NNP NNP B-DRUG
lidocaine NNP NNP I-DRUG
plain NN NN O
with NN NN O
0.5% NNP NNP B-DRUG
Marcaine NNP NNP I-DRUG
plain NN NN O
was NN NN O
injected NN NN O
in NN NN O
a NNP NNP B-PROBLEM
digital NNP NNP I-PROBLEM
block NNP NNP I-PROBLEM
fashion NN NN O
at NN NN O
the NN NN O
base NN NN O
of NN NN O
the NN NN O
left NN NN O
hallux NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
left NN NN O
second NN NN O
toe NN NN O
. NN NN O

The NN NN O
foot NN NN O
was NN NN O
then NN NN O
prepped NNP NNP B-TREATMENT
and NNP NNP I-TREATMENT
draped NNP NNP I-TREATMENT
in NN NN O
the NN NN O
usual NN NN O
sterile NN NN O
orthopedic NN NN O
fashion NN NN O
. NN NN O

The NN NN O
foot NN NN O
was NN NN O
elevated NNP NNP B-PROBLEM
from NN NN O
the NN NN O
operating NN NN O
table NN NN O
and NN NN O
exsanguinated NN NN O
with NN NN O
an NNP NNP B-TREATMENT
Esmarch NNP NNP I-TREATMENT
bandage NNP NNP I-TREATMENT
. NN NN O

Care NN NN O
was NN NN O
taken NN NN O
with NN NN O
the NNP NNP B-TREATMENT
exsanguination NNP NNP I-TREATMENT
to NN NN O
perform NN NN O
exsanguination NNP NNP B-TEST
below NN NN O
the NN NN O
level NN NN O
of NN NN O
the NN NN O
digits NN NN O
so NN NN O
as NN NN O
not NN NN O
to NN NN O
rupture NNP NNP B-PROBLEM
the NNP NNP I-PROBLEM
masses NNP NNP I-PROBLEM
. NN NN O

The NN NN O
foot NN NN O
was NN NN O
lowered NN NN O
to NN NN O
the NN NN O
operating NN NN O
table NN NN O
. NN NN O

The NN NN O
stockinet NN NN O
was NN NN O
reflected NN NN O
and NN NN O
the NN NN O
foot NN NN O
was NN NN O
cleansed NN NN O
with NN NN O
wet NNP NNP B-TREATMENT
and NNP NNP I-TREATMENT
dry NNP NNP I-TREATMENT
sponge NNP NNP I-TREATMENT
. NN NN O

A NNP NNP B-PROBLEM
distal NNP NNP I-PROBLEM
Syme's NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
planned NN NN O
over NN NN O
the NN NN O
distal NN NN O
aspect NN NN O
of NN NN O
the NN NN O
left NN NN O
hallux NN NN O
. NN NN O

The NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
performed NN NN O
with NN NN O
a NNP NNP B-TREATMENT
#10 NNP NNP I-TREATMENT
blade NNP NNP I-TREATMENT
and NN NN O
deepened NN NN O
with NN NN O
#15 NN NN O
down NN NN O
to NN NN O
the NN NN O
level NN NN O
of NN NN O
bone NN NN O
. NN NN O

The NNP NNP B-TREATMENT
dorsal NNP NNP I-TREATMENT
skin NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
was NN NN O
removed NN NN O
and NN NN O
dissected NN NN O
in NN NN O
toto NN NN O
off NN NN O
of NN NN O
the NN NN O
distal NN NN O
phalanx NN NN O
. NN NN O

There NN NN O
was NN NN O
noted NN NN O
to NN NN O
be NN NN O
in NN NN O
growth NNP NNP B-PROBLEM
of NN NN O
the NNP NNP B-PROBLEM
soft NNP NNP I-PROBLEM
tissue NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
into NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
dorsal NNP NNP I-PROBLEM
cortex NNP NNP I-PROBLEM
with NN NN O
erosion NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
dorsal NNP NNP I-PROBLEM
cortex NNP NNP I-PROBLEM
and NN NN O
exposure NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
cortical NNP NNP I-PROBLEM
bone NNP NNP I-PROBLEM
at NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
distal NNP NNP I-PROBLEM
phalanx NNP NNP I-PROBLEM
. NN NN O

The NN NN O
tissue NN NN O
was NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
where NN NN O
Dr NN NN O
. NN NN O
Green NNP NNP B-NAME
stated NN NN O
that NN NN O
a NNP NNP B-TEST
frozen NNP NNP I-TEST
sample NNP NNP I-TEST
would NN NN O
be NN NN O
of NN NN O
less NN NN O
use NN NN O
for NN NN O
examining NN NN O
for NN NN O
cancer NNP NNP B-PROBLEM
. NN NN O

Dr NN NN O
. NN NN O
Green NNP NNP B-NAME
did NN NN O
state NN NN O
that NN NN O
he NN NN O
felt NN NN O
that NN NN O
there NN NN O
was NN NN O
an NNP NNP B-TREATMENT
adequate NNP NNP I-TREATMENT
incomplete NNP NNP I-TREATMENT
excision NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
soft NNP NNP I-TREATMENT
tissue NNP NNP I-TREATMENT
for NN NN O
specimen NN NN O
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
a NN NN O
sagittal NN NN O
saw NN NN O
was NN NN O
then NN NN O
used NN NN O
to NN NN O
resect NNP NNP B-TREATMENT
all NN NN O
ends NN NN O
of NN NN O
bone NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
distal NNP NNP I-PROBLEM
phalanx NNP NNP I-PROBLEM
. NN NN O

The NN NN O
area NN NN O
was NN NN O
inspected NN NN O
for NN NN O
any NNP NNP B-PROBLEM
remaining NNP NNP I-PROBLEM
suspicious NNP NNP I-PROBLEM
tissues NNP NNP I-PROBLEM
. NN NN O

Any NNP NNP B-PROBLEM
suspicious NNP NNP I-PROBLEM
tissue NNP NNP I-PROBLEM
was NN NN O
removed NN NN O
. NN NN O

The NN NN O
area NN NN O
was NN NN O
then NN NN O
flushed NN NN O
with NN NN O
copious NNP NNP B-TREATMENT
amounts NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
sterile NNP NNP I-TREATMENT
saline NNP NNP I-TREATMENT
. NN NN O

The NN NN O
skin NN NN O
was NN NN O
then NN NN O
reapproximated NN NN O
with NN NN O
#4-0 NN NN O
nylon NNP NNP B-TREATMENT
with NN NN O
a NN NN O
combination NN NN O
of NN NN O
simple NNP NNP B-TREATMENT
and NNP NNP I-TREATMENT
vertical NNP NNP I-TREATMENT
mattress NNP NNP I-TREATMENT
sutures NNP NNP I-TREATMENT
. NN NN O

Attention NN NN O
was NN NN O
then NN NN O
directed NN NN O
to NN NN O
the NN NN O
left NN NN O
second NN NN O
toe NN NN O
. NN NN O

There NN NN O
was NN NN O
noted NN NN O
to NN NN O
be NN NN O
a NNP NNP B-PROBLEM
dorsolateral NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
over NN NN O
the NN NN O
dorsal NN NN O
distal NN NN O
aspect NN NN O
of NN NN O
the NN NN O
left NN NN O
second NN NN O
toe NN NN O
. NN NN O

A NNP NNP B-PROBLEM
linear NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
just NN NN O
medial NN NN O
to NN NN O
the NNP NNP B-PROBLEM
tissue NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
was NN NN O
then NN NN O
dissected NN NN O
from NN NN O
the NN NN O
overlying NN NN O
skin NN NN O
and NN NN O
off NN NN O
of NN NN O
the NN NN O
underlying NN NN O
capsule NN NN O
. NN NN O

This NNP NNP B-PROBLEM
tissue NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
was NN NN O
hard NN NN O
, NN NN O
round NN NN O
, NN NN O
and NN NN O
pearly-gray NN NN O
in NN NN O
appearance NN NN O
. NN NN O

It NN NN O
does NN NN O
not NN NN O
invade NN NN O
into NN NN O
any NN NN O
other NN NN O
surrounding NN NN O
tissues NN NN O
. NN NN O

The NN NN O
area NN NN O
was NN NN O
then NN NN O
flushed NN NN O
with NN NN O
copious NN NN O
amounts NN NN O
of NN NN O
sterile NNP NNP B-TREATMENT
saline NNP NNP I-TREATMENT
and NN NN O
the NN NN O
skin NN NN O
was NN NN O
closed NN NN O
with NN NN O
#4-0 NNP NNP B-TREATMENT
nylon NNP NNP I-TREATMENT
. NN NN O

Dressings NNP NNP B-TREATMENT
consisted NN NN O
of NN NN O
Owen NN NN O
silk NN NN O
soaked NN NN O
in NN NN O
Betadine NNP NNP B-DRUG
, NN NN O
4x4s NN NN O
, NN NN O
Kling NNP NNP B-TREATMENT
, NN NN O
Kerlix NNP NNP B-TREATMENT
, NN NN O
and NN NN O
an NNP NNP B-TREATMENT
Ace NNP NNP I-TREATMENT
wrap NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-TREATMENT
pneumatic NNP NNP I-TREATMENT
ankle NNP NNP I-TREATMENT
tourniquet NNP NNP I-TREATMENT
was NN NN O
released NN NN O
and NN NN O
immediate NNP NNP B-TREATMENT
hyperemic NNP NNP I-TREATMENT
flush NNP NNP I-TREATMENT
was NN NN O
noted NN NN O
to NN NN O
all NN NN O
five NN NN O
digits NN NN O
of NN NN O
the NN NN O
left NN NN O
foot NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
the NNP NNP B-TREATMENT
above NNP NNP I-TREATMENT
procedure NNP NNP I-TREATMENT
and NN NN O
anesthesia NNP NNP B-DRUG
well NN NN O
without NN NN O
complications NNP NNP B-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
transported NN NN O
to NN NN O
PACU NN NN O
with NN NN O
vital NNP NNP B-TEST
signs NNP NNP I-TEST
stable NN NN O
and NN NN O
vascular NN NN O
status NN NN O
intact NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
given NN NN O
postoperative NNP NNP B-TREATMENT
pain NNP NNP I-TREATMENT
prescription NNP NNP I-TREATMENT
for NN NN O
Vicodin NNP NNP B-DRUG
and NN NN O
instructed NN NN O
to NN NN O
follow NN NN O
up NN NN O
with NN NN O
Dr NN NN O
. NN NN O
Bonnani NNP NNP B-NAME
in NN NN O
his NN NN O
office NN NN O
as NN NN O
directed NN NN O
. NN NN O

The NN NN O
patient NN NN O
will NN NN O
be NN NN O
contacted NN NN O
immediately NN NN O
pending NN NN O
the NN NN O
results NN NN O
of NN NN O
pathology NN NN O
. NN NN O

Cultures NNP NNP B-TEST
obtained NN NN O
in NN NN O
the NN NN O
case NN NN O
were NN NN O
aerobic NNP NNP B-TEST
and NNP NNP I-TEST
anaerobic NNP NNP I-TEST
gram NNP NNP I-TEST
stain NNP NNP I-TEST
, NN NN O
Silver NNP NNP B-TEST
stain NNP NNP I-TEST
, NN NN O
and NN NN O
a NNP NNP B-TEST
CBC NNP NNP I-TEST
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
distal NN NN O
phalanx NN NN O
, NN NN O
mass NNP NNP B-PROBLEM
, NN NN O
tumor NNP NNP B-PROBLEM
. NN NN O

, NN NN O
hallux NNP NNP B-TREATMENT
bone NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
phalanx NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
symes NNP NNP I-TREATMENT
amputation NNP NNP I-TREATMENT
, NN NN O
excisional NNP NNP B-TEST
biopsy NNP NNP I-TEST
, NN NN O
distal NNP NNP B-TEST
, NN NN O
amputation NNP NNP B-TREATMENT
, NN NN O
invasion NNP NNP B-TREATMENT
, NN NN O
toe NNP NNP B-TREATMENT
, NN NN O
symes NNP NNP B-TREATMENT
, NN NN O
incision NNP NNP B-TREATMENT
, NN NN O
flushed NN NN O
, NN NN O
excision NNP NNP B-TREATMENT
, NN NN O
tissue NNP NNP B-TREATMENT
, NNP NNP I-TREATMENT
hallux NNP NNP I-TREATMENT
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
BCCa NNP NNP B-TREATMENT
Excision NNP NNP I-TREATMENT
- NNP NNP I-TREATMENT
Cheek NNP NNP I-TREATMENT
Description NNP NNP I-TREATMENT
: NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

Closure NNP NNP B-PROBLEM
complex NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
open NNP NNP I-PROBLEM
wound NNP NNP I-PROBLEM
. NN NN O

Bilateral NN NN O
capsulectomies NN NN O
. NN NN O

Bilateral NNP NNP B-TREATMENT
explantation NNP NNP I-TREATMENT
and NN NN O
removal NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
ruptured NNP NNP I-TREATMENT
silicone NNP NNP I-TREATMENT
gel NNP NNP I-TREATMENT
implants NNP NNP I-TREATMENT
( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSES NN NN O

1 NN NN O
. NN NN O
Basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NN NN O
cheek NN NN O
. NN NN O

2 NN NN O
. NN NN O
Basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
left NN NN O
cheek NN NN O
. NN NN O

3 NN NN O
. NN NN O
Bilateral NNP NNP B-TREATMENT
ruptured NNP NNP I-TREATMENT
silicone NNP NNP I-TREATMENT
gel NNP NNP I-TREATMENT
implants NNP NNP I-TREATMENT
. NN NN O

4 NN NN O
. NN NN O
Bilateral NNP NNP B-PROBLEM
Baker NNP NNP I-PROBLEM
grade NNP NNP I-PROBLEM
IV NNP NNP I-PROBLEM
capsular NNP NNP I-PROBLEM
contracture NNP NNP I-PROBLEM
. NN NN O

5 NN NN O
. NN NN O
Breast NNP NNP B-PROBLEM
ptosis NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSES NN NN O

1 NN NN O
. NN NN O
Basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NN NN O
cheek NN NN O
. NN NN O

2 NN NN O
. NN NN O
Basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
left NN NN O
cheek NN NN O
. NN NN O

3 NN NN O
. NN NN O
Bilateral NNP NNP B-TREATMENT
ruptured NNP NNP I-TREATMENT
silicone NNP NNP I-TREATMENT
gel NNP NNP I-TREATMENT
implants NNP NNP I-TREATMENT
. NN NN O

4 NN NN O
. NN NN O
Bilateral NNP NNP B-PROBLEM
Baker NNP NNP I-PROBLEM
grade NNP NNP I-PROBLEM
IV NNP NNP I-PROBLEM
capsular NNP NNP I-PROBLEM
contracture NNP NNP I-PROBLEM
. NN NN O

5 NN NN O
. NN NN O
Breast NNP NNP B-PROBLEM
ptosis NNP NNP I-PROBLEM
. NN NN O

PROCEDURE NN NN O

1 NN NN O
. NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NN NN O
cheek NN NN O
, NN NN O
2.7 NN NN O
cm NN NN O
x NN NN O
1.5 NN NN O
cm NN NN O
. NN NN O

2 NN NN O
. NN NN O
Excision NNP NNP B-TREATMENT
of NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
left NN NN O
cheek NN NN O
, NN NN O
2.3 NN NN O
x NN NN O
1.5 NN NN O
cm NN NN O
. NN NN O

3 NN NN O
. NN NN O
Closure NNP NNP B-PROBLEM
complex NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
open NNP NNP I-PROBLEM
wound NNP NNP I-PROBLEM
utilizing NN NN O
local NNP NNP B-TREATMENT
tissue NNP NNP I-TREATMENT
advancement NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
, NN NN O
right NN NN O
cheek NN NN O
. NN NN O

4 NN NN O
. NN NN O
Closure NNP NNP B-PROBLEM
complex NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
open NNP NNP I-PROBLEM
wound NNP NNP I-PROBLEM
, NN NN O
left NN NN O
cheek NN NN O
utilizing NN NN O
local NNP NNP B-TREATMENT
tissue NNP NNP I-TREATMENT
advancement NNP NNP I-TREATMENT
flap NNP NNP I-TREATMENT
. NN NN O

5 NN NN O
. NN NN O
Bilateral NNP NNP B-TREATMENT
explantation NNP NNP I-TREATMENT
and NN NN O
removal NNP NNP B-TREATMENT
of NN NN O
ruptured NNP NNP B-PROBLEM
silicone NNP NNP I-PROBLEM
gel NNP NNP I-PROBLEM
implants NNP NNP I-PROBLEM
. NN NN O

6 NN NN O
. NN NN O
Bilateral NNP NNP B-TEST
capsulectomies NNP NNP I-TEST
. NN NN O

7 NN NN O
. NN NN O
Replacement NNP NNP B-TREATMENT
with NN NN O
bilateral NNP NNP B-TREATMENT
silicone NNP NNP I-TREATMENT
gel NNP NNP I-TREATMENT
implants NNP NNP I-TREATMENT
, NN NN O
325 NN NN O
cc NN NN O
. NN NN O

INDICATIONS NN NN O
FOR NN NN O
PROCEDURES NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
61-year-old NN NN O
woman NN NN O
who NN NN O
presents NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
biopsy-proven NNP NNP B-PROBLEM
basal NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NN NN O
and NN NN O
left NN NN O
cheek NN NN O
. NN NN O

She NN NN O
had NN NN O
no NN NN O
prior NN NN O
history NN NN O
of NN NN O
skin NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

She NN NN O
is NN NN O
status NN NN O
post NN NN O
bilateral NNP NNP B-TREATMENT
cosmetic NNP NNP I-TREATMENT
breast NNP NNP I-TREATMENT
augmentation NNP NNP I-TREATMENT
many NN NN O
years NN NN O
ago NN NN O
and NN NN O
the NN NN O
records NN NN O
are NN NN O
not NN NN O
available NN NN O
for NN NN O
this NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
. NN NN O

She NN NN O
has NN NN O
noted NN NN O
progressive NNP NNP B-PROBLEM
hardening NNP NNP I-PROBLEM
and NN NN O
distortion NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
implant NNP NNP I-PROBLEM
. NN NN O

She NN NN O
desires NN NN O
to NN NN O
have NN NN O
the NNP NNP B-TREATMENT
implants NNP NNP I-TREATMENT
removed NN NN O
, NN NN O
capsulectomy NNP NNP B-TREATMENT
and NN NN O
replacement NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
implants NNP NNP I-TREATMENT
. NN NN O

She NN NN O
would NN NN O
like NN NN O
to NN NN O
go NN NN O
slightly NN NN O
smaller NN NN O
than NN NN O
her NN NN O
current NN NN O
size NN NN O
as NN NN O
she NN NN O
has NN NN O
ptosis NNP NNP B-PROBLEM
going NN NN O
with NN NN O
a NNP NNP B-TREATMENT
smaller NNP NNP I-TREATMENT
implant NNP NNP I-TREATMENT
combined NN NN O
with NN NN O
capsulectomy NNP NNP B-TREATMENT
will NN NN O
result NN NN O
in NN NN O
worsening NN NN O
of NN NN O
her NNP NNP B-PROBLEM
ptosis NNP NNP I-PROBLEM
. NN NN O

She NN NN O
may NN NN O
require NN NN O
a NNP NNP B-TREATMENT
lift NNP NNP I-TREATMENT
. NN NN O

She NN NN O
is NN NN O
not NN NN O
consenting NN NN O
to NN NN O
lift NN NN O
due NN NN O
to NN NN O
the NNP NNP B-PROBLEM
surgical NNP NNP I-PROBLEM
scars NNP NNP I-PROBLEM
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
Significant NN NN O
for NN NN O
deep NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
and NN NN O
acid NNP NNP B-PROBLEM
reflux NNP NNP I-PROBLEM
. NN NN O

PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O
Significant NN NN O
for NN NN O
appendectomy NNP NNP B-TREATMENT
, NN NN O
colonoscopy NNP NNP B-TEST
and NN NN O
BAM NNP NNP B-TREATMENT
. NN NN O

MEDICATIONS NN NN O

1 NN NN O
. NN NN O
Coumadin NNP NNP B-DRUG
. NN NN O

She NN NN O
stopped NN NN O
her NN NN O
Coumadin NNP NNP B-DRUG
five NN NN O
days NN NN O
prior NN NN O
to NN NN O
the NNP NNP B-TREATMENT
procedures NNP NNP I-TREATMENT
. NN NN O

2 NN NN O
. NN NN O
Lipitor NNP NNP B-DRUG

3 NN NN O
. NN NN O
Effexor NNP NNP B-DRUG
. NN NN O

4 NN NN O
. NN NN O
Klonopin NNP NNP B-DRUG
. NN NN O

ALLERGIES NN NN O
None NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
Negative NN NN O
for NN NN O
dyspnea NNP NNP B-PROBLEM
on NN NN O
exertion NN NN O
, NN NN O
palpitations NNP NNP B-PROBLEM
, NN NN O
chest NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
and NN NN O
phlebitis NNP NNP B-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
Height NNP NNP B-TEST
5'8 NN NN O
", NN NN O
weight NNP NNP B-TEST
155 NN NN O
pounds NN NN O
. NN NN O

FACE NN NN O
: NN NN O
Examination NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
face NNP NNP I-TEST
demonstrates NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
right NN NN O
and NN NN O
left NN NN O
cheek NN NN O
. NN NN O

No NN NN O
lesions NNP NNP B-PROBLEM
are NN NN O
noted NN NN O
in NN NN O
the NN NN O
regional NN NN O
lymph NN NN O
node NN NN O
base NN NN O
and NN NN O
no NN NN O
mass NNP NNP B-PROBLEM
is NN NN O
appreciated NN NN O
. NN NN O

BREAST NN NN O
: NN NN O
Examination NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
breast NNP NNP I-TEST
demonstrates NN NN O
bilateral NNP NNP B-PROBLEM
grade NNP NNP I-PROBLEM
IV NNP NNP I-PROBLEM
capsular NNP NNP I-PROBLEM
contracture NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
asymmetry NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
distortion NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
. NN NN O

No NN NN O
masses NNP NNP B-PROBLEM
are NN NN O
appreciated NN NN O
in NN NN O
the NN NN O
breast NN NN O
or NN NN O
the NN NN O
axilla NN NN O
. NN NN O

The NNP NNP B-TREATMENT
implants NNP NNP I-TREATMENT
appear NN NN O
to NN NN O
be NN NN O
subglandular NN NN O
. NN NN O

CHEST NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
and NN NN O
percussion NNP NNP B-TEST
. NN NN O

CARDIOVASCULAR NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
Show NN NN O
full NN NN O
range NN NN O
of NN NN O
motion NN NN O
. NN NN O

No NN NN O
clubbing NNP NNP B-PROBLEM
, NN NN O
cyanosis NNP NNP B-PROBLEM
or NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

SKIN NN NN O
: NN NN O
Significant NNP NNP B-PROBLEM
environmental NNP NNP I-PROBLEM
actinic NNP NNP I-PROBLEM
skin NNP NNP I-PROBLEM
damage NNP NNP I-PROBLEM
. NN NN O

I NN NN O
recommended NN NN O
excision NNP NNP B-TREATMENT
of NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
cancers NNP NNP I-PROBLEM
with NN NN O
frozen NNP NNP B-TREATMENT
section NNP NNP I-TREATMENT
control NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
margin NNP NNP I-TREATMENT
, NN NN O
closure NNP NNP B-TREATMENT
will NN NN O
require NN NN O
local NNP NNP B-TREATMENT
tissue NNP NNP I-TREATMENT
flaps NNP NNP I-TREATMENT
. NN NN O

I NN NN O
recommended NN NN O
exchange NN NN O
of NN NN O
the NNP NNP B-TREATMENT
implants NNP NNP I-TREATMENT
with NN NN O
reaugmentation NNP NNP B-TREATMENT
. NN NN O

No NN NN O
final NN NN O
size NN NN O
is NN NN O
guaranteed NN NN O
or NN NN O
implied NN NN O
. NN NN O

We NN NN O
will NN NN O
decrease NN NN O
the NN NN O
size NN NN O
of NN NN O
the NNP NNP B-TREATMENT
implants NNP NNP I-TREATMENT
based NN NN O
on NN NN O
the NN NN O
intraoperative NN NN O
findings NN NN O
as NN NN O
the NN NN O
size NN NN O
is NN NN O
not NN NN O
known NN NN O
. NN NN O

Several NN NN O
options NN NN O
are NN NN O
available NN NN O
. NN NN O

Sizer NNP NNP B-TREATMENT
implants NNP NNP I-TREATMENT
will NN NN O
be NN NN O
placed NN NN O
to NN NN O
best NN NN O
estimate NN NN O
postoperative NN NN O
size NN NN O
. NN NN O

Ptosis NNP NNP B-PROBLEM
will NN NN O
be NN NN O
worse NN NN O
following NN NN O
capsulectomy NNP NNP B-TREATMENT
and NN NN O
going NN NN O
with NN NN O
a NNP NNP B-TREATMENT
smaller NNP NNP I-TREATMENT
implant NNP NNP I-TREATMENT
. NN NN O

She NN NN O
may NN NN O
require NN NN O
a NNP NNP B-TREATMENT
lift NNP NNP I-TREATMENT
in NN NN O
the NN NN O
future NN NN O
. NN NN O

We NN NN O
have NN NN O
obtained NN NN O
preoperative NN NN O
clearance NN NN O
from NN NN O
the NN NN O
patient's NN NN O
cardiologist NN NN O
, NN NN O
Dr NN NN O
. NN NN O
K NNP NNP B-NAME
. NN NN O

The NN NN O
patient NN NN O
has NN NN O
been NN NN O
taken NN NN O
off NN NN O
Coumadin NNP NNP B-DRUG
for NN NN O
five NN NN O
days NN NN O
and NN NN O
will NN NN O
be NN NN O
placed NN NN O
back NN NN O
on NN NN O
Coumadin NNP NNP B-DRUG
the NN NN O
day NN NN O
after NN NN O
the NNP NNP B-TREATMENT
surgery NNP NNP I-TREATMENT
. NN NN O

The NN NN O
risk NN NN O
of NN NN O
deep NNP NNP B-PROBLEM
venous NNP NNP I-PROBLEM
thrombosis NNP NNP I-PROBLEM
is NN NN O
discussed NN NN O
. NN NN O

Other NN NN O
risk NN NN O
including NN NN O
bleeding NNP NNP B-PROBLEM
, NN NN O
infection NNP NNP B-PROBLEM
, NN NN O
allergic NNP NNP B-PROBLEM
reaction NNP NNP I-PROBLEM
, NN NN O
pain NNP NNP B-PROBLEM
, NN NN O
scarring NNP NNP B-PROBLEM
, NN NN O
hypertrophic NNP NNP B-PROBLEM
scarring NNP NNP I-PROBLEM
and NN NN O
poor NNP NNP B-PROBLEM
cosmetic NNP NNP I-PROBLEM
resolve NN NN O
, NN NN O
worsening NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
ptosis NNP NNP I-PROBLEM
, NN NN O
exposure NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
extrusion NNP NNP I-PROBLEM
, NN NN O
the NNP NNP B-PROBLEM
rupture NNP NNP I-PROBLEM
of NN NN O
the NNP NNP B-TREATMENT
implants NNP NNP I-TREATMENT
, NN NN O
numbness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
nipple-areolar NNP NNP I-PROBLEM
complex NNP NNP I-PROBLEM
, NN NN O
hematoma NNP NNP B-PROBLEM
, NN NN O
need NN NN O
for NN NN O
additional NNP NNP B-TREATMENT
surgery NNP NNP I-TREATMENT
, NN NN O
recurrent NNP NNP B-PROBLEM
capsular NNP NNP I-PROBLEM
contracture NNP NNP I-PROBLEM
and NN NN O
recurrence NNP NNP B-PROBLEM
of NN NN O
the NNP NNP B-PROBLEM
skin NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
was NN NN O
all NN NN O
discussed NN NN O
, NN NN O
which NN NN O
she NN NN O
understands NN NN O
and NN NN O
informed NN NN O
consent NN NN O
is NN NN O
obtained NN NN O
. NN NN O

PROCEDURE NN NN O
IN NN NN O
DETAIL NN NN O
After NN NN O
appropriate NN NN O
informed NN NN O
consent NN NN O
was NN NN O
obtained NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
placed NN NN O
in NN NN O
the NN NN O
preoperative NN NN O
holding NN NN O
area NN NN O
with NN NN O
**** NN NN O
input NN NN O
. NN NN O

She NN NN O
was NN NN O
then NN NN O
taken NN NN O
to NN NN O
the NN NN O
major NN NN O
operating NN NN O
room NN NN O
with NN NN O
ABCD NN NN O
Surgery NN NN O
Center NN NN O
, NN NN O
placed NN NN O
in NN NN O
a NN NN O
supine NN NN O
position NN NN O
. NN NN O

Intravenous NNP NNP B-DRUG
antibiotics NNP NNP I-DRUG
were NN NN O
given NN NN O
. NN NN O

TED NNP NNP B-TREATMENT
hose NNP NNP I-TREATMENT
and NN NN O
SCDs NNP NNP B-TREATMENT
were NN NN O
placed NN NN O
. NN NN O

After NN NN O
the NN NN O
induction NN NN O
of NN NN O
adequate NNP NNP B-TREATMENT
general NNP NNP I-TREATMENT
endotracheal NNP NNP I-TREATMENT
anesthesia NNP NNP I-TREATMENT
, NN NN O
she NN NN O
was NN NN O
prepped NNP NNP B-TREATMENT
and NNP NNP I-TREATMENT
draped NNP NNP I-TREATMENT
in NN NN O
the NN NN O
usual NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

Sites NN NN O
for NN NN O
excision NNP NNP B-TREATMENT
and NN NN O
skin NNP NNP B-PROBLEM
cancers NNP NNP I-PROBLEM
were NN NN O
carefully NN NN O
marked NN NN O
with NN NN O
5 NN NN O
mm NN NN O
margin NN NN O
. NN NN O

These NN NN O
were NN NN O
injected NN NN O
with NN NN O
1% NNP NNP B-DRUG
lidocaine NNP NNP I-DRUG
with NN NN O
epinephrine NNP NNP B-DRUG
. NN NN O

After NN NN O
allowing NN NN O
adequate NN NN O
time NN NN O
for NN NN O
basal NNP NNP B-TREATMENT
constriction NNP NNP I-TREATMENT
hemostasis NNP NNP I-TREATMENT
, NN NN O
excision NNP NNP B-TREATMENT
was NN NN O
performed NN NN O
, NN NN O
full NN NN O
thickness NN NN O
of NN NN O
the NN NN O
skin NN NN O
. NN NN O

They NN NN O
were NN NN O
tagged NN NN O
at NN NN O
the NN NN O
12 NN NN O
o'clock NN NN O
position NN NN O
and NN NN O
sent NN NN O
for NN NN O
frozen NNP NNP B-TEST
section NNP NNP I-TEST
. NN NN O

Hemostasis NN NN O
was NN NN O
achieved NN NN O
using NN NN O
electrocautery NNP NNP B-TREATMENT
. NN NN O

Once NN NN O
margins NN NN O
were NN NN O
determined NN NN O
to NN NN O
be NN NN O
free NN NN O
of NN NN O
involvement NNP NNP B-PROBLEM
, NN NN O
local NNP NNP B-TREATMENT
tissue NNP NNP I-TREATMENT
flaps NNP NNP I-TREATMENT
were NN NN O
designed NN NN O
for NN NN O
advancement NN NN O
. NN NN O

Undermining NNP NNP B-TREATMENT
was NN NN O
performed NN NN O
. NN NN O

Hemostasis NN NN O
was NN NN O
achieved NN NN O
using NN NN O
electrocautery NNP NNP B-TREATMENT
. NN NN O

Closure NNP NNP B-TREATMENT
was NN NN O
performed NN NN O
under NN NN O
moderate NNP NNP B-TREATMENT
tension NNP NNP I-TREATMENT
with NN NN O
interrupted NN NN O
5-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
. NN NN O

Skin NN NN O
was NN NN O
closed NN NN O
under NN NN O
loop NNP NNP B-TREATMENT
magnification NNP NNP I-TREATMENT
paying NN NN O
meticulous NN NN O
attention NN NN O
and NN NN O
cosmetic NN NN O
details NN NN O
with NN NN O
6-0 NNP NNP B-TREATMENT
Prolene NNP NNP I-TREATMENT
. NN NN O

Attention NN NN O
was NN NN O
then NN NN O
turned NN NN O
to NN NN O
the NN NN O
breast NN NN O
, NN NN O
clothes NN NN O
were NN NN O
changed NN NN O
, NN NN O
gloves NNP NNP B-TREATMENT
were NN NN O
changed NN NN O
, NN NN O
incision NNP NNP B-TREATMENT
was NN NN O
planned NN NN O
and NN NN O
the NNP NNP B-PROBLEM
previous NNP NNP I-PROBLEM
inframammary NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
beginning NN NN O
on NN NN O
the NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
. NN NN O

Dissection NNP NNP B-TREATMENT
was NN NN O
carried NN NN O
down NN NN O
to NN NN O
the NN NN O
capsule NN NN O
. NN NN O

It NN NN O
was NN NN O
extremely NNP NNP B-PROBLEM
calcified NNP NNP I-PROBLEM
. NN NN O

Dissection NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
anterior NNP NNP I-TREATMENT
surface NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
capsule NNP NNP I-TREATMENT
was NN NN O
performed NN NN O
. NN NN O

The NNP NNP B-TREATMENT
implant NNP NNP I-TREATMENT
was NN NN O
subglandular NN NN O
, NN NN O
the NN NN O
capsule NN NN O
was NN NN O
entered NN NN O
, NN NN O
implant NNP NNP B-TREATMENT
was NN NN O
noted NN NN O
to NN NN O
be NN NN O
grossly NN NN O
intact NN NN O
; NN NN O

however NN NN O
, NN NN O
there NN NN O
was NN NN O
free NNP NNP B-TREATMENT
silicone NNP NNP I-TREATMENT
. NN NN O

Implant NNP NNP B-TREATMENT
was NN NN O
removed NN NN O
and NN NN O
noted NN NN O
to NN NN O
be NN NN O
ruptured NNP NNP B-PROBLEM
. NN NN O

No NN NN O
marking NN NN O
as NN NN O
to NN NN O
the NN NN O
size NN NN O
of NN NN O
the NNP NNP B-TREATMENT
implant NNP NNP I-TREATMENT
was NN NN O
found NN NN O
. NN NN O

Capsulectomy NNP NNP B-TREATMENT
was NN NN O
performed NN NN O
leaving NN NN O
a NN NN O
small NN NN O
portion NN NN O
in NN NN O
the NN NN O
axilla NN NN O
in NN NN O
the NN NN O
inframammary NN NN O
fold NN NN O
. NN NN O

Pocket NN NN O
was NN NN O
modified NN NN O
to NN NN O
medialize NN NN O
the NNP NNP B-TREATMENT
implant NNP NNP I-TREATMENT
by NN NN O
placing NN NN O
2-0 NNP NNP B-TREATMENT
Prolene NNP NNP I-TREATMENT
laterally NN NN O
in NN NN O
mattress NNP NNP B-TREATMENT
sutures NNP NNP I-TREATMENT
to NN NN O
restrict NN NN O
the NNP NNP B-PROBLEM
pocket NNP NNP I-PROBLEM
. NN NN O

In NN NN O
identical NN NN O
fashion NN NN O
, NN NN O
capsulectomy NNP NNP B-TREATMENT
was NN NN O
performed NN NN O
on NN NN O
the NN NN O
left NN NN O
. NN NN O

Implant NNP NNP B-TREATMENT
was NN NN O
noted NN NN O
to NN NN O
be NN NN O
grossly NNP NNP B-PROBLEM
ruptured NNP NNP I-PROBLEM
. NN NN O

No NN NN O
marking NN NN O
was NN NN O
found NN NN O
for NN NN O
the NN NN O
size NN NN O
of NN NN O
the NNP NNP B-TREATMENT
implant NNP NNP I-TREATMENT
. NN NN O

The NN NN O
entire NN NN O
content NN NN O
was NN NN O
weighed NN NN O
and NN NN O
found NN NN O
to NN NN O
be NN NN O
350 NN NN O
grams NN NN O
. NN NN O

Right NN NN O
side NN NN O
was NN NN O
weighed NN NN O
and NN NN O
noted NN NN O
to NN NN O
be NN NN O
338 NN NN O
grams NN NN O
, NN NN O
although NN NN O
some NNP NNP B-TREATMENT
silicone NNP NNP I-TREATMENT
was NN NN O
lost NN NN O
in NN NN O
the NN NN O
transfer NN NN O
and NN NN O
most NN NN O
likely NN NN O
was NN NN O
identical NN NN O
350 NN NN O
grams NN NN O
. NN NN O

The NNP NNP B-TREATMENT
implants NNP NNP I-TREATMENT
appeared NN NN O
to NN NN O
be NN NN O
double NNP NNP B-TREATMENT
lumen NNP NNP I-TREATMENT
with NN NN O
the NNP NNP B-TREATMENT
saline NNP NNP I-TREATMENT
portion NN NN O
deflated NN NN O
. NN NN O

Completion NN NN O
of NN NN O
the NNP NNP B-TREATMENT
capsulectomy NNP NNP I-TREATMENT
was NN NN O
performed NN NN O
on NN NN O
the NN NN O
left NN NN O
. NN NN O

The NNP NNP B-PROBLEM
pocket NNP NNP I-PROBLEM
was NN NN O
again NN NN O
fashioned NN NN O
to NN NN O
improve NN NN O
symmetry NN NN O
with NN NN O
the NN NN O
right NN NN O
with NN NN O
Prolene NNP NNP B-TREATMENT
. NN NN O

Pockets NN NN O
were NN NN O
thoroughly NN NN O
irrigated NN NN O
. NN NN O

Hemostasis NN NN O
was NN NN O
achieved NN NN O
using NN NN O
electrocautery NNP NNP B-TREATMENT
, NN NN O
checked NN NN O
for NN NN O
symmetry NN NN O
, NN NN O
which NN NN O
is NN NN O
determined NN NN O
to NN NN O
be NN NN O
excellent NN NN O
. NN NN O

Several NN NN O
liters NN NN O
of NN NN O
normal NNP NNP B-DRUG
saline NNP NNP I-DRUG
were NN NN O
utilized NN NN O
to NN NN O
irrigate NN NN O
the NN NN O
pocket NN NN O
. NN NN O

Hemostasis NN NN O
was NN NN O
determined NN NN O
to NN NN O
be NN NN O
excellent NN NN O
. NN NN O

Drains NNP NNP B-TREATMENT
were NN NN O
placed NN NN O
. NN NN O

2-0 NN NN O
Vicryl NNP NNP B-TREATMENT
sutures NNP NNP I-TREATMENT
were NN NN O
preplaced NN NN O
. NN NN O

Pockets NN NN O
were NN NN O
checked NN NN O
for NN NN O
hemostasis NNP NNP B-TREATMENT
, NN NN O
irrigated NN NN O
with NN NN O
normal NNP NNP B-DRUG
saline NNP NNP I-DRUG
, NN NN O
sizing NNP NNP B-TREATMENT
was NN NN O
performed NN NN O
with NN NN O
placement NNP NNP B-TREATMENT
of NN NN O
275 NN NN O
cc NN NN O
implants NN NN O
. NN NN O

She NN NN O
was NN NN O
placed NN NN O
in NN NN O
a NN NN O
sitting NN NN O
position NN NN O
. NN NN O

This NNP NNP B-PROBLEM
significantly NNP NNP I-PROBLEM
worsened NNP NNP I-PROBLEM
ptosis NNP NNP I-PROBLEM
and NN NN O
for NN NN O
this NN NN O
reason NN NN O
, NN NN O
325 NN NN O
cc NN NN O
implants NNP NNP B-TREATMENT
were NN NN O
chosen NN NN O
. NN NN O

She NN NN O
is NN NN O
placed NN NN O
back NN NN O
in NN NN O
a NN NN O
supine NN NN O
position NN NN O
. NN NN O

Pockets NN NN O
were NN NN O
irrigated NN NN O
with NN NN O
antibiotic NNP NNP B-DRUG
solution NNP NNP I-DRUG
, NN NN O
2-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
sutures NNP NNP I-TREATMENT
were NN NN O
preplaced NN NN O
and NN NN O
gloves NNP NNP B-TREATMENT
were NN NN O
changed NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
reprepped NN NN O
with NN NN O
Betadine NNP NNP B-DRUG
, NN NN O
towels NNP NNP B-TREATMENT
were NN NN O
changed NN NN O
. NN NN O

These NN NN O
were NN NN O
soaked NN NN O
in NN NN O
antibiotic NNP NNP B-DRUG
solution NNP NNP I-DRUG
. NN NN O

Gloves NNP NNP B-TREATMENT
were NN NN O
changed NN NN O
, NN NN O
gowns NN NN O
were NN NN O
changed NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
reprepped NN NN O
, NN NN O
towels NNP NNP B-TREATMENT
were NN NN O
changed NN NN O
and NN NN O
implants NNP NNP B-TREATMENT
were NN NN O
placed NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
placed NN NN O
in NN NN O
a NN NN O
sitting NN NN O
position NN NN O
. NN NN O

Symmetry NN NN O
was NN NN O
excellent NN NN O
. NN NN O

There NN NN O
was NN NN O
noted NN NN O
to NN NN O
be NN NN O
a NNP NNP B-PROBLEM
decrease NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
volume NNP NNP I-PROBLEM
of NN NN O
approximately NN NN O
40 NN NN O
cc NN NN O
from NN NN O
the NNP NNP B-TREATMENT
capsulectomy NNP NNP I-TREATMENT
as NN NN O
well NN NN O
as NN NN O
the NNP NNP B-TREATMENT
additional NNP NNP I-TREATMENT
reduction NNP NNP I-TREATMENT
of NN NN O
25 NN NN O
cc NN NN O
. NN NN O

Ptosis NNP NNP B-PROBLEM
was NN NN O
slightly NN NN O
worse NN NN O
; NN NN O

however NN NN O
, NN NN O
excellent NN NN O
shape NN NN O
of NN NN O
the NN NN O
breast NN NN O
. NN NN O

She NN NN O
was NN NN O
placed NN NN O
back NN NN O
in NN NN O
a NN NN O
supine NN NN O
position NN NN O
, NN NN O
preplaced NNP NNP B-TREATMENT
2-0 NNP NNP I-TREATMENT
Vicryl NNP NNP I-TREATMENT
sutures NNP NNP I-TREATMENT
were NN NN O
tied NN NN O
; NN NN O

a NN NN O
second NN NN O
layer NN NN O
subcutaneous NN NN O
of NN NN O
3-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
was NN NN O
placed NN NN O
followed NN NN O
by NN NN O
a NN NN O
third NN NN O
of NN NN O
4-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
. NN NN O

The NN NN O
skin NN NN O
was NN NN O
closed NN NN O
with NN NN O
a NNP NNP B-TREATMENT
running NNP NNP I-TREATMENT
4-0 NNP NNP I-TREATMENT
Prolene NNP NNP I-TREATMENT
. NN NN O

Drains NNP NNP B-TREATMENT
were NN NN O
secured NN NN O
. NN NN O

All NNP NNP B-TREATMENT
sponge NNP NNP I-TREATMENT
and NN NN O
needle NNP NNP B-TEST
counts NNP NNP I-TEST
were NN NN O
correct NN NN O
. NN NN O

Dressing NNP NNP B-TREATMENT
was NN NN O
applied NN NN O
. NN NN O

COMPLICATIONS NN NN O
None NN NN O
. NN NN O

DISPOSITION NN NN O
To NN NN O
recovery NN NN O
room NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
basal NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
baker NNP NNP B-TREATMENT
, NN NN O
breast NNP NNP B-PROBLEM
ptosis NNP NNP I-PROBLEM
, NN NN O
closure NNP NNP B-TREATMENT
complex NNP NNP I-TREATMENT
, NN NN O
excision NNP NNP B-TREATMENT
, NN NN O
ted NNP NNP B-TREATMENT
hose NNP NNP I-TREATMENT
, NN NN O
advancement NNP NNP B-TREATMENT
flap NNP NNP I-TREATMENT
, NN NN O
capsular NNP NNP B-TREATMENT
contracture NNP NNP I-TREATMENT
, NN NN O
capsulectomies NNP NNP B-TREATMENT
, NN NN O
capsulectomy NNP NNP B-TREATMENT
, NN NN O
silicone NNP NNP B-TREATMENT
gel NNP NNP I-TREATMENT
, NN NN O
silicone NNP NNP B-TREATMENT
gel NNP NNP I-TREATMENT
implants NNP NNP I-TREATMENT
, NN NN O
excision NNP NNP B-TREATMENT
of NNP NNP I-TREATMENT
basal NNP NNP I-TREATMENT
cell NNP NNP I-TREATMENT
, NN NN O
ruptured NNP NNP B-TREATMENT
silicone NNP NNP I-TREATMENT
gel NNP NNP I-TREATMENT
implants NNP NNP I-TREATMENT
, NN NN O
ruptured NNP NNP B-TREATMENT
silicone NNP NNP I-TREATMENT
gel NNP NNP I-TREATMENT
, NN NN O
basal NNP NNP B-TREATMENT
cell NNP NNP I-TREATMENT
, NN NN O
bilateral NNP NNP B-TREATMENT
capsulectomies NNP NNP I-TREATMENT
, NN NN O
cell NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
cell NNP NNP B-TREATMENT
, NNP NNP I-TREATMENT
cheek NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
basal NNP NNP I-TREATMENT
, NN NN O
implants NNP NNP B-TREATMENT
, NN NN O
silicone NNP NNP B-TREATMENT
, NN NN O
carcinoma NNP NNP B-PROBLEM
, NN NN O
breast NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
True NN NN O
Cut NN NN O
Needle NN NN O
Biopsy NN NN O
- NN NN O
Breast NN NN O
Description NN NN O
: NN NN O
True NNP NNP B-TEST
cut NNP NNP I-TEST
needle NNP NNP I-TEST
biopsy NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
breast NNP NNP I-TEST
. NN NN O

This NN NN O
65-year-old NN NN O
female NN NN O
on NN NN O
exam NNP NNP B-TEST
was NN NN O
noted NN NN O
to NN NN O
have NN NN O
dimpling NNP NNP B-PROBLEM
and NN NN O
puckering NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
skin NNP NNP I-PROBLEM
associated NN NN O
with NN NN O
nipple NNP NNP B-PROBLEM
discharge NNP NNP I-PROBLEM
. NN NN O

On NN NN O
exam NNP NNP B-TEST
, NN NN O
she NN NN O
has NN NN O
a NNP NNP B-PROBLEM
noticeable NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
with NN NN O
dimpling NNP NNP B-PROBLEM
, NN NN O
puckering NNP NNP B-PROBLEM
, NN NN O
and NN NN O
erosion NNP NNP B-PROBLEM
through NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
skin NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Carcinoma NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Carcinoma NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
. NN NN O

PROCEDURE NN NN O
PERFORMED NN NN O
: NN NN O
True NNP NNP B-TEST
cut NNP NNP I-TEST
needle NNP NNP I-TEST
biopsy NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
breast NNP NNP I-TEST
. NN NN O

GROSS NN NN O
FINDINGS NN NN O
: NN NN O
This NN NN O
65-year-old NN NN O
female NN NN O
on NN NN O
exam NNP NNP B-TEST
was NN NN O
noted NN NN O
to NN NN O
have NN NN O
dimpling NNP NNP B-PROBLEM
and NN NN O
puckering NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
skin NNP NNP I-PROBLEM
associated NN NN O
with NN NN O
nipple NNP NNP B-PROBLEM
discharge NNP NNP I-PROBLEM
. NN NN O

On NN NN O
exam NNP NNP B-TEST
, NN NN O
she NN NN O
has NN NN O
a NNP NNP B-PROBLEM
noticeable NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
with NN NN O
dimpling NNP NNP B-PROBLEM
, NN NN O
puckering NNP NNP B-PROBLEM
, NN NN O
and NN NN O
erosion NNP NNP B-PROBLEM
through NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
skin NNP NNP I-PROBLEM
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
a NNP NNP B-TEST
true NNP NNP I-TEST
cut NNP NNP I-TEST
needle NNP NNP I-TEST
biopsy NNP NNP I-TEST
was NN NN O
performed NN NN O
. NN NN O

PROCEDURE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
operating NN NN O
room NN NN O
, NN NN O
is NN NN O
laid NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
, NN NN O
sterilely NN NN O
prepped NN NN O
and NN NN O
draped NN NN O
in NN NN O
the NN NN O
usual NN NN O
fashion NN NN O
. NN NN O

The NN NN O
area NN NN O
over NN NN O
the NN NN O
left NN NN O
breast NN NN O
was NN NN O
infiltrated NN NN O
with NN NN O
1:1 NN NN O
mixture NN NN O
of NN NN O
0.25% NNP NNP B-DRUG
Marcaine NNP NNP I-DRUG
and NNP NNP I-DRUG
1% NNP NNP I-DRUG
Xylocaine NNP NNP B-DRUG
. NN NN O

Using NN NN O
a NNP NNP B-TEST
#18 NNP NNP I-TEST
gauge NNP NNP I-TEST
automatic NNP NNP I-TEST
true NNP NNP I-TEST
cut NNP NNP I-TEST
needle NNP NNP I-TEST
core NNP NNP I-TEST
biopsy NNP NNP I-TEST
, NN NN O
five NNP NNP B-TEST
biopsies NNP NNP I-TEST
were NN NN O
taken NN NN O
of NN NN O
the NN NN O
left NN NN O
breast NN NN O
in NN NN O
core NN NN O
fashion NN NN O
. NN NN O

Hemostasis NN NN O
was NN NN O
controlled NN NN O
with NN NN O
pressure NNP NNP B-TEST
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
well NN NN O
, NN NN O
pending NN NN O
the NN NN O
results NN NN O
of NN NN O
biopsy NNP NNP B-TEST
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
carcinoma NNP NNP B-PROBLEM
, NN NN O
true NN NN O
cut NN NN O
needle NN NN O
biopsy NN NN O
, NN NN O
nipple NN NN O
, NN NN O
discharge NN NN O
, NN NN O
dimpling NN NN O
, NN NN O
puckering NN NN O
, NN NN O
breast NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Thrombocytopenia NNP NNP B-PROBLEM
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Consultation NN NN O
for NN NN O
evaluation NNP NNP B-TEST
of NN NN O
thrombocytopenia NNP NNP B-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULTATION NN NN O
: NN NN O
Thrombocytopenia NNP NNP B-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
Mrs NN NN O
. NN NN O

XXX NN NN O
is NN NN O
a NN NN O
17-year-old NN NN O
lady NN NN O
who NN NN O
is NN NN O
going NN NN O
to NN NN O
be NN NN O
18 NN NN O
in NN NN O
about NN NN O
3 NN NN O
weeks NN NN O
. NN NN O

She NN NN O
has NN NN O
been NN NN O
referred NN NN O
for NN NN O
the NNP NNP B-TEST
further NNP NNP I-TEST
evaluation NNP NNP I-TEST
of NN NN O
her NNP NNP B-PROBLEM
thrombocytopenia NNP NNP I-PROBLEM
. NN NN O

This NNP NNP B-PROBLEM
thrombocytopenia NNP NNP I-PROBLEM
was NN NN O
detected NN NN O
on NN NN O
a NNP NNP B-TEST
routine NNP NNP I-TEST
blood NNP NNP I-TEST
test NNP NNP I-TEST
performed NN NN O
on NN NN O
the NN NN O
10th NNP NNP B-DATE
of NNP NNP I-DATE
June NNP NNP I-DATE
2006 NNP NNP I-DATE
. NN NN O

Her NNP NNP B-TEST
hemoglobin NNP NNP I-TEST
was NN NN O
13.3 NN NN O
with NN NN O
white NNP NNP B-TEST
count NNP NNP I-TEST
of NN NN O
11.8 NN NN O
at NN NN O
that NN NN O
time NN NN O
. NN NN O

Her NNP NNP B-TEST
lymphocyte NNP NNP I-TEST
count NNP NNP I-TEST
was NN NN O
6.7 NN NN O
. NN NN O

The NN NN O
patient NN NN O
, NN NN O
subsequently NN NN O
, NN NN O
had NN NN O
a NNP NNP B-TEST
CBC NNP NNP I-TEST
repeated NN NN O
on NN NN O
the NN NN O
10th NNP NNP B-DATE
at NN NN O
Hospital NN NN O
where NN NN O
her NNP NNP B-TEST
hemoglobin NNP NNP I-TEST
was NN NN O
12.4 NN NN O
with NN NN O
a NNP NNP B-TEST
platelet NNP NNP I-TEST
count NNP NNP I-TEST
of NN NN O
26,000 NN NN O
. NN NN O

She NN NN O
had NN NN O
a NN NN O
repeat NN NN O
of NN NN O
her NNP NNP B-TEST
CBC NNP NNP I-TEST
again NN NN O
on NN NN O
the NN NN O
12th NNP NNP B-DATE
of NNP NNP I-DATE
June NNP NNP I-DATE
2006 NNP NNP I-DATE
with NN NN O
hemoglobin NNP NNP B-TEST
of NN NN O
14 NN NN O
, NN NN O
white NNP NNP B-TEST
count NNP NNP I-TEST
of NN NN O
11.6 NN NN O
with NN NN O
an NNP NNP B-PROBLEM
increase NNP NNP I-PROBLEM
in NN NN O
the NN NN O
number NN NN O
of NN NN O
lymphocytes NN NN O
. NN NN O

Platelet NNP NNP B-TEST
count NNP NNP I-TEST
was NN NN O

38 NN NN O
. NN NN O
Her NNP NNP B-TEST
rapid NNP NNP I-TEST
strep NNP NNP I-TEST
screen NNP NNP I-TEST
was NN NN O
negative NN NN O
but NN NN O
the NNP NNP B-TEST
infectious NNP NNP I-TEST
mononucleosis NNP NNP I-TEST
screen NNP NNP I-TEST
is NN NN O
positive NNP NNP B-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
had NN NN O
a NN NN O
normal NN NN O
platelet NN NN O
count NN NN O
prior NN NN O
too NN NN O
and NN NN O
she NN NN O
is NN NN O
being NN NN O
evaluated NN NN O
for NN NN O
this NNP NNP B-PROBLEM
low NNP NNP I-PROBLEM
platelet NNP NNP I-PROBLEM
count NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
gives NN NN O
a NN NN O
history NN NN O
of NN NN O
feeling NN NN O
generally NNP NNP B-PROBLEM
unwell NNP NNP I-PROBLEM
for NN NN O
a NN NN O
couple NN NN O
of NN NN O
days NN NN O
towards NN NN O
the NN NN O
end NN NN O
of NN NN O
May NNP NNP B-DATE
. NN NN O

She NN NN O
was NN NN O
fine NN NN O
for NN NN O
a NN NN O
few NN NN O
days NN NN O
after NN NN O
that NN NN O
but NN NN O
then NN NN O
she NN NN O
had NN NN O
sore NNP NNP B-PROBLEM
throat NNP NNP I-PROBLEM
and NN NN O
fever NNP NNP B-PROBLEM
2-3 NN NN O
days NN NN O
subsequent NN NN O
to NN NN O
that NN NN O
. NN NN O

The NN NN O
patient NN NN O
continues NN NN O
to NN NN O
have NN NN O
sore NNP NNP B-PROBLEM
throat NNP NNP I-PROBLEM
. NN NN O

She NN NN O
denies NN NN O
any NN NN O
history NN NN O
of NN NN O
epistaxis NNP NNP B-PROBLEM
. NN NN O

Denies NN NN O
any NN NN O
history NN NN O
of NN NN O
gum NNP NNP B-PROBLEM
bleeding NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
denies NN NN O
any NN NN O
history NN NN O
of NN NN O
petechiae NNP NNP B-PROBLEM
. NN NN O

She NN NN O
denies NN NN O
any NN NN O
history NN NN O
of NN NN O
abnormal NNP NNP B-PROBLEM
bleeding NNP NNP I-PROBLEM
. NN NN O

Denies NN NN O
any NN NN O
history NN NN O
of NN NN O
nausea NNP NNP B-PROBLEM
, NN NN O
vomiting NNP NNP B-PROBLEM
, NN NN O
neck NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
or NN NN O
any NNP NNP B-PROBLEM
headaches NNP NNP I-PROBLEM
at NN NN O
the NN NN O
present NN NN O
time NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
her NN NN O
parents NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Asthma NNP NNP B-PROBLEM
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Birth NNP NNP B-TREATMENT
control NNP NNP I-TREATMENT
pills NNP NNP I-TREATMENT
, NN NN O
Albuterol NNP NNP B-DRUG
, NN NN O
QVAR NNP NNP B-DRUG
and NN NN O
Rhinocort NNP NNP B-DRUG
. NN NN O

DRUG NN NN O
ALLERGIES NN NN O
: NN NN O
None NN NN O
. NN NN O

PERSONAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
lives NN NN O
with NN NN O
her NN NN O
parents NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
Denies NN NN O
the NN NN O
use NN NN O
of NN NN O
alcohol NN NN O
or NN NN O
tobacco NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

OCCUPATION NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
currently NN NN O
in NN NN O
school NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
Constitutional NN NN O
: NN NN O
The NN NN O
history NN NN O
of NN NN O
fever NNP NNP B-PROBLEM
about NN NN O
2 NN NN O
weeks NN NN O
ago NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
Complains NN NN O
of NN NN O
some NNP NNP B-PROBLEM
difficulty NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
swallowing NNP NNP I-PROBLEM
. NN NN O

Cardiovascular NN NN O
: NN NN O
Negative NN NN O
. NN NN O

Respiratory NN NN O
: NN NN O
Negative NN NN O
. NN NN O

Gastrointestinal NN NN O
: NN NN O
No NN NN O
nausea NNP NNP B-PROBLEM
, NN NN O
vomiting NNP NNP B-PROBLEM
, NN NN O
or NN NN O
abdominal NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

Genitourinary NN NN O
: NN NN O
No NN NN O
dysuria NNP NNP B-PROBLEM
or NN NN O
hematuria NNP NNP B-PROBLEM
. NN NN O

Musculoskeletal NN NN O
: NN NN O
Complains NN NN O
of NN NN O
generalized NNP NNP B-PROBLEM
body NNP NNP I-PROBLEM
aches NNP NNP I-PROBLEM
. NN NN O

Psychiatric NN NN O
: NN NN O
No NN NN O
anxiety NNP NNP B-PROBLEM
or NN NN O
depression NNP NNP B-PROBLEM
. NN NN O

Neurologic NN NN O
: NN NN O
Complains NN NN O
of NN NN O
episode NN NN O
of NN NN O
headaches NNP NNP B-PROBLEM
about NN NN O
2-3 NN NN O
weeks NN NN O
ago NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
She NN NN O
was NN NN O
not NN NN O
in NN NN O
any NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

She NN NN O
appears NN NN O
her NN NN O
stated NN NN O
age NN NN O
. NN NN O

Temperature NNP NNP B-TEST
97.9 NN NN O
. NN NN O

Pulse NNP NNP B-TEST

84 NN NN O
. NN NN O
Blood NNP NNP B-TEST
pressure NNP NNP I-TEST
was NN NN O
110/60 NN NN O
. NN NN O

Weighs NN NN O
162 NN NN O
pounds NN NN O
. NN NN O

Height NNP NNP B-TEST
of NN NN O
61 NN NN O
inches NN NN O
. NN NN O

Lungs NN NN O
- NN NN O
Normal NN NN O
effort NN NN O
. NN NN O

Clear NN NN O
. NN NN O

No NN NN O
wheezing NNP NNP B-PROBLEM
. NN NN O

Heart NN NN O
- NN NN O
Rate NN NN O
and NN NN O
rhythm NN NN O
regular NN NN O
. NN NN O

No NN NN O
S3 NNP NNP B-PROBLEM
, NN NN O
no NN NN O
S4 NNP NNP B-PROBLEM
. NN NN O

Abdomen NN NN O
- NN NN O
Soft NN NN O
. NN NN O

Bowel NN NN O
sounds NN NN O
are NN NN O
present NN NN O
. NN NN O

No NN NN O
palpable NNP NNP B-PROBLEM
hepatosplenomegaly NNP NNP I-PROBLEM
. NN NN O

Extremities NN NN O
- NN NN O
Without NN NN O
any NNP NNP B-PROBLEM
edema NNP NNP I-PROBLEM
, NN NN O
pallor NNP NNP B-PROBLEM
, NN NN O
or NN NN O
cyanosis NNP NNP B-PROBLEM
. NN NN O

Neurological NN NN O
: NN NN O
Alert NN NN O
and NN NN O
oriented NN NN O
x NN NN O

3 NN NN O
. NN NN O
No NN NN O
focal NNP NNP B-PROBLEM
deficit NNP NNP I-PROBLEM
. NN NN O

Lymph NN NN O
Nodes NN NN O
- NN NN O
No NN NN O
palpable NNP NNP B-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
axilla NNP NNP I-PROBLEM
. NN NN O

Skin NNP NNP B-TEST
examination NNP NNP I-TEST
reveals NN NN O
few NNP NNP B-PROBLEM
petechiae NNP NNP I-PROBLEM
along NN NN O
the NN NN O
lateral NN NN O
aspect NN NN O
of NN NN O
the NN NN O
left NN NN O
thigh NN NN O
but NN NN O
otherwise NN NN O
there NN NN O
were NN NN O
no NN NN O
ecchymotic NNP NNP B-PROBLEM
patches NNP NNP I-PROBLEM
. NN NN O

DIAGNOSTIC NN NN O
DATA NN NN O
: NN NN O
The NN NN O
patient's NN NN O
CBC NN NN O
results NN NN O
from NN NN O
before NN NN O
were NN NN O
reviewed NN NN O
. NN NN O

Her NNP NNP B-TEST
CBC NNP NNP I-TEST
performed NN NN O
in NN NN O
the NN NN O
office NN NN O
today NN NN O
showed NN NN O
hemoglobin NNP NNP B-TEST
of NN NN O
13.7 NN NN O
, NN NN O
white NNP NNP B-TEST
count NNP NNP I-TEST
of NN NN O
13.3 NN NN O
, NN NN O
lymphocyte NNP NNP B-TEST
count NNP NNP I-TEST
of NN NN O
7.6 NN NN O
, NN NN O
and NN NN O
platelet NNP NNP B-TEST
count NNP NNP I-TEST
of NN NN O
26,000 NN NN O
. NN NN O

IMPRESSION NN NN O
: NN NN O
ITP NNP NNP B-PROBLEM
, NN NN O
the NN NN O
patient NN NN O
has NN NN O
a NN NN O
normal NN NN O
platelet NN NN O
count NN NN O
. NN NN O

PLAN NN NN O
: NN NN O

1 NN NN O
. NN NN O
I NN NN O
had NN NN O
a NN NN O
long NN NN O
discussion NN NN O
with NN NN O
family NN NN O
regarding NN NN O
the NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
of NN NN O
ITP NNP NNP B-PROBLEM
. NN NN O

In NN NN O
view NN NN O
of NN NN O
the NN NN O
fact NN NN O
that NN NN O
the NNP NNP B-TEST
patient's NNP NNP I-TEST
platelet NNP NNP I-TEST
count NNP NNP I-TEST
is NN NN O
26,000 NN NN O
and NN NN O
she NN NN O
is NN NN O
asymptomatic NNP NNP B-PROBLEM
, NN NN O
we NN NN O
will NN NN O
continue NN NN O
to NN NN O
monitor NN NN O
the NNP NNP B-TEST
counts NNP NNP I-TEST
. NN NN O

2 NN NN O
. NN NN O
An NNP NNP B-TEST
ultrasound NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
abdomen NNP NNP I-TEST
will NN NN O
be NN NN O
performed NN NN O
tomorrow NN NN O
. NN NN O

3 NN NN O
. NN NN O
I NN NN O
have NN NN O
given NN NN O
her NN NN O
a NN NN O
requisition NN NN O
to NN NN O
obtain NN NN O
some NN NN O
blood NN NN O
work NN NN O
tomorrow NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
rapid NNP NNP B-TEST
strep NNP NNP I-TEST
screen NNP NNP I-TEST
, NN NN O
infectious NNP NNP B-TEST
mononucleosis NNP NNP I-TEST
screen NNP NNP I-TEST
, NN NN O
lymphocyte NNP NNP B-TEST
count NNP NNP I-TEST
, NN NN O
platelet NNP NNP B-TEST
count NNP NNP I-TEST
, NN NN O
itp NNP NNP B-TEST
, NN NN O
lymphocyte NNP NNP B-TEST
, NN NN O
hemoglobin NNP NNP B-TEST
, NN NN O
cbc NNP NNP B-TEST
, NN NN O
thrombocytopenia NNP NNP B-PROBLEM
, NN NN O
platelet NNP NNP B-TEST
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Lung NN NN O
Cancer NN NN O
Followup NN NN O
Description NN NN O
: NN NN O
Extensive NNP NNP B-PROBLEM
stage NNP NNP I-PROBLEM
small NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

Chemotherapy NNP NNP B-DRUG
with NN NN O
carboplatin NNP NNP B-DRUG
and NN NN O
etoposide NNP NNP B-DRUG
. NN NN O

Left NNP NNP B-PROBLEM
scapular NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
status NN NN O
post NN NN O
CT NNP NNP B-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
thorax NNP NNP I-TEST
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O

1 NN NN O
. NN NN O
Extensive NNP NNP B-PROBLEM
stage NNP NNP I-PROBLEM
small NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
Chemotherapy NNP NNP B-DRUG
with NN NN O
carboplatin NNP NNP B-DRUG
and NN NN O
etoposide NNP NNP B-DRUG
. NN NN O

3 NN NN O
. NN NN O
Left NNP NNP B-PROBLEM
scapular NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
status NN NN O
post NN NN O
CT NNP NNP B-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
thorax NNP NNP I-TEST
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
67-year-old NN NN O
female NN NN O
with NN NN O
extensive NNP NNP B-PROBLEM
stage NNP NNP I-PROBLEM
small NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

She NN NN O
is NN NN O
currently NN NN O
receiving NN NN O
treatment NNP NNP B-TREATMENT
with NN NN O
carboplatin NNP NNP B-DRUG
and NN NN O
etoposide NNP NNP B-DRUG
. NN NN O

She NN NN O
completed NN NN O
her NN NN O
fifth NN NN O
cycle NN NN O
on NN NN O
08/12/10 NNP NNP B-DATE
. NN NN O

She NN NN O
has NN NN O
had NN NN O
ongoing NNP NNP B-PROBLEM
back NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
and NN NN O
was NN NN O
sent NN NN O
for NN NN O
a NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
thorax NNP NNP I-TEST
. NN NN O

She NN NN O
comes NN NN O
into NN NN O
clinic NN NN O
today NN NN O
accompanied NN NN O
by NN NN O
her NN NN O
daughters NN NN O
to NN NN O
review NN NN O
the NN NN O
results NN NN O
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Levothyroxine NNP NNP B-DRUG
88 NNP NNP I-DRUG
mcg NNP NNP I-DRUG
daily NN NN O
, NN NN O
Soriatane NNP NNP B-DRUG
25 NNP NNP I-DRUG
mg NNP NNP I-DRUG
daily NN NN O
, NN NN O
Timoptic NNP NNP B-DRUG
0.5% NNP NNP I-DRUG
solution NNP NNP I-DRUG
b.i.d NN NN O
., NN NN O
Vicodin NNP NNP B-DRUG
5/500 NNP NNP I-DRUG
mg NNP NNP I-DRUG
one NNP NNP I-DRUG
to NNP NNP I-DRUG
two NNP NNP I-DRUG
tablets NNP NNP I-DRUG
q.6 NN NN O
hours NN NN O
p.r.n NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
The NN NN O
patient NN NN O
continues NN NN O
to NN NN O
have NN NN O
back NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
some NN NN O
time NN NN O
she NN NN O
also NN NN O
take NN NN O
two NNP NNP B-TREATMENT
pain NNP NNP I-TREATMENT
pill NNP NNP I-TREATMENT
. NN NN O

She NN NN O
received NN NN O
platelet NNP NNP B-DRUG
transfusion NNP NNP I-DRUG
the NN NN O
other NN NN O
day NN NN O
and NN NN O
reported NN NN O
mild NNP NNP B-PROBLEM
fever NNP NNP I-PROBLEM
. NN NN O

She NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
chills NNP NNP I-PROBLEM
, NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
, NN NN O
chest NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
or NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
. NN NN O

The NN NN O
rest NN NN O
of NN NN O
her NNP NNP B-TEST
review NNP NNP I-TEST
of NNP NNP I-TEST
systems NNP NNP I-TEST
is NN NN O
negative NN NN O
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
VITALS NN NN O
: NN NN O
BP NNP NNP B-TEST
: NN NN O
118/60 NN NN O
. NN NN O

HEART NN NN O
RATE NN NN O
: NN NN O

76 NN NN O
. NN NN O
TEMP NNP NNP B-TEST
: NN NN O
97.8 NN NN O
. NN NN O

Weight NNP NNP B-TEST
: NN NN O
65.5 NN NN O
kg NN NN O
. NN NN O

GEN NN NN O
: NN NN O
She NN NN O
looks NN NN O
well NN NN O
, NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
Her NN NN O
pupils NN NN O
were NN NN O
noted NN NN O
for NN NN O
surgical NNP NNP B-PROBLEM
changes NNP NNP I-PROBLEM
bilaterally NNP NNP I-PROBLEM
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
cervical NNP NNP B-PROBLEM
or NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

CV NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
; NN NN O

normal NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
, NN NN O
no NN NN O
murmurs NNP NNP B-PROBLEM
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
. NN NN O

He NN NN O
has NN NN O
positive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

EXT NN NN O
: NN NN O
Lower NN NN O
extremities NN NN O
are NN NN O
without NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

IMAGING NN NN O
: NN NN O
Her NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
shows NN NN O
a NNP NNP B-PROBLEM
pleural NNP NNP I-PROBLEM
base NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
apex NNP NNP I-PROBLEM
appears NN NN O
to NN NN O
have NN NN O
some NNP NNP B-PROBLEM
growth NNP NNP I-PROBLEM
along NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
medial NNP NNP I-PROBLEM
margin NNP NNP I-PROBLEM
comparing NN NN O
with NN NN O
PET/CT NNP NNP B-TEST
assessment NNP NNP I-TEST
07/08/10 NNP NNP B-DATE
. NN NN O

While NN NN O
this NN NN O
extends NN NN O
to NN NN O
the NN NN O
pleural NN NN O
surface NN NN O
it NN NN O
does NN NN O
not NN NN O
clearly NN NN O
invade NN NN O
directly NN NN O
into NN NN O
the NN NN O
chest NN NN O
wall NN NN O
or NN NN O
the NN NN O
adjacent NN NN O
posterior NN NN O
lateral NN NN O
left NN NN O
third NN NN O
rib NN NN O
. NN NN O

Left NNP NNP B-PROBLEM
suprahilar NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
mediastinal NNP NNP I-PROBLEM
adenopathy NNP NNP I-PROBLEM
appears NN NN O
to NN NN O
be NN NN O
essentially NN NN O
stable NN NN O
since NN NN O
07/08/10 NNP NNP B-DATE
. NN NN O

Multilevel NNP NNP B-PROBLEM
thoracic NNP NNP I-PROBLEM
bony NNP NNP I-PROBLEM
metastatic NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
is NN NN O
present NN NN O
. NN NN O

Hypodense NNP NNP B-PROBLEM
liver NNP NNP I-PROBLEM
metastasis NNP NNP I-PROBLEM
appears NN NN O
slightly NN NN O
improved NN NN O
comparing NN NN O
with NN NN O
July NNP NNP B-DATE
, NN NN O
more NN NN O
substantially NN NN O
improved NN NN O
comparing NN NN O
with NN NN O
chest NNP NNP B-TEST
CT NNP NNP I-TEST
of NN NN O
04/21/10 NNP NNP B-DATE
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
female NN NN O
67-year-old NN NN O
female NN NN O
with NN NN O
extensive NNP NNP B-PROBLEM
stage NNP NNP I-PROBLEM
small NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

She NN NN O
had NN NN O
one NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
postponed NN NN O
due NN NN O
to NN NN O
counts NNP NNP B-TEST
. NN NN O

She NN NN O
had NN NN O
low NNP NNP B-PROBLEM
blood NNP NNP I-PROBLEM
counts NNP NNP I-PROBLEM
this NN NN O
week NN NN O
requiring NN NN O
platelet NNP NNP B-DRUG
transfusion NNP NNP I-DRUG
, NN NN O
so NN NN O
we NN NN O
are NN NN O
going NN NN O
to NN NN O
dose NN NN O
reduce NN NN O
for NN NN O
six NNP NNP B-TREATMENT
treatments NNP NNP I-TREATMENT
by NN NN O
10% NN NN O
. NN NN O

As NN NN O
far NN NN O
as NN NN O
the NNP NNP B-PROBLEM
back NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
she NN NN O
clearly NN NN O
has NN NN O
evidence NN NN O
of NN NN O
progressive NNP NNP B-PROBLEM
bone NNP NNP I-PROBLEM
metastasis NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
T3 NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
T11 NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
T12 NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
T1 NNP NNP I-PROBLEM
and NNP NNP I-PROBLEM
questions NNP NNP I-PROBLEM
about NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
soft NNP NNP I-PROBLEM
tissue NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
pleural NNP NNP I-PROBLEM
base NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
lateral NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
apex NNP NNP I-PROBLEM
. NN NN O

I NN NN O
am NN NN O
going NN NN O
to NN NN O
refer NN NN O
back NN NN O
to NN NN O
Dr NN NN O
. NN NN O
X NN NN O
to NN NN O
see NN NN O
if NN NN O
there NN NN O
might NN NN O
be NN NN O
some NNP NNP B-TREATMENT
palliative NNP NNP I-TREATMENT
radiation NNP NNP I-TREATMENT
to NN NN O
deal NN NN O
with NN NN O
the NN NN O
left NN NN O
back NN NN O
and NN NN O
scapular NN NN O
region NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
small NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
carboplatin NNP NNP B-DRUG
, NN NN O
etoposide NNP NNP B-DRUG
, NN NN O
pet/ct NNP NNP B-TEST
, NN NN O
pleural NNP NNP B-PROBLEM
base NNP NNP I-PROBLEM
, NN NN O
base NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
extensive NNP NNP B-PROBLEM
stage NNP NNP I-PROBLEM
, NN NN O
ct NNP NNP B-TEST
scan NNP NNP I-TEST
, NN NN O
lung NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
lung NNP NNP B-PROBLEM
, NN NN O
cancer NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Neck NN NN O
Mass NN NN O
Biopsy NN NN O
Description NN NN O
: NN NN O
Malignant NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
, NN NN O
squamous NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

Left NNP NNP B-TEST
neck NNP NNP I-TEST
mass NNP NNP I-TEST
biopsy NNP NNP I-TEST
and NN NN O
selective NNP NNP B-TREATMENT
surgical NNP NNP I-TREATMENT
neck NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
, NN NN O
left NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Malignant NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Malignant NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
, NN NN O
squamous NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

PROCEDURES NN NN O

1 NN NN O
. NN NN O
Left NNP NNP B-TEST
neck NNP NNP I-TEST
mass NNP NNP I-TEST
biopsy NNP NNP I-TEST
. NN NN O

2 NN NN O
. NN NN O
Selective NNP NNP B-TREATMENT
surgical NNP NNP I-TREATMENT
neck NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
left NNP NNP I-TREATMENT
. NN NN O

DESCRIPTION NN NN O
OF NN NN O
PROCEDURE NN NN O
: NN NN O
After NN NN O
obtaining NN NN O
an NN NN O
informed NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
where NN NN O
a NN NN O
time-out NN NN O
process NN NN O
was NN NN O
followed NN NN O
. NN NN O

Preoperative NN NN O
antibiotic NNP NNP B-DRUG
was NN NN O
given NN NN O
and NN NN O
Dr NN NN O
. NN NN O
X NN NN O
proceeded NN NN O
to NN NN O
intubate NN NN O
the NN NN O
patient NN NN O
after NN NN O
a NNP NNP B-TREATMENT
detailed NNP NNP I-TREATMENT
anesthetic NNP NNP I-TREATMENT
preparation NNP NNP I-TREATMENT
that NN NN O
started NN NN O
in NN NN O
the NN NN O
Same NN NN O
Day NN NN O
Surgery NN NN O
and NN NN O
followed NN NN O
in NN NN O
the NN NN O
operating NN NN O
room NN NN O
. NN NN O

Finally NN NN O
, NN NN O
a NNP NNP B-TREATMENT
5.5-French NNP NNP I-TREATMENT
endotracheal NNP NNP I-TREATMENT
tube NNP NNP I-TREATMENT
was NN NN O
inserted NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
able NN NN O
to NN NN O
tolerate NN NN O
that NN NN O
and NN NN O
did NN NN O
have NN NN O
stable NN NN O
vital NN NN O
signs NN NN O
and NN NN O
a NNP NNP B-TEST
proper NNP NNP I-TEST
oxygenation NNP NNP I-TEST
. NN NN O

Then NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
positioned NN NN O
with NN NN O
the NNP NNP B-PROBLEM
neck NNP NNP I-PROBLEM
slightly NNP NNP I-PROBLEM
distended NNP NNP I-PROBLEM
and NN NN O
turned NN NN O
toward NN NN O
the NN NN O
opposite NN NN O
side NN NN O
of NN NN O
the NNP NNP B-TREATMENT
operation NNP NNP I-TREATMENT
. NN NN O

The NN NN O
neck NN NN O
was NN NN O
prepped NN NN O
and NN NN O
draped NN NN O
in NN NN O
the NN NN O
usual NN NN O
fashion NN NN O
. NN NN O

I NN NN O
proceeded NN NN O
to NN NN O
mark NN NN O
the NN NN O
site NN NN O
of NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
and NN NN O
then NN NN O
also NN NN O
to NN NN O
mark NN NN O
the NN NN O
proposed NN NN O
site NN NN O
for NN NN O
the NN NN O
creation NN NN O
of NN NN O
a NNP NNP B-TREATMENT
flap NNP NNP I-TREATMENT
. NN NN O

Then NN NN O
, NN NN O
I NN NN O
performed NN NN O
an NNP NNP B-TREATMENT
extensive NNP NNP I-TREATMENT
anesthetic NNP NNP I-TREATMENT
block NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
the NNP NNP I-TREATMENT
area NNP NNP I-TREATMENT
. NN NN O

Then NN NN O
, NN NN O
an NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
along NN NN O
the NN NN O
area NN NN O
marked NN NN O
for NN NN O
development NN NN O
of NN NN O
the NNP NNP B-TREATMENT
flap NNP NNP I-TREATMENT
, NN NN O
but NN NN O
in NN NN O
a NN NN O
very NN NN O
limited NN NN O
extent NN NN O
, NN NN O
just NN NN O
to NN NN O
expose NN NN O
the NNP NNP B-PROBLEM
cervical NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
cervical NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
which NN NN O
was NN NN O
about NN NN O
4 NN NN O
cm NN NN O
in NN NN O
diameter NN NN O
and NN NN O
very NN NN O
firm NN NN O
and NN NN O
rubbery NNP NNP B-PROBLEM
, NN NN O
was NN NN O
found NN NN O
lodged NN NN O
between NN NN O
the NN NN O
sternocleidomastoid NN NN O
muscle NN NN O
and NN NN O
the NN NN O
internal NN NN O
jugular NN NN O
vein NN NN O
in NN NN O
the NN NN O
area NN NN O
III NN NN O
of NN NN O
the NN NN O
neck NN NN O
. NN NN O

A NNP NNP B-TEST
wedge NNP NNP I-TEST
sample NNP NNP I-TEST
was NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
for NN NN O
frozen NNP NNP B-TEST
section NNP NNP I-TEST
. NN NN O

At NN NN O
the NN NN O
same NN NN O
time NN NN O
, NN NN O
we NN NN O
waited NN NN O
for NN NN O
the NN NN O
result NN NN O
and NN NN O
the NN NN O
initial NN NN O
report NN NN O
was NN NN O
not NN NN O
clear NN NN O
in NN NN O
the NN NN O
sense NN NN O
that NN NN O
a NN NN O
lot NN NN O
of NN NN O
lymphoepithelial NNP NNP B-PROBLEM
reaction NNP NNP I-PROBLEM
was NN NN O
seen NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
a NN NN O
larger NN NN O
sample NN NN O
was NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
and NN NN O
at NN NN O
that NN NN O
particular NN NN O
time NN NN O
, NN NN O
the NNP NNP B-TEST
fresh NNP NNP I-TEST
frozen NNP NNP I-TEST
was NN NN O
reported NN NN O
as NN NN O
having NN NN O
squamous NNP NNP B-PROBLEM
elements NNP NNP I-PROBLEM
. NN NN O

This NN NN O
was NN NN O
not NN NN O
totally NN NN O
clear NN NN O
in NN NN O
my NN NN O
mind NN NN O
and NN NN O
therefore NN NN O
I NN NN O
proceeded NN NN O
to NN NN O
excise NN NN O
the NNP NNP B-PROBLEM
full NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
which NN NN O
luckily NN NN O
was NN NN O
not NN NN O
attached NN NN O
to NN NN O
any NN NN O
structures NN NN O
except NN NN O
in NN NN O
the NN NN O
very NN NN O
deep NN NN O
surface NN NN O
. NN NN O

There NN NN O
, NN NN O
there NN NN O
were NN NN O
some NN NN O
attachments NN NN O
to NN NN O
branches NN NN O
of NN NN O
the NN NN O
external NN NN O
carotid NN NN O
artery NN NN O
, NN NN O
which NN NN O
had NN NN O
to NN NN O
be NN NN O
suture NNP NNP B-TREATMENT
ligated NNP NNP I-TREATMENT
. NN NN O

At NN NN O
any NNP NNP B-TEST
rate NNP NNP I-TEST
, NN NN O
the NNP NNP B-TEST
whole NNP NNP I-TEST
specimen NNP NNP I-TEST
was NN NN O
to NN NN O
the NN NN O
lab NN NN O
and NN NN O
finally NN NN O
the NN NN O
diagnosis NN NN O
was NN NN O
that NN NN O
of NN NN O
a NNP NNP B-PROBLEM
metastatic NNP NNP I-PROBLEM
squamous NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

With NN NN O
that NN NN O
information NN NN O
in NN NN O
hand NN NN O
, NN NN O
we NN NN O
proceeded NN NN O
to NN NN O
continue NN NN O
with NN NN O
a NNP NNP B-TREATMENT
neck NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
and NN NN O
proceeded NN NN O
to NN NN O
make NN NN O
an NNP NNP B-PROBLEM
incision NNP NNP I-PROBLEM
along NN NN O
the NN NN O
previously NN NN O
marked NN NN O
sites NN NN O
of NN NN O
the NNP NNP B-TREATMENT
flap NNP NNP I-TREATMENT
, NN NN O
which NN NN O
basically NN NN O
involved NN NN O
a NN NN O
reverse NN NN O
U NN NN O
shape NN NN O
on NN NN O
the NN NN O
left NN NN O
neck NN NN O
. NN NN O

This NN NN O
worked NN NN O
out NN NN O
quite NN NN O
nicely NN NN O
. NN NN O

The NN NN O
external NN NN O
jugular NN NN O
vein NN NN O
was NN NN O
out NN NN O
of NN NN O
the NN NN O
way NN NN O
, NN NN O
so NN NN O
initially NN NN O
we NN NN O
did NN NN O
not NN NN O
deal NN NN O
with NN NN O
it NN NN O
. NN NN O

We NN NN O
proceeded NN NN O
to NN NN O
tackle NN NN O
the NN NN O
area NN NN O
III NN NN O
and NN NN O
extended NN NN O
into NN NN O
II-A NNP NNP B-TREATMENT
. NN NN O

When NN NN O
we NN NN O
excised NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
the NN NN O
upper NN NN O
end NN NN O
was NN NN O
in NN NN O
intimate NN NN O
relationship NN NN O
with NN NN O
the NN NN O
parotid NN NN O
gland NN NN O
, NN NN O
which NN NN O
was NN NN O
relatively NN NN O
large NN NN O
in NN NN O
this NN NN O
patient NN NN O
, NN NN O
but NN NN O
it NN NN O
looked NN NN O
normal NN NN O
otherwise NN NN O
. NN NN O

Also NN NN O
, NN NN O
I NN NN O
felt NN NN O
that NN NN O
the NN NN O
submaxillary NN NN O
gland NN NN O
was NN NN O
enlarged NNP NNP B-PROBLEM
. NN NN O

At NN NN O
any NN NN O
rate NN NN O
, NN NN O
we NN NN O
decided NN NN O
to NN NN O
clean NN NN O
up NN NN O
the NN NN O
areas NN NN O
III NN NN O
and NN NN O
IV NNP NNP B-TREATMENT
and NN NN O
a NNP NNP B-PROBLEM
few NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
from NN NN O
II-A NNP NNP B-TREATMENT
that NN NN O
were NN NN O
removed NN NN O
, NN NN O
and NN NN O
then NN NN O
we NN NN O
went NN NN O
into NN NN O
the NN NN O
posterior NN NN O
triangle NN NN O
where NN NN O
we NN NN O
identified NN NN O
the NN NN O
spinal NN NN O
accessory NN NN O
nerve NN NN O
, NN NN O
which NN NN O
we NN NN O
protected NN NN O
, NN NN O
actually NN NN O
did NN NN O
not NN NN O
even NN NN O
dissect NN NN O
close NN NN O
to NN NN O
it NN NN O
. NN NN O

The NN NN O
same NN NN O
nerve NN NN O
had NN NN O
been NN NN O
already NN NN O
identified NN NN O
anterior NN NN O
to NN NN O
the NN NN O
internal NN NN O
jugular NN NN O
vein NN NN O
, NN NN O
very NN NN O
proximally NN NN O
behind NN NN O
the NN NN O
digastric NN NN O
and NN NN O
the NN NN O
sternocleidomastoid NN NN O
muscle NN NN O
. NN NN O

At NN NN O
any NN NN O
rate NN NN O
, NN NN O
there NN NN O
were NN NN O
large NNP NNP B-PROBLEM
nodes NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
posterior NNP NNP I-PROBLEM
triangle NNP NNP I-PROBLEM
, NN NN O
in NN NN O
areas NN NN O
V-A NNP NNP B-TREATMENT
and NN NN O
V-B NNP NNP B-TREATMENT
, NN NN O
which NN NN O
were NN NN O
excised NN NN O
and NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
for NN NN O
examination NNP NNP B-TEST
. NN NN O

Also NN NN O
, NN NN O
there NN NN O
was NN NN O
a NNP NNP B-PROBLEM
remnant NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
a NNP NNP I-PROBLEM
capsule NNP NNP I-PROBLEM
of NN NN O
the NNP NNP B-PROBLEM
main NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
that NN NN O
we NN NN O
proceeded NN NN O
to NN NN O
excise NN NN O
and NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
as NN NN O
an NNP NNP B-TEST
extra NNP NNP I-TEST
specimen NNP NNP I-TEST
. NN NN O

Hemostasis NN NN O
was NN NN O
revised NN NN O
and NN NN O
found NN NN O
to NN NN O
be NN NN O
adequate NN NN O
. NN NN O

The NNP NNP B-TREATMENT
flaps NNP NNP I-TREATMENT
had NN NN O
been NN NN O
protected NN NN O
by NN NN O
folding NN NN O
it NN NN O
to NN NN O
the NN NN O
chest NN NN O
and NN NN O
protected NN NN O
by NN NN O
wet NNP NNP B-TREATMENT
sponges NNP NNP I-TREATMENT
on NN NN O
both NN NN O
sides NN NN O
of NN NN O
the NNP NNP B-TREATMENT
flap NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-TREATMENT
flap NNP NNP I-TREATMENT
was NN NN O
replaced NN NN O
in NN NN O
its NN NN O
position NN NN O
. NN NN O

A NNP NNP B-TREATMENT
soft NNP NNP I-TREATMENT
Jackson-Pratt NNP NNP I-TREATMENT
catheter NNP NNP I-TREATMENT
was NN NN O
left NN NN O
in NN NN O
the NN NN O
area NN NN O
, NN NN O
and NN NN O
then NN NN O
we NN NN O
proceeded NN NN O
to NN NN O
approximate NN NN O
the NN NN O
flap NN NN O
with NN NN O
a NN NN O
number NN NN O
of NN NN O
subcutaneous NNP NNP B-TREATMENT
sutures NNP NNP I-TREATMENT
of NN NN O
Vicryl NNP NNP B-TREATMENT
and NN NN O
then NN NN O
running NNP NNP B-TREATMENT
sutures NNP NNP I-TREATMENT
of NN NN O
subcuticular NNP NNP B-TREATMENT
Monocryl NNP NNP I-TREATMENT
to NN NN O
the NN NN O
skin NN NN O
. NN NN O

I NN NN O
would NN NN O
like NN NN O
to NN NN O
mention NN NN O
that NN NN O
also NN NN O
the NN NN O
facial NN NN O
vein NN NN O
was NN NN O
excised NNP NNP B-TREATMENT
and NN NN O
the NN NN O
external NN NN O
jugular NN NN O
vein NN NN O
was NN NN O
ligated NNP NNP B-TREATMENT
. NN NN O

It NN NN O
was NN NN O
in NN NN O
very NN NN O
lateral NN NN O
location NN NN O
and NN NN O
it NN NN O
was NN NN O
on NN NN O
the NN NN O
site NN NN O
of NN NN O
the NNP NNP B-TREATMENT
drain NNP NNP I-TREATMENT
, NN NN O
so NN NN O
we NN NN O
ligated NN NN O
that NN NN O
but NN NN O
did NN NN O
not NN NN O
excise NN NN O
it NN NN O
. NN NN O

A NNP NNP B-TREATMENT
pressure NNP NNP I-TREATMENT
dressing NNP NNP I-TREATMENT
was NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
well NN NN O
. NN NN O

Estimated NNP NNP B-PROBLEM
blood NNP NNP I-PROBLEM
loss NNP NNP I-PROBLEM
was NN NN O
no NN NN O
more NN NN O
than NN NN O
100 NN NN O
mL NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
extubated NN NN O
in NN NN O
the NN NN O
operating NN NN O
room NN NN O
and NN NN O
sent NN NN O
for NN NN O
recovery NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
neck NNP NNP B-TEST
mass NNP NNP I-TEST
biopsy NNP NNP I-TEST
, NN NN O
surgical NNP NNP B-PROBLEM
neck NNP NNP I-PROBLEM
dissection NNP NNP I-PROBLEM
, NN NN O
internal NN NN O
jugular NN NN O
vein NN NN O
, NN NN O
external NN NN O
jugular NN NN O
vein NN NN O
, NN NN O
squamous NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
neck NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
malignant NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
, NN NN O
neck NNP NNP B-PROBLEM
dissection NNP NNP I-PROBLEM
, NN NN O
mass NNP NNP B-PROBLEM
, NN NN O
neck NN NN O
, NN NN O
wedge NN NN O
, NN NN O
vein NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Nuclear NN NN O
Medicine NN NN O
Lymphatic NN NN O
Scan NN NN O
Description NN NN O
: NN NN O
Left NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

Nuclear NNP NNP B-TEST
medicine NNP NNP I-TEST
lymphatic NNP NNP I-TEST
scan NNP NNP I-TEST
. NN NN O

A NNP NNP B-TEST
16-hour NNP NNP I-TEST
left NNP NNP I-TEST
anterior NNP NNP I-TEST
oblique NNP NNP I-TEST
imaging NNP NNP I-TEST
was NN NN O
performed NN NN O
with NN NN O
and NN NN O
without NN NN O
shielding NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
original NNP NNP I-PROBLEM
injection NNP NNP I-PROBLEM
site NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
EXAM NN NN O
: NN NN O
Nuclear NNP NNP B-TEST
medicine NNP NNP I-TEST
lymphatic NNP NNP I-TEST
scan NNP NNP I-TEST
. NN NN O

REASON NN NN O
FOR NN NN O
EXAM NN NN O
: NN NN O
Left NNP NNP B-PROBLEM
breast NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

TECHNIQUE NN NN O
: NN NN O
1.0 NNP NNP B-DRUG
mCi NNP NNP I-DRUG
of NNP NNP I-DRUG
Technetium-99m NNP NNP I-DRUG
sulfur NNP NNP I-DRUG
colloid NNP NNP I-DRUG
was NN NN O
injected NN NN O
within NN NN O
the NN NN O
dermis NN NN O
surrounding NN NN O
the NN NN O
left NN NN O
breast NN NN O
biopsy NN NN O
site NN NN O
at NN NN O
four NN NN O
locations NN NN O
. NN NN O

A NNP NNP B-TEST
16-hour NNP NNP I-TEST
left NNP NNP I-TEST
anterior NNP NNP I-TEST
oblique NNP NNP I-TEST
imaging NNP NNP I-TEST
was NN NN O
performed NN NN O
with NN NN O
and NN NN O
without NN NN O
shielding NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
original NNP NNP I-PROBLEM
injection NNP NNP I-PROBLEM
site NNP NNP I-PROBLEM
. NN NN O

FINDINGS NN NN O
: NN NN O
There NN NN O
are NN NN O
two NNP NNP B-PROBLEM
small NNP NNP I-PROBLEM
foci NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
increased NNP NNP I-PROBLEM
activity NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
axilla NNP NNP I-PROBLEM
. NN NN O

This NN NN O
is NN NN O
consistent NN NN O
with NN NN O
the NN NN O
sentinel NN NN O
lymph NN NN O
node NN NN O
. NN NN O

No NN NN O
other NN NN O
areas NN NN O
of NN NN O
activity NN NN O
are NN NN O
visualized NN NN O
outside NN NN O
of NN NN O
the NN NN O
injection NN NN O
site NN NN O
and NN NN O
two NN NN O
axillary NN NN O
lymph NN NN O
nodes NN NN O
. NN NN O

IMPRESSION NN NN O
: NN NN O
Technically NN NN O
successful NNP NNP B-TREATMENT
lymph NNP NNP I-TREATMENT
node NNP NNP I-TREATMENT
injection NNP NNP I-TREATMENT
with NN NN O
two NN NN O
areas NN NN O
of NN NN O
increased NNP NNP B-PROBLEM
activity NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
axilla NNP NNP I-PROBLEM
consistent NN NN O
with NN NN O
sentinel NN NN O
lymph NN NN O
node NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
technetium-99m NNP NNP B-TEST
, NN NN O
mci NNP NNP B-TEST
, NN NN O
biopsy NNP NNP B-TEST
, NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
nuclear NNP NNP B-TEST
medicine NNP NNP I-TEST
, NN NN O
lymphatic NNP NNP B-TEST
scan NNP NNP I-TEST
, NN NN O
lymph NN NN O
node NN NN O
, NN NN O
nuclear NN NN O
, NN NN O
breast NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Mantle NNP NNP B-PROBLEM
Cell NNP NNP I-PROBLEM
Lymphoma NNP NNP I-PROBLEM
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
mantle NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
, NN NN O
admitted NN NN O
now NN NN O
to NN NN O
start NN NN O
chemotherapy NNP NNP B-DRUG
. NN NN O

She NN NN O
will NN NN O
start NN NN O
treatment NNP NNP B-TREATMENT
with NN NN O
hyperfractionated NN NN O
cyclophosphamide NNP NNP B-DRUG
, NN NN O
vincristine NNP NNP B-DRUG
, NN NN O
doxorubicin NNP NNP B-DRUG
, NN NN O
dexamethasone NNP NNP B-DRUG
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
mantle NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
47-year-old NN NN O
woman NN NN O
who NN NN O
presented NN NN O
with NN NN O
abdominal NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
in NN NN O
September NNP NNP B-DATE
2006 NNP NNP I-DATE
. NN NN O

On NN NN O
chest NNP NNP B-TEST
x-ray NNP NNP I-TEST
, NN NN O
she NN NN O
had NN NN O
a NN NN O
possible NN NN O
infiltrate NNP NNP B-PROBLEM
and NN NN O
it NN NN O
was NN NN O
thought NN NN O
she NN NN O
might NN NN O
have NN NN O
pneumonia NNP NNP B-PROBLEM
and NN NN O
she NN NN O
was NN NN O
treated NN NN O
with NN NN O
antibiotics NNP NNP B-DRUG
and NN NN O
prednisone NNP NNP B-DRUG
. NN NN O

Symptoms NNP NNP B-PROBLEM
improved NN NN O
temporarily NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
completely NN NN O
resolve NN NN O
. NN NN O

By NN NN O
the NN NN O
end NN NN O
of NN NN O
September NNP NNP B-DATE
, NN NN O
her NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
had NN NN O
worsened NN NN O
and NN NN O
she NN NN O
was NN NN O
seen NN NN O
in NN NN O
the NN NN O
emergency NN NN O
room NN NN O
at NN NN O
ABC NN NN O
. NN NN O

Chest NNP NNP B-TEST
x-ray NNP NNP I-TEST
was NN NN O
compatible NN NN O
with NN NN O
pleurisy NNP NNP B-PROBLEM
and NN NN O
she NN NN O
was NN NN O
treated NN NN O
with NN NN O
Percocet NNP NNP B-DRUG
. NN NN O

Few NN NN O
days NN NN O
later NN NN O
, NN NN O
she NN NN O
was NN NN O
seen NN NN O
and NN NN O
given NN NN O
a NN NN O
prescription NN NN O
for NN NN O
Ultram NNP NNP B-DRUG
because NN NN O
Percocet NNP NNP B-TREATMENT
was NN NN O
causing NN NN O
nausea NNP NNP B-PROBLEM
. NN NN O

Eventually NN NN O
, NN NN O
she NN NN O
was NN NN O
seen NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
and NN NN O
noted NN NN O
to NN NN O
have NN NN O
splenomegaly NNP NNP B-PROBLEM
. NN NN O

Repeat NNP NNP B-TEST
ultrasound NNP NNP I-TEST
was NN NN O
done NN NN O
and NN NN O
showed NN NN O
the NNP NNP B-PROBLEM
spleen NNP NNP I-PROBLEM
enlarged NNP NNP I-PROBLEM
at NN NN O
19 NN NN O
cm NN NN O
. NN NN O

In NN NN O
retrospect NN NN O
, NN NN O
this NN NN O
was NN NN O
not NN NN O
changed NN NN O
in NN NN O
comparison NN NN O
to NN NN O
an NNP NNP B-TEST
ultrasound NNP NNP I-TEST
that NN NN O
was NN NN O
done NN NN O
in NN NN O
September NNP NNP B-DATE
. NN NN O

She NN NN O
underwent NN NN O
positron NNP NNP B-TEST
emission NNP NNP I-TEST
tomography NNP NNP I-TEST
( NNP NNP I-TEST
PET NNP NNP I-TEST
) NNP NNP I-TEST
scanning NNP NNP I-TEST
, NN NN O
which NN NN O
showed NN NN O
diffuse NNP NNP B-PROBLEM
hypermetabolic NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
measuring NN NN O
1 NN NN O
to NN NN O
2 NN NN O
cm NN NN O
in NN NN O
diameter NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
a NNP NNP B-PROBLEM
hypermetabolic NNP NNP I-PROBLEM
spleen NNP NNP I-PROBLEM
that NN NN O
was NN NN O
enlarged NNP NNP B-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
underwent NN NN O
lymph NNP NNP B-TEST
node NNP NNP I-TEST
biopsy NNP NNP I-TEST
on NNP NNP I-TEST
the NNP NNP I-TEST
right NNP NNP I-TEST
neck NNP NNP I-TEST
on NN NN O
10/27/2006 NNP NNP B-DATE
. NN NN O

Pathology NN NN O
is NN NN O
consistent NN NN O
with NN NN O
mantle NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

On NN NN O
10/31/2006 NNP NNP B-DATE
, NN NN O
she NN NN O
had NN NN O
a NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
. NN NN O

This NN NN O
does NN NN O
show NN NN O
involvement NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
bone NNP NNP I-PROBLEM
marrow NNP NNP I-PROBLEM
with NN NN O
lymphoma NNP NNP B-PROBLEM
. NN NN O

She NN NN O
was NN NN O
noted NN NN O
to NN NN O
have NN NN O
circulating NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
cells NNP NNP I-PROBLEM
on NN NN O
peripheral NNP NNP B-TEST
smear NNP NNP I-TEST
as NN NN O
well NN NN O
. NN NN O

Although NN NN O
CBC NNP NNP B-TEST
was NN NN O
normal NN NN O
, NN NN O
MCV NNP NNP B-TEST
was NN NN O
low NNP NNP B-PROBLEM
and NN NN O
the NNP NNP B-TEST
ferritin NNP NNP I-TEST
was NN NN O
assessed NN NN O
and NN NN O
was NN NN O
low NN NN O
at NN NN O
8 NN NN O
, NN NN O
consistent NN NN O
with NN NN O
iron NNP NNP B-PROBLEM
deficiency NNP NNP I-PROBLEM
. NN NN O

ALLERGIES NN NN O
: NN NN O
NONE NNP NNP B-DRUG
. NN NN O

MEDICATIONS NN NN O
: NN NN O

1 NN NN O
. NN NN O
Estradiol/Prometrium NNP NNP B-DRUG
. NN NN O

2 NN NN O
. NN NN O
Ultram NNP NNP B-DRUG
p.r.n NN NN O
. NN NN O

3 NN NN O
. NN NN O
Baby NNP NNP B-DRUG
aspirin NNP NNP I-DRUG
. NN NN O

4 NN NN O
. NN NN O
Lunesta NNP NNP B-DRUG
for NN NN O
sleep NN NN O
. NN NN O

5 NN NN O
. NN NN O
She NN NN O
has NN NN O
been NN NN O
started NN NN O
on NN NN O
iron NNP NNP B-DRUG
supplements NNP NNP I-DRUG
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O

1 NN NN O
. NN NN O
Tubal NNP NNP B-TREATMENT
ligation NNP NNP I-TREATMENT
in NN NN O
1986 NN NN O
. NN NN O

2 NN NN O
. NN NN O
Possible NN NN O
cyst NNP NNP B-PROBLEM
removed NN NN O
from NN NN O
the NN NN O
left NN NN O
neck NN NN O
in NN NN O
1991 NN NN O
. NN NN O

3 NN NN O
. NN NN O
Tonsillectomy NNP NNP B-TREATMENT
. NN NN O

4 NN NN O
. NN NN O
Migraines NNP NNP B-PROBLEM
, NN NN O
which NN NN O
are NN NN O
rare NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
does NN NN O
not NN NN O
smoke NN NN O
cigarettes NN NN O
and NN NN O
drinks NN NN O
alcohol NN NN O
only NN NN O
occasionally NN NN O
. NN NN O

She NN NN O
is NN NN O
married NN NN O
and NN NN O
has NN NN O
two NN NN O
children NN NN O
, NN NN O
ages NN NN O
24 NN NN O
and NN NN O

20 NN NN O
. NN NN O
She NN NN O
works NN NN O
as NN NN O
a NN NN O
project NN NN O
administrator NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Father NN NN O
is NN NN O
deceased NN NN O
. NN NN O

He NN NN O
had NN NN O
emphysema NNP NNP B-PROBLEM
and NN NN O
colon NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
at NN NN O
age NN NN O

68 NN NN O
. NN NN O
Mother NN NN O
has NN NN O
arrhythmia NNP NNP B-PROBLEM
and NN NN O
hypertension NNP NNP B-PROBLEM
. NN NN O

Her NN NN O
sister NN NN O
has NN NN O
hypertension NNP NNP B-PROBLEM
and NN NN O
her NN NN O
brother NN NN O
is NN NN O
healthy NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
GENERAL NN NN O
: NN NN O
She NN NN O
is NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

VITAL NN NN O
SIGNS NN NN O
: NN NN O
Her NNP NNP B-TEST
weight NNP NNP I-TEST
is NN NN O
168 NN NN O
pounds NN NN O
, NN NN O
and NN NN O
she NN NN O
is NN NN O
afebrile NNP NNP B-PROBLEM
with NN NN O
a NN NN O
normal NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
pulse NNP NNP B-TEST
. NN NN O

HEENT NN NN O
: NN NN O
The NN NN O
oropharynx NN NN O
is NN NN O
benign NN NN O
. NN NN O

SKIN NN NN O
: NN NN O
The NN NN O
skin NN NN O
is NN NN O
warm NN NN O
and NN NN O
dry NN NN O
and NN NN O
shows NN NN O
no NN NN O
jaundice NNP NNP B-PROBLEM
. NN NN O

NECK NN NN O
: NN NN O
There NN NN O
is NN NN O
shotty NNP NNP B-PROBLEM
adenopathy NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
. NN NN O

CARDIAC NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
without NN NN O
murmur NNP NNP B-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
and NN NN O
nontender NNP NNP B-PROBLEM
and NN NN O
shows NN NN O
the NN NN O
spleen NN NN O
palpable NN NN O
about NN NN O
10 NN NN O
cm NN NN O
below NN NN O
the NN NN O
right NN NN O
costal NN NN O
margin NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
peripheral NNP NNP B-PROBLEM
edema NNP NNP I-PROBLEM
is NN NN O
noted NN NN O
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
CBC NNP NNP B-TEST
and NN NN O
chemistry NNP NNP B-TEST
panel NNP NNP I-TEST
are NN NN O
pending NN NN O
. NN NN O

CBC NNP NNP B-TEST
was NN NN O
normal NN NN O
last NN NN O
week NN NN O
. NN NN O

PT/INR NNP NNP B-TEST
was NN NN O
normal NN NN O
as NN NN O
well NN NN O
. NN NN O

IMPRESSION NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
mantle NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
, NN NN O
admitted NN NN O
now NN NN O
to NN NN O
start NN NN O
chemotherapy NNP NNP B-DRUG
. NN NN O

She NN NN O
will NN NN O
start NN NN O
treatment NNP NNP B-TREATMENT
with NN NN O
hyperfractionated NN NN O
cyclophosphamide NNP NNP B-DRUG
, NN NN O
vincristine NNP NNP B-DRUG
, NN NN O
doxorubicin NNP NNP B-DRUG
, NN NN O
dexamethasone NNP NNP B-DRUG
. NN NN O

Toxicities NNP NNP B-PROBLEM
have NN NN O
already NN NN O
been NN NN O
discussed NN NN O
with NN NN O
her NNP NNP B-PROBLEM
including NNP NNP I-PROBLEM
myelosuppression NNP NNP I-PROBLEM
, NN NN O
mucositis NNP NNP B-PROBLEM
, NN NN O
diarrhea NNP NNP B-PROBLEM
, NN NN O
nausea NNP NNP B-PROBLEM
, NN NN O
alopecia NNP NNP B-PROBLEM
, NN NN O
the NNP NNP B-PROBLEM
low NNP NNP I-PROBLEM
risk NNP NNP I-PROBLEM
for NN NN O
cardiac NNP NNP B-PROBLEM
toxicity NNP NNP I-PROBLEM
, NN NN O
bladder NNP NNP B-PROBLEM
toxicity NNP NNP I-PROBLEM
, NN NN O
neuropathy NNP NNP B-PROBLEM
, NN NN O
constipation NNP NNP B-PROBLEM
, NN NN O
etc NN NN O
. NN NN O

Written NN NN O
materials NN NN O
were NN NN O
provided NN NN O
to NN NN O
her NN NN O
last NN NN O
week NN NN O
. NN NN O

PLAN NN NN O
: NN NN O
Plan NN NN O
will NN NN O
be NN NN O
to NN NN O
add NN NN O
Rituxan NNP NNP B-DRUG
a NN NN O
little NN NN O
later NN NN O
in NN NN O
her NN NN O
course NN NN O
because NN NN O
she NN NN O
has NN NN O
circulating NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
cells NNP NNP I-PROBLEM
. NN NN O

She NN NN O
will NN NN O
be NN NN O
started NN NN O
on NN NN O
allopurinol NNP NNP B-DRUG
today NN NN O
as NN NN O
well NN NN O
as NN NN O
hydration NNP NNP B-TREATMENT
further NN NN O
to NN NN O
avoid NN NN O
the NN NN O
possibility NN NN O
of NN NN O
tumor NNP NNP B-PROBLEM
lysis NNP NNP I-PROBLEM
syndrome NNP NNP I-PROBLEM
. NN NN O

Plan NN NN O
will NN NN O
be NN NN O
to NN NN O
have NN NN O
her NN NN O
evaluated NN NN O
for NN NN O
bone NNP NNP B-TREATMENT
marrow NNP NNP I-TREATMENT
transplant NNP NNP I-TREATMENT
in NN NN O
first NN NN O
remission NN NN O
. NN NN O

I NN NN O
will NN NN O
have NN NN O
Dr NN NN O
. NN NN O
Y NNP NNP B-NAME
see NN NN O
her NN NN O
while NN NN O
she NN NN O
is NN NN O
in NN NN O
the NN NN O
hospital NN NN O
. NN NN O

The NN NN O
patient NN NN O
is NN NN O
anxious NNP NNP B-PROBLEM
, NN NN O
and NN NN O
will NN NN O
be NN NN O
given NN NN O
Ativan NNP NNP B-DRUG
as NN NN O
needed NN NN O
. NN NN O

We NN NN O
will NN NN O
discontinue NN NN O
aspirin NNP NNP B-DRUG
for NN NN O
now NN NN O
, NN NN O
but NN NN O
continue NN NN O
estradiol/Prometrium NNP NNP B-DRUG
. NN NN O

Iron NNP NNP B-PROBLEM
deficiency NNP NNP I-PROBLEM
will NN NN O
be NN NN O
treated NN NN O
with NN NN O
oral NNP NNP B-DRUG
iron NNP NNP I-DRUG
supplements NNP NNP I-DRUG
and NN NN O
we NN NN O
will NN NN O
follow NN NN O
her NNP NNP B-TEST
counts NNP NNP I-TEST
. NN NN O

She NN NN O
may NN NN O
well NN NN O
have NN NN O
gastrointestinal NNP NNP B-PROBLEM
( NNP NNP I-PROBLEM
GI NNP NNP I-PROBLEM
) NNP NNP I-PROBLEM
involvement NNP NNP I-PROBLEM
, NN NN O
which NN NN O
is NN NN O
not NN NN O
uncommon NN NN O
with NN NN O
mantle NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

After NN NN O
she NN NN O
undergoes NN NN O
remission NN NN O
, NN NN O
we NN NN O
will NN NN O
consider NN NN O
colonoscopy NNP NNP B-TEST
for NN NN O
biopsies NNP NNP B-TEST
prior NN NN O
to NN NN O
proceeding NN NN O
to NN NN O
transplant NNP NNP B-TREATMENT
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
cyclophosphamide NNP NNP B-DRUG
, NN NN O
vincristine NNP NNP B-DRUG
, NN NN O
doxorubicin NNP NNP B-DRUG
, NN NN O
dexamethasone NNP NNP B-DRUG
, NN NN O
myelosuppression NNP NNP B-DRUG
, NN NN O
mucositis NNP NNP B-PROBLEM
, NN NN O
diarrhea NNP NNP B-PROBLEM
, NN NN O
nausea NNP NNP B-PROBLEM
, NN NN O
alopecia NNP NNP B-PROBLEM
, NN NN O
cardiac NNP NNP B-PROBLEM
toxicity NNP NNP I-PROBLEM
, NN NN O
bladder NNP NNP B-PROBLEM
toxicity NNP NNP I-PROBLEM
, NN NN O
neuropathy NNP NNP B-PROBLEM
, NN NN O
constipation NNP NNP B-PROBLEM
, NN NN O
newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
, NN NN O
mantle NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
, NN NN O
bone NNP NNP B-PROBLEM
marrow NNP NNP I-PROBLEM
, NN NN O
lymphoma NNP NNP B-PROBLEM
, NN NN O
cbc NNP NNP B-PROBLEM
, NN NN O
iron NNP NNP B-DRUG
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Concomitant NN NN O
Chemoradiotherapy NNP NNP B-DRUG
Description NN NN O
: NN NN O
Concomitant NN NN O
chemoradiotherapy NNP NNP B-DRUG
for NN NN O
curative NN NN O
intent NN NN O
patients NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CONCOMITANT NN NN O
CHEMORADIOTHERAPY NN NN O
FOR NN NN O
CURATIVE NN NN O
INTENT NN NN O
PATIENTS NN NN O
This NN NN O
patient NN NN O
is NN NN O
receiving NN NN O
combined NN NN O
radiotherapy NNP NNP B-DRUG
and NN NN O
chemotherapy NNP NNP B-DRUG
in NN NN O
an NN NN O
effort NN NN O
to NN NN O
maximize NN NN O
the NN NN O
chance NN NN O
of NN NN O
control NN NN O
of NN NN O
this NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

The NN NN O
chemotherapy NNP NNP B-DRUG
is NN NN O
given NN NN O
in NN NN O
addition NN NN O
to NN NN O
the NNP NNP B-TREATMENT
radiotherapy NNP NNP I-TREATMENT
, NN NN O
not NN NN O
only NN NN O
to NN NN O
act NN NN O
as NN NN O
a NN NN O
cytotoxic NNP NNP B-DRUG
agent NNP NNP I-DRUG
on NN NN O
its NN NN O
own NN NN O
, NN NN O
but NN NN O
also NN NN O
to NN NN O
potentiate NN NN O
and NN NN O
enhance NN NN O
the NN NN O
effect NN NN O
of NN NN O
radiotherapy NNP NNP B-TREATMENT
on NN NN O
tumor NNP NNP B-TREATMENT
cells NNP NNP I-TREATMENT
. NN NN O

It NN NN O
has NN NN O
been NN NN O
shown NN NN O
in NN NN O
the NN NN O
literature NN NN O
that NN NN O
this NN NN O
will NN NN O
maximize NN NN O
the NN NN O
chance NN NN O
of NN NN O
control NN NN O
. NN NN O

During NN NN O
the NN NN O
course NN NN O
of NN NN O
the NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
, NN NN O
the NNP NNP B-TREATMENT
patient's NNP NNP I-TREATMENT
therapy NNP NNP I-TREATMENT
must NN NN O
be NN NN O
closely NN NN O
monitored NN NN O
by NN NN O
the NN NN O
attending NN NN O
physician NN NN O
to NN NN O
be NN NN O
sure NN NN O
that NN NN O
the NN NN O
proper NN NN O
chemotherapy NNP NNP B-DRUG
drugs NNP NNP I-DRUG
are NN NN O
given NN NN O
at NN NN O
the NN NN O
proper NN NN O
time NN NN O
during NN NN O
the NNP NNP B-TREATMENT
radiotherapy NNP NNP I-TREATMENT
course NNP NNP I-TREATMENT
. NN NN O

It NN NN O
is NN NN O
also NN NN O
important NN NN O
to NN NN O
closely NNP NNP B-TEST
monitor NNP NNP I-TEST
the NN NN O
patient NN NN O
to NN NN O
know NN NN O
when NN NN O
treatment NNP NNP B-TREATMENT
with NN NN O
either NN NN O
chemotherapy NNP NNP B-DRUG
or NN NN O
radiotherapy NNP NNP B-DRUG
needs NN NN O
to NN NN O
be NN NN O
held NN NN O
. NN NN O

This NNP NNP B-TREATMENT
combined NNP NNP I-TREATMENT
treatment NNP NNP I-TREATMENT
usually NN NN O
produces NN NN O
greater NNP NNP B-PROBLEM
side NNP NNP I-PROBLEM
effects NNP NNP I-PROBLEM
than NN NN O
either NN NN O
treatment NNP NNP B-TREATMENT
alone NN NN O
, NN NN O
and NN NN O
these NN NN O
need NN NN O
to NN NN O
be NN NN O
constantly NN NN O
monitored NN NN O
and NN NN O
treatment NNP NNP B-TREATMENT
initiated NN NN O
on NN NN O
a NN NN O
timely NN NN O
basis NN NN O
to NN NN O
minimize NN NN O
these NNP NNP B-PROBLEM
effects NNP NNP I-PROBLEM
. NN NN O

In NN NN O
accordance NN NN O
, NN NN O
this NN NN O
requires NN NN O
more NN NN O
frequency NN NN O
consultation NN NN O
and NN NN O
coordination NN NN O
with NN NN O
the NN NN O
medical NN NN O
oncologist NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
this NN NN O
becomes NN NN O
a NN NN O
very NN NN O
time NN NN O
intensive NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
and NN NN O
justifies NN NN O
CPT NN NN O
Code NN NN O
77470 NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
tumor NNP NNP B-TREATMENT
cells NNP NNP I-TREATMENT
, NN NN O
concomitant NN NN O
chemoradiotherapy NNP NNP B-DRUG
, NN NN O
chemotherapy NNP NNP B-DRUG
, NN NN O
radiotherapy NNP NNP B-DRUG
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Colon NN NN O
Cancer NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
stage NNP NNP I-PROBLEM
II NNP NNP I-PROBLEM
colon NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
with NN NN O
a NNP NNP B-PROBLEM
stage NNP NNP I-PROBLEM
T3c NNP NNP I-PROBLEM
, NN NN O
N0 NNP NNP B-PROBLEM
, NN NN O
M0 NN NN O
colon NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
grade NN NN O

1 NN NN O
. NN NN O
Although NN NN O
, NN NN O
the NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
was NN NN O
near NN NN O
obstructing NN NN O
, NN NN O
she NN NN O
was NN NN O
not NN NN O
having NN NN O
symptoms NNP NNP B-PROBLEM
and NN NN O
in NN NN O
fact NN NN O
was NN NN O
having NN NN O
normal NN NN O
bowel NN NN O
movements NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULTATION NN NN O
: NN NN O
I NN NN O
was NN NN O
asked NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
to NN NN O
see NN NN O
the NN NN O
patient NN NN O
in NN NN O
consultation NN NN O
for NN NN O
a NN NN O
new NN NN O
diagnosis NN NN O
of NN NN O
colon NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
The NN NN O
patient NN NN O
presented NN NN O
to NN NN O
medical NN NN O
attention NN NN O
after NN NN O
she NN NN O
noticed NN NN O
mild NNP NNP B-PROBLEM
abdominal NNP NNP I-PROBLEM
cramping NNP NNP I-PROBLEM
in NN NN O
February NNP NNP B-DATE
2007 NNP NNP I-DATE
. NN NN O

At NN NN O
that NN NN O
time NN NN O
, NN NN O
she NN NN O
was NN NN O
pregnant NN NN O
and NN NN O
was NN NN O
unsure NN NN O
if NN NN O
her NNP NNP B-PROBLEM
symptoms NNP NNP I-PROBLEM
might NN NN O
have NN NN O
been NN NN O
due NN NN O
to NN NN O
the NNP NNP B-PROBLEM
pregnancy NNP NNP I-PROBLEM
. NN NN O

Unfortunately NN NN O
, NN NN O
she NN NN O
had NN NN O
miscarriage NNP NNP B-PROBLEM
at NN NN O
about NN NN O
seven NN NN O
weeks NN NN O
. NN NN O

She NN NN O
again NN NN O
had NN NN O
abdominal NNP NNP B-PROBLEM
cramping NNP NNP I-PROBLEM
, NN NN O
severe NN NN O
, NN NN O
in NN NN O
late NN NN O
March NNP NNP B-DATE
2007 NNP NNP I-DATE
. NN NN O

She NN NN O
underwent NN NN O
colonoscopy NNP NNP B-TEST
on NN NN O
04/30/2007 NNP NNP B-DATE
by NN NN O
Dr NN NN O
. NN NN O
Y NNP NNP B-NAME
. NN NN O

Of NN NN O
note NN NN O
, NN NN O
she NN NN O
is NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
early NNP NNP B-PROBLEM
colon NNP NNP I-PROBLEM
cancers NNP NNP I-PROBLEM
and NN NN O
had NN NN O
her NNP NNP B-TEST
first NNP NNP I-TEST
colonoscopy NNP NNP I-TEST
at NN NN O
age NN NN O
35 NN NN O
and NN NN O
no NN NN O
polyps NNP NNP B-PROBLEM
were NN NN O
seen NN NN O
at NN NN O
that NN NN O
time NN NN O
. NN NN O

On NN NN O
colonoscopy NNP NNP B-TEST
, NN NN O
she NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NNP NNP B-PROBLEM
near-obstructing NNP NNP I-PROBLEM
lesion NNP NNP I-PROBLEM
at NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
splenic NNP NNP I-PROBLEM
flexure NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
not NN NN O
able NN NN O
to NN NN O
have NN NN O
the NN NN O
scope NN NN O
passed NN NN O
past NN NN O
this NNP NNP B-PROBLEM
lesion NNP NNP I-PROBLEM
. NN NN O

Pathology NNP NNP B-TEST
showed NN NN O
a NNP NNP B-PROBLEM
colon NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
although NN NN O
I NN NN O
do NN NN O
not NN NN O
have NN NN O
a NN NN O
copy NN NN O
of NN NN O
that NN NN O
report NN NN O
at NN NN O
this NN NN O
time NN NN O
. NN NN O

She NN NN O
had NN NN O
surgical NNP NNP B-TREATMENT
resection NNP NNP I-TREATMENT
done NN NN O
yesterday NN NN O
. NN NN O

The NNP NNP B-TREATMENT
surgery NNP NNP I-TREATMENT
was NN NN O
laparoscopic NN NN O
assisted NN NN O
with NN NN O
anastomosis NNP NNP B-TREATMENT
. NN NN O

At NN NN O
the NN NN O
time NN NN O
of NN NN O
surgery NNP NNP B-TREATMENT
, NN NN O
lymph NN NN O
nodes NN NN O
were NN NN O
palpable NN NN O
. NN NN O

Pathology NNP NNP B-TEST
showed NN NN O
colon NNP NNP B-PROBLEM
adenocarcinoma NNP NNP I-PROBLEM
, NN NN O
low NN NN O
grade NN NN O
, NN NN O
measuring NN NN O
3.8 NN NN O
x NN NN O
1.7 NN NN O
cm NN NN O
, NN NN O
circumferential NN NN O
and NN NN O
invading NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
to NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
subserosal NNP NNP I-PROBLEM
mucosa NNP NNP I-PROBLEM
greater NN NN O
than NN NN O
5 NN NN O
mm NN NN O
, NN NN O
13 NN NN O
lymph NN NN O
nodes NN NN O
were NN NN O
negative NN NN O
for NN NN O
metastasis NNP NNP B-PROBLEM
. NN NN O

There NN NN O
was NN NN O
no NN NN O
angiolymphatic NNP NNP B-PROBLEM
invasion NNP NNP I-PROBLEM
noted NN NN O
. NN NN O

Radial NNP NNP B-TEST
margin NNP NNP I-TEST
was NN NN O
0.1 NN NN O
mm NN NN O
. NN NN O

Other NNP NNP B-TEST
margins NNP NNP I-TEST
were NN NN O
5 NN NN O
and NN NN O
6 NN NN O
mm NN NN O
. NN NN O

Testing NNP NNP B-TEST
for NN NN O
microsatellite NNP NNP B-PROBLEM
instability NNP NNP I-PROBLEM
is NN NN O
still NN NN O
pending NN NN O
. NN NN O

Staging NNP NNP B-TEST
has NN NN O
already NN NN O
been NN NN O
done NN NN O
with NN NN O
a NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
chest NNP NNP I-TEST
, NNP NNP I-TEST
abdomen NNP NNP I-TEST
, NNP NNP I-TEST
and NNP NNP I-TEST
pelvis NNP NNP I-TEST
. NN NN O

This NN NN O
showed NN NN O
a NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
at NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
splenic NNP NNP I-PROBLEM
flexure NNP NNP I-PROBLEM
, NN NN O
mildly NNP NNP B-PROBLEM
enlarged NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
there NN NN O
, NN NN O
and NN NN O
no NN NN O
evidence NN NN O
of NN NN O
metastasis NNP NNP B-PROBLEM
to NNP NNP I-PROBLEM
liver NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
lungs NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
other NNP NNP I-PROBLEM
organs NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
degenerative NNP NNP I-PROBLEM
changes NNP NNP I-PROBLEM
were NN NN O
noted NN NN O
at NN NN O
L5-S1 NN NN O
. NN NN O

The NN NN O
ovaries NN NN O
were NN NN O
normal NN NN O
. NN NN O

An NNP NNP B-PROBLEM
intrauterine NNP NNP I-PROBLEM
device NNP NNP I-PROBLEM
( NNP NNP I-PROBLEM
IUD NNP NNP I-PROBLEM
) NNP NNP I-PROBLEM
was NN NN O
present NN NN O
in NN NN O
the NN NN O
uterus NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
She NN NN O
has NN NN O
otherwise NN NN O
been NN NN O
feeling NN NN O
well NN NN O
. NN NN O

She NN NN O
has NN NN O
not NN NN O
had NN NN O
fevers NNP NNP B-PROBLEM
, NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
, NN NN O
or NN NN O
noticed NN NN O
lymphadenopathy NNP NNP B-PROBLEM
. NN NN O

She NN NN O
has NN NN O
not NN NN O
had NN NN O
cough NNP NNP B-PROBLEM
, NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
, NN NN O
back NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
bone NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
blood NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
stool NNP NNP I-PROBLEM
, NN NN O
melena NNP NNP B-PROBLEM
, NN NN O
or NN NN O
change NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
stool NNP NNP I-PROBLEM
caliber NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
eating NN NN O
well NN NN O
up NN NN O
until NN NN O
the NN NN O
time NN NN O
of NN NN O
her NNP NNP B-TREATMENT
surgery NNP NNP I-TREATMENT
. NN NN O

She NN NN O
is NN NN O
up-to-date NN NN O
on NN NN O
mammography NNP NNP B-TEST
, NN NN O
which NN NN O
will NN NN O
be NN NN O
due NN NN O
again NN NN O
in NN NN O
June NNP NNP B-DATE
. NN NN O

She NN NN O
has NN NN O
no NN NN O
history NN NN O
of NN NN O
pulmonary NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
cardiac NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
renal NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
hepatic NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
thyroid NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
central NNP NNP I-PROBLEM
nervous NNP NNP I-PROBLEM
system NNP NNP I-PROBLEM
( NNP NNP I-PROBLEM
CNS NNP NNP I-PROBLEM
) NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

ALLERGIES NN NN O
: NN NN O
PENICILLIN NNP NNP B-TREATMENT
, NN NN O
WHICH NN NN O
CAUSED NNP NNP B-PROBLEM
HIVES NNP NNP I-PROBLEM
WHEN NN NN O
SHE NN NN O
WAS NN NN O
A NN NN O
CHILD NN NN O
. NN NN O

MEDICATIONS NN NN O
PRIOR NN NN O
TO NN NN O
ADMISSION NN NN O
: NN NN O
None NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
No NN NN O
significant NNP NNP B-PROBLEM
medical NNP NNP I-PROBLEM
problem NNP NNP I-PROBLEM
. NN NN O

She NN NN O
has NN NN O
had NN NN O
three NNP NNP B-PROBLEM
miscarriages NNP NNP I-PROBLEM
, NN NN O
all NN NN O
of NN NN O
them NN NN O
at NN NN O
about NN NN O
seven NN NN O
weeks NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
prior NNP NNP B-TREATMENT
surgeries NNP NNP I-TREATMENT
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
smoked NN NN O
cigarettes NN NN O
socially NN NN O
while NN NN O
in NN NN O
her NN NN O
20s NN NN O
. NN NN O

A NN NN O
pack NN NN O
of NN NN O
cigarettes NN NN O
would NN NN O
last NN NN O
for NN NN O
more NN NN O
than NN NN O
a NN NN O
week NN NN O
. NN NN O

She NN NN O
does NN NN O
not NN NN O
smoke NN NN O
now NN NN O
. NN NN O

She NN NN O
has NN NN O
two NN NN O
glasses NN NN O
of NN NN O
wine NN NN O
per NN NN O
day NN NN O
, NN NN O
both NN NN O
red NN NN O
and NN NN O
white NN NN O
wine NN NN O
. NN NN O

She NN NN O
is NN NN O
married NN NN O
and NN NN O
has NN NN O
no NN NN O
children NN NN O
. NN NN O

An NNP NNP B-TREATMENT
IUD NNP NNP I-TREATMENT
was NN NN O
recently NN NN O
placed NN NN O
. NN NN O

She NN NN O
works NN NN O
as NN NN O
an NN NN O
esthetician NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Father NN NN O
died NN NN O
of NN NN O
stage NNP NNP B-PROBLEM
IV NNP NNP I-PROBLEM
colon NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
at NN NN O
age NN NN O

45 NN NN O
. NN NN O
This NN NN O
occurred NN NN O
when NN NN O
the NN NN O
patient NN NN O
was NN NN O
young NN NN O
and NN NN O
she NN NN O
is NN NN O
not NN NN O
sure NN NN O
of NN NN O
the NN NN O
rest NN NN O
of NN NN O
the NN NN O
paternal NN NN O
family NN NN O
history NN NN O
. NN NN O

She NN NN O
does NN NN O
believe NN NN O
that NN NN O
aunts NN NN O
and NN NN O
uncles NN NN O
on NN NN O
that NN NN O
side NN NN O
may NN NN O
have NN NN O
died NN NN O
early NN NN O
. NN NN O

Her NN NN O
brother NN NN O
died NN NN O
of NN NN O
pancreas NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
at NN NN O
age NN NN O

44 NN NN O
. NN NN O
Another NN NN O
brother NN NN O
is NN NN O
aged NN NN O
52 NN NN O
and NN NN O
he NN NN O
had NN NN O
polyps NNP NNP B-PROBLEM
on NN NN O
colonoscopy NNP NNP B-TEST
a NN NN O
couple NN NN O
of NN NN O
years NN NN O
ago NN NN O
. NN NN O

Otherwise NN NN O
, NN NN O
he NN NN O
has NN NN O
no NN NN O
medical NNP NNP B-PROBLEM
problem NNP NNP I-PROBLEM
. NN NN O

Mother NN NN O
is NN NN O
aged NN NN O
82 NN NN O
and NN NN O
healthy NN NN O
. NN NN O

She NN NN O
was NN NN O
recently NN NN O
diagnosed NN NN O
with NN NN O
hemochromatosis NNP NNP B-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
GENERAL NN NN O
: NN NN O
She NN NN O
is NN NN O
in NN NN O
no NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

VITAL NN NN O
SIGNS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
afebrile NNP NNP B-PROBLEM
with NN NN O
a NNP NNP B-TEST
pulse NNP NNP I-TEST
of NN NN O
78 NN NN O
, NN NN O
respirations NNP NNP B-TEST
16 NN NN O
, NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
124/70 NN NN O
, NN NN O
and NN NN O
pulse NNP NNP B-TEST
oximetry NNP NNP I-TEST
is NN NN O
93% NN NN O
on NN NN O
3 NN NN O
L NN NN O
of NN NN O
oxygen NNP NNP B-DRUG
by NNP NNP I-DRUG
nasal NNP NNP I-DRUG
cannula NNP NNP I-DRUG
. NN NN O

SKIN NN NN O
: NN NN O
Warm NN NN O
and NN NN O
dry NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
jaundice NNP NNP B-PROBLEM
. NN NN O

LYMPHATICS NN NN O
: NN NN O
No NN NN O
cervical NNP NNP B-PROBLEM
or NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
are NN NN O
palpable NN NN O
. NN NN O

LUNGS NN NN O
: NN NN O
There NN NN O
is NN NN O
no NN NN O
respiratory NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

CARDIAC NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
and NN NN O
mildly NNP NNP B-PROBLEM
tender NNP NNP I-PROBLEM
. NN NN O

Dressings NNP NNP B-TREATMENT
are NN NN O
clean NN NN O
and NN NN O
dry NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
peripheral NNP NNP B-PROBLEM
edema NNP NNP I-PROBLEM
is NN NN O
noted NN NN O
. NN NN O

Sequential NNP NNP B-TREATMENT
compression NNP NNP I-TREATMENT
devices NNP NNP I-TREATMENT
( NNP NNP I-TREATMENT
SCDs NNP NNP I-TREATMENT
) NN NN O
are NN NN O
in NN NN O
place NN NN O
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
White NNP NNP B-TEST
blood NNP NNP I-TEST
count NNP NNP I-TEST
of NN NN O
11.7 NN NN O
, NN NN O
hemoglobin NNP NNP B-TEST
12.8 NN NN O
, NN NN O
hematocrit NNP NNP B-TEST
37.8 NN NN O
, NN NN O
platelets NNP NNP B-TEST
408 NN NN O
, NN NN O
differential NNP NNP B-TEST
shows NN NN O
left NNP NNP B-PROBLEM
shift NNP NNP I-PROBLEM
, NN NN O
MCV NNP NNP B-TEST
is NN NN O
99.6 NN NN O
. NN NN O

Sodium NNP NNP B-DRUG
is NNP NNP I-DRUG
136 NNP NNP I-DRUG
, NN NN O
potassium NNP NNP B-DRUG
4.1 NNP NNP I-DRUG
, NN NN O
bicarb NNP NNP B-TEST
25 NN NN O
, NN NN O
chloride NNP NNP B-TEST
104 NN NN O
, NN NN O
BUN NNP NNP B-TEST
5 NN NN O
, NN NN O
creatinine NNP NNP B-TEST
0.7 NN NN O
, NN NN O
and NN NN O
glucose NNP NNP B-TEST
is NN NN O
133 NN NN O
. NN NN O

Calcium NNP NNP B-TEST
is NN NN O
8.8 NN NN O
and NN NN O
magnesium NNP NNP B-TEST
is NN NN O
1.8 NN NN O
. NN NN O

IMPRESSION NN NN O
AND NN NN O
PLAN NN NN O
: NN NN O
Newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
stage NNP NNP I-PROBLEM
II NNP NNP I-PROBLEM
colon NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
with NN NN O
a NNP NNP B-PROBLEM
stage NNP NNP I-PROBLEM
T3c NNP NNP I-PROBLEM
, NN NN O
N0 NNP NNP B-PROBLEM
, NN NN O
M0 NNP NNP B-PROBLEM
colon NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
grade NN NN O

1 NN NN O
. NN NN O
She NN NN O
does NN NN O
not NN NN O
have NN NN O
high-risk NNP NNP B-PROBLEM
factors NNP NNP I-PROBLEM
such NN NN O
as NN NN O
high NNP NNP B-PROBLEM
grade NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
angiolymphatic NNP NNP I-PROBLEM
invasion NNP NNP I-PROBLEM
, NN NN O
and NN NN O
adequate NN NN O
number NN NN O
of NN NN O
lymph NNP NNP B-PROBLEM
nodes NNP NNP I-PROBLEM
were NN NN O
sampled NN NN O
. NN NN O

Although NN NN O
, NN NN O
the NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
was NN NN O
near NN NN O
obstructing NN NN O
, NN NN O
she NN NN O
was NN NN O
not NN NN O
having NN NN O
symptoms NNP NNP B-PROBLEM
and NN NN O
in NN NN O
fact NN NN O
was NN NN O
having NN NN O
normal NN NN O
bowel NN NN O
movements NN NN O
. NN NN O

A NN NN O
lengthy NN NN O
discussion NN NN O
was NN NN O
held NN NN O
with NN NN O
the NN NN O
patient NN NN O
regarding NN NN O
her NN NN O
diagnosis NN NN O
and NN NN O
prognosis NN NN O
. NN NN O

Firstly NN NN O
, NN NN O
she NN NN O
has NN NN O
a NN NN O
good NN NN O
prognosis NN NN O
for NN NN O
being NN NN O
cured NN NN O
without NN NN O
adjuvant NNP NNP B-TREATMENT
therapy NNP NNP I-TREATMENT
. NN NN O

I NN NN O
would NN NN O
consider NN NN O
her NN NN O
borderline NN NN O
for NN NN O
chemotherapy NNP NNP B-DRUG
given NN NN O
her NN NN O
young NN NN O
age NN NN O
. NN NN O

Referring NN NN O
to NN NN O
the NN NN O
database NN NN O
that NN NN O
had NN NN O
been NN NN O
online NN NN O
, NN NN O
she NN NN O
has NN NN O
a NN NN O
13% NN NN O
chance NN NN O
of NN NN O
relapse NNP NNP B-PROBLEM
in NN NN O
the NN NN O
next NN NN O
five NN NN O
years NN NN O
, NN NN O
and NN NN O
with NN NN O
aggressive NN NN O
chemotherapy NNP NNP B-DRUG
( NN NN O
X-linked NNP NNP B-PROBLEM
agammaglobulinemia NNP NNP I-PROBLEM
( NN NN O
XLA NNP NNP B-PROBLEM
) NN NN O
platinum-based NNP NNP B-DRUG
), NN NN O
this NN NN O
would NN NN O
be NN NN O
reduced NN NN O
to NN NN O
an NN NN O
8% NN NN O
risk NN NN O
of NN NN O
relapse NNP NNP B-PROBLEM
with NN NN O
a NN NN O
5% NN NN O
benefit NN NN O
. NN NN O

Chemotherapy NNP NNP B-DRUG
with NN NN O
5-FU NNP NNP B-DRUG
based NN NN O
regimen NNP NNP B-TREATMENT
would NN NN O
have NN NN O
a NN NN O
smaller NN NN O
benefit NN NN O
of NN NN O
around NN NN O
2.5% NN NN O
. NN NN O

Plan NN NN O
was NN NN O
made NN NN O
to NN NN O
allow NN NN O
her NN NN O
to NN NN O
recuperate NN NN O
and NN NN O
then NN NN O
meet NN NN O
with NN NN O
her NN NN O
and NN NN O
her NN NN O
husband NN NN O
to NN NN O
discuss NN NN O
the NN NN O
pros NN NN O
and NN NN O
cons NN NN O
of NN NN O
adjuvant NN NN O
chemotherapy NNP NNP B-DRUG
including NN NN O
what NN NN O
regimen NN NN O
she NN NN O
could NN NN O
consider NN NN O
including NN NN O
the NNP NNP B-PROBLEM
side NNP NNP I-PROBLEM
effects NNP NNP I-PROBLEM
. NN NN O

We NN NN O
did NN NN O
not NN NN O
review NN NN O
all NN NN O
that NN NN O
information NN NN O
today NN NN O
. NN NN O

She NN NN O
has NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
early NNP NNP B-PROBLEM
colon NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

Her NN NN O
mother NN NN O
will NN NN O
be NN NN O
visiting NN NN O
in NN NN O
the NN NN O
weekend NN NN O
and NN NN O
plan NN NN O
is NN NN O
to NN NN O
obtain NN NN O
the NN NN O
rest NN NN O
of NN NN O
the NN NN O
paternal NN NN O
family NN NN O
history NN NN O
if NN NN O
we NN NN O
can NN NN O
. NN NN O

Tumor NNP NNP B-PROBLEM
is NN NN O
being NN NN O
tested NN NN O
for NN NN O
microsatellite NNP NNP B-PROBLEM
instability NNP NNP I-PROBLEM
and NN NN O
we NN NN O
will NN NN O
discuss NN NN O
this NN NN O
when NN NN O
those NN NN O
results NN NN O
are NN NN O
available NN NN O
. NN NN O

She NN NN O
has NN NN O
one NN NN O
sibling NN NN O
and NN NN O
he NN NN O
is NN NN O
up-to-date NN NN O
on NN NN O
colonoscopy NNP NNP B-TEST
. NN NN O

She NN NN O
does NN NN O
report NN NN O
multiple NNP NNP B-TREATMENT
tubes NNP NNP I-TREATMENT
of NNP NNP I-TREATMENT
blood NNP NNP I-TREATMENT
were NN NN O
drawn NN NN O
prior NN NN O
to NN NN O
her NN NN O
admission NN NN O
. NN NN O

I NN NN O
will NN NN O
check NN NN O
with NN NN O
Dr NN NN O
. NN NN O
Y's NNP NNP B-NAME
office NN NN O
whether NN NN O
she NN NN O
has NN NN O
had NN NN O
a NNP NNP B-TEST
CEA NNP NNP I-TEST
and NN NN O
liver-associated NNP NNP B-TEST
enzymes NNP NNP I-TEST
assessed NN NN O
. NN NN O

If NN NN O
not NN NN O
, NN NN O
those NN NN O
can NN NN O
be NN NN O
drawn NN NN O
tomorrow NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
abdominal NNP NNP B-PROBLEM
cramping NNP NNP I-PROBLEM
, NN NN O
angiolymphatic NNP NNP B-PROBLEM
invasion NNP NNP I-PROBLEM
, NN NN O
newly NNP NNP B-PROBLEM
diagnosed NNP NNP I-PROBLEM
, NN NN O
lymph NNP NNP B-PROBLEM
nodes NNP NNP I-PROBLEM
, NN NN O
colon NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
blood NNP NNP B-PROBLEM
, NN NN O
chemotherapy NNP NNP B-DRUG
, NN NN O
colonoscopy NNP NNP B-TEST
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Radical NN NN O
Mastectomy NN NN O
Description NN NN O
: NN NN O
Invasive NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
. NN NN O

Left NNP NNP B-TREATMENT
modified NNP NNP I-TREATMENT
radical NNP NNP I-TREATMENT
mastectomy NNP NNP I-TREATMENT
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Invasive NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Invasive NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
. NN NN O

OPERATION NN NN O
PERFORMED NN NN O
: NN NN O
Left NNP NNP B-TREATMENT
modified NNP NNP I-TREATMENT
radical NNP NNP I-TREATMENT
mastectomy NNP NNP I-TREATMENT
. NN NN O

ANESTHESIA NN NN O
: NN NN O
General NN NN O
endotracheal NN NN O
. NN NN O

INDICATION NN NN O
FOR NN NN O
THE NN NN O
PROCEDURE NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
52-year-old NN NN O
female NN NN O
who NN NN O
recently NN NN O
underwent NN NN O
a NNP NNP B-TEST
left NNP NNP I-TEST
breast NNP NNP I-TEST
biopsy NNP NNP I-TEST
and NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
invasive NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
elected NN NN O
to NN NN O
have NN NN O
a NNP NNP B-TREATMENT
left NNP NNP I-TREATMENT
modified NNP NNP I-TREATMENT
radical NNP NNP I-TREATMENT
mastectomy NNP NNP I-TREATMENT
, NN NN O
she NN NN O
was NN NN O
not NN NN O
interested NN NN O
in NN NN O
a NNP NNP B-TREATMENT
partial NNP NNP I-TREATMENT
mastectomy NNP NNP I-TREATMENT
. NN NN O

She NN NN O
is NN NN O
aware NN NN O
of NN NN O
the NN NN O
risks NN NN O
and NN NN O
complications NN NN O
of NN NN O
surgery NNP NNP B-TREATMENT
, NN NN O
and NN NN O
wished NN NN O
to NN NN O
proceed NN NN O
. NN NN O

DESCRIPTION NN NN O
OF NN NN O
PROCEDURE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
. NN NN O

She NN NN O
underwent NN NN O
general NNP NNP B-TREATMENT
endotracheal NNP NNP I-TREATMENT
anesthetic NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-TREATMENT
TED NNP NNP I-TREATMENT
stockings NNP NNP I-TREATMENT
and NN NN O
venous NNP NNP B-TREATMENT
compression NNP NNP I-TREATMENT
devices NNP NNP I-TREATMENT
were NN NN O
placed NN NN O
on NN NN O
both NN NN O
lower NN NN O
extremities NN NN O
and NN NN O
they NN NN O
were NN NN O
functioning NN NN O
well NN NN O
. NN NN O

The NN NN O
patient's NN NN O
left NN NN O
anterior NN NN O
chest NN NN O
wall NN NN O
, NN NN O
neck NN NN O
, NN NN O
axilla NN NN O
, NN NN O
and NN NN O
left NN NN O
arm NN NN O
were NN NN O
prepped NN NN O
and NN NN O
draped NN NN O
in NN NN O
the NN NN O
usual NN NN O
sterile NN NN O
manner NN NN O
. NN NN O

The NNP NNP B-TEST
recent NNP NNP I-TEST
biopsy NNP NNP I-TEST
site NNP NNP I-TEST
was NN NN O
located NN NN O
in NN NN O
the NN NN O
upper NN NN O
and NN NN O
outer NN NN O
quadrant NN NN O
of NN NN O
left NN NN O
breast NN NN O
. NN NN O

The NNP NNP B-PROBLEM
plain NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
marked NN NN O
along NN NN O
the NN NN O
skin NN NN O
. NN NN O

Tissues NN NN O
and NN NN O
the NNP NNP B-TREATMENT
flaps NNP NNP I-TREATMENT
were NN NN O
injected NN NN O
with NN NN O
0.25% NNP NNP B-DRUG
Marcaine NNP NNP I-DRUG
with NN NN O
epinephrine NNP NNP B-DRUG
solution NNP NNP I-DRUG
and NN NN O
then NN NN O
a NNP NNP B-PROBLEM
transverse NNP NNP I-PROBLEM
elliptical NNP NNP I-PROBLEM
incision NNP NNP I-PROBLEM
was NN NN O
made NN NN O
in NN NN O
the NN NN O
breast NN NN O
of NN NN O
the NN NN O
skin NN NN O
to NN NN O
include NN NN O
nipple NN NN O
areolar NN NN O
complex NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
recent NN NN O
biopsy NN NN O
site NN NN O
. NN NN O

The NNP NNP B-TREATMENT
flaps NNP NNP I-TREATMENT
were NN NN O
raised NN NN O
superiorly NN NN O
and NN NN O
just NN NN O
below NN NN O
the NN NN O
clavicle NN NN O
medially NN NN O
to NN NN O
the NN NN O
sternum NN NN O
, NN NN O
laterally NN NN O
towards NN NN O
the NN NN O
latissimus NN NN O
dorsi NN NN O
, NN NN O
rectus NN NN O
abdominus NN NN O
fascia NN NN O
. NN NN O

Following NN NN O
this NN NN O
, NN NN O
the NN NN O
breast NN NN O
tissue NN NN O
along NN NN O
with NN NN O
the NN NN O
pectoralis NN NN O
major NN NN O
fascia NN NN O
were NN NN O
dissected NN NN O
off NN NN O
the NN NN O
pectoralis NN NN O
major NN NN O
muscle NN NN O
. NN NN O

The NNP NNP B-PROBLEM
dissection NNP NNP I-PROBLEM
was NN NN O
started NN NN O
medially NN NN O
and NN NN O
extended NN NN O
laterally NN NN O
towards NN NN O
the NN NN O
left NN NN O
axilla NN NN O
. NN NN O

The NN NN O
breast NN NN O
was NN NN O
removed NN NN O
and NN NN O
then NN NN O
the NN NN O
axillary NN NN O
contents NN NN O
were NN NN O
dissected NNP NNP B-TREATMENT
out NNP NNP I-TREATMENT
. NN NN O

Left NN NN O
axillary NN NN O
vein NN NN O
and NN NN O
artery NN NN O
were NN NN O
identified NN NN O
and NN NN O
preserved NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
lung NN NN O
_____ NN NN O
. NN NN O

The NN NN O
patient NN NN O
had NN NN O
several NNP NNP B-PROBLEM
clinically NNP NNP I-PROBLEM
palpable NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
, NN NN O
they NN NN O
were NN NN O
removed NN NN O
with NN NN O
the NNP NNP B-TREATMENT
axillary NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
. NN NN O

Care NN NN O
was NN NN O
taken NN NN O
to NN NN O
avoid NN NN O
injury NNP NNP B-PROBLEM
to NN NN O
any NN NN O
of NN NN O
the NN NN O
above NN NN O
mentioned NN NN O
neurovascular NN NN O
structures NN NN O
. NN NN O

After NN NN O
the NN NN O
tissues NN NN O
were NN NN O
irrigated NN NN O
, NN NN O
we NN NN O
made NN NN O
sure NN NN O
there NN NN O
were NN NN O
no NN NN O
signs NN NN O
of NN NN O
bleeding NNP NNP B-PROBLEM
. NN NN O

Hemostasis NN NN O
had NN NN O
been NN NN O
achieved NN NN O
with NN NN O
Hemoclips NNP NNP B-TREATMENT
. NN NN O

Hemovac NNP NNP B-TREATMENT
drains NNP NNP I-TREATMENT
x2 NN NN O
were NN NN O
then NN NN O
brought NN NN O
in NN NN O
and NN NN O
placed NN NN O
under NN NN O
the NN NN O
left NN NN O
axilla NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
the NN NN O
superior NN NN O
and NN NN O
inferior NNP NNP B-TREATMENT
breast NNP NNP I-TREATMENT
flaps NNP NNP I-TREATMENT
. NN NN O

The NN NN O
subcu NN NN O
was NN NN O
then NN NN O
approximated NN NN O
with NN NN O
interrupted NN NN O
4-0 NNP NNP B-TREATMENT
Vicryl NNP NNP I-TREATMENT
sutures NNP NNP I-TREATMENT
and NNP NNP I-TREATMENT
skin NNP NNP I-TREATMENT
with NN NN O
clips NNP NNP B-TREATMENT
. NN NN O

The NNP NNP B-TREATMENT
drains NNP NNP I-TREATMENT
were NN NN O
sutured NN NN O
to NN NN O
the NN NN O
chest NN NN O
wall NN NN O
with NN NN O
3-0 NNP NNP B-TREATMENT
nylon NNP NNP I-TREATMENT
sutures NNP NNP I-TREATMENT
. NN NN O

Dressing NNP NNP B-TREATMENT
was NN NN O
applied NN NN O
and NN NN O
the NNP NNP B-TREATMENT
procedure NNP NNP I-TREATMENT
was NN NN O
completed NN NN O
. NN NN O

The NN NN O
patient NN NN O
went NN NN O
to NN NN O
the NN NN O
recovery NN NN O
room NN NN O
in NN NN O
stable NN NN O
condition NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
invasive NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
chest NNP NNP B-PROBLEM
wall NNP NNP I-PROBLEM
, NN NN O
neck NNP NNP B-TREATMENT
, NNP NNP I-TREATMENT
axilla NNP NNP I-TREATMENT
, NNP NNP I-TREATMENT
modified NNP NNP I-TREATMENT
radical NNP NNP I-TREATMENT
mastectomy NNP NNP I-TREATMENT
, NN NN O
radical NNP NNP B-TREATMENT
mastectomy NNP NNP I-TREATMENT
, NN NN O
invasive NNP NNP B-TREATMENT
, NN NN O
carcinoma NNP NNP B-PROBLEM
, NN NN O
mastectomy NNP NNP B-TREATMENT
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Thrombocytopenia NNP NNP B-PROBLEM
- NN NN O
SOAP NN NN O
Note NN NN O
Description NN NN O
: NN NN O
Patient NN NN O
with NN NN O
immune NNP NNP B-PROBLEM
thrombocytopenia NNP NNP I-PROBLEM
( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
SUBJECTIVE NN NN O
: NN NN O
I NN NN O
am NN NN O
following NN NN O
the NN NN O
patient NN NN O
today NN NN O
for NN NN O
immune NNP NNP B-PROBLEM
thrombocytopenia NNP NNP I-PROBLEM
. NN NN O

Her NNP NNP B-TEST
platelets NNP NNP I-TEST
fell NN NN O
to NN NN O
10 NN NN O
on NN NN O
01/09/07 NNP NNP B-DATE
and NN NN O
shortly NN NN O
after NN NN O
learning NN NN O
of NN NN O
that NN NN O
result NN NN O
, NN NN O
I NN NN O
increased NN NN O
her NN NN O
prednisone NNP NNP B-DRUG
to NNP NNP I-DRUG
60 NNP NNP I-DRUG
mg NNP NNP I-DRUG
a NN NN O
day NN NN O
. NN NN O

Repeat NN NN O
on NN NN O
01/16/07 NNP NNP B-DATE
revealed NN NN O
platelets NNP NNP B-TEST
up NN NN O
at NN NN O

43 NN NN O
. NN NN O
No NN NN O
bleeding NNP NNP B-PROBLEM
problems NNP NNP I-PROBLEM
have NN NN O
been NN NN O
noted NN NN O
. NN NN O

I NN NN O
have NN NN O
spoken NN NN O
with NN NN O
her NN NN O
hematologist NN NN O
who NN NN O
recommends NN NN O
at NN NN O
this NN NN O
point NN NN O
we NN NN O
decrease NN NN O
her NN NN O
prednisone NNP NNP B-DRUG
to NNP NNP I-DRUG
40 NNP NNP I-DRUG
mg NNP NNP I-DRUG
for NN NN O
3 NN NN O
days NN NN O
and NN NN O
then NN NN O
go NN NN O
down NN NN O
to NN NN O
20 NN NN O
mg NN NN O
a NN NN O
day NN NN O
. NN NN O

The NN NN O
patient NN NN O
had NN NN O
been NN NN O
on NN NN O
20 NN NN O
mg NN NN O
every NN NN O
other NN NN O
day NN NN O
at NN NN O
least NN NN O
for NN NN O
a NN NN O
while NN NN O
, NN NN O
and NN NN O
her NNP NNP B-TEST
platelets NNP NNP I-TEST
hovered NN NN O
at NN NN O
least NN NN O
above NN NN O
20 NN NN O
or NN NN O
so NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
Vitals NN NN O
: NN NN O
As NN NN O
in NN NN O
chart NN NN O
. NN NN O

The NN NN O
patient NN NN O
is NN NN O
alert NN NN O
, NN NN O
pleasant NN NN O
, NN NN O
and NN NN O
cooperative NN NN O
. NN NN O

She NN NN O
is NN NN O
in NN NN O
no NN NN O
apparent NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
. NN NN O

The NNP NNP B-PROBLEM
petechial NNP NNP I-PROBLEM
areas NNP NNP I-PROBLEM
on NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
legs NNP NNP I-PROBLEM
have NN NN O
resolved NN NN O
. NN NN O

ASSESSMENT NN NN O
AND NN NN O
PLAN NN NN O
: NN NN O
Patient NN NN O
with NN NN O
improvement NN NN O
of NN NN O
her NNP NNP B-TEST
platelet NNP NNP I-TEST
count NNP NNP I-TEST
on NN NN O
burst NN NN O
of NN NN O
prednisone NNP NNP B-DRUG
. NN NN O

We NN NN O
will NN NN O
decrease NN NN O
her NN NN O
prednisone NNP NNP B-DRUG
to NNP NNP I-DRUG
40 NNP NNP I-DRUG
mg NNP NNP I-DRUG
for NN NN O
3 NN NN O
days NN NN O
, NN NN O
then NN NN O
go NN NN O
down NN NN O
to NN NN O
20 NN NN O
mg NN NN O
a NN NN O
day NN NN O
. NN NN O

Basically NN NN O
thereafter NN NN O
, NN NN O
over NN NN O
time NN NN O
, NN NN O
I NN NN O
may NN NN O
try NN NN O
to NN NN O
sneak NN NN O
it NN NN O
back NN NN O
a NN NN O
little NN NN O
bit NN NN O
further NN NN O
. NN NN O

She NN NN O
is NN NN O
on NN NN O
medicines NNP NNP B-TREATMENT
for NN NN O
osteoporosis NNP NNP B-PROBLEM
including NN NN O
bisphosphonate NNP NNP B-DRUG
and NN NN O
calcium NNP NNP B-DRUG
with NN NN O
vitamin NNP NNP B-DRUG
D NNP NNP I-DRUG
. NN NN O

We NN NN O
will NN NN O
arrange NN NN O
to NN NN O
have NN NN O
a NNP NNP B-TEST
CBC NNP NNP I-TEST
drawn NN NN O
weekly NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
platelets NNP NNP B-TEST
, NN NN O
platelet NNP NNP B-TEST
count NNP NNP I-TEST
, NN NN O
thrombocytopenia NNP NNP B-PROBLEM
, NN NN O
prednisone NNP NNP B-DRUG
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Non-Small NN NN O
Cell NN NN O
Lung NN NN O
Cancer NN NN O
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
New NN NN O
diagnosis NN NN O
of NN NN O
non-small NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
stage NNP NNP I-PROBLEM
IV NNP NNP I-PROBLEM
metastatic NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
he NN NN O
and NN NN O
his NN NN O
wife NN NN O
ask NN NN O
about NN NN O
whether NN NN O
this NN NN O
is NN NN O
curable NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
and NN NN O
it NN NN O
was NN NN O
difficult NN NN O
to NN NN O
inform NN NN O
that NN NN O
this NN NN O
was NN NN O
not NN NN O
curable NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
but NN NN O
would NN NN O
be NN NN O
treatable NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULTATION NN NN O
: NN NN O
New NN NN O
diagnosis NN NN O
of NN NN O
non-small NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
ABCD NN NN O
is NN NN O
a NN NN O
very NN NN O
nice NN NN O
47-year-old NN NN O
gentleman NN NN O
without NN NN O
much NN NN O
past NN NN O
medical NN NN O
history NN NN O
who NN NN O
has NN NN O
now NN NN O
been NN NN O
diagnosed NN NN O
with NN NN O
a NNP NNP B-PROBLEM
new NNP NNP I-PROBLEM
non-small NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
stage NNP NNP I-PROBLEM
IV NNP NNP I-PROBLEM
metastatic NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

We NN NN O
are NN NN O
consulted NN NN O
at NN NN O
this NN NN O
time NN NN O
to NN NN O
discuss NN NN O
further NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
options NNP NNP I-TREATMENT
. NN NN O

ABCD NN NN O
and NN NN O
his NN NN O
wife NN NN O
state NN NN O
that NN NN O
his NN NN O
history NN NN O
goes NN NN O
back NN NN O
to NN NN O
approximately NN NN O
2-2-1/2 NN NN O
weeks NN NN O
ago NN NN O
when NN NN O
he NN NN O
developed NN NN O
some NNP NNP B-PROBLEM
left-sided NNP NNP I-PROBLEM
flank NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

Initially NN NN O
, NN NN O
he NN NN O
did NN NN O
not NN NN O
think NN NN O
much NN NN O
of NN NN O
this NN NN O
and NN NN O
tried NN NN O
to NN NN O
go NN NN O
about NN NN O
doing NN NN O
work NN NN O
and NN NN O
everything NN NN O
else NN NN O
but NN NN O
the NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
gradually NN NN O
worsened NN NN O
. NN NN O

Eventually NN NN O
this NN NN O
prompted NN NN O
him NN NN O
to NN NN O
present NN NN O
to NN NN O
the NN NN O
emergency NN NN O
room NN NN O
. NN NN O

A NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
was NN NN O
done NN NN O
there NN NN O
, NN NN O
and NN NN O
he NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NNP NNP B-PROBLEM
large NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
worrisome NN NN O
for NN NN O
metastatic NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

At NN NN O
that NN NN O
point NN NN O
, NN NN O
he NN NN O
was NN NN O
transferred NN NN O
to NN NN O
XYZ NN NN O
Hospital NN NN O
for NN NN O
further NNP NNP B-TEST
evaluation NNP NNP I-TEST
. NN NN O

On NN NN O
admission NN NN O
on NN NN O
12/19/08 NNP NNP B-DATE
, NN NN O
a NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
chest NNP NNP I-TEST
, NNP NNP I-TEST
abdomen NNP NNP I-TEST
, NNP NNP I-TEST
and NNP NNP I-TEST
pelvis NNP NNP I-TEST
was NN NN O
done NN NN O
for NN NN O
full NNP NNP B-TEST
staging NNP NNP I-TEST
purposes NNP NNP I-TEST
. NN NN O

The NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
chest NNP NNP I-TEST
showed NN NN O
an NNP NNP B-PROBLEM
abnormal NNP NNP I-PROBLEM
soft NNP NNP I-PROBLEM
tissue NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
paratracheal NNP NNP I-PROBLEM
region NNP NNP I-PROBLEM
, NN NN O
extending NN NN O
into NN NN O
the NN NN O
precarinal NN NN O
region NN NN O
, NN NN O
the NN NN O
subcarinal NN NN O
region NN NN O
, NN NN O
and NN NN O
the NN NN O
right NN NN O
hilum NN NN O
. NN NN O

This NN NN O
was NN NN O
causing NN NN O
some NNP NNP B-PROBLEM
compression NNP NNP I-PROBLEM
on NN NN O
the NN NN O
inferior NN NN O
aspect NN NN O
of NN NN O
the NN NN O
SVC NN NN O
and NN NN O
also NN NN O
some NNP NNP B-PROBLEM
narrowing NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
pulmonary NNP NNP I-PROBLEM
artery NNP NNP I-PROBLEM
. NN NN O

There NN NN O
was NN NN O
an NNP NNP B-PROBLEM
abnormal NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
noted NN NN O
in NN NN O
the NN NN O
AP NN NN O
window NN NN O
and NN NN O
left NN NN O
hilar NN NN O
region NN NN O
. NN NN O

There NN NN O
was NN NN O
another NNP NNP B-PROBLEM
spiculated NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
within NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
measuring NN NN O
2.0 NN NN O
x NN NN O
1.5 NN NN O
cm NN NN O
. NN NN O

There NN NN O
was NN NN O
also NN NN O
an NNP NNP B-PROBLEM
8 NNP NNP I-PROBLEM
mm NNP NNP I-PROBLEM
non-calcified NNP NNP I-PROBLEM
nodule NNP NNP I-PROBLEM
noted NN NN O
in NN NN O
the NN NN O
posterior-inferior NN NN O
aspect NN NN O
of NN NN O
the NN NN O
left NN NN O
upper NN NN O
lobe NN NN O
suspicious NN NN O
for NN NN O
metastatic NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

There NN NN O
were NN NN O
areas NN NN O
of NN NN O
atelectasis NNP NNP B-PROBLEM
particularly NN NN O
in NN NN O
the NN NN O
right NN NN O
base NN NN O
. NN NN O

There NN NN O
was NN NN O
also NN NN O
some NNP NNP B-PROBLEM
mild NNP NNP I-PROBLEM
ground NNP NNP I-PROBLEM
glass NNP NNP I-PROBLEM
opacity NNP NNP I-PROBLEM
within NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
adjacent NN NN O
to NN NN O
the NN NN O
right NN NN O
hilum NN NN O
potentially NN NN O
representing NN NN O
focal NN NN O
area NN NN O
of NN NN O
pulmonary NNP NNP B-PROBLEM
edema NNP NNP I-PROBLEM
versus NN NN O
small NNP NNP B-PROBLEM
infarction NNP NNP I-PROBLEM
related NN NN O
to NN NN O
the NNP NNP B-PROBLEM
right NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
lobe NNP NNP I-PROBLEM
pulmonary NNP NNP I-PROBLEM
artery NNP NNP I-PROBLEM
narrowing NNP NNP I-PROBLEM
. NN NN O

There NN NN O
was NN NN O
a NNP NNP B-PROBLEM
small NNP NNP I-PROBLEM
lucency NNP NNP I-PROBLEM
adjacent NN NN O
to NN NN O
the NN NN O
medial NN NN O
aspect NN NN O
of NN NN O
the NN NN O
left NN NN O
upper NN NN O
lobe NN NN O
compatible NN NN O
with NN NN O
a NNP NNP B-PROBLEM
small NNP NNP I-PROBLEM
pneumothorax NNP NNP I-PROBLEM
. NN NN O

In NN NN O
the NN NN O
abdomen NN NN O
, NN NN O
there NN NN O
was NN NN O
a NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
involved NN NN O
in NN NN O
the NN NN O
left NN NN O
adrenal NN NN O
gland NN NN O
as NN NN O
well NN NN O
as NN NN O
a NNP NNP B-PROBLEM
nodule NNP NNP I-PROBLEM
involving NN NN O
the NN NN O
right NN NN O
adrenal NN NN O
gland NN NN O
both NN NN O
of NN NN O
which NNP NNP B-PROBLEM
appeared NNP NNP I-PROBLEM
necrotic NNP NNP I-PROBLEM
compatible NN NN O
with NN NN O
metastatic NNP NNP B-PROBLEM
tumor NNP NNP I-PROBLEM
. NN NN O

All NN NN O
other NN NN O
structures NN NN O
appeared NN NN O
normal NN NN O
. NN NN O

On NN NN O
12/22/08 NNP NNP B-DATE
, NN NN O
a NNP NNP B-TEST
CT-guided NNP NNP I-TEST
biopsy NNP NNP I-TEST
of NN NN O
the NNP NNP B-PROBLEM
left NNP NNP I-PROBLEM
adrenal NNP NNP I-PROBLEM
mass NNP NNP I-PROBLEM
was NN NN O
performed NN NN O
. NN NN O

Pathology NNP NNP B-TEST
from NN NN O
this NN NN O
returned NN NN O
showing NN NN O
metastatic NNP NNP B-PROBLEM
poorly NNP NNP I-PROBLEM
differentiated NNP NNP I-PROBLEM
non-small NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
we NN NN O
have NN NN O
been NN NN O
consulted NN NN O
to NN NN O
discuss NN NN O
further NNP NNP B-TREATMENT
treatment NNP NNP I-TREATMENT
options NNP NNP I-TREATMENT
. NN NN O

On NN NN O
further NN NN O
review NN NN O
, NN NN O
ABCD NN NN O
states NN NN O
that NN NN O
he NN NN O
has NN NN O
may NN NN O
be NN NN O
had NN NN O
a NNP NNP B-PROBLEM
20 NNP NNP I-PROBLEM
pound NNP NNP I-PROBLEM
weight NNP NNP I-PROBLEM
loss NNP NNP I-PROBLEM
over NN NN O
the NN NN O
last NN NN O
couple NN NN O
of NN NN O
months NN NN O
which NN NN O
he NN NN O
relates NN NN O
to NN NN O
anorexia NNP NNP B-PROBLEM
or NN NN O
decreased NNP NNP B-PROBLEM
appetite NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
not NN NN O
ever NN NN O
had NN NN O
a NNP NNP B-PROBLEM
chronic NNP NNP I-PROBLEM
smoker's NNP NNP I-PROBLEM
cough NNP NNP I-PROBLEM
and NN NN O
still NN NN O
does NN NN O
not NN NN O
have NN NN O
a NNP NNP B-PROBLEM
cough NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
no NN NN O
sputum NNP NNP B-PROBLEM
production NNP NNP I-PROBLEM
or NN NN O
hemoptysis NNP NNP B-PROBLEM
. NN NN O

He NN NN O
and NN NN O
his NN NN O
wife NN NN O
are NN NN O
very NNP NNP B-PROBLEM
anxious NNP NNP I-PROBLEM
about NN NN O
this NN NN O
diagnosis NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
denies NN NN O
any NN NN O
history NN NN O
of NN NN O
heart NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
lung NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
kidney NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
liver NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
hepatitis NNP NNP B-PROBLEM
major NNP NNP I-PROBLEM
infection NNP NNP I-PROBLEM
, NN NN O
seizure NNP NNP B-PROBLEM
disorders NNP NNP I-PROBLEM
or NN NN O
other NNP NNP B-PROBLEM
problems NNP NNP I-PROBLEM
. NN NN O

PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
denies NN NN O
having NN NN O
any NNP NNP B-TREATMENT
surgeries NNP NNP I-TREATMENT
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

MEDICATIONS NN NN O
: NN NN O
At NN NN O
home NN NN O
he NN NN O
takes NN NN O
no NN NN O
medication NNP NNP B-TREATMENT
except NN NN O
occasional NN NN O
aspirin NNP NNP B-DRUG
or NN NN O
ibuprofen NNP NNP B-DRUG
, NN NN O
recently NN NN O
for NN NN O
his NNP NNP B-PROBLEM
flank NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

He NN NN O
does NN NN O
take NN NN O
a NN NN O
multivitamin NNP NNP B-DRUG
on NN NN O
occasion NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
has NN NN O
about NN NN O
a NN NN O
30-pack-a-year NN NN O
history NN NN O
of NN NN O
smoking NN NN O
. NN NN O

He NN NN O
used NN NN O
to NN NN O
drink NN NN O
alcohol NN NN O
heavily NN NN O
and NN NN O
has NN NN O
a NN NN O
history NN NN O
of NN NN O
getting NN NN O
a NN NN O
DUI NN NN O
about NN NN O
a NNP NNP B-TREATMENT
year-and-half NNP NNP I-TREATMENT
ago NN NN O
resulting NN NN O
in NN NN O
him NN NN O
having NN NN O
his NN NN O
truck-driving NN NN O
license NN NN O
revoked NN NN O
. NN NN O

Since NN NN O
that NN NN O
time NN NN O
he NN NN O
has NN NN O
worked NN NN O
with NN NN O
printing NN NN O
press NN NN O
. NN NN O

He NN NN O
is NN NN O
married NN NN O
and NN NN O
has NN NN O
two NN NN O
children NN NN O
, NN NN O
both NN NN O
of NN NN O
whom NN NN O
are NN NN O
grown NN NN O
in NN NN O
their NN NN O
20s NN NN O
, NN NN O
but NN NN O
are NN NN O
now NN NN O
living NN NN O
at NN NN O
home NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
His NN NN O
mother NN NN O
died NN NN O
for NN NN O
alcohol-related NNP NNP B-PROBLEM
complications NNP NNP I-PROBLEM
. NN NN O

He NN NN O
otherwise NN NN O
denies NN NN O
any NN NN O
history NN NN O
of NN NN O
cancers NNP NNP B-PROBLEM
, NN NN O
bleeding NNP NNP B-PROBLEM
disorders NNP NNP I-PROBLEM
, NN NN O
clotting NNP NNP B-PROBLEM
disorders NNP NNP I-PROBLEM
, NN NN O
or NN NN O
other NNP NNP B-PROBLEM
problems NNP NNP I-PROBLEM
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
GENERAL/CONSTITUTIONAL NN NN O
: NN NN O
He NN NN O
has NN NN O
lost NNP NNP B-PROBLEM
about NNP NNP I-PROBLEM
20 NNP NNP I-PROBLEM
pounds NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
weight NNP NNP I-PROBLEM
as NN NN O
described NN NN O
above NN NN O
. NN NN O

He NN NN O
also NN NN O
has NN NN O
a NNP NNP B-PROBLEM
trouble NNP NNP I-PROBLEM
with NNP NNP I-PROBLEM
fatigue NNP NNP I-PROBLEM
. NN NN O

No NN NN O
lightheadedness NNP NNP B-PROBLEM
or NN NN O
dizziness NNP NNP B-PROBLEM
. NN NN O

HEENT NN NN O
: NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
new NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
changing NNP NNP I-PROBLEM
headache NNP NNP I-PROBLEM
, NN NN O
change NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
vision NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
double NNP NNP I-PROBLEM
vision NNP NNP I-PROBLEM
, NN NN O
or NN NN O
loss NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
vision NNP NNP I-PROBLEM
, NN NN O
ringing NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
ears NNP NNP I-PROBLEM
, NN NN O
loss NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
hearing NNP NNP I-PROBLEM
in NN NN O
one NN NN O
year NN NN O
. NN NN O

He NN NN O
does NN NN O
not NN NN O
take NN NN O
care NN NN O
of NN NN O
his NN NN O
teeth NN NN O
very NN NN O
well NN NN O
but NN NN O
currently NN NN O
he NN NN O
has NN NN O
no NN NN O
mouth NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
jaw NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
teeth NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

RESPIRATORY NN NN O
: NN NN O
He NN NN O
has NN NN O
had NN NN O
some NN NN O
little NN NN O
bit NN NN O
of NN NN O
dyspnea NNP NNP B-PROBLEM
on NN NN O
exertion NN NN O
but NN NN O
otherwise NN NN O
denies NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
at NN NN O
rest NN NN O
. NN NN O

No NN NN O
cough NNP NNP B-PROBLEM
, NN NN O
congestion NNP NNP B-PROBLEM
, NN NN O
wheezing NNP NNP B-PROBLEM
, NN NN O
hemoptysis NNP NNP B-PROBLEM
, NN NN O
and NN NN O
sputum NNP NNP B-PROBLEM
production NNP NNP I-PROBLEM
. NN NN O

CVS NN NN O
: NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
chest NNP NNP I-PROBLEM
pains NNP NNP I-PROBLEM
, NN NN O
palpitations NNP NNP B-PROBLEM
, NN NN O
PND NNP NNP B-PROBLEM
, NN NN O
orthopnea NNP NNP B-PROBLEM
, NN NN O
or NN NN O
swelling NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
extremities NNP NNP I-PROBLEM
. NN NN O

GI NN NN O
: NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
odynophagia NNP NNP I-PROBLEM
, NN NN O
dysphagia NNP NNP B-PROBLEM
, NN NN O
heartburn NNP NNP B-PROBLEM
on NN NN O
a NN NN O
regular NN NN O
basis NN NN O
, NN NN O
abdominal NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
abdominal NNP NNP B-PROBLEM
swelling NNP NNP I-PROBLEM
, NN NN O
diarrhea NNP NNP B-PROBLEM
, NN NN O
blood NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
stool NNP NNP I-PROBLEM
, NN NN O
or NN NN O
black NNP NNP B-PROBLEM
tarry NNP NNP I-PROBLEM
stools NNP NNP I-PROBLEM
. NN NN O

He NN NN O
has NN NN O
been NN NN O
somewhat NNP NNP B-PROBLEM
constipated NNP NNP I-PROBLEM
recently NN NN O
. NN NN O

GU NN NN O
: NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
burning NNP NNP I-PROBLEM
with NNP NNP I-PROBLEM
urination NNP NNP I-PROBLEM
, NN NN O
kidney NNP NNP B-PROBLEM
stones NNP NNP I-PROBLEM
, NN NN O
blood NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
urine NNP NNP I-PROBLEM
, NN NN O
dysuria NNP NNP B-PROBLEM
, NN NN O
difficulty NNP NNP B-PROBLEM
getting NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
urine NNP NNP I-PROBLEM
out NNP NNP I-PROBLEM
or NN NN O
other NNP NNP B-PROBLEM
problems NNP NNP I-PROBLEM
. NN NN O

MUSCULOSKELETAL NN NN O
: NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
new NNP NNP I-PROBLEM
bony NNP NNP I-PROBLEM
aches NNP NNP I-PROBLEM
or NN NN O
pains NNP NNP B-PROBLEM
including NN NN O
back NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
hip NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
and NN NN O
rib NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

No NN NN O
muscle NNP NNP B-PROBLEM
aches NNP NNP I-PROBLEM
, NN NN O
no NN NN O
joint NNP NNP B-PROBLEM
swelling NNP NNP I-PROBLEM
, NN NN O
and NN NN O
no NN NN O
history NN NN O
of NN NN O
gout NNP NNP B-PROBLEM
. NN NN O

SKIN NN NN O
: NN NN O
No NN NN O
rashes NNP NNP B-PROBLEM
, NN NN O
no NN NN O
bruising NNP NNP B-PROBLEM
, NN NN O
petechia NNP NNP B-PROBLEM
, NN NN O
non-healing NNP NNP B-PROBLEM
wounds NNP NNP I-PROBLEM
, NN NN O
or NN NN O
ulcerations NNP NNP B-PROBLEM
. NN NN O

He NN NN O
has NN NN O
had NN NN O
no NN NN O
nail NNP NNP B-PROBLEM
or NNP NNP I-PROBLEM
hair NNP NNP I-PROBLEM
changes NNP NNP I-PROBLEM
. NN NN O

HEM NN NN O
: NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
bloody NNP NNP I-PROBLEM
nose NNP NNP I-PROBLEM
, NN NN O
bleeding NNP NNP B-PROBLEM
gums NNP NNP I-PROBLEM
, NN NN O
easy NNP NNP B-PROBLEM
bruising NNP NNP I-PROBLEM
, NN NN O
easy NNP NNP B-PROBLEM
bleeding NNP NNP I-PROBLEM
, NN NN O
swollen NNP NNP B-PROBLEM
lymphs NNP NNP I-PROBLEM
or NN NN O
bumps NNP NNP B-PROBLEM
. NN NN O

ENDOCRINE NN NN O
: NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
tremor NNP NNP I-PROBLEM
, NN NN O
shakiness NNP NNP B-PROBLEM
, NN NN O
history NN NN O
of NN NN O
diabetes NNP NNP B-PROBLEM
, NN NN O
thyroid NNP NNP B-PROBLEM
problems NNP NNP I-PROBLEM
, NN NN O
new NNP NNP B-PROBLEM
or NNP NNP I-PROBLEM
enlarging NNP NNP I-PROBLEM
stretch NNP NNP I-PROBLEM
marks NNP NNP I-PROBLEM
, NN NN O
exophthalmos NNP NNP B-PROBLEM
, NN NN O
insomnia NNP NNP B-PROBLEM
, NN NN O
or NN NN O
tremors NNP NNP B-PROBLEM
. NN NN O

NEURO NN NN O
: NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
mental NNP NNP I-PROBLEM
status NNP NNP I-PROBLEM
changes NNP NNP I-PROBLEM
, NN NN O
anxiety NNP NNP B-PROBLEM
, NN NN O
confusion NNP NNP B-PROBLEM
, NN NN O
depression NNP NNP B-PROBLEM
, NN NN O
hallucinations NNP NNP B-PROBLEM
, NN NN O
loss NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
feeling NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
her NNP NNP I-PROBLEM
arm NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
leg NNP NNP I-PROBLEM
, NN NN O
numbness NNP NNP B-PROBLEM
or NN NN O
tingling NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
hands NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
feet NNP NNP I-PROBLEM
, NN NN O
loss NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
balance NNP NNP I-PROBLEM
, NN NN O
syncope NNP NNP B-PROBLEM
, NN NN O
seizures NNP NNP B-PROBLEM
, NN NN O
or NN NN O
loss NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
coordination NNP NNP I-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
His NNP NNP B-TEST
T-max NNP NNP I-TEST
is NN NN O
98.8 NN NN O
. NN NN O

His NNP NNP B-TEST
pulse NNP NNP I-TEST
is NN NN O
85 NN NN O
, NN NN O
respirations NNP NNP B-TEST
18 NN NN O
, NN NN O
and NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
126/80 NN NN O
saturating NN NN O
over NN NN O
90% NN NN O
on NN NN O
room NN NN O
air NN NN O
. NN NN O

GENERAL NN NN O
: NN NN O
No NN NN O
acute NNP NNP B-PROBLEM
distress NNP NNP I-PROBLEM
, NN NN O
pleasant NN NN O
gentleman NN NN O
who NN NN O
appears NN NN O
stated NN NN O
age NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
NC/AT NNP NNP B-PROBLEM
. NN NN O

Sclerae NNP NNP B-PROBLEM
anicteric NNP NNP I-PROBLEM
. NN NN O

Conjunctiva NN NN O
clear NN NN O
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
without NN NN O
erythema NNP NNP B-PROBLEM
, NN NN O
exudate NNP NNP B-PROBLEM
, NN NN O
or NN NN O
discharge NNP NNP B-PROBLEM
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

Nontender NNP NNP B-PROBLEM
. NN NN O

No NN NN O
elevated NNP NNP B-PROBLEM
JVP NNP NNP I-PROBLEM
. NN NN O

No NN NN O
carotid NNP NNP B-PROBLEM
bruits NNP NNP I-PROBLEM
. NN NN O

No NN NN O
thyromegaly NNP NNP B-PROBLEM
. NN NN O

No NN NN O
thyroid NNP NNP B-PROBLEM
nodules NNP NNP I-PROBLEM
. NN NN O

Carotids NNP NNP B-TEST
are NN NN O
2+ NN NN O
and NN NN O
symmetric NN NN O
. NN NN O

BACK NN NN O
: NN NN O
Spine NN NN O
is NN NN O
straight NN NN O
. NN NN O

No NN NN O
spinal NNP NNP B-PROBLEM
tenderness NNP NNP I-PROBLEM
. NN NN O

No NN NN O
CVA NNP NNP B-PROBLEM
tenderness NNP NNP I-PROBLEM
. NN NN O

No NN NN O
presacral NNP NNP B-PROBLEM
edema NNP NNP I-PROBLEM
. NN NN O

CHEST NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
and NN NN O
percussion NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

No NN NN O
wheezes NNP NNP B-PROBLEM
, NN NN O
rales NNP NNP B-PROBLEM
, NN NN O
or NN NN O
rhonchi NNP NNP B-PROBLEM
. NN NN O

Normal NN NN O
symmetric NN NN O
chest NN NN O
wall NN NN O
expansion NN NN O
with NN NN O
inspiration NN NN O
. NN NN O

CVS NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

No NN NN O
murmurs NNP NNP B-PROBLEM
, NN NN O
gallops NNP NNP B-PROBLEM
, NN NN O
or NN NN O
rubs NNP NNP B-PROBLEM
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
, NN NN O
nontender NNP NNP B-PROBLEM
, NN NN O
nondistended NNP NNP B-PROBLEM
. NN NN O

No NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

No NN NN O
guarding NNP NNP B-PROBLEM
or NN NN O
rebound NNP NNP B-PROBLEM
. NN NN O

No NN NN O
masses NNP NNP B-PROBLEM
. NN NN O

Normoactive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
cyanosis NNP NNP B-PROBLEM
, NN NN O
clubbing NNP NNP B-PROBLEM
, NN NN O
or NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

No NN NN O
joint NNP NNP B-PROBLEM
swelling NNP NNP I-PROBLEM
. NN NN O

Full NN NN O
range NN NN O
of NN NN O
motion NN NN O
. NN NN O

SKIN NN NN O
: NN NN O
No NN NN O
rashes NNP NNP B-PROBLEM
, NN NN O
wounds NNP NNP B-PROBLEM
, NN NN O
ulcerations NNP NNP B-PROBLEM
, NN NN O
bruises NNP NNP B-PROBLEM
, NN NN O
or NN NN O
petechia NNP NNP B-PROBLEM
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Cranial NN NN O
nerves NN NN O
II NN NN O
through NN NN O
XII NN NN O
are NN NN O
intact NN NN O
. NN NN O

He NN NN O
has NN NN O
intact NN NN O
sensation NN NN O
to NN NN O
light NNP NNP B-TEST
touch NNP NNP I-TEST
throughout NN NN O
. NN NN O

He NN NN O
has NN NN O
2+ NNP NNP B-TEST
deep NNP NNP I-TEST
tendon NNP NNP I-TEST
reflexes NNP NNP I-TEST
bilaterally NN NN O
in NN NN O
the NN NN O
biceps NN NN O
, NN NN O
triceps NN NN O
, NN NN O
brachioradialis NN NN O
, NN NN O
patellar NNP NNP B-TEST
and NNP NNP I-TEST
ankle NNP NNP I-TEST
reflexes NNP NNP I-TEST
. NN NN O

He NN NN O
is NN NN O
alert NN NN O
and NN NN O
oriented NN NN O
x3 NN NN O
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
His NNP NNP B-TEST
white NNP NNP I-TEST
blood NNP NNP I-TEST
cell NNP NNP I-TEST
count NNP NNP I-TEST
is NN NN O
9.4 NN NN O
, NN NN O
hemoglobin NNP NNP B-TEST
13.0 NN NN O
, NN NN O
hematocrit NNP NNP B-TEST
38% NN NN O
, NN NN O
and NN NN O
platelets NNP NNP B-TEST
365,000 NN NN O
. NN NN O

The NNP NNP B-TEST
differential NNP NNP I-TEST
shows NN NN O
73% NN NN O
neutrophils NNP NNP B-TEST
, NN NN O
17% NNP NNP B-TEST
lymphocytes NNP NNP I-TEST
, NN NN O
7.6% NN NN O
monocytes NNP NNP B-TEST
, NN NN O
1.9% NN NN O
eosinophils NNP NNP B-TEST
, NN NN O
and NN NN O
0.7% NN NN O
basophils NNP NNP B-TEST
. NN NN O

Chemistry NN NN O
shows NN NN O
sodium NNP NNP B-TEST
138 NN NN O
, NN NN O
potassium NNP NNP B-TEST
3.8 NN NN O
, NN NN O
chloride NNP NNP B-TEST
104 NN NN O
, NN NN O
CO2 NNP NNP B-TEST
of NN NN O
31 NN NN O
, NN NN O
BUN NNP NNP B-TEST
9 NN NN O
, NN NN O
creatinine NNP NNP B-TEST
1.0 NN NN O
, NN NN O
glucose NNP NNP B-TEST
104 NN NN O
, NN NN O
calcium NNP NNP B-TEST
12.3 NN NN O
, NN NN O
alkaline NNP NNP B-TEST
phosphatase NNP NNP I-TEST
104 NN NN O
, NN NN O
AST NNP NNP B-TEST
16 NN NN O
, NN NN O
ALT NNP NNP B-TEST
12 NN NN O
, NN NN O
total NNP NNP B-TEST
protein NNP NNP I-TEST
7.6 NN NN O
, NN NN O
albumin NNP NNP B-TEST
3.5 NN NN O
, NN NN O
total NNP NNP B-TEST
bilirubin NNP NNP I-TEST
0.5 NN NN O
, NN NN O
ionized NNP NNP B-TEST
calcium NNP NNP I-TEST
1.7 NN NN O
. NN NN O

His NNP NNP B-TEST
INR NNP NNP I-TEST
is NN NN O
1.0 NN NN O
with NN NN O
the NNP NNP B-TEST
PT NNP NNP I-TEST
of NN NN O
11.4 NN NN O
and NN NN O
a NNP NNP B-TEST
PTT NNP NNP I-TEST
of NN NN O
31.3 NN NN O
. NN NN O

IMAGINING NN NN O
DATA NN NN O
: NN NN O
MRI NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
brain NNP NNP I-TEST
on NN NN O
12/23/08 NNP NNP B-DATE
- NN NN O
this NN NN O
shows NN NN O
some NNP NNP B-PROBLEM
mild NNP NNP I-PROBLEM
white NNP NNP I-PROBLEM
matter NNP NNP I-PROBLEM
disease NNP NNP I-PROBLEM
, NN NN O
question NN NN O
of NN NN O
minimal NNP NNP B-PROBLEM
pontine NNP NNP I-PROBLEM
ischemic NNP NNP I-PROBLEM
gliosis NNP NNP I-PROBLEM
as NN NN O
well NN NN O
as NN NN O
a NNP NNP B-PROBLEM
small NNP NNP I-PROBLEM
incidental NNP NNP I-PROBLEM
venous NNP NNP I-PROBLEM
angioma NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
posterior NNP NNP I-PROBLEM
frontal NNP NNP I-PROBLEM
deep NNP NNP I-PROBLEM
white NNP NNP I-PROBLEM
matter NNP NNP I-PROBLEM
. NN NN O

There NN NN O
is NN NN O
no NN NN O
evidence NN NN O
of NN NN O
cerebral NNP NNP B-PROBLEM
metastasis NNP NNP I-PROBLEM
, NN NN O
hemorrhage NNP NNP B-PROBLEM
, NN NN O
or NN NN O
acute NNP NNP B-PROBLEM
infarction NNP NNP I-PROBLEM
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
ABCD NN NN O
is NN NN O
a NN NN O
very NN NN O
nice NN NN O
47-year-old NN NN O
gentleman NN NN O
without NN NN O
much NN NN O
past NN NN O
medical NN NN O
history NN NN O
, NN NN O
who NN NN O
now NN NN O
presents NN NN O
with NN NN O
metastatic NNP NNP B-PROBLEM
non-small NNP NNP I-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
he NN NN O
and NN NN O
his NN NN O
wife NN NN O
ask NN NN O
about NN NN O
whether NN NN O
this NN NN O
is NN NN O
curable NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
and NN NN O
it NN NN O
was NN NN O
difficult NN NN O
to NN NN O
inform NN NN O
that NN NN O
this NN NN O
was NN NN O
not NN NN O
curable NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
but NN NN O
would NN NN O
be NN NN O
treatable NN NN O
. NN NN O

His NN NN O
wife NN NN O
particularly NN NN O
had NN NN O
a NNP NNP B-PROBLEM
very NNP NNP I-PROBLEM
hard NNP NNP I-PROBLEM
time NNP NNP I-PROBLEM
with NN NN O
this NN NN O
prognosis NN NN O
. NN NN O

They NN NN O
preferred NN NN O
not NN NN O
to NN NN O
know NN NN O
the NN NN O
exact NN NN O
average NN NN O
as NN NN O
to NN NN O
how NN NN O
long NN NN O
someone NN NN O
lives NN NN O
with NN NN O
this NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

I NN NN O
did NN NN O
offer NN NN O
chemotherapy NNP NNP B-DRUG
as NN NN O
a NN NN O
way NN NN O
to NN NN O
treat NN NN O
this NNP NNP B-PROBLEM
disease NNP NNP I-PROBLEM
. NN NN O

Chemotherapy NNP NNP B-DRUG
has NN NN O
been NN NN O
associated NN NN O
both NN NN O
with NN NN O
palliation NNP NNP B-TREATMENT
of NN NN O
symptoms NNP NNP B-PROBLEM
as NN NN O
well NN NN O
as NN NN O
prolong NN NN O
survival NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
he NN NN O
has NN NN O
an NN NN O
excellent NN NN O
functional NN NN O
status NN NN O
and NN NN O
I NN NN O
think NN NN O
he NN NN O
would NN NN O
tolerate NN NN O
chemotherapy NNP NNP B-DRUG
quite NN NN O
well NN NN O
. NN NN O

In NN NN O
terms NN NN O
of NN NN O
chemotherapy NNP NNP B-DRUG
, NN NN O
I NN NN O
talked NN NN O
briefly NN NN O
about NN NN O
the NN NN O
side NN NN O
affects NN NN O
including NN NN O
but NN NN O
not NN NN O
limited NN NN O
to NN NN O
GI NNP NNP B-PROBLEM
upset NNP NNP I-PROBLEM
, NN NN O
diarrhea NNP NNP B-PROBLEM
, NN NN O
nausea NNP NNP B-PROBLEM
, NN NN O
vomiting NNP NNP B-PROBLEM
, NN NN O
mucositis NNP NNP B-PROBLEM
, NN NN O
fatigue NNP NNP B-PROBLEM
, NN NN O
loss NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
appetite NNP NNP I-PROBLEM
, NN NN O
low NNP NNP B-PROBLEM
blood NNP NNP I-PROBLEM
counts NNP NNP I-PROBLEM
including NN NN O
the NN NN O
possible NN NN O
need NN NN O
for NN NN O
transfusion NNP NNP B-TREATMENT
as NN NN O
well NN NN O
as NN NN O
the NN NN O
risk NN NN O
of NN NN O
infections NNP NNP B-PROBLEM
, NN NN O
which NN NN O
in NN NN O
some NN NN O
rare NN NN O
cases NN NN O
can NN NN O
be NN NN O
fatal NN NN O
. NN NN O

I NN NN O
would NN NN O
likely NN NN O
use NN NN O
carboplatin NNP NNP B-DRUG
and NN NN O
gemcitabine NNP NNP B-DRUG
. NN NN O

This NN NN O
would NN NN O
be NN NN O
both NN NN O
medications NNP NNP B-TREATMENT
given NN NN O
on NN NN O
day NN NN O
1 NN NN O
with NN NN O
a NN NN O
dose NN NN O
of NN NN O
gemcitabine NNP NNP B-DRUG
on NN NN O
day NN NN O

8 NN NN O
. NN NN O
This NN NN O
cycle NN NN O
will NN NN O
be NN NN O
repeated NN NN O
after NN NN O
1-week NN NN O
break NN NN O
so NN NN O
that NN NN O
the NN NN O
cycle NN NN O
lasts NN NN O
21 NN NN O
days NN NN O
. NN NN O

The NN NN O
goal NN NN O
will NN NN O
be NN NN O
to NN NN O
complete NN NN O
6 NN NN O
cycles NN NN O
of NN NN O
this NN NN O
as NN NN O
long NN NN O
as NN NN O
he NN NN O
is NN NN O
responding NN NN O
and NN NN O
tolerating NN NN O
the NNP NNP B-TREATMENT
medication NNP NNP I-TREATMENT
. NN NN O

In NN NN O
terms NN NN O
of NN NN O
staging NN NN O
Mr NN NN O
. NN NN O
ABCD'S NNP NNP B-DRUG
had NN NN O
all NN NN O
the NN NN O
appropriate NN NN O
staging NN NN O
. NN NN O

A NNP NNP B-TEST
PET-CT NNP NNP I-TEST
scan NNP NNP I-TEST
could NN NN O
be NN NN O
done NN NN O
, NN NN O
but NN NN O
at NN NN O
this NN NN O
point NN NN O
would NN NN O
not NN NN O
provide NN NN O
much NN NN O
mean NN NN O
full NN NN O
information NN NN O
beyond NN NN O
the NNP NNP B-TEST
CT NNP NNP I-TEST
scans NNP NNP I-TEST
that NN NN O
we NN NN O
have NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
his NN NN O
biggest NN NN O
issue NN NN O
is NN NN O
pain NNP NNP B-PROBLEM
and NN NN O
he NN NN O
is NN NN O
getting NN NN O
a NN NN O
pain NN NN O
consult NN NN O
to NN NN O
help NN NN O
control NN NN O
his NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
. NN NN O

He NN NN O
will NN NN O
be NN NN O
ready NN NN O
to NN NN O
be NN NN O
discharged NN NN O
from NN NN O
the NN NN O
hospital NN NN O
once NN NN O
his NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
is NN NN O
under NN NN O
better NN NN O
control NN NN O
. NN NN O

As NN NN O
this NN NN O
is NN NN O
the NN NN O
holiday NN NN O
weekend NN NN O
, NN NN O
I NN NN O
do NN NN O
not NN NN O
have NN NN O
a NN NN O
way NN NN O
of NN NN O
scheduling NN NN O
a NN NN O
followup NN NN O
appointment NN NN O
with NN NN O
them NN NN O
, NN NN O
but NN NN O
I NN NN O
did NN NN O
give NN NN O
he NN NN O
and NN NN O
his NN NN O
wife NN NN O
my NN NN O
card NN NN O
and NN NN O
instructed NN NN O
them NN NN O
to NN NN O
call NN NN O
on NN NN O
Monday NNP NNP B-DATE
. NN NN O

At NN NN O
that NN NN O
point NN NN O
, NN NN O
we NN NN O
will NN NN O
get NN NN O
him NN NN O
in NN NN O
and NN NN O
I NN NN O
will NN NN O
also NN NN O
begin NN NN O
working NN NN O
on NN NN O
making NN NN O
arrangements NN NN O
for NN NN O
his NN NN O
chemotherapy NNP NNP B-DRUG
. NN NN O

Thank NN NN O
you NN NN O
very NN NN O
much NN NN O
for NN NN O
this NN NN O
interesting NN NN O
consult NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
non-small NNP NNP B-PROBLEM
cell NNP NNP I-PROBLEM
lung NNP NNP I-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
treatment NNP NNP B-TREATMENT
options NNP NNP I-TREATMENT
, NN NN O
lung NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
disease NNP NNP B-PROBLEM
, NN NN O
chemotherapy NNP NNP B-DRUG
, NN NN O
metastatic NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Non-Hodgkin NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
Followup NN NN O
Description NN NN O
: NN NN O
Follicular NNP NNP B-PROBLEM
non-Hodgkin's NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

Biopsy NNP NNP B-TEST
of NNP NNP I-TEST
a NNP NNP I-TEST
left NNP NNP I-TEST
posterior NNP NNP I-TEST
auricular NNP NNP I-TEST
lymph NNP NNP I-TEST
node NNP NNP I-TEST
and NNP NNP I-TEST
pathology NNP NNP I-TEST
showed NN NN O
follicular NNP NNP B-PROBLEM
non-Hodgkin's NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

Received NN NN O
six NN NN O
cycles NN NN O
of NN NN O
CHOP NNP NNP B-DRUG
chemotherapy NNP NNP I-DRUG
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
Follicular NNP NNP B-PROBLEM
non-Hodgkin's NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
This NN NN O
is NN NN O
an NN NN O
extremely NN NN O
pleasant NN NN O
69 NN NN O
year-old NN NN O
gentleman NN NN O
, NN NN O
who NN NN O
I NN NN O
follow NN NN O
for NN NN O
his NNP NNP B-PROBLEM
follicular NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

His NN NN O
history NN NN O
is NN NN O
that NN NN O
in NN NN O
February NNP NNP B-DATE
of NNP NNP I-DATE
1988 NNP NNP I-DATE
he NN NN O
had NN NN O
a NNP NNP B-TEST
biopsy NNP NNP I-TEST
of NN NN O
a NNP NNP B-TEST
left NNP NNP I-TEST
posterior NNP NNP I-TEST
auricular NNP NNP I-TEST
lymph NNP NNP I-TEST
node NNP NNP I-TEST
and NN NN O
pathology NNP NNP B-TEST
showed NN NN O
follicular NNP NNP B-PROBLEM
non-Hodgkin's NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

From NN NN O
03/29/88 NNP NNP B-DATE
to NN NN O
08/02/88 NNP NNP B-DATE
, NN NN O
he NN NN O
received NN NN O
six NN NN O
cycles NN NN O
of NN NN O
CHOP NNP NNP B-DRUG
chemotherapy NNP NNP I-DRUG
. NN NN O

In NN NN O
1990 NN NN O
, NN NN O
his NNP NNP B-TEST
CT NNP NNP I-TEST
scan NNP NNP I-TEST
showed NN NN O
retroperitoneal NNP NNP B-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

Therefore NN NN O
from NN NN O
04/02/90 NNP NNP B-DATE
to NN NN O
08/20/90 NNP NNP B-DATE
, NN NN O
he NN NN O
received NN NN O
seven NN NN O
cycles NN NN O
of NN NN O
CVP NNP NNP B-TREATMENT
. NN NN O

In NN NN O
1999 NN NN O
, NN NN O
he NN NN O
was NN NN O
treated NN NN O
with NN NN O
m-BACOD NNP NNP B-DRUG
. NN NN O

He NN NN O
also NN NN O
received NN NN O
radiation NNP NNP B-TREATMENT
to NNP NNP I-TREATMENT
his NNP NNP I-TREATMENT
pelvis NNP NNP I-TREATMENT
. NN NN O

On NN NN O
03/21/01 NNP NNP B-DATE
, NN NN O
he NN NN O
had NN NN O
a NNP NNP B-TEST
right NNP NNP I-TEST
cervical NNP NNP I-TEST
lymph NNP NNP I-TEST
node NNP NNP I-TEST
biopsy NNP NNP I-TEST
, NN NN O
which NN NN O
again NN NN O
showed NN NN O
follicular NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

His NNP NNP B-TEST
most NNP NNP I-TEST
recent NNP NNP I-TEST
PET NNP NNP I-TEST
scan NNP NNP I-TEST
dated NN NN O
12/31/08 NNP NNP B-DATE
showed NN NN O
resolution NN NN O
of NN NN O
previously NNP NNP B-PROBLEM
described NNP NNP I-PROBLEM
hypermetabolic NNP NNP I-PROBLEM
lymph NNP NNP I-PROBLEM
nodes NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
right NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
neck NNP NNP I-PROBLEM
. NN NN O

Overall NN NN O
, NN NN O
he NN NN O
is NN NN O
doing NN NN O
well NN NN O
. NN NN O

He NN NN O
has NN NN O
a NN NN O
good NN NN O
energy NN NN O
level NN NN O
, NN NN O
his NN NN O
ECOG NN NN O
performance NN NN O
status NN NN O
is NN NN O

0 NN NN O
. NN NN O
He NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
fever NNP NNP I-PROBLEM
, NN NN O
chills NNP NNP B-PROBLEM
or NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
. NN NN O

No NN NN O
lymphadenopathy NNP NNP B-PROBLEM
. NN NN O

No NN NN O
nausea NNP NNP B-PROBLEM
or NN NN O
vomiting NNP NNP B-PROBLEM
. NN NN O

No NN NN O
change NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
bowel NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
bladder NNP NNP I-PROBLEM
habits NNP NNP I-PROBLEM
. NN NN O

CURRENT NNP NNP B-TREATMENT
MEDICATIONS NNP NNP I-TREATMENT
: NN NN O
Avelox NNP NNP B-TREATMENT
400 NN NN O
mg NN NN O
q.d NN NN O
. NN NN O
p.r.n NN NN O
., NN NN O
cefuroxime NNP NNP B-DRUG
200 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.d NN NN O
. NN NN O
to NN NN O
be NN NN O
altered NN NN O
monthly NN NN O
with NN NN O
doxycycline NNP NNP B-DRUG
100 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.d NN NN O
., NN NN O
Coumadin NNP NNP B-DRUG
5 NNP NNP I-DRUG
mg NNP NNP I-DRUG
on NN NN O
Monday NNP NNP B-DATE
and NN NN O
2.5 NN NN O
mg NN NN O
on NN NN O
all NN NN O
other NN NN O
days NN NN O
, NN NN O
dicyclomine NNP NNP B-DRUG
10 NNP NNP I-DRUG
mg NNP NNP I-DRUG
q.d NN NN O
., NN NN O
Coreg NNP NNP B-TREATMENT
6.25 NN NN O
mg NN NN O
b.i.d NN NN O
., NN NN O
Vasotec NNP NNP B-DRUG
2.5 NNP NNP I-DRUG
mg NNP NNP I-DRUG
b.i.d NN NN O
., NN NN O
Zantac NNP NNP B-DRUG
150 NN NN O
mg NN NN O
q.d NN NN O
., NN NN O
Claritin NNP NNP B-DRUG
D NNP NNP I-DRUG
q.d NN NN O
., NN NN O
Centrum NN NN O
q.d NN NN O
., NN NN O
calcium NNP NNP B-DRUG
q.d NN NN O
., NN NN O
omega-3 NNP NNP B-TREATMENT
b.i.d NN NN O
., NN NN O
Metamucil NNP NNP B-DRUG
q.d NN NN O
., NN NN O
and NN NN O
Lasix NNP NNP B-DRUG
40 NNP NNP I-DRUG
mg NNP NNP I-DRUG
t.i.d NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
As NN NN O
per NN NN O
the NN NN O
HPI NN NN O
, NN NN O
otherwise NN NN O
negative NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O

1 NN NN O
. NN NN O
He NN NN O
has NN NN O
chronic NNP NNP B-PROBLEM
lymphedema NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
bilateral NNP NNP I-PROBLEM
lower NNP NNP I-PROBLEM
extremities NNP NNP I-PROBLEM
secondary NN NN O
to NN NN O
his NNP NNP B-PROBLEM
pelvic NNP NNP I-PROBLEM
radiation NNP NNP I-PROBLEM
. NN NN O

2 NN NN O
. NN NN O
He NN NN O
had NN NN O
bilateral NNP NNP B-PROBLEM
ureteral NNP NNP I-PROBLEM
obstruction NNP NNP I-PROBLEM
and NN NN O
is NN NN O
status NN NN O
post NN NN O
a NNP NNP B-TREATMENT
stent NNP NNP I-TREATMENT
placement NNP NNP I-TREATMENT
. NN NN O

The NNP NNP B-PROBLEM
obstruction NNP NNP I-PROBLEM
was NN NN O
secondary NN NN O
to NN NN O
his NNP NNP B-PROBLEM
pelvic NNP NNP I-PROBLEM
radiation NNP NNP I-PROBLEM
. NN NN O

3 NN NN O
. NN NN O
History NN NN O
of NN NN O
congestive NNP NNP B-PROBLEM
heart NNP NNP I-PROBLEM
failure NNP NNP I-PROBLEM
. NN NN O

4 NN NN O
. NN NN O
History NN NN O
of NN NN O
schwannoma NNP NNP B-TREATMENT
resection NNP NNP I-TREATMENT
. NN NN O

It NN NN O
was NN NN O
resected NNP NNP B-TREATMENT
from NN NN O
T12 NN NN O
to NN NN O
L1 NN NN O
in NN NN O
1991 NNP NNP B-DATE
. NN NN O

5 NN NN O
. NN NN O
He NN NN O
has NN NN O
chronic NNP NNP B-PROBLEM
obstruction NNP NNP I-PROBLEM
of NNP NNP I-PROBLEM
his NNP NNP I-PROBLEM
inferior NNP NNP I-PROBLEM
vena NNP NNP I-PROBLEM
cava NNP NNP I-PROBLEM
. NN NN O

6 NN NN O
. NN NN O
Recurrent NNP NNP B-PROBLEM
lower NNP NNP I-PROBLEM
extremity NNP NNP I-PROBLEM
cellulitis NNP NNP I-PROBLEM
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
has NN NN O
no NN NN O
tobacco NN NN O
use NN NN O
. NN NN O

No NN NN O
alcohol NN NN O
use NN NN O
. NN NN O

He NN NN O
is NN NN O
married NN NN O
. NN NN O

He NN NN O
is NN NN O
a NN NN O
retired NN NN O
Methodist NN NN O
minister NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
His NN NN O
mother NN NN O
just NN NN O
died NN NN O
two NN NN O
days NN NN O
ago NN NN O
. NN NN O

There NN NN O
is NN NN O
no NN NN O
history NN NN O
of NN NN O
solid NNP NNP B-PROBLEM
tumors NNP NNP I-PROBLEM
or NN NN O
hematologic NNP NNP B-PROBLEM
malignancies NNP NNP I-PROBLEM
in NN NN O
his NN NN O
family NN NN O
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
VIT NN NN O
: NN NN O
Height NNP NNP B-TEST
168 NN NN O
cm NN NN O
, NN NN O
weight NNP NNP B-TEST
90.5 NN NN O
kg NN NN O
, NN NN O
blood NNP NNP B-TEST
pressure NNP NNP I-TEST
106/58 NN NN O
, NN NN O
pulse NNP NNP B-TEST
68 NN NN O
, NN NN O
and NN NN O
temperature NNP NNP B-TEST
is NN NN O
97.3 NN NN O
. NN NN O

GEN NN NN O
: NN NN O
He NN NN O
is NN NN O
nontoxic NN NN O
, NN NN O
noncachectic NNP NNP B-PROBLEM
appearing NN NN O
. NN NN O

HEAD NN NN O
: NN NN O
Examined NN NN O
and NN NN O
normal NN NN O
. NN NN O

EYES NN NN O
: NN NN O
Anicteric NNP NNP B-PROBLEM
. NN NN O

ENT NN NN O
: NN NN O
No NN NN O
oropharyngeal NNP NNP B-PROBLEM
lesions NNP NNP I-PROBLEM
. NN NN O

LYMPH NN NN O
: NN NN O
No NN NN O
cervical NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

HEART NN NN O
: NN NN O
Regular NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
; NN NN O

no NN NN O
murmurs NNP NNP B-PROBLEM
, NN NN O
rubs NNP NNP B-PROBLEM
, NN NN O
or NN NN O
gallops NNP NNP B-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Nontender NN NN O
, NN NN O
nondistended NNP NNP B-PROBLEM
; NN NN O

normal NN NN O
bowel NN NN O
sounds NN NN O
; NN NN O

no NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

EXT NN NN O
: NN NN O
Reveal NNP NNP B-TREATMENT
no NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
Follicular NNP NNP B-PROBLEM
non-Hodgkin's NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
. NN NN O

His NNP NNP B-TEST
CBC NNP NNP I-TEST
and NN NN O
CMP NNP NNP B-TEST
are NN NN O
acceptable NN NN O
and NN NN O
LDH NNP NNP B-TEST
is NN NN O
121 NN NN O
. NN NN O

Overall NN NN O
, NN NN O
he NN NN O
is NN NN O
doing NN NN O
well NN NN O
. NN NN O

When NN NN O
I NN NN O
see NN NN O
him NN NN O
again NN NN O
in NN NN O
three NN NN O
months NN NN O
, NN NN O
I NN NN O
will NN NN O
repeat NN NN O
his NNP NNP B-TEST
laboratory NNP NNP I-TEST
studies NNP NNP I-TEST
as NN NN O
well NN NN O
his NNP NNP B-TEST
PET NNP NNP I-TEST
scan NNP NNP I-TEST
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
non-hodgkin's NNP NNP B-PROBLEM
, NN NN O
chop NN NN O
, NN NN O
follicular NN NN O
, NN NN O
hypermetabolic NNP NNP B-PROBLEM
, NN NN O
ecog NNP NNP B-PROBLEM
, NN NN O
follicular NNP NNP B-PROBLEM
non NNP NNP I-PROBLEM
hodgkin's NNP NNP I-PROBLEM
lymphoma NNP NNP I-PROBLEM
, NN NN O
chop NN NN O
chemotherapy NNP NNP B-DRUG
, NN NN O
follicular NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
, NN NN O
pet NNP NNP B-TEST
scan NNP NNP I-TEST
, NN NN O
pelvic NNP NNP B-PROBLEM
radiation NNP NNP I-PROBLEM
, NN NN O
hodgkin's NNP NNP B-PROBLEM
lymphoma NNP NNP I-PROBLEM
, NN NN O
lymphoma NNP NNP B-PROBLEM
, NN NN O
hodgkin's NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Iron NNP NNP B-PROBLEM
deficiency NNP NNP I-PROBLEM
anemia NNP NNP I-PROBLEM
Description NN NN O
: NN NN O
Iron NNP NNP B-PROBLEM
deficiency NNP NNP I-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

She NN NN O
underwent NN NN O
a NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
which NN NN O
showed NN NN O
a NN NN O
normal NN NN O
cellular NN NN O
marrow NN NN O
with NN NN O
trilineage NNP NNP B-PROBLEM
hematopoiesis NNP NNP I-PROBLEM
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
Iron NNP NNP B-PROBLEM
deficiency NNP NNP I-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
19-year-old NN NN O
woman NN NN O
, NN NN O
who NN NN O
was NN NN O
recently NN NN O
hospitalized NN NN O
with NN NN O
iron NNP NNP B-PROBLEM
deficiency NNP NNP I-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

She NN NN O
was NN NN O
seen NN NN O
in NN NN O
consultation NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
. NN NN O
She NN NN O
underwent NN NN O
a NNP NNP B-TEST
bone NNP NNP I-TEST
marrow NNP NNP I-TEST
biopsy NNP NNP I-TEST
on NN NN O
07/21/10 NNP NNP B-DATE
, NN NN O
which NN NN O
showed NN NN O
a NN NN O
normal NN NN O
cellular NN NN O
marrow NN NN O
with NN NN O
trilineage NNP NNP B-PROBLEM
hematopoiesis NNP NNP I-PROBLEM
. NN NN O

On NN NN O
07/22/10 NNP NNP B-DATE
, NN NN O
her NNP NNP B-TEST
hemoglobin NNP NNP I-TEST
was NN NN O
6.5 NN NN O
and NN NN O
therefore NN NN O
she NN NN O
was NN NN O
transfused NNP NNP B-DRUG
2 NNP NNP I-DRUG
units NNP NNP I-DRUG
of NNP NNP I-DRUG
packed NNP NNP I-DRUG
red NNP NNP I-DRUG
blood NNP NNP I-DRUG
cells NNP NNP I-DRUG
. NN NN O

Her NNP NNP B-TEST
iron NNP NNP I-TEST
levels NNP NNP I-TEST
were NN NN O
5 NN NN O
and NN NN O
her NNP NNP B-TEST
percent NNP NNP I-TEST
transferrin NNP NNP I-TEST
was NN NN O

2 NN NN O
. NN NN O
There NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
hemolysis NNP NNP B-PROBLEM
. NN NN O

Of NN NN O
note NN NN O
, NN NN O
she NN NN O
had NN NN O
a NN NN O
baby NN NN O
5 NN NN O
months NN NN O
ago NN NN O
; NN NN O

however NN NN O
she NN NN O
does NN NN O
not NN NN O
describe NN NN O
excessive NNP NNP B-PROBLEM
bleeding NNP NNP I-PROBLEM
at NN NN O
the NN NN O
time NN NN O
of NN NN O
birth NN NN O
. NN NN O

She NN NN O
currently NN NN O
has NN NN O
an NNP NNP B-TREATMENT
IUD NNP NNP I-TREATMENT
, NN NN O
so NN NN O
she NN NN O
is NN NN O
not NN NN O
menstruating NN NN O
. NN NN O

She NN NN O
was NN NN O
discharged NN NN O
from NN NN O
the NN NN O
hospital NN NN O
on NN NN O
iron NNP NNP B-DRUG
supplements NNP NNP I-DRUG
. NN NN O

She NN NN O
denies NN NN O
any NN NN O
fevers NNP NNP B-PROBLEM
, NN NN O
chills NNP NNP B-PROBLEM
, NN NN O
or NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
. NN NN O

No NN NN O
lymphadenopathy NNP NNP B-PROBLEM
. NN NN O

No NN NN O
nausea NNP NNP B-PROBLEM
or NN NN O
vomiting NNP NNP B-PROBLEM
. NN NN O

No NN NN O
change NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
bowel NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
bladder NNP NNP I-PROBLEM
habits NNP NNP I-PROBLEM
. NN NN O

She NN NN O
specifically NN NN O
denies NN NN O
melena NNP NNP B-PROBLEM
or NN NN O
hematochezia NNP NNP B-PROBLEM
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Iron NNP NNP B-DRUG
supplements NNP NNP I-DRUG
and NN NN O
Levaquin NNP NNP B-DRUG
. NN NN O

ALLERGIES NN NN O
: NN NN O
Penicillin NNP NNP B-DRUG
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
As NN NN O
per NN NN O
the NN NN O
HPI NN NN O
, NN NN O
otherwise NN NN O
negative NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
is NN NN O
status NN NN O
post NN NN O
birth NN NN O
of NN NN O
a NN NN O
baby NN NN O
girl NN NN O
5 NN NN O
months NN NN O
ago NN NN O
. NN NN O

She NN NN O
is NN NN O
G1 NN NN O
, NN NN O
P1 NN NN O
. NN NN O

She NN NN O
is NN NN O
currently NN NN O
using NN NN O
an NNP NNP B-TREATMENT
IUD NNP NNP I-TREATMENT
for NN NN O
contraception NNP NNP B-TREATMENT
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
has NN NN O
no NN NN O
tobacco NN NN O
use NN NN O
. NN NN O

She NN NN O
has NN NN O
rare NN NN O
alcohol NN NN O
use NN NN O
. NN NN O

No NN NN O
illicit NN NN O
drug NN NN O
use NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Her NN NN O
maternal NN NN O
grandmother NN NN O
had NN NN O
stomach NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

There NN NN O
is NN NN O
no NN NN O
history NN NN O
of NN NN O
hematologic NNP NNP B-PROBLEM
malignancies NNP NNP I-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAM NN NN O
: NN NN O
GEN NN NN O
: NN NN O
She NN NN O
is NN NN O
nontoxic NN NN O
, NN NN O
noncachectic NNP NNP B-PROBLEM
appearing NN NN O
. NN NN O

HEAD NN NN O
: NN NN O
Examined NN NN O
and NN NN O
normal NN NN O
. NN NN O

EYES NN NN O
: NN NN O
Anicteric NNP NNP B-PROBLEM
. NN NN O

ENT NN NN O
: NN NN O
No NN NN O
oropharyngeal NNP NNP B-PROBLEM
lesions NNP NNP I-PROBLEM
. NN NN O

LYMPH NN NN O
: NN NN O
No NN NN O
cervical NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
supraclavicular NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
lymphadenopathy NNP NNP I-PROBLEM
. NN NN O

HEART NN NN O
: NN NN O
Regular NN NN O
S1 NN NN O
, NN NN O
S2 NN NN O
; NN NN O

no NN NN O
murmurs NNP NNP B-PROBLEM
, NN NN O
rubs NNP NNP B-PROBLEM
, NN NN O
or NN NN O
gallops NNP NNP B-PROBLEM
. NN NN O

LUNGS NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultation NNP NNP B-TEST
bilaterally NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Nontender NN NN O
, NN NN O
nondistended NNP NNP B-PROBLEM
; NN NN O

normal NN NN O
bowel NN NN O
sounds NN NN O
; NN NN O

no NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
. NN NN O

EXT NN NN O
: NN NN O
Reveal NNP NNP B-TREATMENT
no NN NN O
edema NNP NNP B-PROBLEM
. NN NN O

ASSESSMENT/PLAN NN NN O
: NN NN O
Iron NNP NNP B-PROBLEM
deficiency NNP NNP I-PROBLEM
anemia NNP NNP I-PROBLEM
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
I NN NN O
am NN NN O
going NN NN O
to NN NN O
schedule NN NN O
her NN NN O
for NN NN O
an NNP NNP B-TEST
EGD NNP NNP I-TEST
and NN NN O
a NNP NNP B-TEST
colonscopy NNP NNP I-TEST
. NN NN O

I NN NN O
am NN NN O
also NN NN O
going NN NN O
to NN NN O
repeat NN NN O
her NN NN O
iron NNP NNP B-DRUG
studies NNP NNP I-DRUG
. NN NN O

She NN NN O
had NN NN O
a NNP NNP B-TEST
CBC NNP NNP I-TEST
from NN NN O
yesterday NN NN O
, NN NN O
which NN NN O
showed NN NN O
hemoglobin NNP NNP B-TEST
of NN NN O
10.4 NN NN O
. NN NN O

Her NNP NNP B-TEST
MCV NNP NNP I-TEST
was NN NN O
still NNP NNP B-PROBLEM
low NNP NNP I-PROBLEM
at NN NN O
74.2 NN NN O
and NN NN O
the NNP NNP B-TEST
mean NNP NNP I-TEST
cell NNP NNP I-TEST
hemoglobin NNP NNP I-TEST
was NN NN O
25.0 NN NN O
. NN NN O

I NN NN O
would NN NN O
also NN NN O
like NN NN O
to NN NN O
check NN NN O
her NNP NNP B-TEST
fecal NNP NNP I-TEST
occult NNP NNP I-TEST
blood NNP NNP I-TEST
test NNP NNP I-TEST
x3 NN NN O
. NN NN O

I NN NN O
believe NN NN O
with NN NN O
her NNP NNP B-PROBLEM
low NNP NNP I-PROBLEM
iron NNP NNP I-PROBLEM
levels NNP NNP I-PROBLEM
it NN NN O
is NN NN O
going NN NN O
to NN NN O
be NN NN O
very NN NN O
difficult NN NN O
for NN NN O
her NN NN O
to NN NN O
replace NN NN O
it NNP NNP B-TREATMENT
orally NNP NNP I-TREATMENT
. NN NN O

I NN NN O
believe NN NN O
she NN NN O
may NN NN O
need NN NN O
intravenous NNP NNP B-DRUG
iron NNP NNP I-DRUG
infusions NNP NNP I-DRUG
. NN NN O

If NN NN O
that NN NN O
is NN NN O
case NN NN O
, NN NN O
we NN NN O
can NN NN O
arrange NN NN O
for NN NN O
her NN NN O
to NN NN O
find NN NN O
a NN NN O
doctor NN NN O
who NN NN O
can NN NN O
give NN NN O
the NN NN O
iron NNP NNP B-DRUG
infusions NNP NNP I-DRUG
. NN NN O

She NN NN O
will NN NN O
follow NN NN O
up NN NN O
with NN NN O
Dr NN NN O
. NN NN O
X NNP NNP B-NAME
. NNP NNP I-NAME
Keywords NNP NNP I-NAME
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
trilineage NNP NNP B-PROBLEM
hematopoiesis NNP NNP I-PROBLEM
, NN NN O
cellular NNP NNP B-PROBLEM
marrow NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
bone NNP NNP I-PROBLEM
marrow NNP NNP I-PROBLEM
biopsy NNP NNP I-PROBLEM
, NN NN O
iron NNP NNP B-PROBLEM
deficiency NNP NNP I-PROBLEM
anemia NNP NNP I-PROBLEM
, NN NN O
bone NNP NNP B-PROBLEM
marrow NNP NNP I-PROBLEM
, NN NN O
anemia NNP NNP B-PROBLEM
, NN NN O
hemoglobin NNP NNP B-PROBLEM
, NN NN O
lymphadenopathy NNP NNP B-PROBLEM
, NN NN O
deficiency NNP NNP B-PROBLEM
, NN NN O
tobacco NNP NNP B-PROBLEM
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Consult NN NN O
- NN NN O
Breast NN NN O
Cancer NN NN O
Description NN NN O
: NN NN O
Patient NN NN O
presents NN NN O
with NN NN O
complaint NN NN O
of NN NN O
lump NNP NNP B-PROBLEM
in NN NN O
the NN NN O
upper NN NN O
outer NN NN O
quadrant NN NN O
of NN NN O
the NN NN O
right NN NN O
breast NN NN O
( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
CHIEF NN NN O
COMPLAINT NN NN O
/ NN NN O
REASON NN NN O
FOR NN NN O
THE NN NN O
VISIT NN NN O
: NN NN O
Patient NN NN O
has NN NN O
been NN NN O
diagnosed NN NN O
to NN NN O
have NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
. NN NN O

BREAST NN NN O
CANCER NN NN O
HISTORY NN NN O
: NN NN O
Patient NN NN O
presented NN NN O
with NN NN O
the NN NN O
following NN NN O
complaints NN NN O
: NN NN O
Lump NNP NNP B-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
upper NNP NNP I-PROBLEM
outer NNP NNP I-PROBLEM
quadrant NNP NNP I-PROBLEM
of NN NN O
the NN NN O
right NN NN O
breast NN NN O
that NN NN O
has NN NN O
been NN NN O
present NN NN O
for NN NN O
the NN NN O
last NN NN O
4 NN NN O
weeks NN NN O
. NN NN O

The NNP NNP B-PROBLEM
lump NNP NNP I-PROBLEM
is NN NN O
painless NNP NNP B-PROBLEM
and NN NN O
the NNP NNP B-PROBLEM
skin NNP NNP I-PROBLEM
over NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
lump NNP NNP I-PROBLEM
is NN NN O
normal NN NN O
. NN NN O

Patient NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
redness NNP NNP I-PROBLEM
, NN NN O
warmth NNP NNP B-PROBLEM
, NN NN O
edema NNP NNP B-PROBLEM
and NN NN O
nipple NNP NNP B-PROBLEM
discharge NNP NNP I-PROBLEM
. NN NN O

Patient NN NN O
had NN NN O
a NNP NNP B-TEST
mammogram NNP NNP I-TEST
recently NN NN O
and NN NN O
was NN NN O
told NN NN O
to NN NN O
have NN NN O
a NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
measuring NN NN O
2 NN NN O
cm NN NN O
in NN NN O
the NN NN O
UOQ NN NN O
and NN NN O
of NN NN O
the NN NN O
left NN NN O
breast NN NN O
. NN NN O

Patient NN NN O
had NN NN O
an NNP NNP B-TEST
excisional NNP NNP I-TEST
biopsy NNP NNP I-TEST
of NN NN O
the NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
and NN NN O
subsequently NNP NNP B-PROBLEM
axillary NNP NNP I-PROBLEM
nodal NNP NNP I-PROBLEM
sampling NNP NNP I-PROBLEM
. NN NN O

PATHOLOGY NN NN O
: NN NN O
Infiltrating NNP NNP B-PROBLEM
ductal NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
Estrogen NNP NNP B-DRUG
receptor NNP NNP I-DRUG
56 NNP NNP I-DRUG
, NN NN O
Progesterone NNP NNP B-DRUG
receptor NN NN O
23 NN NN O
, NN NN O
S-phase NNP NNP B-TEST
fraction NNP NNP I-TEST
2 NN NN O
., NN NN O
Her NNP NNP B-TEST
2 NNP NNP I-TEST
neu NNP NNP I-TEST
0 NN NN O
and NN NN O
all NN NN O
nodes NN NN O
negative NN NN O
. NN NN O

STAGE NN NN O
: NN NN O
Stage NN NN O
I NN NN O
. NN NN O
TNM NN NN O
STAGE NN NN O
: NN NN O
T1 NN NN O
, NN NN O
N0 NNP NNP B-PROBLEM
and NN NN O
M0 NN NN O
. NN NN O

SURGERY NN NN O
: NN NN O
S/P NN NN O
lumpectomy NNP NNP B-TREATMENT
left NNP NNP I-TREATMENT
breast NNP NNP I-TREATMENT
and NN NN O
Left NNP NNP B-TREATMENT
axillary NNP NNP I-TREATMENT
node NNP NNP I-TREATMENT
sampling NNP NNP I-TREATMENT
. NN NN O

Patient NN NN O
is NN NN O
here NN NN O
for NN NN O
further NN NN O
recommendation NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Osteoarthritis NNP NNP B-PROBLEM
for NN NN O
5 NN NN O
years NN NN O
. NN NN O

ASHD NNP NNP B-DRUG
for NN NN O
10 NN NN O
years NN NN O
. NN NN O

Kidney NNP NNP B-PROBLEM
stones NNP NNP I-PROBLEM
recurrent NN NN O
for NN NN O
10 NN NN O
years NN NN O
. NN NN O

SCREENING NN NN O
TEST NN NN O
HISTORY NN NN O
: NN NN O
Last NNP NNP B-TEST
rectal NNP NNP I-TEST
exam NNP NNP I-TEST
was NN NN O
done NN NN O
on NN NN O
10/99 NNP NNP B-DATE
. NN NN O

Last NNP NNP B-TEST
mammogram NNP NNP I-TEST
was NN NN O
done NN NN O
on NN NN O
12/99 NNP NNP B-DATE
. NN NN O

Last NN NN O
gynecological NNP NNP B-TEST
exam NNP NNP I-TEST
was NN NN O
done NN NN O
on NN NN O
10/99 NNP NNP B-DATE
. NN NN O

Last NNP NNP B-TEST
PAP NNP NNP I-TEST
smear NNP NNP I-TEST
was NN NN O
done NN NN O
on NN NN O
10/99 NNP NNP B-DATE
. NN NN O

Last NNP NNP B-TEST
chest NNP NNP I-TEST
x-ray NNP NNP I-TEST
was NN NN O
done NN NN O
on NN NN O
10/99 NNP NNP B-DATE
. NN NN O

Last NN NN O
F.O.B NN NN O
. NN NN O
was NN NN O
done NN NN O
on NN NN O
10/99-X3 NNP NNP B-DATE
. NN NN O

Last NN NN O
sigmoidoscopy NNP NNP B-TEST
was NN NN O
done NN NN O
on NN NN O
1998 NNP NNP B-DATE
. NN NN O

Last NN NN O
colonoscopy NNP NNP B-TEST
was NN NN O
done NN NN O
on NN NN O
1996 NNP NNP B-DATE
. NN NN O

IMMUNIZATION NN NN O
HISTORY NN NN O
: NN NN O
Last NN NN O
flu NN NN O
vaccine NNP NNP B-DRUG
was NN NN O
given NN NN O
on NN NN O
1999 NNP NNP B-DATE
. NN NN O

Last NN NN O
pneumonia NN NN O
vaccine NNP NNP B-DRUG
was NN NN O
given NN NN O
on NN NN O
1996 NNP NNP B-DATE
. NN NN O

FAMILY NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Father NN NN O
age NN NN O
85 NN NN O
, NN NN O
history NN NN O
of NN NN O
cerebrovascular NNP NNP B-PROBLEM
accident NNP NNP I-PROBLEM
( NN NN O
stroke NNP NNP B-PROBLEM
) NNP NNP I-PROBLEM
and NN NN O
hypertension NNP NNP B-PROBLEM
. NN NN O

Mother NN NN O
history NN NN O
of NN NN O
CHF NNP NNP B-PROBLEM
and NN NN O
emphysema NNP NNP B-PROBLEM
that NN NN O
died NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O

78 NN NN O
. NN NN O
No NN NN O
brothers NN NN O
and NN NN O
sisters NN NN O
. NN NN O

1 NN NN O
son NN NN O
healthy NN NN O
at NN NN O
age NN NN O

54 NN NN O
. NN NN O
PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O
: NN NN O
Appendectomy NNP NNP B-TREATMENT
. NN NN O

Biopsy NNP NNP B-TEST
of NNP NNP I-TEST
the NNP NNP I-TEST
left NNP NNP I-TEST
breast NNP NNP I-TEST
1996 NN NN O
- NN NN O
benign NN NN O
. NN NN O

Cholecystectomy NNP NNP B-TREATMENT
. NN NN O

PERSONAL NN NN O
AND NN NN O
SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
Marital NN NN O
status NN NN O
: NN NN O
Married NN NN O
. NN NN O

Smoking NN NN O
history NN NN O
: NN NN O
Smoked NNP NNP B-PROBLEM
1 NNP NNP I-PROBLEM
PPD NNP NNP I-PROBLEM
, NN NN O
quit NN NN O
12 NN NN O
years NN NN O
ago NN NN O
and NN NN O
after NN NN O
smoking NN NN O
for NN NN O
30 NN NN O
years NN NN O
. NN NN O

Alcohol NN NN O
history NN NN O
: NN NN O
Drinks NN NN O
socially NN NN O
. NN NN O

Denies NN NN O
any NN NN O
history NN NN O
of NN NN O
drug NN NN O
abuse NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
There NN NN O
are NN NN O
no NN NN O
known NNP NNP B-PROBLEM
drug NNP NNP I-PROBLEM
allergies NNP NNP I-PROBLEM
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O
: NN NN O
Aspirin NNP NNP B-DRUG
1 NNP NNP I-DRUG
tab NNP NNP I-DRUG
x NN NN O
1 NN NN O
/ NN NN O
day NN NN O
. NN NN O

Calan NNP NNP B-DRUG
SR NNP NNP I-DRUG
120 NNP NNP I-DRUG
mg NNP NNP I-DRUG
. NN NN O

x NN NN O
1 NN NN O
/ NN NN O
day NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
General NN NN O
: NN NN O
Patient NN NN O
feels NN NN O
fairly NN NN O
well NN NN O
. NN NN O

Patient NN NN O
denies NN NN O
history NN NN O
of NN NN O
fever NNP NNP B-PROBLEM
, NN NN O
chills NNP NNP B-PROBLEM
, NN NN O
night NNP NNP B-PROBLEM
sweats NNP NNP I-PROBLEM
and NN NN O
weight NNP NNP B-PROBLEM
loss NNP NNP I-PROBLEM
. NN NN O

Head NN NN O
and NN NN O
Eyes NN NN O
: NN NN O
Patient NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
problems NNP NNP I-PROBLEM
relating NN NN O
to NN NN O
the NN NN O
head NN NN O
and NN NN O
eyes NN NN O
. NN NN O

Ears NN NN O
Nose NN NN O
and NN NN O
Throat NN NN O
: NN NN O
Patient NN NN O
has NN NN O
no NN NN O
problems NNP NNP B-PROBLEM
related NN NN O
to NN NN O
the NN NN O
ears NN NN O
, NN NN O
nose NN NN O
or NN NN O
throat NN NN O
. NN NN O

Respiratory NN NN O
: NN NN O
Patient NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
respiratory NNP NNP I-PROBLEM
complaints NNP NNP I-PROBLEM
, NN NN O
such NN NN O
as NN NN O
cough NNP NNP B-PROBLEM
, NN NN O
shortness NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
breath NNP NNP I-PROBLEM
, NN NN O
chest NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
wheezing NNP NNP B-PROBLEM
, NN NN O
hemoptysis NNP NNP B-PROBLEM
, NN NN O
etc NN NN O
. NN NN O

Cardiovascular NN NN O
: NN NN O
Chest NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
retrosternal NNP NNP I-PROBLEM
area NNP NNP I-PROBLEM
, NN NN O
Occasional NNP NNP B-PROBLEM
anginal NNP NNP I-PROBLEM
pain NNP NNP I-PROBLEM
and NN NN O
patient NN NN O
describes NN NN O
it NN NN O
as NN NN O
a NN NN O
sensation NN NN O
of NN NN O
tightness NNP NNP B-PROBLEM
. NN NN O

It NN NN O
radiates NN NN O
to NN NN O
the NN NN O
left NN NN O
shoulder NN NN O
. NN NN O

Patient NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
palpitation NNP NNP I-PROBLEM
, NN NN O
syncope NNP NNP B-PROBLEM
, NN NN O
paroxysmal NNP NNP B-PROBLEM
nocturnal NNP NNP I-PROBLEM
dyspnea NNP NNP I-PROBLEM
and NN NN O
orthopnea NNP NNP B-PROBLEM
. NN NN O

Gastrointestinal NN NN O
: NN NN O
Patient NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
nausea NNP NNP I-PROBLEM
, NN NN O
vomiting NNP NNP B-PROBLEM
, NN NN O
abdominal NNP NNP B-PROBLEM
pain NNP NNP I-PROBLEM
, NN NN O
dysphagia NNP NNP B-PROBLEM
or NN NN O
any NNP NNP B-PROBLEM
altered NNP NNP I-PROBLEM
bowel NNP NNP I-PROBLEM
movements NNP NNP I-PROBLEM
. NN NN O

Genitourinary NN NN O
: NN NN O
Denies NN NN O
any NNP NNP B-PROBLEM
genito-urinary NNP NNP I-PROBLEM
complaints NNP NNP I-PROBLEM
. NN NN O

Musculoskeletal NN NN O
: NN NN O
The NN NN O
patient NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
musculoskeletal NNP NNP I-PROBLEM
complaints NNP NNP I-PROBLEM
. NN NN O

Neurological NN NN O
: NN NN O
Patient NN NN O
denies NN NN O
any NNP NNP B-PROBLEM
focal NNP NNP I-PROBLEM
motor NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
sensory NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
other NNP NNP I-PROBLEM
neurological NNP NNP I-PROBLEM
symptoms NNP NNP I-PROBLEM
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
General NN NN O
: NN NN O
Patient NN NN O
appears NN NN O
well NN NN O
developed NN NN O
, NN NN O
well NN NN O
nourished NN NN O
and NN NN O
healthy NN NN O
. NN NN O

Personality NN NN O
: NN NN O
pleasant NN NN O
and NN NN O
cooperative NN NN O
. NN NN O

Mental NN NN O
status NN NN O
: NN NN O
Alert NN NN O
and NN NN O
oriented NN NN O
. NN NN O

Stature NN NN O
: NN NN O
slender NNP NNP B-PROBLEM
. NN NN O

ECOG NN NN O
performance NN NN O
score NN NN O

0 NN NN O
. NN NN O
HEENT NN NN O
: NN NN O
Examination NNP NNP B-TEST
of NNP NNP I-TEST
head NNP NNP I-TEST
, NNP NNP I-TEST
eyes NNP NNP I-TEST
, NNP NNP I-TEST
ears NNP NNP I-TEST
, NNP NNP I-TEST
nose NNP NNP I-TEST
and NNP NNP I-TEST
throat NNP NNP I-TEST
is NN NN O
unremarkable NN NN O
. NN NN O

Hematologic NN NN O
/ NN NN O
Lymphatic NN NN O
: NN NN O
There NN NN O
is NN NN O
no NN NN O
palpable NNP NNP B-PROBLEM
adenopathy NNP NNP I-PROBLEM
in NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
inguinal NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
, NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
cervical NNP NNP I-PROBLEM
areas NNP NNP I-PROBLEM
. NN NN O

Cardiovascular NN NN O
: NN NN O
Heart NN NN O
: NN NN O
Regular NN NN O
rhythm NN NN O
, NN NN O
normal NN NN O
rate NN NN O
without NN NN O
any NNP NNP B-PROBLEM
murmurs NNP NNP I-PROBLEM
or NN NN O
gallops NNP NNP B-PROBLEM
. NN NN O

Breast NN NN O
: NN NN O
RIGHT NN NN O
BREAST NN NN O
: NN NN O
Within NN NN O
normal NN NN O
limits NN NN O
. NN NN O

LEFT NN NN O
BREAST NN NN O
: NN NN O
Consistency NN NN O
: NN NN O
slight NNP NNP B-PROBLEM
induration NNP NNP I-PROBLEM
noted NN NN O
due NN NN O
to NN NN O
recent NNP NNP B-TREATMENT
surgery NNP NNP I-TREATMENT
. NN NN O

Respiratory NN NN O
: NN NN O
Chest NN NN O
symmetrical NN NN O
, NN NN O
normal NN NN O
, NN NN O
breath NN NN O
sounds NN NN O
equal NN NN O
, NN NN O
bilateral NN NN O
symmetrical NN NN O
, NN NN O
no NN NN O
rales NNP NNP B-PROBLEM
or NN NN O
rhonchi NNP NNP B-PROBLEM
and NN NN O
no NN NN O
dullness NNP NNP B-PROBLEM
to NN NN O
percussion NNP NNP B-TEST
. NN NN O

Abdomen NN NN O
/ NN NN O
Gastrointestinal NN NN O
: NN NN O
Abdomen NN NN O
is NN NN O
soft NN NN O
, NN NN O
non-tender NNP NNP B-PROBLEM
, NN NN O
and NN NN O
without NN NN O
palpable NNP NNP B-PROBLEM
masses NNP NNP I-PROBLEM
. NN NN O

No NN NN O
hepatosplenomegaly NNP NNP B-PROBLEM
is NN NN O
appreciable NN NN O
. NN NN O

Extremities NN NN O
: NN NN O
Peripheral NNP NNP B-TEST
pulses NNP NNP I-TEST
are NN NN O
normal NN NN O
. NN NN O

There NN NN O
is NN NN O
no NN NN O
edema NNP NNP B-PROBLEM
, NN NN O
cyanosis NNP NNP B-PROBLEM
, NN NN O
clubbing NNP NNP B-PROBLEM
or NN NN O
significant NNP NNP B-PROBLEM
varicosities NNP NNP I-PROBLEM
. NN NN O

No NN NN O
skin NNP NNP B-PROBLEM
lesions NNP NNP I-PROBLEM
identified NN NN O
. NN NN O

Musculoskelatal NN NN O
: NN NN O
No NN NN O
evidence NN NN O
of NN NN O
joint NNP NNP B-PROBLEM
swelling NNP NNP I-PROBLEM
, NN NN O
bone NNP NNP B-PROBLEM
tenderness NNP NNP I-PROBLEM
or NN NN O
muscle NNP NNP B-PROBLEM
tenderness NNP NNP I-PROBLEM
is NN NN O
appreciable NN NN O
. NN NN O

Neurological NN NN O
: NN NN O
Brief NNP NNP B-TEST
neurological NNP NNP I-TEST
examination NNP NNP I-TEST
reveals NN NN O
motor NN NN O
power NN NN O
grossly NN NN O
normal NN NN O
in NN NN O
all NN NN O
groups NN NN O
and NN NN O
no NN NN O
gross NNP NNP B-PROBLEM
sensory NNP NNP I-PROBLEM
or NNP NNP I-PROBLEM
other NNP NNP I-PROBLEM
abnormality NNP NNP I-PROBLEM
appreciable NN NN O
. NN NN O

RADIOLOGY NN NN O
: NN NN O
Mammogram NNP NNP B-TEST
: NN NN O
A NNP NNP B-PROBLEM
mass NNP NNP I-PROBLEM
measuring NN NN O
2X2 NN NN O
cm NN NN O
. NN NN O

in NN NN O
the NN NN O
upper NN NN O
outer NN NN O
quadrant NN NN O
of NN NN O
the NN NN O
left NN NN O
breast NN NN O
. NN NN O

Lab NN NN O
: NN NN O
LAB NN NN O
DATA NN NN O
: NN NN O
CMP NN NN O
( NN NN O
comprehensive NN NN O
metabolic NN NN O
panel NN NN O
): NN NN O
WNL NN NN O
. NN NN O

Liver NNP NNP B-TEST
function NNP NNP I-TEST
tests NNP NNP I-TEST
are NN NN O
WNL NN NN O
. NN NN O

CBC NNP NNP B-TEST
with NN NN O
diff NNP NNP B-TEST
shows NN NN O
WBC NNP NNP B-TEST
3.2 NN NN O
/ NN NN O
cmm NN NN O
. NN NN O

Hemoglobin NNP NNP B-TEST
12.0 NN NN O
grams NN NN O
/ NN NN O
dl NN NN O
, NN NN O
Platelets NNP NNP B-TEST
250000 NN NN O
/ NN NN O
cmm NN NN O
and NN NN O
it NN NN O
is NN NN O
dated NN NN O
1/4/2000 NNP NNP B-DATE
. NN NN O

IMPRESSION NN NN O
/ NN NN O
DIAGNOSIS NN NN O
: NN NN O
Carcinoma NNP NNP B-PROBLEM
of NNP NNP I-PROBLEM
the NNP NNP I-PROBLEM
left NNP NNP I-PROBLEM
breast NNP NNP I-PROBLEM
( NN NN O
174.9 NN NN O
- NN NN O
female NN NN O
), NN NN O
Upper NNP NNP B-PROBLEM
outer NNP NNP I-PROBLEM
quadrant NNP NNP I-PROBLEM
( NN NN O
174.4 NN NN O
) NN NN O
PATHOLOGY NN NN O
: NN NN O
Infiltrating NNP NNP B-PROBLEM
ductal NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
. NN NN O

S/P NN NN O
lumpectomy NNP NNP B-TREATMENT
and NN NN O
axillary NNP NNP B-TREATMENT
node NNP NNP I-TREATMENT
dissection NNP NNP I-TREATMENT
. NN NN O

( NN NN O
Details NN NN O
as NN NN O
per NN NN O
HPI NN NN O
). NN NN O

DISCUSSION NN NN O
: NN NN O
Discussed NN NN O
in NN NN O
detail NN NN O
the NN NN O
diagnosis NN NN O
, NN NN O
prognosis NN NN O
and NN NN O
treatment NN NN O
alternatives NN NN O
. NN NN O

Options NN NN O
of NN NN O
treatment NNP NNP B-TREATMENT
discussed NN NN O
. NN NN O

Side NN NN O
effects NN NN O
of NN NN O
Tamoxifen NNP NNP B-DRUG
discussed NN NN O
in NN NN O
detail NN NN O
. NN NN O

RECOMMENDATIONS NN NN O
: NN NN O
Hormonal NNP NNP B-TREATMENT
therapy NNP NNP I-TREATMENT
with NN NN O
Tamoxifen NNP NNP B-DRUG
and NN NN O
Radiation NNP NNP B-TREATMENT
therapy NNP NNP I-TREATMENT
to NN NN O
the NN NN O
breast NN NN O
is NN NN O
recommended NN NN O
. NN NN O

TESTS NN NN O
ORDERED NN NN O
: NN NN O
The NN NN O
following NN NN O
labs NNP NNP B-TEST
are NN NN O
to NN NN O
be NN NN O
drawn NN NN O
about NN NN O
a NN NN O
week NN NN O
or NN NN O
so NN NN O
prior NN NN O
to NN NN O
next NN NN O
appointment NN NN O
: NN NN O
HEMATOLOGY NN NN O
: NN NN O
CBC NNP NNP B-TEST
. NN NN O

CHEMISTRY NN NN O
: NN NN O
comprehensive NN NN O
metabolic NN NN O
panel NN NN O
( NN NN O
CMP NNP NNP B-TEST
) NNP NNP I-TEST
and NN NN O
liver NNP NNP B-TEST
function NNP NNP I-TEST
panel NNP NNP I-TEST
( NN NN O
LFT NNP NNP B-TEST
). NN NN O

MEDICATIONS NNP NNP B-TREATMENT
PRESCRIBED NNP NNP I-TREATMENT
: NN NN O
Nolvadex NNP NNP B-DRUG
20 NNP NNP I-DRUG
mg NNP NNP I-DRUG
. NN NN O

1 NN NN O
time NN NN O
a NN NN O
day NN NN O
. NN NN O

FOLLOW-UP NN NN O
INSTRUCTIONS NN NN O
: NN NN O
Return NN NN O
to NN NN O
see NN NN O
William NNP NNP B-NAME
Smith NNP NNP I-NAME
. NN NN O

M.D NN NN O
. NN NN O
for NN NN O
follow NN NN O
up NN NN O
in NN NN O
3 NN NN O
month NN NN O

( NN NN O
s NN NN O
). NN NN O

Make NN NN O
appointment NN NN O
to NN NN O
Radiation NN NN O
therapy NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
breast NNP NNP B-PROBLEM
cancer NNP NNP I-PROBLEM
, NN NN O
lump NNP NNP B-PROBLEM
, NN NN O
progesterone NNP NNP B-DRUG
receptor NNP NNP I-DRUG
, NN NN O
estrogen NNP NNP B-DRUG
receptor NNP NNP I-DRUG
, NN NN O
her NNP NNP B-PROBLEM
2 NNP NNP I-PROBLEM
neu NNP NNP I-PROBLEM
, NN NN O
tnm NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
axillary NNP NNP I-PROBLEM
node NNP NNP I-PROBLEM
dissection NNP NNP I-PROBLEM
, NN NN O
tamoxifen NNP NNP B-DRUG
, NN NN O
infiltrating NNP NNP B-PROBLEM
ductal NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
upper NNP NNP B-PROBLEM
outer NNP NNP I-PROBLEM
quadrant NNP NNP I-PROBLEM
, NN NN O
ductal NNP NNP B-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
breast NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
carcinoma NNP NNP I-PROBLEM
, NN NN O
axillary NNP NNP B-PROBLEM
, NNP NNP I-PROBLEM
chest NNP NNP I-PROBLEM
, NN NN O
mammogram NNP NNP B-TEST
, NN NN O

